{"321c1ed61f525e371edc12c200b85f836826405d": [["It is an enlightening and sometimes conflicted mixture from eight authorscollective writing that strives to make sense of the global crisis.", [["the global crisis", "PROBLEM", 122, 139], ["global", "OBSERVATION_MODIFIER", 126, 132], ["crisis", "OBSERVATION", 133, 139]]], ["At times it is polemical, ensconced in the history of conflict between capital and workers.", [["polemical", "OBSERVATION", 15, 24]]], ["At other times, it is close to heart-rending as it includes testaments from the oppressed.", [["heart", "ANATOMY", 31, 36], ["heart", "ORGAN", 31, 36], ["heart", "ANATOMY", 31, 36]]], ["The collection conflates the past, present and future.", [["collection", "OBSERVATION", 4, 14]]], ["It suggests that activism may triumph whilst offering up a bleaker picture of the postpandemic world.", [["activism", "OBSERVATION", 17, 25]]], ["At times it reveals an ethnographic intent to see the world through the eyes of the oppressed.", [["eyes", "ANATOMY", 72, 76], ["eyes", "ORGAN", 72, 76]]], ["Above all else, it provides a wealth of data from six countries (Belgium, Brazil, France, Italy, UK, USA) that provides a neatly balanced overview of how the pandemic may have impacted on the struggle for workers' rights and how self-organisation may yet provide the means for triumph against the pervasive control mechanisms of global capitalism.A Tool of StruggleIn the introduction, the editors' suggestion that workers' inquiry 'can be developed as a tool of struggle' (Workers Inquiry Network 2020: 1) springs from Karl Marx's A Workers' Inquiry (1880).", [["global capitalism", "OBSERVATION", 329, 346]]], ["This recognises that 'statements of labor's grievances are the first act which socialist democracy must perform in order to prepare the way for social regeneration' (1).", [["labor", "PROBLEM", 36, 41]]], ["In comparison with Marx's collection of data from the French proletariat by the use of questionnaires, Invis\u00edveis Goi\u00e2nia (a small collective of activists) recorded the plight of Brazilian call centre operators.", [["small", "OBSERVATION_MODIFIER", 125, 130]]], ["As Covid-19 cases increased, workers reported that colleagues 'are being fired and disappearing from their workstations' (70).", [["Covid", "TEST", 3, 8]]], ["This inclusion is a moment of brilliant editorship, as the chapter provides a useful background to the entirety of the book and especially Robert Ovetz's discussion of recent wildcat strikes in the USA.", [["recent wildcat strikes", "PROBLEM", 168, 190]]], ["Most importantly, he recounts how workers' self-organisation provided a platform for an integrated social movement that drew upon the support of Italian society at large.", [["large", "OBSERVATION_MODIFIER", 164, 169]]], ["However, its presence in the text is impressive and revealing.", [["impressive", "OBSERVATION_MODIFIER", 37, 47]]], ["The importance of the transfer of knowledge between workers is an important lesson to be learnt here, and I appreciate how this lesson is reciprocated by the publication of Struggle in a Pandemic.", [["Pandemic", "DISEASE", 187, 195]]], ["This attitude threads its way through the entire Covid-19 pandemic-related book.Protecting Workers' HealthWho has not felt the need to protect themselves, their family and loved ones and their co-workers from exposure to the Covid-19 virus?", [["Covid-19 virus", "ORGANISM", 225, 239], ["Covid-19 virus", "SPECIES", 225, 239], ["the Covid", "TEST", 221, 230]]], ["Simon Downs created the illustration in Fig. 1 as a personal and evocative response to these feelings that are common to us all.", [["Fig", "OBSERVATION_MODIFIER", 40, 43]]], ["Chapter 4 of Struggle in a Pandemic, jointly written by Into the Black Box and Officina Primo Maggio, highlights the vulnerability of the precariat, but also describes workers' protests for 'social-distancing measures in the storage places, sanitizations, plastic gloves, protective masks and other basic safety measures' (35).", [["Pandemic", "DISEASE", 27, 35], ["plastic gloves", "TREATMENT", 256, 270], ["protective masks", "TREATMENT", 272, 288]]], ["This aspect of the vulnerability of the precariat in terms of health (in opposition to the need of capitalism for continual production) is repeated from a French perspective by Plateforme d'enqu\u00eates militantes in Chapter 2 and ACTA in Chapter 3.", [["vulnerability", "OBSERVATION_MODIFIER", 19, 32]]], ["In this case, that the Belgian government's priority was 'to secure the continuity of the accumulation process over the need to respond to the health, sanitary, and socio-economic crisis triggered by the pandemic' (6).", [["the accumulation process", "PROBLEM", 86, 110], ["socio-economic crisis", "PROBLEM", 165, 186], ["accumulation process", "OBSERVATION", 90, 110]]], ["With so much domestic concern about Covid-19 (worrying about highly vulnerable members of the family, the increasing local death rates, the number of ambulances on the street outside), the situation in Belgium did not register with me.", [["death", "DISEASE", 123, 128]]], ["Yet, AnkerMag cite the Johns Hopkins Coronavirus Resource Center (2020), who stated that Belgium had the highest Covid-19 death rate in the world proportional to its population.", [["death", "DISEASE", 122, 127]]], ["According to AnkerMag, this death rate was a direct outcome of delayed adoption of preventive measures-'the result of negotiations between the government and the Federation of Belgian Entrepreneurs (FEB)' (5).Protecting Workers' HealthChecking the Johns Hopkins (2020) site today, I note that the UK now occupies this unwelcome top spot.", [["death", "DISEASE", 28, 33], ["UK", "GENE_OR_GENE_PRODUCT", 297, 299], ["preventive measures", "TREATMENT", 83, 102]]], ["Chapter 5 in the 'Notes from Below' (Workers Inquiry Network 2020: 43) repeats the accusation that our governments have not prioritised the health of its citizens, dictating that the UK government 'must be held accountable for tens of thousands of deaths'.", [["deaths", "DISEASE", 248, 254]]], ["Just a few months ago, these same workers were 'told they were no longer welcome in the UK' (45).Workers' DemandsThere are many interesting instances of oppression and manipulation of vulnerable workers within Struggle in a Pandemic, and if this can at times seem truly dreadful, it is worth noting the sense of opportunity contained within the eight chapters.", [["Pandemic", "DISEASE", 224, 232]]], ["The increased sense of worth that many 'essential' workers have found and that has been offered in response by society is not to be dismissed lightly.", [["increased", "OBSERVATION_MODIFIER", 4, 13]]], ["Suspension of rents, mortgages and bills 3.", [["rents", "OBSERVATION", 14, 19]]], ["Requisitioning of private equipment and infrastructure needed to respond to the emergency, particularly in the health sector 4.", [["private equipment", "TREATMENT", 18, 35]]], ["Stop of all non-essential production activities 5.", [["all", "OBSERVATION_MODIFIER", 8, 11], ["non-essential", "OBSERVATION_MODIFIER", 12, 25], ["production activities", "OBSERVATION", 26, 47]]], ["Amnesty for detainees and immediate regularization of undocumented migrants (Workers Inquiry Network 2020: 4) Whilst these demands constitute a reasonable response to the Covid-19 crisis, they are but one step in the formulation of a new egalitarian regard for workers by society at large and the development of governance that prioritises people over production.Workers' DemandsThere are many warnings in the book that capitalism will ultimately make use of the pandemic to forge its own future.", [["people", "ORGANISM", 340, 346], ["people", "SPECIES", 340, 346]]], ["A future in which the worker pays for the failure of global capitalism, not the businesses that depend on it.", [["the failure of global capitalism", "PROBLEM", 38, 70], ["global", "OBSERVATION_MODIFIER", 53, 59], ["capitalism", "OBSERVATION", 60, 70]]], ["Skyrocketing deficits, borrowing, and corporate bailouts will become justification for further neoliberal austerity, privatization, disinvestment, and tax cuts for the rich and capital and regressive taxes on workers.", [["Skyrocketing deficits", "DISEASE", 0, 21], ["tax", "PROTEIN", 151, 154], ["Skyrocketing deficits", "PROBLEM", 0, 21]]], ["Emergency executive powers will become normalized wielded with In conclusion, I found Struggle in a Pandemic (Workers Inquiry Network 2020) an interesting and informative read.", [["Pandemic", "DISEASE", 100, 108]]], ["It lays down challenges regarding self-organisation, transfer of knowledge and the upkeep of egalitarian principles.", [["egalitarian principles", "TREATMENT", 93, 115]]], ["It highlights the disparity between the plight of the precariat and the needs of capitalism to continue production.", [["disparity", "OBSERVATION_MODIFIER", 18, 27], ["capitalism", "OBSERVATION", 81, 91]]], ["Lastly, thanks to the inclusion of Bologna's piece, it asks us to learn lessons from the history of class struggle.", [["Bologna's piece", "TREATMENT", 35, 50]]], ["This understanding of history as both malleable and forward-looking is reinforced when looking at today's news reports about the Covid-19 crisis.", [["the Covid", "TEST", 125, 134]]], ["With the growing ease of lockdown in Europe, there is an increased risk of a resurgent virus.", [["a resurgent virus", "PROBLEM", 75, 92], ["growing", "OBSERVATION_MODIFIER", 9, 16], ["increased", "OBSERVATION_MODIFIER", 57, 66], ["resurgent", "OBSERVATION_MODIFIER", 77, 86], ["virus", "OBSERVATION", 87, 92]]], ["When President Bolsonaro (Phillips 2020) depicts the death of hundreds of thousands of human beings as so much collateral damage inflicted in defence of the Brazilian economy, is he a spokesperson for global capitalism?", [["death", "DISEASE", 53, 58], ["collateral damage", "DISEASE", 111, 128], ["human", "ORGANISM", 87, 92], ["human", "SPECIES", 87, 92], ["human", "SPECIES", 87, 92], ["capitalism", "OBSERVATION", 208, 218]]], ["Struggle in a Pandemic: A Collection of Contributions on the COVID-19 Crisis (Workers Inquiry Network 2020) has been published as an immediate and vital response to the global crisis.", [["Pandemic", "DISEASE", 14, 22], ["the global crisis", "PROBLEM", 165, 182], ["global", "OBSERVATION_MODIFIER", 169, 175], ["crisis", "OBSERVATION", 176, 182]]]], "d3e8bcf5b115da5656e780b655650e6cfdaf89de": [["Web of Science and PubMed databases were searched for references to papers on severe acute respiratory syndrome, avian influenza/flu, H5N1, swine influenza/flu, H1N1, and pandemics.", [["acute respiratory syndrome", "DISEASE", 85, 111], ["influenza/flu", "DISEASE", 119, 132], ["H5N1", "DISEASE", 134, 138], ["swine influenza/flu", "DISEASE", 140, 159], ["H1N1", "DISEASE", 161, 165], ["pandemics", "DISEASE", 171, 180], ["avian influenza", "ORGANISM", 113, 128], ["H5N1", "ORGANISM", 134, 138], ["swine influenza", "ORGANISM", 140, 155], ["avian influenza", "SPECIES", 113, 128], ["H5N1", "SPECIES", 134, 138], ["swine influenza/flu", "SPECIES", 140, 159], ["swine influenza/flu, H1N1", "SPECIES", 140, 165], ["severe acute respiratory syndrome", "PROBLEM", 78, 111], ["influenza", "PROBLEM", 119, 128], ["flu", "PROBLEM", 129, 132], ["H5N1", "PROBLEM", 134, 138], ["swine influenza", "PROBLEM", 140, 155], ["flu", "PROBLEM", 156, 159], ["H1N1", "PROBLEM", 161, 165], ["pandemics", "PROBLEM", 171, 180], ["severe", "OBSERVATION_MODIFIER", 78, 84], ["acute", "OBSERVATION_MODIFIER", 85, 90], ["respiratory syndrome", "OBSERVATION", 91, 111]]], ["In addition, references were gleaned from an expert panel of the Behaviour and Communications sub-group of the UK Scientific Pandemic Influenza Advisory Group.", [["Influenza", "DISEASE", 134, 143], ["an expert panel", "TEST", 42, 57]]]], "PMC7126374": [["IntroductionNeonatal calf diarrhea poses a marked threat to animal welfare and causes significant economic losses due to high mortality, higher medical costs, and low weight gain (Waltner-Toews et al., 1986; Warnick et al., 1995; Mohd Nor et al., 2012).", [["calf diarrhea", "DISEASE", 21, 34], ["weight gain", "DISEASE", 167, 178], ["calf", "ORGANISM", 21, 25], ["calf", "SPECIES", 21, 25], ["Neonatal calf diarrhea", "PROBLEM", 12, 34], ["significant economic losses", "PROBLEM", 86, 113], ["high mortality", "PROBLEM", 121, 135], ["low weight gain", "PROBLEM", 163, 178], ["calf", "ANATOMY", 21, 25], ["diarrhea", "OBSERVATION", 26, 34], ["significant", "OBSERVATION_MODIFIER", 86, 97], ["economic losses", "OBSERVATION", 98, 113], ["low weight", "OBSERVATION_MODIFIER", 163, 173]]], ["Infectious and noninfectious causes can lead to severe diarrhea in calves.", [["diarrhea", "DISEASE", 55, 63], ["calves", "ORGANISM", 67, 73], ["calves", "SPECIES", 67, 73], ["Infectious and noninfectious causes", "PROBLEM", 0, 35], ["severe diarrhea in calves", "PROBLEM", 48, 73], ["noninfectious", "OBSERVATION", 15, 28], ["severe", "OBSERVATION_MODIFIER", 48, 54], ["diarrhea", "OBSERVATION", 55, 63], ["calves", "ANATOMY", 67, 73]]], ["In the first 4 wk of life, infections with bovine coronavirus (BCV), bovine rotavirus (BRV), Cryptosporidium parvum, and enterotoxic Escherichia coli in particular can cause inflammatory and functional damage to the intestine (Kaske, 1993; Al Mawly et al., 2015).", [["intestine", "ANATOMY", 216, 225], ["infections", "DISEASE", 27, 37], ["bovine coronavirus (BCV)", "DISEASE", 43, 67], ["bovine rotavirus (BRV)", "DISEASE", 69, 91], ["Cryptosporidium parvum", "DISEASE", 93, 115], ["bovine coronavirus", "ORGANISM", 43, 61], ["BCV", "ORGANISM", 63, 66], ["bovine rotavirus", "ORGANISM", 69, 85], ["BRV", "ORGANISM", 87, 90], ["Cryptosporidium parvum", "ORGANISM", 93, 115], ["enterotoxic Escherichia coli", "ORGANISM", 121, 149], ["intestine", "ORGAN", 216, 225], ["bovine", "SPECIES", 43, 49], ["coronavirus", "SPECIES", 50, 61], ["bovine", "SPECIES", 69, 75], ["rotavirus", "SPECIES", 76, 85], ["Cryptosporidium parvum", "SPECIES", 93, 115], ["Escherichia coli", "SPECIES", 133, 149], ["bovine coronavirus", "SPECIES", 43, 61], ["BCV", "SPECIES", 63, 66], ["bovine", "SPECIES", 69, 75], ["BRV", "SPECIES", 87, 90], ["Cryptosporidium parvum", "SPECIES", 93, 115], ["Escherichia coli", "SPECIES", 133, 149], ["infections", "PROBLEM", 27, 37], ["bovine coronavirus (BCV)", "PROBLEM", 43, 67], ["bovine rotavirus (BRV", "PROBLEM", 69, 90], ["Cryptosporidium parvum", "PROBLEM", 93, 115], ["enterotoxic Escherichia coli", "PROBLEM", 121, 149], ["inflammatory and functional damage to the intestine", "PROBLEM", 174, 225], ["infections", "OBSERVATION", 27, 37], ["bovine coronavirus", "OBSERVATION", 43, 61], ["enterotoxic Escherichia coli", "OBSERVATION", 121, 149], ["inflammatory", "OBSERVATION_MODIFIER", 174, 186], ["functional damage", "OBSERVATION", 191, 208], ["intestine", "ANATOMY", 216, 225]]], ["Insufficient management of the diseased calves can quickly result in a fatal outcome (Meganck et al., 2014).", [["calves", "ORGANISM", 40, 46], ["calves", "SPECIES", 40, 46], ["the diseased calves", "PROBLEM", 27, 46], ["diseased", "OBSERVATION", 31, 39]]], ["A reliable prognostic marker for the progress of diarrhea would enable dairy farmers and veterinarians to monitor critical patients more closely.IntroductionIn several disorders, interleukins and especially IL-6, appear to be such a marker of early inflammation and prognosis (Rincon, 2012).", [["diarrhea", "DISEASE", 49, 57], ["inflammation", "DISEASE", 249, 261], ["patients", "ORGANISM", 123, 131], ["interleukins", "GENE_OR_GENE_PRODUCT", 179, 191], ["IL-6", "GENE_OR_GENE_PRODUCT", 207, 211], ["interleukins", "PROTEIN", 179, 191], ["IL-6", "PROTEIN", 207, 211], ["patients", "SPECIES", 123, 131], ["diarrhea", "PROBLEM", 49, 57], ["IntroductionIn several disorders", "PROBLEM", 145, 177], ["interleukins", "TREATMENT", 179, 191], ["early inflammation", "PROBLEM", 243, 261], ["early", "OBSERVATION_MODIFIER", 243, 248], ["inflammation", "OBSERVATION", 249, 261]]], ["The helical 208-AA glycoprotein IL-6 is produced by several cell types and mainly operates as an inducer of the acute phase response (Droogmans et al., 1992; Barton, 1997).", [["cell", "ANATOMY", 60, 64], ["IL-6", "GENE_OR_GENE_PRODUCT", 32, 36], ["cell", "CELL", 60, 64], ["helical 208-AA glycoprotein IL-6", "PROTEIN", 4, 36], ["AA glycoprotein IL", "TREATMENT", 16, 34], ["several cell", "OBSERVATION_MODIFIER", 52, 64], ["acute", "OBSERVATION_MODIFIER", 112, 117]]], ["Therefore, it is upregulated in the early stage of an inflammatory process and rapidly decreases after 12 to 24 h (Okabe et al., 1996; Volante et al., 2004).", [["an inflammatory process", "PROBLEM", 51, 74], ["upregulated", "OBSERVATION_MODIFIER", 17, 28], ["early stage", "OBSERVATION_MODIFIER", 36, 47], ["inflammatory", "OBSERVATION", 54, 66], ["rapidly", "OBSERVATION_MODIFIER", 79, 86], ["decreases", "OBSERVATION_MODIFIER", 87, 96]]], ["Thus, IL-6 could serve as an early marker for inflammation because serum titers increase before the inflammation becomes clinically apparent.IntroductionSeveral studies in human medicine investigated IL-6 as a prognostic marker related to a specific pathogen.", [["serum", "ANATOMY", 67, 72], ["inflammation", "DISEASE", 46, 58], ["inflammation", "DISEASE", 100, 112], ["IL-6", "GENE_OR_GENE_PRODUCT", 6, 10], ["serum", "ORGANISM_SUBSTANCE", 67, 72], ["human", "ORGANISM", 172, 177], ["IL-6", "GENE_OR_GENE_PRODUCT", 200, 204], ["IL-6", "PROTEIN", 6, 10], ["IL-6", "PROTEIN", 200, 204], ["human", "SPECIES", 172, 177], ["human", "SPECIES", 172, 177], ["IL-6", "TREATMENT", 6, 10], ["inflammation", "PROBLEM", 46, 58], ["serum titers", "TEST", 67, 79], ["the inflammation", "PROBLEM", 96, 112], ["IntroductionSeveral studies", "TEST", 141, 168], ["a specific pathogen", "PROBLEM", 239, 258], ["inflammation", "OBSERVATION", 100, 112]]], ["Children displaying hemolytic uremic syndrome due to an infection with enterohemorrhagic E. coli showed higher levels of IL-6 when the disease became more severe in nature (e.g., anuria, extrarenal manifestation, chronic renal sequelae; Karpman et al., 1995).", [["extrarenal", "ANATOMY", 187, 197], ["renal", "ANATOMY", 221, 226], ["hemolytic uremic syndrome", "DISEASE", 20, 45], ["infection", "DISEASE", 56, 65], ["anuria", "DISEASE", 179, 185], ["chronic renal sequelae", "DISEASE", 213, 235], ["Children", "ORGANISM", 0, 8], ["E. coli", "ORGANISM", 89, 96], ["IL-6", "GENE_OR_GENE_PRODUCT", 121, 125], ["renal", "ORGAN", 221, 226], ["IL-6", "PROTEIN", 121, 125], ["Children", "SPECIES", 0, 8], ["E. coli", "SPECIES", 89, 96], ["E. coli", "SPECIES", 89, 96], ["hemolytic uremic syndrome", "PROBLEM", 20, 45], ["an infection", "PROBLEM", 53, 65], ["enterohemorrhagic E. coli", "PROBLEM", 71, 96], ["IL", "TEST", 121, 123], ["the disease", "PROBLEM", 131, 142], ["anuria", "PROBLEM", 179, 185], ["extrarenal manifestation", "PROBLEM", 187, 211], ["chronic renal sequelae", "PROBLEM", 213, 235], ["hemolytic uremic syndrome", "OBSERVATION", 20, 45], ["infection", "OBSERVATION", 56, 65], ["higher", "OBSERVATION_MODIFIER", 104, 110], ["levels", "OBSERVATION_MODIFIER", 111, 117], ["disease", "OBSERVATION", 135, 142], ["more severe", "OBSERVATION_MODIFIER", 150, 161], ["anuria", "OBSERVATION", 179, 185], ["extrarenal", "ANATOMY", 187, 197], ["chronic", "OBSERVATION_MODIFIER", 213, 220], ["renal", "ANATOMY", 221, 226], ["sequelae", "OBSERVATION", 227, 235]]], ["Likewise, high IL-6 values were present in children suffering from shigellosis when complications arose during illness (de Silva et al., 1993).", [["shigellosis", "DISEASE", 67, 78], ["IL-6", "GENE_OR_GENE_PRODUCT", 15, 19], ["children", "ORGANISM", 43, 51], ["IL", "PROTEIN", 15, 17], ["children", "SPECIES", 43, 51], ["shigellosis", "PROBLEM", 67, 78], ["high", "OBSERVATION_MODIFIER", 10, 14], ["shigellosis", "OBSERVATION", 67, 78]]], ["For humans and pigs, it was shown that serum IL-6 values were elevated in individuals displaying diarrhea due to an infection with rotavirus (Jiang et al., 2003; Azevedo et al., 2006).IntroductionDespite the direct connection of IL-6 to a specific pathogen, IL-6 has also been established as a reliable marker for the clinical outcome of human patients, independent from the type of underlying disease.", [["serum", "ANATOMY", 39, 44], ["diarrhea", "DISEASE", 97, 105], ["infection", "DISEASE", 116, 125], ["rotavirus", "DISEASE", 131, 140], ["humans", "ORGANISM", 4, 10], ["pigs", "ORGANISM", 15, 19], ["serum", "ORGANISM_SUBSTANCE", 39, 44], ["IL-6", "GENE_OR_GENE_PRODUCT", 45, 49], ["IL-6", "GENE_OR_GENE_PRODUCT", 229, 233], ["IL-6", "GENE_OR_GENE_PRODUCT", 258, 262], ["human", "ORGANISM", 338, 343], ["patients", "ORGANISM", 344, 352], ["IL", "PROTEIN", 45, 47], ["IL-6", "PROTEIN", 229, 233], ["IL-6", "PROTEIN", 258, 262], ["humans", "SPECIES", 4, 10], ["pigs", "SPECIES", 15, 19], ["human", "SPECIES", 338, 343], ["patients", "SPECIES", 344, 352], ["humans", "SPECIES", 4, 10], ["pigs", "SPECIES", 15, 19], ["rotavirus", "SPECIES", 131, 140], ["human", "SPECIES", 338, 343], ["pigs", "TREATMENT", 15, 19], ["serum IL", "TEST", 39, 47], ["elevated in individuals", "PROBLEM", 62, 85], ["diarrhea", "PROBLEM", 97, 105], ["an infection", "PROBLEM", 113, 125], ["rotavirus", "PROBLEM", 131, 140], ["underlying disease", "PROBLEM", 383, 401], ["diarrhea", "OBSERVATION", 97, 105], ["infection", "OBSERVATION", 116, 125], ["disease", "OBSERVATION", 394, 401]]], ["Interleukin-6 was prognostic for sepsis and mortality in adult humans suffering from a bacterial infection, regardless of what pathogen was causatively involved (Moscovitz et al., 1994).", [["sepsis", "DISEASE", 33, 39], ["bacterial infection", "DISEASE", 87, 106], ["Interleukin-6", "GENE_OR_GENE_PRODUCT", 0, 13], ["humans", "ORGANISM", 63, 69], ["Interleukin-6", "PROTEIN", 0, 13], ["humans", "SPECIES", 63, 69], ["humans", "SPECIES", 63, 69], ["Interleukin", "TEST", 0, 11], ["sepsis", "PROBLEM", 33, 39], ["a bacterial infection", "PROBLEM", 85, 106], ["sepsis", "OBSERVATION", 33, 39], ["bacterial", "OBSERVATION_MODIFIER", 87, 96], ["infection", "OBSERVATION", 97, 106]]], ["This was confirmed by another study among severely infected humans at an emergency department, where nonsurvivors had higher IL-6 serum concentrations at the initial examination than survivors (Wilhelm et al., 2012).", [["serum", "ANATOMY", 130, 135], ["humans", "ORGANISM", 60, 66], ["IL-6", "GENE_OR_GENE_PRODUCT", 125, 129], ["serum", "ORGANISM_SUBSTANCE", 130, 135], ["IL-6", "PROTEIN", 125, 129], ["humans", "SPECIES", 60, 66], ["humans", "SPECIES", 60, 66], ["another study", "TEST", 22, 35], ["severely infected humans", "PROBLEM", 42, 66], ["serum concentrations", "TEST", 130, 150], ["the initial examination", "TEST", 154, 177], ["severely", "OBSERVATION_MODIFIER", 42, 50], ["infected", "OBSERVATION", 51, 59]]], ["In hospitalized human neonates, an increased IL-6 serum level was proven 100% sensitive in detecting individuals who developed a clinical sepsis at later stages of their disease (Buck et al., 1994).", [["serum", "ANATOMY", 50, 55], ["sepsis", "DISEASE", 138, 144], ["human", "ORGANISM", 16, 21], ["neonates", "ORGANISM", 22, 30], ["IL-6", "GENE_OR_GENE_PRODUCT", 45, 49], ["serum", "ORGANISM_SUBSTANCE", 50, 55], ["IL", "PROTEIN", 45, 47], ["human", "SPECIES", 16, 21], ["human", "SPECIES", 16, 21], ["an increased IL", "TEST", 32, 47], ["serum level", "TEST", 50, 61], ["a clinical sepsis", "PROBLEM", 127, 144], ["their disease", "PROBLEM", 164, 177], ["sepsis", "OBSERVATION", 138, 144]]], ["In veterinary medicine, IL-6 was also a reliable parameter to monitor dogs in intensive care units (Sch\u00fcttler and Neumann, 2015).", [["IL-6", "GENE_OR_GENE_PRODUCT", 24, 28], ["dogs", "ORGANISM", 70, 74], ["IL-6", "PROTEIN", 24, 28], ["dogs", "SPECIES", 70, 74]]], ["The mean IL-6 concentration of these dogs was significantly higher in the nonsurvivor group compared with survivors.IntroductionOnly a small number of studies covered the diagnostic and prognostic potential of IL-6 in cattle.", [["IL-6", "GENE_OR_GENE_PRODUCT", 9, 13], ["dogs", "ORGANISM", 37, 41], ["nonsurvivor", "CANCER", 74, 85], ["IL-6", "GENE_OR_GENE_PRODUCT", 210, 214], ["cattle", "ORGANISM", 218, 224], ["IL", "PROTEIN", 9, 11], ["IL-6", "PROTEIN", 210, 214], ["dogs", "SPECIES", 37, 41], ["cattle", "SPECIES", 218, 224], ["cattle", "SPECIES", 218, 224], ["The mean IL", "TEST", 0, 11], ["IL", "TREATMENT", 210, 212], ["significantly", "OBSERVATION_MODIFIER", 46, 59], ["higher", "OBSERVATION_MODIFIER", 60, 66], ["small", "OBSERVATION_MODIFIER", 135, 140]]], ["For instance, IL-6 values in cows suffering from subclinical mastitis were elevated in the early stages of the disease, even before the number of somatic cells increased (Sakemi et al., 2011).", [["somatic cells", "ANATOMY", 146, 159], ["mastitis", "DISEASE", 61, 69], ["IL-6", "GENE_OR_GENE_PRODUCT", 14, 18], ["cows", "ORGANISM", 29, 33], ["somatic cells", "CELL", 146, 159], ["IL", "PROTEIN", 14, 16], ["somatic cells", "CELL_TYPE", 146, 159], ["cows", "SPECIES", 29, 33], ["IL", "TREATMENT", 14, 16], ["subclinical mastitis", "PROBLEM", 49, 69], ["elevated", "PROBLEM", 75, 83], ["the disease", "PROBLEM", 107, 118], ["somatic cells", "PROBLEM", 146, 159], ["subclinical", "OBSERVATION_MODIFIER", 49, 60], ["mastitis", "OBSERVATION", 61, 69], ["elevated", "OBSERVATION_MODIFIER", 75, 83], ["early stages", "OBSERVATION_MODIFIER", 91, 103], ["disease", "OBSERVATION", 111, 118], ["somatic cells", "OBSERVATION", 146, 159], ["increased", "OBSERVATION_MODIFIER", 160, 169]]], ["Other investigators focused on the IL-6 serum values in pregnant cows prepartum (Ishikawa et al., 2004).", [["serum", "ANATOMY", 40, 45], ["IL-6", "GENE_OR_GENE_PRODUCT", 35, 39], ["serum", "ORGANISM_SUBSTANCE", 40, 45], ["cows", "ORGANISM", 65, 69], ["IL", "PROTEIN", 35, 37], ["cows", "SPECIES", 65, 69], ["the IL", "TEST", 31, 37], ["serum values", "TEST", 40, 52]]], ["They found high IL-6 serum concentrations in those cows that developed endometritis postpartum.", [["serum", "ANATOMY", 21, 26], ["endometritis", "DISEASE", 71, 83], ["IL-6", "GENE_OR_GENE_PRODUCT", 16, 20], ["serum", "ORGANISM_SUBSTANCE", 21, 26], ["cows", "ORGANISM", 51, 55], ["IL-6", "PROTEIN", 16, 20], ["cows", "SPECIES", 51, 55], ["high IL-6 serum concentrations", "PROBLEM", 11, 41], ["endometritis postpartum", "PROBLEM", 71, 94], ["high", "OBSERVATION_MODIFIER", 11, 15], ["IL", "OBSERVATION_MODIFIER", 16, 18], ["endometritis", "OBSERVATION", 71, 83]]], ["In the case of coliform mastitis, serum IL-6 was shown to be significantly higher in nonsurvivors when sampled at d 0 to 9 of the onset of clinical symptoms (Nakajima et al., 1997).IntroductionAs investigations of serum IL-6 concentrations in the case of neonatal calf diarrhea are lacking and the improvement of therapy would benefit from a reliable prognostic marker, this study investigated the prognostic quality of IL-6 for the progress of clinical symptoms in neonatal calf diarrhea.", [["serum", "ANATOMY", 34, 39], ["serum", "ANATOMY", 214, 219], ["coliform mastitis", "DISEASE", 15, 32], ["diarrhea", "DISEASE", 269, 277], ["diarrhea", "DISEASE", 480, 488], ["serum", "ORGANISM_SUBSTANCE", 34, 39], ["IL-6", "GENE_OR_GENE_PRODUCT", 40, 44], ["serum", "ORGANISM_SUBSTANCE", 214, 219], ["IL-6", "GENE_OR_GENE_PRODUCT", 220, 224], ["calf", "ORGANISM", 264, 268], ["IL-6", "GENE_OR_GENE_PRODUCT", 420, 424], ["calf", "ORGANISM_SUBDIVISION", 475, 479], ["serum IL-6", "PROTEIN", 34, 44], ["serum IL-6", "PROTEIN", 214, 224], ["IL-6", "PROTEIN", 420, 424], ["calf", "SPECIES", 264, 268], ["calf", "SPECIES", 475, 479], ["calf", "SPECIES", 264, 268], ["coliform mastitis", "PROBLEM", 15, 32], ["serum IL", "TEST", 34, 42], ["clinical symptoms", "PROBLEM", 139, 156], ["IntroductionAs investigations", "TEST", 181, 210], ["serum IL", "TREATMENT", 214, 222], ["neonatal calf diarrhea", "PROBLEM", 255, 277], ["therapy", "TREATMENT", 313, 320], ["this study", "TEST", 370, 380], ["clinical symptoms", "PROBLEM", 445, 462], ["neonatal calf diarrhea", "PROBLEM", 466, 488], ["coliform mastitis", "OBSERVATION", 15, 32], ["calf", "ANATOMY", 264, 268], ["diarrhea", "OBSERVATION", 269, 277], ["calf", "ANATOMY", 475, 479], ["diarrhea", "OBSERVATION", 480, 488]]], ["Therefore, a controlled cohort study over 10 d was carried out on 20 scouring calves.", [["calves", "ORGANISM", 78, 84], ["calves", "SPECIES", 78, 84], ["a controlled cohort study", "TEST", 11, 36]]], ["Calves were monitored for clinical changes as well as changes in body homeostasis (e.g., hematology, clinical chemistry) related to diarrhea.", [["body", "ANATOMY", 65, 69], ["diarrhea", "DISEASE", 132, 140], ["Calves", "ORGANISM", 0, 6], ["body", "ORGANISM_SUBDIVISION", 65, 69], ["Calves", "SPECIES", 0, 6], ["clinical changes", "PROBLEM", 26, 42], ["changes in body homeostasis", "PROBLEM", 54, 81], ["clinical chemistry", "TEST", 101, 119], ["diarrhea", "PROBLEM", 132, 140], ["diarrhea", "OBSERVATION", 132, 140]]], ["For the determination of the prognostic potential, scouring calves were divided into 2 groups, regarding their classification at d 10 as recovered or nonrecovered.", [["calves", "ORGANISM", 60, 66], ["calves", "SPECIES", 60, 66], ["scouring calves", "TREATMENT", 51, 66]]], ["A receiver operating characteristic (ROC) analysis with calculation of the area under the curve (AUC) was carried out to prove the accuracy of IL-6 determination in serum for the estimation of the prognosis.Animals ::: Materials and MethodsCalves were housed on a commercial dairy farm near Goettingen, Lower Saxony, Germany.", [["serum", "ANATOMY", 165, 170], ["IL-6", "GENE_OR_GENE_PRODUCT", 143, 147], ["serum", "ORGANISM_SUBSTANCE", 165, 170], ["IL", "PROTEIN", 143, 145], ["ROC) analysis", "TEST", 37, 50], ["the curve (AUC", "TEST", 86, 100], ["IL", "TEST", 143, 145], ["MethodsCalves", "TREATMENT", 233, 246]]], ["The farm is organized in terms of 3 locations.", [["farm", "OBSERVATION", 4, 8], ["organized", "OBSERVATION", 12, 21]]], ["One location is for the 500 milk yielding and late pregnant cows, one for the calves and the last one for the offspring, older than 8 wk.", [["cows", "DEVELOPING_ANATOMICAL_STRUCTURE", 60, 64], ["calves", "ORGANISM", 78, 84], ["cows", "SPECIES", 60, 64], ["calves", "SPECIES", 78, 84]]], ["Biotechnical measures directly after birth included disinfection of the umbilicus and application of earmarks.", [["umbilicus", "ANATOMY", 72, 81], ["Biotechnical measures", "TREATMENT", 0, 21], ["disinfection of the umbilicus", "TREATMENT", 52, 81], ["application of earmarks", "TREATMENT", 86, 109], ["umbilicus", "ANATOMY", 72, 81]]], ["Four liters of colostrum was fed to the calves via tube feeder within the first hour of life.", [["colostrum", "ANATOMY", 15, 24], ["tube feeder", "ANATOMY", 51, 62], ["colostrum", "ORGANISM", 15, 24], ["calves", "ORGANISM", 40, 46], ["tube feeder", "MULTI-TISSUE_STRUCTURE", 51, 62], ["calves", "SPECIES", 40, 46], ["colostrum", "TREATMENT", 15, 24], ["tube feeder", "TREATMENT", 51, 62], ["tube feeder", "OBSERVATION", 51, 62]]], ["The colostrum came from the farm\u2019s colostrum bank and was controlled for sufficient quality with a colostrometer.", [["colostrum", "ANATOMY", 4, 13], ["colostrum", "ANATOMY", 35, 44], ["colostrum", "ORGANISM", 4, 13], ["colostrum", "ORGANISM", 35, 44], ["colostrum", "SPECIES", 35, 44], ["a colostrometer", "TREATMENT", 97, 112], ["colostrum", "ANATOMY", 4, 13]]], ["Within 24 h after birth, newborn calves were brought to a special calf location, which was geographically separated from the barn for the milk-yielding cows.", [["calves", "ORGANISM", 33, 39], ["calf", "ORGANISM_SUBDIVISION", 66, 70], ["milk", "ORGANISM_SUBDIVISION", 138, 142], ["cows", "ORGANISM", 152, 156], ["calves", "SPECIES", 33, 39], ["calf", "SPECIES", 66, 70], ["calves", "SPECIES", 33, 39]]], ["The newborn calves were sheltered outdoors in igloos individually and were fed pasteurized waste milk ad libitum in the first week after birth.", [["calves", "ORGANISM", 12, 18], ["milk", "ORGANISM_SUBSTANCE", 97, 101], ["calves", "SPECIES", 12, 18]]], ["Then, a commercial milk replacer (50% skim milk) displaced the milk.", [["milk", "ANATOMY", 43, 47], ["milk", "ANATOMY", 63, 67], ["milk", "ORGANISM", 19, 23], ["milk", "ORGANISM_SUBSTANCE", 43, 47], ["milk", "ORGANISM_SUBSTANCE", 63, 67], ["a commercial milk replacer", "TREATMENT", 6, 32]]], ["From wk 3 on, starter grain was offered and calves had free access to water.", [["calves", "ORGANISM", 44, 50], ["calves", "SPECIES", 44, 50], ["starter grain", "TREATMENT", 14, 27]]], ["Calves were weaned 4 wk after birth.Animals ::: Materials and MethodsSampling was conducted during January to July 2014.", [["Calves", "ORGANISM", 0, 6], ["Calves", "SPECIES", 0, 6], ["Calves", "TREATMENT", 0, 6], ["MethodsSampling", "TREATMENT", 62, 77]]], ["All Holstein Friesian calves displaying diarrhea were included in the study.", [["diarrhea", "DISEASE", 40, 48], ["calves", "ORGANISM", 22, 28], ["calves", "SPECIES", 22, 28], ["Holstein Friesian calves", "SPECIES", 4, 28], ["diarrhea", "PROBLEM", 40, 48], ["the study", "TEST", 66, 75]]], ["Calves were excluded when showing any other diseases, such as respiratory tract infections or infections of the umbilicus.", [["respiratory tract", "ANATOMY", 62, 79], ["umbilicus", "ANATOMY", 112, 121], ["respiratory tract infections", "DISEASE", 62, 90], ["infections", "DISEASE", 94, 104], ["Calves", "ORGANISM", 0, 6], ["tract", "ORGANISM_SUBDIVISION", 74, 79], ["umbilicus", "ORGAN", 112, 121], ["Calves", "SPECIES", 0, 6], ["any other diseases", "PROBLEM", 34, 52], ["respiratory tract infections", "PROBLEM", 62, 90], ["infections of the umbilicus", "PROBLEM", 94, 121], ["diseases", "OBSERVATION", 44, 52], ["respiratory tract", "ANATOMY", 62, 79], ["infections", "OBSERVATION", 80, 90], ["infections", "OBSERVATION", 94, 104], ["umbilicus", "ANATOMY", 112, 121]]], ["Finally, the group of scouring calves consisted of 20 animals (age 12.9 \u00b1 2.0 d; 89% female).", [["calves", "ORGANISM", 31, 37], ["calves", "SPECIES", 31, 37], ["age", "TEST", 63, 66]]], ["Scouring calves were sampled once at the first day of evident symptoms and again 7 to 10 d later.", [["calves", "ORGANISM", 9, 15], ["calves", "SPECIES", 9, 15], ["Scouring calves", "PROBLEM", 0, 15], ["evident symptoms", "PROBLEM", 54, 70]]], ["At these time points, all animals passed a complete clinical examination with information on heart rate, breathing rate, temperature, dehydration, and general condition.", [["heart", "ANATOMY", 93, 98], ["dehydration", "DISEASE", 134, 145], ["heart", "ORGAN", 93, 98], ["a complete clinical examination", "TEST", 41, 72], ["heart rate", "TEST", 93, 103], ["breathing rate", "TEST", 105, 119], ["dehydration", "PROBLEM", 134, 145]]], ["Diarrhea scoring was undertaken using an already established scoring system, evaluating the fecal consistency on a 4-point scale from normal (0) to totally liquid (4) (Hasoksuz et al., 2002).", [["Diarrhea", "DISEASE", 0, 8], ["fecal", "ORGANISM_SUBDIVISION", 92, 97], ["Diarrhea scoring", "PROBLEM", 0, 16], ["fecal", "ANATOMY", 92, 97]]], ["All calves received an oral electrolyte solution from the beginning to the end of diarrhea and were initially treated with 0.5 mg/mL of meloxicam.", [["oral", "ANATOMY", 23, 27], ["diarrhea", "DISEASE", 82, 90], ["meloxicam", "CHEMICAL", 136, 145], ["meloxicam", "CHEMICAL", 136, 145], ["calves", "ORGANISM", 4, 10], ["oral", "ORGANISM_SUBDIVISION", 23, 27], ["meloxicam", "SIMPLE_CHEMICAL", 136, 145], ["calves", "SPECIES", 4, 10], ["an oral electrolyte solution", "TREATMENT", 20, 48], ["diarrhea", "PROBLEM", 82, 90], ["meloxicam", "TREATMENT", 136, 145], ["calves", "OBSERVATION", 4, 10], ["diarrhea", "OBSERVATION", 82, 90]]], ["Throughout the study period, calves were monitored twice per day by the animal caretakers.Animals ::: Materials and MethodsAfter the sampling period, the calves were further divided into 2 subgroups: one subgroup (n = 11; age 15.0 \u00b1 2.8 d) included calves that clinically recovered 7 to 10 d after the first symptoms appeared and the other subgroup (n = 9; age 10.2 \u00b1 1.7 d) included calves evaluated as nonrecovered, because they were still showing diarrhea, still being medically treated, or showing other abnormalities in the clinical examination (e.g., reduced general condition).", [["diarrhea", "DISEASE", 450, 458], ["calves", "ORGANISM", 29, 35], ["calves", "ORGANISM", 154, 160], ["calves", "ORGANISM", 249, 255], ["calves", "ORGANISM", 384, 390], ["calves", "SPECIES", 29, 35], ["calves", "SPECIES", 154, 160], ["calves", "SPECIES", 249, 255], ["calves", "SPECIES", 384, 390], ["calves", "SPECIES", 29, 35], ["age", "TEST", 222, 225], ["the first symptoms", "PROBLEM", 298, 316], ["age", "TEST", 357, 360], ["diarrhea", "PROBLEM", 450, 458], ["other abnormalities", "PROBLEM", 502, 521], ["the clinical examination", "TEST", 525, 549], ["reduced general condition", "PROBLEM", 557, 582], ["calves", "ANATOMY", 154, 160]]], ["All clinical examinations were performed by the same veterinarian to avoid an examiner bias.Samples ::: Materials and MethodsAll samples were acquired with the owner\u2019s consent and the procedures were carried out in accordance with the German Protection of Animals Act under the supervision of the Commissioner for Animal Welfare, Faculty of Agriculture, University of Goettingen.", [["samples", "ANATOMY", 129, 136], ["All clinical examinations", "TEST", 0, 25], ["an examiner bias", "TEST", 75, 91], ["the procedures", "TEST", 180, 194]]], ["For the purpose of laboratory analysis, 5 mL of EDTA-treated blood and 10 mL of whole blood for serum harvest were collected by jugular venipuncture.", [["blood", "ANATOMY", 61, 66], ["whole blood", "ANATOMY", 80, 91], ["serum", "ANATOMY", 96, 101], ["jugular", "ANATOMY", 128, 135], ["EDTA", "CHEMICAL", 48, 52], ["EDTA", "CHEMICAL", 48, 52], ["EDTA", "SIMPLE_CHEMICAL", 48, 52], ["blood", "ORGANISM_SUBSTANCE", 61, 66], ["blood", "ORGANISM_SUBSTANCE", 86, 91], ["serum", "ORGANISM_SUBSTANCE", 96, 101], ["jugular venipuncture", "MULTI-TISSUE_STRUCTURE", 128, 148], ["laboratory analysis", "TEST", 19, 38], ["EDTA", "TREATMENT", 48, 52], ["blood", "TREATMENT", 61, 66], ["whole blood for serum harvest", "TREATMENT", 80, 109], ["jugular venipuncture", "TEST", 128, 148], ["jugular", "ANATOMY", 128, 135]]], ["Stool samples were collected from the rectum following digital stimulation.", [["Stool samples", "ANATOMY", 0, 13], ["rectum", "ANATOMY", 38, 44], ["Stool samples", "ORGANISM_SUBSTANCE", 0, 13], ["rectum", "ORGAN", 38, 44], ["Stool samples", "TEST", 0, 13], ["digital stimulation", "TREATMENT", 55, 74], ["rectum", "ANATOMY", 38, 44]]], ["All samples were cooled immediately after collection and brought to the laboratory within 6 h.", [["samples", "ANATOMY", 4, 11]]], ["Blood samples and feces were processed directly.", [["Blood samples", "ANATOMY", 0, 13], ["feces", "ANATOMY", 18, 23], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["feces", "ORGANISM_SUBSTANCE", 18, 23], ["Blood samples", "TEST", 0, 13]]], ["Serum was stored at \u221220\u00b0C until further use in the IL-6 ELISA.Hematology and Clinical Chemistry ::: Materials and MethodsThe complete blood count and the serum clinical chemistry were analyzed in all calves to ensure the healthiness of the control group and to determine pathological changes due to diarrhea.", [["Serum", "ANATOMY", 0, 5], ["blood", "ANATOMY", 134, 139], ["serum", "ANATOMY", 154, 159], ["diarrhea", "DISEASE", 299, 307], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["C", "GENE_OR_GENE_PRODUCT", 24, 25], ["IL-6", "GENE_OR_GENE_PRODUCT", 51, 55], ["blood", "ORGANISM_SUBSTANCE", 134, 139], ["serum", "ORGANISM_SUBSTANCE", 154, 159], ["calves", "ORGANISM", 200, 206], ["IL", "PROTEIN", 51, 53], ["calves", "SPECIES", 200, 206], ["Serum", "TEST", 0, 5], ["Methods", "TREATMENT", 114, 121], ["The complete blood count", "TEST", 121, 145], ["the serum clinical chemistry", "TEST", 150, 178], ["pathological changes", "PROBLEM", 271, 291], ["diarrhea", "PROBLEM", 299, 307]]], ["The EDTA blood samples were used for a complete blood count using a CellDyn 3500 Analyzer (Abbott GmbH & Co. KG, Wiesbaden, Germany).", [["blood samples", "ANATOMY", 9, 22], ["blood", "ANATOMY", 48, 53], ["EDTA", "CHEMICAL", 4, 8], ["EDTA blood samples", "ORGANISM_SUBSTANCE", 4, 22], ["blood", "ORGANISM_SUBSTANCE", 48, 53], ["The EDTA blood samples", "TEST", 0, 22], ["a complete blood count", "TEST", 37, 59]]], ["Because differentiation of bovine lymphocytes and monocytes can be difficult, the results of the CellDyn 3500 Analyzer were verified by a manual blood count.", [["lymphocytes", "ANATOMY", 34, 45], ["monocytes", "ANATOMY", 50, 59], ["blood", "ANATOMY", 145, 150], ["bovine", "ORGANISM", 27, 33], ["lymphocytes", "CELL", 34, 45], ["monocytes", "CELL", 50, 59], ["blood", "ORGANISM_SUBSTANCE", 145, 150], ["bovine lymphocytes", "CELL_TYPE", 27, 45], ["monocytes", "CELL_TYPE", 50, 59], ["bovine", "SPECIES", 27, 33], ["bovine", "SPECIES", 27, 33], ["bovine lymphocytes and monocytes", "PROBLEM", 27, 59], ["the CellDyn 3500 Analyzer", "TEST", 93, 118], ["a manual blood count", "TEST", 136, 156], ["bovine lymphocytes", "OBSERVATION", 27, 45]]], ["Serum samples were aliquoted to 500-\u03bcL aliquots and stored at \u221220\u00b0C. One aliquot was used directly for the clinical chemistry analysis with the Konelab 20i (Thermo Fisher Scientific Inc., Dreieich, Germany).Stool Analysis ::: Materials and MethodsStool samples were analyzed by a commercial lateral immunochromatography test (Bio-X Diagnostics, Rochefort, Belgium) to identify the causative pathogen for diarrhea, such as BCV, BRV, Cryptosporidium parvum, and E. coli F5 (K99).IL-6 ELISA ::: Materials and MethodsThe IL-6 serum concentrations were determined using the commercial High Sensitive ELISA Kit for bovine IL-6 (USCN Life Science, Wuhan, China).", [["Serum samples", "ANATOMY", 0, 13], ["Stool samples", "ANATOMY", 247, 260], ["serum", "ANATOMY", 522, 527], ["diarrhea", "DISEASE", 404, 412], ["Cryptosporidium parvum", "DISEASE", 432, 454], ["Serum samples", "ORGANISM_SUBSTANCE", 0, 13], ["Stool samples", "CANCER", 247, 260], ["BCV", "ORGANISM", 422, 425], ["Cryptosporidium parvum", "ORGANISM", 432, 454], ["E. coli F5", "ORGANISM", 460, 470], ["IL-6", "GENE_OR_GENE_PRODUCT", 477, 481], ["IL-6", "GENE_OR_GENE_PRODUCT", 517, 521], ["serum", "ORGANISM_SUBSTANCE", 522, 527], ["bovine", "ORGANISM", 609, 615], ["IL-6", "GENE_OR_GENE_PRODUCT", 616, 620], ["IL", "PROTEIN", 477, 479], ["IL", "PROTEIN", 517, 519], ["Cryptosporidium parvum", "SPECIES", 432, 454], ["E. coli", "SPECIES", 460, 467], ["bovine", "SPECIES", 609, 615], ["BCV", "SPECIES", 422, 425], ["BRV", "SPECIES", 427, 430], ["Cryptosporidium parvum", "SPECIES", 432, 454], ["E. coli", "SPECIES", 460, 467], ["Serum samples", "TEST", 0, 13], ["the clinical chemistry analysis", "TEST", 103, 134], ["Stool Analysis", "TEST", 207, 221], ["MethodsStool samples", "TEST", 240, 260], ["a commercial lateral immunochromatography test", "TEST", 278, 324], ["the causative pathogen", "PROBLEM", 377, 399], ["diarrhea", "PROBLEM", 404, 412], ["BCV", "TEST", 422, 425], ["BRV", "PROBLEM", 427, 430], ["Cryptosporidium parvum", "PROBLEM", 432, 454], ["The IL", "TREATMENT", 513, 519], ["serum concentrations", "TEST", 522, 542], ["bovine IL", "TREATMENT", 609, 618]]], ["First, standard and samples were added in duplicate to the pre-coated plate and incubated for 2 h at 37\u00b0C. Subsequently, all liquid was removed and Detection Reagent A (biotin-conjugated antibody specific to IL-6) was added for 1 h at 37\u00b0C. The plate was washed 3 times with wash solution (1\u00d7) and Detection Reagent B (avidin-conjugated horseradish peroxidase) was added and incubated at 37\u00b0C for 30 min.", [["samples", "ANATOMY", 20, 27], ["biotin", "CHEMICAL", 169, 175], ["biotin", "CHEMICAL", 169, 175], ["biotin", "SIMPLE_CHEMICAL", 169, 175], ["IL-6", "GENE_OR_GENE_PRODUCT", 208, 212], ["avidin", "GENE_OR_GENE_PRODUCT", 319, 325], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 337, 359], ["biotin-conjugated antibody specific to IL-6", "PROTEIN", 169, 212], ["avidin-conjugated horseradish peroxidase", "PROTEIN", 319, 359], ["horseradish", "SPECIES", 337, 348], ["all liquid", "TREATMENT", 121, 131], ["Detection Reagent A (biotin-conjugated antibody specific to IL", "TREATMENT", 148, 210], ["The plate", "TREATMENT", 241, 250], ["wash solution", "TREATMENT", 275, 288], ["Detection Reagent B (avidin-conjugated horseradish peroxidase", "TREATMENT", 298, 359], ["plate", "OBSERVATION_MODIFIER", 245, 250]]], ["The plate was washed 5 times with wash solution before substrate solution (TMB substrate) was added for 20 min at 37\u00b0C. Color development was stopped with stop solution (H2SO4) and optical densities were measured in all wells at 450 nm in the Sunrise microplate reader (Tecan, Maennedorf, Switzerland).", [["H2SO4", "CHEMICAL", 170, 175], ["H2SO4", "CHEMICAL", 170, 175], ["The plate", "TREATMENT", 0, 9], ["wash solution", "TREATMENT", 34, 47], ["substrate solution (TMB substrate", "TREATMENT", 55, 88], ["stop solution (H2SO4", "TREATMENT", 155, 175], ["optical densities", "TEST", 181, 198], ["plate", "OBSERVATION_MODIFIER", 4, 9]]], ["For data analysis, average optical densities were calculated and blank reduction was performed.", [["data analysis", "TEST", 4, 17], ["average optical densities", "PROBLEM", 19, 44], ["blank reduction", "TREATMENT", 65, 80]]], ["Standard curves were generated and sample concentrations were determined using the CurveExpert 1.4 software (CurveExpert, Daniel G. Hyams, Hixson, TN; https://www.curveexpert.net/).", [["sample", "ANATOMY", 35, 41], ["sample concentrations", "TEST", 35, 56]]], ["A detection limit of 1.56 pg of IL-6/mL was reported by the kit manufacturer.", [["IL-6", "GENE_OR_GENE_PRODUCT", 32, 36], ["IL", "PROTEIN", 32, 34], ["IL", "TREATMENT", 32, 34]]], ["The coefficient of variation for the intra-assay test precision was <7%.Statistical Analysis ::: Materials and MethodsResults were shown as mean values \u00b1 2 standard errors.", [["the intra-assay test precision", "TEST", 33, 63], ["MethodsResults", "TEST", 111, 125], ["mean values", "TEST", 140, 151]]], ["Data from the clinical examination, the hematology and the IL-6 ELISA were tested for normal distribution.Statistical Analysis ::: Materials and MethodsData of recovering and nonrecovering animals were compared at both sampling time points.", [["IL-6", "GENE_OR_GENE_PRODUCT", 59, 63], ["animals", "ORGANISM", 189, 196], ["IL", "PROTEIN", 59, 61], ["the clinical examination", "TEST", 10, 34], ["Statistical Analysis", "TEST", 106, 126]]], ["Regarding the IL-6 values in these groups, further statistical tests were performed.", [["IL-6", "GENE_OR_GENE_PRODUCT", 14, 18], ["IL-6", "PROTEIN", 14, 18], ["further statistical tests", "TEST", 43, 68]]], ["To investigate a change in the odds of IL-6 concentrations at the onset of diarrhea (first sampling time point), to predict a prolonged course of diarrhea (nonrecovering), a univariate logistic regression analysis was performed.", [["diarrhea", "DISEASE", 75, 83], ["diarrhea", "DISEASE", 146, 154], ["IL-6", "GENE_OR_GENE_PRODUCT", 39, 43], ["IL", "PROTEIN", 39, 41], ["IL-6 concentrations", "TREATMENT", 39, 58], ["diarrhea", "PROBLEM", 75, 83], ["diarrhea", "PROBLEM", 146, 154], ["a univariate logistic regression analysis", "TEST", 172, 213], ["change", "OBSERVATION_MODIFIER", 17, 23], ["diarrhea", "OBSERVATION", 75, 83]]], ["The goodness-of-fit of the model was assessed by performing an Omnibus test of model coefficients and a Hosmer-Lemeshow test, as well as calculating the Nagelkerke R2.", [["Nagelkerke R2", "PROTEIN", 153, 166], ["an Omnibus test", "TEST", 60, 75], ["a Hosmer-Lemeshow test", "TEST", 102, 124]]], ["The influence of the variable IL-6 was estimated using the Wald statistic.Statistical Analysis ::: Materials and MethodsAs the age of calves is described to be a risk factor to develop diarrhea, this variable is analyzed in the same way regarding the age of calves at the first sampling time point (Pare et al., 1993; Gulliksen et al., 2009).", [["diarrhea", "DISEASE", 185, 193], ["IL-6", "GENE_OR_GENE_PRODUCT", 30, 34], ["calves", "ORGANISM", 134, 140], ["calves", "ORGANISM", 258, 264], ["IL-6", "PROTEIN", 30, 34], ["calves", "SPECIES", 134, 140], ["calves", "SPECIES", 258, 264], ["the variable IL", "TREATMENT", 17, 32], ["Methods", "TREATMENT", 113, 120], ["a risk factor", "PROBLEM", 160, 173], ["diarrhea", "PROBLEM", 185, 193], ["diarrhea", "OBSERVATION", 185, 193]]], ["Subsequently, a multivariate logistic regression analysis was performed, with both variables (IL-6, age) and a potential interaction effect between these variables.", [["IL-6", "GENE_OR_GENE_PRODUCT", 94, 98], ["IL", "PROTEIN", 94, 96], ["a multivariate logistic regression analysis", "TEST", 14, 57], ["interaction effect", "OBSERVATION", 121, 139]]], ["The goodness-of-fit for this analysis was conducted as for the univariate analysis.", [["this analysis", "TEST", 24, 37], ["the univariate analysis", "TEST", 59, 82]]], ["Using forward model selection, a P-value of <0.05 was chosen as the cut-off for the respective variable to stay in the model.", [["forward model selection", "TREATMENT", 6, 29], ["a P-value", "TEST", 31, 40]]], ["To further evaluate the prognostic quality of IL-6, a ROC curve was generated with the IL-6 values of the recovering and the nonrecovering animals at the first sampling time point.", [["IL-6", "GENE_OR_GENE_PRODUCT", 46, 50], ["IL-6", "GENE_OR_GENE_PRODUCT", 87, 91], ["IL-6", "PROTEIN", 46, 50], ["IL", "PROTEIN", 87, 89], ["a ROC curve", "TEST", 52, 63]]], ["The sensitivity was defined as the percentage of samples which were classified correctly as nonrecovering.", [["samples", "ANATOMY", 49, 56], ["The sensitivity", "TEST", 0, 15]]], ["The specificity was defined as the percentage of samples which were classified correctly as recovering.", [["samples", "ANATOMY", 49, 56]]], ["The AUC was calculated by trapezoidal summation, and its statistical significance was estimated.", [["The AUC", "TEST", 0, 7], ["trapezoidal summation", "TEST", 26, 47], ["trapezoidal summation", "OBSERVATION", 26, 47]]], ["All analyses were carried out using STATISTICA 12 software [StatSoft (Europe) GmbH, Hamburg, Germany] and IBM SPSS Statistics 20.0 (IBM Corp., 2011, IBM SPSS Statistics for Windows, Armonk, NY).", [["All analyses", "TEST", 0, 12], ["IBM SPSS Statistics", "TEST", 106, 125], ["IBM Corp.", "TEST", 132, 141]]], ["The statistical significance level was set at P< 0.05.Clinical, Biochemical, and Hematological Findings ::: ResultsThe results of the clinical and laboratory examination are shown inTable 1.", [["The statistical significance level", "TEST", 0, 34], ["laboratory examination", "TEST", 147, 169]]], ["Most of the recovering calves showed mild symptoms of diarrhea (score 2, n = 9), and none of them displayed diarrhea at the second sampling time point.", [["diarrhea", "DISEASE", 54, 62], ["diarrhea", "DISEASE", 108, 116], ["calves", "ORGANISM", 23, 29], ["calves", "SPECIES", 23, 29], ["mild symptoms", "PROBLEM", 37, 50], ["diarrhea", "PROBLEM", 54, 62], ["score", "TEST", 64, 69], ["diarrhea", "PROBLEM", 108, 116], ["mild", "OBSERVATION_MODIFIER", 37, 41], ["diarrhea", "OBSERVATION", 54, 62], ["diarrhea", "OBSERVATION", 108, 116]]], ["Severe diarrhea was only seen in the nonrecovering group (score 4, n = 2), in which 5 calves were still displaying diarrhea 7 to 10 d after the onset of symptoms.", [["diarrhea", "DISEASE", 7, 15], ["diarrhea", "DISEASE", 115, 123], ["calves", "ORGANISM", 86, 92], ["calves", "SPECIES", 86, 92], ["Severe diarrhea", "PROBLEM", 0, 15], ["diarrhea", "PROBLEM", 115, 123], ["symptoms", "PROBLEM", 153, 161], ["diarrhea", "OBSERVATION", 7, 15]]], ["The clinical chemistry and the hematology revealed no significant differences between recovering and nonrecovering animals at the first or second sampling time point (data not shown).", [["The clinical chemistry", "TEST", 0, 22], ["the hematology", "TEST", 27, 41], ["no", "UNCERTAINTY", 51, 53], ["significant", "OBSERVATION_MODIFIER", 54, 65], ["differences", "OBSERVATION", 66, 77]]], ["Despite the number of white blood cells at the first sampling being within the reference values (5\u201310 \u00d7 109 cells/L) for recovering (RG; 6.5 \u00b1 1.3 \u00d7 109 cells/L) and nonrecovering (NRG; 10.3 \u00b1 2.1 \u00d7 109 cells/L) calves, animals from the NRG showed higher values than the RG animals (P< 0.01).", [["white blood cells", "ANATOMY", 22, 39], ["cells", "ANATOMY", 108, 113], ["cells", "ANATOMY", 153, 158], ["cells", "ANATOMY", 203, 208], ["white blood cells", "CELL", 22, 39], ["calves", "ORGANISM", 212, 218], ["animals", "ORGANISM", 220, 227], ["NRG", "GENE_OR_GENE_PRODUCT", 237, 240], ["white blood cells", "CELL_TYPE", 22, 39], ["NRG", "PROTEIN", 237, 240], ["calves", "SPECIES", 212, 218], ["white blood cells", "TEST", 22, 39], ["cells", "TEST", 108, 113], ["RG", "TEST", 133, 135], ["cells", "TEST", 153, 158], ["nonrecovering", "TEST", 166, 179], ["NRG", "TEST", 181, 184], ["cells", "TEST", 203, 208], ["calves", "TEST", 212, 218], ["the NRG", "TEST", 233, 240], ["higher", "OBSERVATION_MODIFIER", 248, 254]]], ["This was caused by a higher number of neutrophils (RG: 2.6 \u00b1 0.6 \u00d7 109 cells/L, NRG: 6.1 \u00b1 2.4 \u00d7 109 cells/L, reference range: 1\u20133.5 \u00d7 109 cells/L).", [["neutrophils", "ANATOMY", 38, 49], ["cells", "ANATOMY", 71, 76], ["cells", "ANATOMY", 101, 106], ["cells", "ANATOMY", 139, 144], ["neutrophils", "CELL", 38, 49], ["NRG", "GENE_OR_GENE_PRODUCT", 80, 83], ["neutrophils", "CELL_TYPE", 38, 49], ["NRG", "PROTEIN", 80, 83], ["neutrophils", "TEST", 38, 49], ["RG", "TEST", 51, 53], ["cells", "TEST", 71, 76], ["L", "TEST", 77, 78], ["NRG", "TEST", 80, 83], ["cells", "TEST", 101, 106], ["L", "TEST", 107, 108], ["cells", "TEST", 139, 144], ["higher", "OBSERVATION_MODIFIER", 21, 27]]], ["At the second sampling time point, no significant differences were detected.Detection of Diarrheagenic Pathogens in Fecal Samples ::: ResultsBovine rotavirus and Cryptosporidium parvum were identified as the diarrhea-causing pathogens in scouring calves (Table 1).", [["Bovine rotavirus and Cryptosporidium parvum", "DISEASE", 141, 184], ["diarrhea", "DISEASE", 208, 216], ["Bovine rotavirus", "ORGANISM", 141, 157], ["Cryptosporidium parvum", "ORGANISM", 162, 184], ["calves", "ORGANISM", 247, 253], ["Bovine", "SPECIES", 141, 147], ["Cryptosporidium parvum", "SPECIES", 162, 184], ["calves", "SPECIES", 247, 253], ["Bovine rotavirus", "SPECIES", 141, 157], ["Cryptosporidium parvum", "SPECIES", 162, 184], ["significant differences", "PROBLEM", 38, 61], ["Diarrheagenic Pathogens", "PROBLEM", 89, 112], ["Bovine rotavirus", "PROBLEM", 141, 157], ["Cryptosporidium parvum", "PROBLEM", 162, 184], ["the diarrhea", "PROBLEM", 204, 216], ["pathogens", "PROBLEM", 225, 234], ["no", "UNCERTAINTY", 35, 37], ["significant", "OBSERVATION_MODIFIER", 38, 49], ["Diarrheagenic Pathogens", "OBSERVATION", 89, 112], ["Fecal", "ANATOMY", 116, 121]]], ["Mono-infections with only 1 pathogen, as well as double infections, were detected.", [["Mono-infections", "DISEASE", 0, 15], ["infections", "DISEASE", 56, 66], ["Mono-infections", "PROBLEM", 0, 15], ["1 pathogen", "PROBLEM", 26, 36], ["double infections", "PROBLEM", 49, 66], ["pathogen", "OBSERVATION", 28, 36], ["infections", "OBSERVATION", 56, 66]]], ["Pathogens changed from the first to the second sampling time points, in both the RG and the NRG.", [["NRG", "GENE_OR_GENE_PRODUCT", 92, 95], ["NRG", "PROTEIN", 92, 95], ["Pathogens", "PROBLEM", 0, 9], ["RG", "ANATOMY", 81, 83], ["NRG", "ANATOMY", 92, 95]]], ["In the RG infections with BRV decreased from 3 to 1 positive samples, infections with C. parvum decreased from 5 to 4 positive samples and double infections were no longer detected at the second sampling.", [["samples", "ANATOMY", 61, 68], ["samples", "ANATOMY", 127, 134], ["infections", "DISEASE", 10, 20], ["infections", "DISEASE", 70, 80], ["C. parvum", "DISEASE", 86, 95], ["infections", "DISEASE", 146, 156], ["BRV", "CANCER", 26, 29], ["C. parvum", "ORGANISM", 86, 95], ["C. parvum", "SPECIES", 86, 95], ["BRV", "SPECIES", 26, 29], ["C. parvum", "SPECIES", 86, 95], ["the RG infections", "PROBLEM", 3, 20], ["BRV", "PROBLEM", 26, 29], ["infections", "PROBLEM", 70, 80], ["C. parvum", "PROBLEM", 86, 95], ["double infections", "PROBLEM", 139, 156], ["RG", "OBSERVATION_MODIFIER", 7, 9], ["infections", "OBSERVATION", 10, 20], ["infections", "OBSERVATION", 70, 80], ["parvum", "OBSERVATION_MODIFIER", 89, 95], ["decreased", "OBSERVATION_MODIFIER", 96, 105], ["infections", "OBSERVATION", 146, 156], ["no longer", "UNCERTAINTY", 162, 171]]], ["In the NRG infections with C. parvum decreased from 7 to 4 positive samples, double infections decreased from 2 to 1 and 2 new BRV infections were detected at the second sampling time point.Interleukin-6 in Serum Samples ::: ResultsInterleukin-6 results are presented as means \u00b1 2 SE (Figure 1).", [["samples", "ANATOMY", 68, 75], ["infections", "DISEASE", 11, 21], ["C. parvum", "DISEASE", 27, 36], ["infections", "DISEASE", 84, 94], ["infections", "DISEASE", 131, 141], ["SE", "DISEASE", 281, 283], ["NRG", "GENE_OR_GENE_PRODUCT", 7, 10], ["C. parvum", "ORGANISM", 27, 36], ["BRV", "ORGANISM", 127, 130], ["Interleukin-6", "GENE_OR_GENE_PRODUCT", 190, 203], ["Serum", "ORGANISM_SUBSTANCE", 207, 212], ["Interleukin-6", "GENE_OR_GENE_PRODUCT", 232, 245], ["Interleukin-6", "PROTEIN", 190, 203], ["C. parvum", "SPECIES", 27, 36], ["C. parvum", "SPECIES", 27, 36], ["BRV", "SPECIES", 127, 130], ["the NRG infections", "PROBLEM", 3, 21], ["C. parvum", "PROBLEM", 27, 36], ["double infections", "PROBLEM", 77, 94], ["2 new BRV infections", "PROBLEM", 121, 141], ["Interleukin", "TEST", 190, 201], ["Serum Samples", "TEST", 207, 220], ["Interleukin", "TEST", 232, 243], ["infections", "OBSERVATION", 11, 21], ["parvum", "OBSERVATION_MODIFIER", 30, 36], ["decreased", "OBSERVATION_MODIFIER", 37, 46], ["double", "OBSERVATION_MODIFIER", 77, 83], ["infections", "OBSERVATION", 84, 94], ["decreased", "OBSERVATION_MODIFIER", 95, 104], ["new", "OBSERVATION_MODIFIER", 123, 126], ["BRV", "OBSERVATION_MODIFIER", 127, 130], ["infections", "OBSERVATION", 131, 141]]], ["No significant interaction was found between the effects of group (RG, NRG) and sampling time point (1, 2) on serum IL-6 [F= (1, 36) = 1.776, P= 0.191].Interleukin-6 in Serum Samples ::: ResultsIn terms of disease progression, initially the NRG calves showed a higher (P= 0.02) IL-6 mean value (42.3 \u00b1 6 pg/mL) than the RG calves (31.8 \u00b1 5.5 pg/mL).Interleukin-6 in Serum Samples ::: ResultsA logistic regression was conducted to determine the effects of age and IL-6 at the onset of diarrhea (first sampling time point) on the odds for calves to develop a prolonged course of diarrhea (Table 2).", [["serum", "ANATOMY", 110, 115], ["diarrhea", "DISEASE", 484, 492], ["diarrhea", "DISEASE", 577, 585], ["serum", "ORGANISM_SUBSTANCE", 110, 115], ["IL-6", "GENE_OR_GENE_PRODUCT", 116, 120], ["Interleukin-6", "GENE_OR_GENE_PRODUCT", 152, 165], ["Serum", "ORGANISM_SUBSTANCE", 169, 174], ["calves", "ORGANISM", 245, 251], ["IL-6", "GENE_OR_GENE_PRODUCT", 278, 282], ["RG calves", "ORGANISM", 320, 329], ["Interleukin-6", "GENE_OR_GENE_PRODUCT", 349, 362], ["Serum", "ORGANISM_SUBSTANCE", 366, 371], ["IL-6", "GENE_OR_GENE_PRODUCT", 463, 467], ["calves", "ORGANISM", 537, 543], ["NRG", "PROTEIN", 71, 74], ["Interleukin-6", "PROTEIN", 152, 165], ["Interleukin-6", "PROTEIN", 349, 362], ["IL-6", "PROTEIN", 463, 467], ["calves", "SPECIES", 245, 251], ["calves", "SPECIES", 323, 329], ["calves", "SPECIES", 537, 543], ["calves", "SPECIES", 537, 543], ["significant interaction", "PROBLEM", 3, 26], ["serum IL", "TEST", 110, 118], ["P", "TEST", 142, 143], ["Interleukin", "TEST", 152, 163], ["Serum Samples", "TEST", 169, 182], ["disease progression", "PROBLEM", 206, 225], ["the NRG calves", "TEST", 237, 251], ["IL", "TEST", 278, 280], ["mean value", "TEST", 283, 293], ["the RG calves", "TEST", 316, 329], ["Interleukin", "TEST", 349, 360], ["Serum Samples", "TEST", 366, 379], ["diarrhea", "PROBLEM", 484, 492], ["diarrhea", "PROBLEM", 577, 585], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["interaction", "OBSERVATION", 15, 26], ["disease", "OBSERVATION", 206, 213], ["diarrhea", "OBSERVATION", 484, 492]]], ["The univariate logistic regression model for IL-6 (model 1) was statistically significant, as the P-value for the chi-squared statistic (Omnibus test of model coefficients) was 0.014 and the Hosmer-Lemeshow test showed no statistical significance (P= 0.640).", [["IL-6", "GENE_OR_GENE_PRODUCT", 45, 49], ["IL", "PROTEIN", 45, 47], ["the P-value", "TEST", 94, 105], ["Omnibus test", "TEST", 137, 149], ["the Hosmer-Lemeshow test", "TEST", 187, 211], ["P", "TEST", 248, 249], ["no", "UNCERTAINTY", 219, 221]]], ["The model explained 34% (Nagelkerke R2) of variance.", [["variance", "PROBLEM", 43, 51]]], ["The Wald statistic revealed a significant influence of IL-6 in the model (P= 0.041).", [["IL-6", "GENE_OR_GENE_PRODUCT", 55, 59], ["IL-6", "PROTEIN", 55, 59], ["The Wald statistic", "TEST", 0, 18], ["IL", "TEST", 55, 57], ["significant", "OBSERVATION_MODIFIER", 30, 41]]], ["The odds for calves developing a prolonged course of the disease increase by 14% for each unit of IL-6 (odds ratio 1.14; 95% CI 1.0\u20131.3).", [["calves", "ORGANISM", 13, 19], ["IL-6", "GENE_OR_GENE_PRODUCT", 98, 102], ["IL", "PROTEIN", 98, 100], ["calves", "SPECIES", 13, 19], ["the disease", "PROBLEM", 53, 64], ["IL", "TEST", 98, 100], ["ratio", "TEST", 109, 114], ["CI", "TEST", 125, 127]]], ["A t-test revealed the age of the RG and the NRG animals being significantly different (P= 0.01).", [["NRG", "GENE_OR_GENE_PRODUCT", 44, 47], ["A t-test", "TEST", 0, 8], ["significantly", "OBSERVATION_MODIFIER", 62, 75], ["different", "OBSERVATION_MODIFIER", 76, 85]]], ["A univariate logistic regression model was conducted to test for a significant influence of the variable \u201cage\u201d on the odds for a prolonged course of diarrhea.", [["diarrhea", "DISEASE", 149, 157], ["A univariate logistic regression model", "TEST", 0, 38], ["diarrhea", "PROBLEM", 149, 157], ["diarrhea", "OBSERVATION", 149, 157]]], ["As the analysis revealed significance (P= 0.039), a multivariate logistic regression was performed including IL-6 and age (model 2).", [["IL-6", "GENE_OR_GENE_PRODUCT", 109, 113], ["IL", "PROTEIN", 109, 111], ["the analysis", "TEST", 3, 15], ["a multivariate logistic regression", "PROBLEM", 50, 84]]], ["Additionally, no confounding by age was noted as there was less than a 20% change in the coefficient for IL-6 with the addition of age in the model.", [["IL-6", "GENE_OR_GENE_PRODUCT", 105, 109], ["IL-6", "PROTEIN", 105, 109], ["no", "UNCERTAINTY", 14, 16]]], ["Furthermore, even the interaction term (age \u00d7 IL-6; model 3) showed no significance when included in the model.Interleukin-6 in Serum Samples ::: ResultsThe value of IL-6 as a prognostic marker for the clinical outcome of scouring calves was further evaluated in a ROC analysis (Figure 2).", [["IL-6", "GENE_OR_GENE_PRODUCT", 46, 50], ["Interleukin-6", "GENE_OR_GENE_PRODUCT", 111, 124], ["Serum", "ORGANISM_SUBSTANCE", 128, 133], ["IL-6", "GENE_OR_GENE_PRODUCT", 166, 170], ["calves", "ORGANISM", 231, 237], ["Interleukin-6", "PROTEIN", 111, 124], ["IL-6", "PROTEIN", 166, 170], ["calves", "SPECIES", 231, 237], ["IL", "TEST", 46, 48], ["Interleukin", "TEST", 111, 122], ["Serum Samples", "TEST", 128, 141], ["a prognostic marker", "TEST", 174, 193], ["a ROC analysis", "TEST", 263, 277]]], ["The ROC analysis for IL-6 values of the diarrhea group at the beginning of diarrhea revealed a cut-off of 38.7 pg/mL, with a sensitivity of 77% and specificity of 82% for identifying calves with a prolonged recovery period.", [["diarrhea", "DISEASE", 40, 48], ["diarrhea", "DISEASE", 75, 83], ["IL-6", "GENE_OR_GENE_PRODUCT", 21, 25], ["calves", "ORGANISM", 183, 189], ["IL", "PROTEIN", 21, 23], ["calves", "SPECIES", 183, 189], ["calves", "SPECIES", 183, 189], ["The ROC analysis", "TEST", 0, 16], ["IL", "TEST", 21, 23], ["the diarrhea", "PROBLEM", 36, 48], ["diarrhea", "PROBLEM", 75, 83], ["a sensitivity", "TEST", 123, 136], ["specificity", "TEST", 148, 159], ["diarrhea", "OBSERVATION", 40, 48]]], ["The area under the curve (AUC = 0.808, 95% CI: 0.609\u20131, P= 0.02) showed a good predictive ability for IL-6 to discriminate between RG and NRG animals at the onset of diarrhea.DiscussionIn this study, the prognostic value of the IL-6 serum concentration was investigated over the course of neonatal calf diarrhea.", [["serum", "ANATOMY", 233, 238], ["diarrhea", "DISEASE", 166, 174], ["diarrhea", "DISEASE", 303, 311], ["IL-6", "GENE_OR_GENE_PRODUCT", 102, 106], ["NRG", "GENE_OR_GENE_PRODUCT", 138, 141], ["IL-6", "GENE_OR_GENE_PRODUCT", 228, 232], ["serum", "ORGANISM_SUBSTANCE", 233, 238], ["calf", "ORGANISM_SUBDIVISION", 298, 302], ["IL-6", "PROTEIN", 102, 106], ["IL-6", "PROTEIN", 228, 232], ["calf", "SPECIES", 298, 302], ["the curve", "TEST", 15, 24], ["AUC", "TEST", 26, 29], ["CI", "TEST", 43, 45], ["P", "TEST", 56, 57], ["IL", "TEST", 102, 104], ["diarrhea", "PROBLEM", 166, 174], ["this study", "TEST", 188, 198], ["the IL", "TEST", 224, 230], ["serum concentration", "TEST", 233, 252], ["neonatal calf diarrhea", "PROBLEM", 289, 311], ["diarrhea", "OBSERVATION", 166, 174], ["calf", "ANATOMY", 298, 302], ["diarrhea", "OBSERVATION", 303, 311]]], ["The main result was that calves developing a prolonged course of the disease showed significantly higher IL-6 values at the onset of symptoms.DiscussionInitially, hematology and clinical chemistry were analyzed.", [["calves", "ORGANISM", 25, 31], ["IL-6", "GENE_OR_GENE_PRODUCT", 105, 109], ["IL", "PROTEIN", 105, 107], ["calves", "SPECIES", 25, 31], ["the disease", "PROBLEM", 65, 76], ["symptoms", "PROBLEM", 133, 141], ["clinical chemistry", "TEST", 178, 196], ["main", "OBSERVATION_MODIFIER", 4, 8], ["calves", "OBSERVATION", 25, 31], ["prolonged", "OBSERVATION_MODIFIER", 45, 54], ["significantly", "OBSERVATION_MODIFIER", 84, 97], ["higher", "OBSERVATION_MODIFIER", 98, 104]]], ["The calves showed elevated levels of neutrophils, whereas the total number of white blood cells was within the reference range.", [["calves", "ANATOMY", 4, 10], ["neutrophils", "ANATOMY", 37, 48], ["white blood cells", "ANATOMY", 78, 95], ["calves", "ORGANISM", 4, 10], ["neutrophils", "CELL", 37, 48], ["white blood cells", "CELL", 78, 95], ["neutrophils", "CELL_TYPE", 37, 48], ["white blood cells", "CELL_TYPE", 78, 95], ["calves", "SPECIES", 4, 10], ["elevated levels of neutrophils", "PROBLEM", 18, 48], ["white blood cells", "TEST", 78, 95], ["calves", "ANATOMY", 4, 10], ["elevated", "OBSERVATION_MODIFIER", 18, 26], ["levels", "OBSERVATION_MODIFIER", 27, 33], ["total", "OBSERVATION_MODIFIER", 62, 67], ["number", "OBSERVATION_MODIFIER", 68, 74]]], ["The neutrophilia wasrelated to handling stress during sampling rather than to diarrhea, as it was similar in both groups.", [["neutrophilia", "DISEASE", 4, 16], ["diarrhea", "DISEASE", 78, 86], ["The neutrophilia", "PROBLEM", 0, 16], ["handling stress", "PROBLEM", 31, 46], ["diarrhea", "PROBLEM", 78, 86], ["neutrophilia", "OBSERVATION", 4, 16]]], ["An increase of neutrophils due to stress was already described for cattle in cases of shipping and heat stress (Kegley et al., 1997; Mitlohner et al., 2002).", [["neutrophils", "ANATOMY", 15, 26], ["neutrophils", "CELL", 15, 26], ["neutrophils", "CELL_TYPE", 15, 26], ["cattle", "SPECIES", 67, 73], ["cattle", "SPECIES", 67, 73], ["An increase of neutrophils", "PROBLEM", 0, 26], ["stress", "PROBLEM", 34, 40], ["increase", "OBSERVATION_MODIFIER", 3, 11], ["neutrophils", "OBSERVATION", 15, 26]]], ["The differential blood count, measured by the CellDyn 3500 Analyzer, revealed increased numbers of monocytes when compared with the reference values.", [["blood", "ANATOMY", 17, 22], ["monocytes", "ANATOMY", 99, 108], ["blood", "ORGANISM_SUBSTANCE", 17, 22], ["monocytes", "CELL", 99, 108], ["monocytes", "CELL_TYPE", 99, 108], ["The differential blood count", "TEST", 0, 28], ["the CellDyn 3500 Analyzer", "TEST", 42, 67], ["increased numbers of monocytes", "PROBLEM", 78, 108], ["increased", "OBSERVATION_MODIFIER", 78, 87], ["numbers", "OBSERVATION_MODIFIER", 88, 95], ["of monocytes", "OBSERVATION", 96, 108]]], ["However, manual counting of blood smears could not confirm the monocytosis.", [["blood", "ANATOMY", 28, 33], ["monocytosis", "DISEASE", 63, 74], ["blood", "ORGANISM_SUBSTANCE", 28, 33], ["manual counting of blood smears", "TEST", 9, 40], ["the monocytosis", "PROBLEM", 59, 74], ["monocytosis", "OBSERVATION", 63, 74]]], ["The CellDyn 3500 Analyzer classifies cells by measuring volume and granularity.", [["cells", "ANATOMY", 37, 42], ["cells", "CELL", 37, 42], ["CellDyn 3500", "CELL_LINE", 4, 16], ["volume", "TEST", 56, 62], ["granularity", "OBSERVATION_MODIFIER", 67, 78]]], ["It is likely that the number of monocytes was overestimated by mistaking them for large lymphocytes (Stoeber and Heubner, 1967).DiscussionThe detection of diarrhea-causing pathogens revealed differences between the first and the second sampling time point in both groups (recovering, nonrecovering).", [["monocytes", "ANATOMY", 32, 41], ["lymphocytes", "ANATOMY", 88, 99], ["diarrhea", "DISEASE", 155, 163], ["monocytes", "CELL", 32, 41], ["lymphocytes", "CELL", 88, 99], ["monocytes", "CELL_TYPE", 32, 41], ["lymphocytes", "CELL_TYPE", 88, 99], ["large lymphocytes", "PROBLEM", 82, 99], ["diarrhea", "PROBLEM", 155, 163], ["pathogens", "PROBLEM", 172, 181], ["is likely", "UNCERTAINTY", 3, 12], ["monocytes", "OBSERVATION", 32, 41]]], ["In the recovering group, 5 calves still shed either BRV or C. parvum at the second sampling time point, although none of them showed diarrhea.", [["diarrhea", "DISEASE", 133, 141], ["calves", "ORGANISM", 27, 33], ["C. parvum", "ORGANISM", 59, 68], ["calves", "SPECIES", 27, 33], ["C. parvum", "SPECIES", 59, 68], ["BRV", "SPECIES", 52, 55], ["C. parvum", "SPECIES", 59, 68], ["BRV", "PROBLEM", 52, 55], ["C. parvum", "PROBLEM", 59, 68], ["diarrhea", "PROBLEM", 133, 141], ["parvum", "OBSERVATION", 62, 68], ["diarrhea", "OBSERVATION", 133, 141]]], ["This was described in other studies also, were BRV shedding occurred up to 11 d after infection, whereas diarrhea only lasts 7 d (Vega et al., 2015).", [["infection", "DISEASE", 86, 95], ["diarrhea", "DISEASE", 105, 113], ["other studies", "TEST", 22, 35], ["BRV shedding", "PROBLEM", 47, 59], ["infection", "PROBLEM", 86, 95], ["diarrhea", "PROBLEM", 105, 113], ["infection", "OBSERVATION", 86, 95]]], ["Similarly, C. parvum detection in feces was shown to be not always connected to diarrhea in the corresponding animals (Bjorkman et al., 2015).", [["feces", "ANATOMY", 34, 39], ["diarrhea", "DISEASE", 80, 88], ["C. parvum", "ORGANISM", 11, 20], ["feces", "ORGANISM_SUBSTANCE", 34, 39], ["C. parvum", "SPECIES", 11, 20], ["C. parvum", "SPECIES", 11, 20], ["C. parvum detection in feces", "PROBLEM", 11, 39], ["diarrhea", "PROBLEM", 80, 88], ["parvum", "OBSERVATION", 14, 20], ["diarrhea", "OBSERVATION", 80, 88]]], ["In the nonrecovering group, 2 animals showed a BRV infection at the second sampling time point, which had not been apparent at the first sampling time point.", [["infection", "DISEASE", 51, 60], ["animals", "ORGANISM", 30, 37], ["a BRV infection", "PROBLEM", 45, 60], ["BRV", "OBSERVATION_MODIFIER", 47, 50], ["infection", "OBSERVATION", 51, 60]]], ["It was suggested that this was due to a secondary infection, which is frequently described in neonatal calf diarrhea (Bartels et al., 2010; Silverlas et al., 2010).", [["infection", "DISEASE", 50, 59], ["diarrhea", "DISEASE", 108, 116], ["calf", "ORGANISM_SUBDIVISION", 103, 107], ["calf", "SPECIES", 103, 107], ["a secondary infection", "PROBLEM", 38, 59], ["neonatal calf diarrhea", "PROBLEM", 94, 116], ["secondary", "OBSERVATION_MODIFIER", 40, 49], ["infection", "OBSERVATION", 50, 59], ["calf", "ANATOMY", 103, 107], ["diarrhea", "OBSERVATION", 108, 116]]], ["In the classification of calves as recovered or nonrecovered, the pathogen detection was less important than the results of the clinical examination when focusing on the establishment of a prognostic marker.DiscussionSerum IL-6 concentrations were greater in the diarrhea group than in controls.", [["diarrhea", "DISEASE", 263, 271], ["calves", "ORGANISM", 25, 31], ["IL-6", "GENE_OR_GENE_PRODUCT", 223, 227], ["IL", "PROTEIN", 223, 225], ["calves", "SPECIES", 25, 31], ["the pathogen detection", "TEST", 62, 84], ["the clinical examination", "TEST", 124, 148], ["IL-6 concentrations", "TREATMENT", 223, 242], ["calves", "ANATOMY", 25, 31]]], ["This is consistent with findings of an increased IL-6 gene expression in peripheral blood mononuclear cells and in intestinal epithelial cells from scouring calves ex vivo due to an infection with BRV (Aich et al., 2007; Qadis et al., 2014).", [["peripheral blood mononuclear cells", "ANATOMY", 73, 107], ["intestinal epithelial cells", "ANATOMY", 115, 142], ["infection", "DISEASE", 182, 191], ["IL-6", "GENE_OR_GENE_PRODUCT", 49, 53], ["peripheral blood mononuclear cells", "CELL", 73, 107], ["intestinal epithelial cells", "CELL", 115, 142], ["calves", "ORGANISM", 157, 163], ["IL", "PROTEIN", 49, 51], ["peripheral blood mononuclear cells", "CELL_TYPE", 73, 107], ["intestinal epithelial cells", "CELL_TYPE", 115, 142], ["calves", "SPECIES", 157, 163], ["BRV", "SPECIES", 197, 200], ["an increased IL", "PROBLEM", 36, 51], ["peripheral blood mononuclear cells", "PROBLEM", 73, 107], ["intestinal epithelial cells", "PROBLEM", 115, 142], ["scouring calves", "TREATMENT", 148, 163], ["an infection", "PROBLEM", 179, 191], ["consistent with", "UNCERTAINTY", 8, 23], ["increased", "OBSERVATION_MODIFIER", 39, 48], ["IL", "OBSERVATION_MODIFIER", 49, 51], ["peripheral", "ANATOMY_MODIFIER", 73, 83], ["blood", "ANATOMY", 84, 89], ["mononuclear cells", "OBSERVATION", 90, 107], ["intestinal epithelial cells", "OBSERVATION", 115, 142], ["infection", "OBSERVATION", 182, 191]]]], "8e40e884a788c5b2968505a1f266f9d5fd06d6b5": [["Echoes of wartime lexicon, insinuating that opinions should be placed on hold for the greater good.COVER FEATURETake GMB's Piers Morgan.", [["wartime lexicon", "OBSERVATION", 10, 25]]], ["Deduct the suspiciously looking accounts and political bias, and you're left with the bare bones of a coherent defence.COVER FEATUREAnd that is why, even now, it is right to ask how much longer NHS dentistry in England has left.Pushed over the edgeAlthough March felt like it lasted 857 days, it's worth recalling where things were.", [["bones", "ORGAN", 91, 96], ["left", "ANATOMY_MODIFIER", 72, 76], ["right", "ANATOMY_MODIFIER", 165, 170], ["left", "ANATOMY_MODIFIER", 223, 227]]], ["Recruitment crisis, morale lower than ever, a remuneration model that was unsuitable and a contract few wanted when it was introduced, let alone 14 years later.", [["Recruitment crisis", "PROBLEM", 0, 18]]], ["Patients and the profession alike were being failed.Pushed over the edgeIn 2017, this publication asked whether NHS dentistry was at tipping point.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Questions were posed: were associates and dental practice owners reaching a stage that significant numbers were going to either give back their NHS contracts, spend more time on private dentistry and fail to meet their UDA targets or in other ways provide less NHS care?", [["significant numbers", "PROBLEM", 87, 106]]], ["Would all of this happen in sufficient numbers to start to create real workforce shortages and impact on access to NHS care?Pushed over the edgeIn the intervening time, it would not be a stretch to say these things have all -to a certain degree -happened or are still happening, and the situation is worse than it was then.", [["edge", "ANATOMY", 140, 144], ["NHS care", "TREATMENT", 115, 123], ["edge", "ANATOMY_MODIFIER", 140, 144]]], ["And, I' d hazard a guess that if such an article existed in 2014, it would show a similar pattern of stagnation, deeprooted problems and growing resentment, with the 2017 article surmising the same outcomes.", [["deeprooted problems", "PROBLEM", 113, 132], ["growing resentment", "PROBLEM", 137, 155], ["stagnation", "OBSERVATION", 101, 111]]], ["It has been a long and testing process, and only last October the BDA reported the end could be in sight, with a degree of certainty known about dates that were being committed to.", [["BDA", "SIMPLE_CHEMICAL", 66, 69]]], ["Further waves of prototypes were anticipated -although unconfirmed -to be taking place from April 2020.", [["Further waves of prototypes", "PROBLEM", 0, 27]]], ["From my perspective, success will be a dental contract that improves access to care and, critically, a contract that recognises and facilitates the ability of the dental team to develop longer term relationships with patients in order to support an individual in taking charge of their health and preventing dental disease. ' 2 With that in mind, you would fully expect contract reform to be picked up once again.Pushed over the edgeAt the heart of the matter One of the more interesting observations from Dr Hurley's quote relates to access to care.", [["heart", "ANATOMY", 440, 445], ["dental disease", "DISEASE", 308, 322], ["patients", "ORGANISM", 217, 225], ["heart", "ORGAN", 440, 445], ["patients", "SPECIES", 217, 225], ["dental disease", "PROBLEM", 308, 322], ["heart", "ANATOMY", 440, 445]]], ["In the 2017 article, it was suggested that if the UK's decision was to leave the EU and it led to fewer dentists from Europe practising in England, then there may well be a workforce crisis that would not be confined to dentistry.Pushed over the edgeThat particular observation came to fruition.", [["edge", "ANATOMY", 246, 250], ["a workforce crisis", "PROBLEM", 171, 189], ["edge", "ANATOMY_MODIFIER", 246, 250]]], ["It may be too simplistic to suggest Brexit alone is the reason for the current workforce crisis, although there is no doubt the landscape in the UK has changed since 26 June 2016.", [["Brexit", "CHEMICAL", 36, 42], ["UK", "CANCER", 145, 147], ["no doubt", "UNCERTAINTY", 115, 123], ["landscape", "OBSERVATION", 128, 137]]], ["The compounding factors surrounding dentistry don't entice people into the workforce -who wants to work in a target-driven profession with an over-bearing regulator and derisory pay rises?", [["people", "ORGANISM", 59, 65], ["people", "SPECIES", 59, 65], ["an over-bearing regulator", "TREATMENT", 139, 164]]], ["The postcode lottery of being able to access NHS treatment versus the recruitment crisis begins to sound more like 'which came first: the chicken or the egg' than sound government policy.Pushed over the edgeThe constant narrative of dragging feet has created an NHS dental workforce lacking in motivation to such an extent it's on the verge of collapse, leading to pockets and hotspots around the UK severely lacking.", [["edge", "ANATOMY", 203, 207], ["chicken", "ORGANISM", 138, 145], ["feet", "ORGANISM_SUBDIVISION", 242, 246], ["chicken", "SPECIES", 138, 145], ["chicken", "SPECIES", 138, 145], ["NHS treatment", "TREATMENT", 45, 58], ["the recruitment crisis", "PROBLEM", 66, 88], ["dragging feet", "PROBLEM", 233, 246], ["an NHS dental workforce", "TREATMENT", 259, 282], ["collapse", "PROBLEM", 344, 352], ["pockets", "PROBLEM", 365, 372], ["recruitment crisis", "OBSERVATION", 70, 88], ["edge", "ANATOMY_MODIFIER", 203, 207], ["collapse", "OBSERVATION", 344, 352]]], ["Alongside London devolving, more and more practices outside of the city are offering better remuneration and attractive golden hellos -some worth up to \u00a320,000which theoretically means more and more candidates are considering a move from the capital.Pushed over the edgeWrong.", [["attractive golden hellos", "PROBLEM", 109, 133], ["capital", "ANATOMY", 242, 249]]], ["BDA analysis of the government's last GP Survey indicates over 1.4 million adult patients have tried and failed to access carewith a further two million estimated to have not tried in the belief they would be unable to secure an appointment.", [["BDA", "SIMPLE_CHEMICAL", 0, 3], ["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["BDA analysis", "TEST", 0, 12]]], ["With 130,000 reporting they are on waiting lists, and over 700,000 citing cost as a barrier, thus bringing a level of unmet need to over 4 million people.Pushed over the edgeAreas facing challenges have not previously experienced significant problems, with many of the worst affected areas in parts of London and the South East, including the overwhelming majority of London boroughs, Brighton, and parts of Kent and Surrey.Pushed over the edgeThe government has acknowledged issues in a few hotspots with a history of access problems, such as West Yorkshire, Cumbria and Cornwall.", [["edge", "ANATOMY", 440, 444], ["people", "ORGANISM", 147, 153], ["people", "SPECIES", 147, 153], ["access problems", "PROBLEM", 519, 534], ["edge", "ANATOMY_MODIFIER", 440, 444]]], ["Data also indicate lower success rates among patients attempting to secure an appointment for the first time, the young, and ethnic minorities.Pushed over the edgeThe BDA claims these figures reflect the 'perfect storm' facing patients, as budget cuts, contract failure and staffing problems bite.", [["edge", "ANATOMY", 159, 163], ["patients", "ORGANISM", 45, 53], ["BDA", "SIMPLE_CHEMICAL", 167, 170], ["patients", "ORGANISM", 227, 235], ["patients", "SPECIES", 45, 53], ["patients", "SPECIES", 227, 235], ["staffing problems bite", "PROBLEM", 274, 296], ["lower", "OBSERVATION_MODIFIER", 19, 24], ["edge", "ANATOMY_MODIFIER", 159, 163]]], ["NHS dentistry is operating on a budget that has remained largely static since 2010, but with patients contributing a greater share each year through increasing NHS charges.", [["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101], ["increasing NHS charges", "PROBLEM", 149, 171]]], ["The current target-driven NHS contract funds care for little over half the population, and has prompted a collapse in morale within the workforce.", [["a collapse in morale", "PROBLEM", 104, 124], ["collapse", "OBSERVATION", 106, 114]]], ["Recruitment problems have become endemic, with BDA surveys indicating 75% of practices struggling to fill vacancies, and 59% of dentists stating their intentions to reduce or end NHS work.", [["BDA", "SIMPLE_CHEMICAL", 47, 50], ["Recruitment problems", "PROBLEM", 0, 20], ["BDA surveys", "TEST", 47, 58]]], ["Problems are most severe among practices doing most NHS work.Pushed over the edgeIf Dr Hurley judges the success of a dental contract as one that improves access to care, it's entirely reasonable to state success is not around the corner.Broken beyond repair?If the service was close to breaking point, has this time served to assess whether things are broken beyond repair and we carry on as we were, or whether there's a relationship left to salvage?", [["a dental contract", "TREATMENT", 116, 133], ["repair", "TREATMENT", 252, 258], ["repair", "TREATMENT", 367, 373], ["salvage", "TREATMENT", 444, 451], ["most severe", "OBSERVATION_MODIFIER", 13, 24], ["repair", "OBSERVATION", 252, 258]]], ["I fear dentistry will simply resume as it was with all of the humdrum and campaign for change in the background.", [["change in the background", "PROBLEM", 87, 111]]], ["With many economists expecting a global recession, is NHS dentistry doomed, or is there one last lifeline?", [["a global recession", "PROBLEM", 31, 49], ["global", "OBSERVATION_MODIFIER", 33, 39], ["recession", "OBSERVATION", 40, 49]]], ["Access is now the worst it has been for a decade, with just half of adults undergoing regular checks.", [["adults", "ORGANISM", 68, 74], ["regular checks", "TEST", 86, 100]]], ["In October last year, for the first time in a decade, dentists in England received an uplift close to inflation levels.", [["inflation levels", "TEST", 102, 118]]], ["The Department of Health and Social Care confirmed that the annual uplift for 2019/2020 of 2.42% would be backdated to April 2019.Broken beyond repair?Dentists have seen a 30% decrease in income across a 10-year period.", [["repair", "TREATMENT", 144, 150], ["repair", "OBSERVATION", 144, 150]]], ["3 Yes, their healthcare model differs substantially to ours, but the downward trend should serve as a warning.Broken beyond repair?Providing there is a service to return to, lessons from 2009 and 2010 show there may be an opportunity for NHS dentistry to recover.Broken beyond repair?In 2009, news stories emerged of dentists who left the NHS over the introduction of the 2006 contract to pursue fully private work returning to the NHS due to recession.", [["repair", "TREATMENT", 124, 130], ["repair", "TREATMENT", 277, 283], ["recession", "PROBLEM", 443, 452], ["repair", "OBSERVATION", 124, 130], ["repair", "OBSERVATION", 277, 283], ["recession", "OBSERVATION", 443, 452]]], ["With an estimated 5,500 general dental practitioners in purely private practice -an increase of 44% from when figures were first recorded in 2008/09 -and 3,000 purely private practicesan increase of 32% on 2009/10, 4 history could be about to repeat itself.Broken beyond repair?Perhaps not a total surprise, but an opportunity nonetheless.", [["repair", "TREATMENT", 271, 277], ["increase", "OBSERVATION_MODIFIER", 84, 92], ["repair", "OBSERVATION", 271, 277]]], ["Consumers want the best deal they can, a theory particularly true during times of recession.", [["recession", "PROBLEM", 82, 91]]], ["As the economic downturn took hold, patients began to think twice about paying for private treatment if they could get it cheaper as an NHS patient.", [["patients", "ORGANISM", 36, 44], ["patient", "ORGANISM", 140, 147], ["patients", "SPECIES", 36, 44], ["patient", "SPECIES", 140, 147]]], ["There were reports one private practice offered a package to which patients sign up for life membership that included one visit a year with a dentist, two visits a year with a hygienist, all necessary X-rays, preventive and dietary advice, UK and worldwide dental injury and emergency insurance, 10% reduction off all dental treatments (excluding referral for specialist treatment) and free teeth whitening, all for \u00a319.99 a month.Broken beyond repair?Last year a report by LaingBuisson 5 suggested that while the high street dental sector forecast annual growth of 2%-2.5% over the next three years, this was primarily down to expanding private care, particularly cosmetic treatments such as teeth whitening and straightening.", [["teeth", "ANATOMY", 391, 396], ["teeth", "ANATOMY", 693, 698], ["dental injury", "DISEASE", 257, 270], ["patients", "ORGANISM", 67, 75], ["teeth", "ORGAN", 391, 396], ["teeth", "ORGAN", 693, 698], ["patients", "SPECIES", 67, 75], ["a package", "TREATMENT", 48, 57], ["all dental treatments", "TREATMENT", 314, 335], ["specialist treatment", "TREATMENT", 360, 380], ["repair", "TREATMENT", 445, 451], ["expanding private care", "TREATMENT", 628, 650], ["cosmetic treatments", "TREATMENT", 665, 684], ["teeth whitening", "PROBLEM", 693, 708], ["repair", "OBSERVATION", 445, 451]]], ["The overall UK dental market is worth \u00a37.1bn a year -NHS market share is at the \u00a33.5bn mark and private sector at around \u00a33.6bn -and there is very real reason to suggest this growth will not be seen in the private sector.", [["this growth", "PROBLEM", 170, 181]]], ["Will patients be driven back to the NHS out of necessity?", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13]]], ["The last recession forced practitioners to add more strings to their bow, and so non-surgical facial aesthetics and a boom in cosmetic dentistry happened.", [["facial", "ANATOMY", 94, 100], ["non-surgical facial aesthetics", "TREATMENT", 81, 111], ["facial", "ANATOMY", 94, 100], ["aesthetics", "OBSERVATION", 101, 111]]], ["Time will tell which way the pendulum swings, but if there's one thing we do know for certain about consumers, it's about getting the best deal.What happens next?The million-dollar question, to which not even the cheating Who Wants To Be A Millionaire Major can cough up an answer to.What happens next?The real question is what do we want to happen, and how do we make it happen -are we to expect evolution, or is the time right for revolution?What happens next?It would be remiss of me not to highlight that while many of the problems at the heart of NHS dentistry have been present for a decade and beyond, there has still been little in the way of significant key-change improvements of any note.", [["heart", "ANATOMY", 543, 548], ["heart", "ORGAN", 543, 548], ["heart", "ANATOMY", 543, 548]]], ["The issue has spawned groups on social media calling for change and overhaul to the UDA system and echoing other areas of campaign work the BDA has undertaken.", [["BDA", "CHEMICAL", 140, 143], ["BDA", "SIMPLE_CHEMICAL", 140, 143]]], ["People are understandably frustrated with the lack of progress, so why would we expect NHS dentistry to alter its path once a degree of normality is resumed?What happens next?Let me state that this is not a slight towards the OCDO.", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6]]], ["Many friends have colleagues have been disillusioned with the chronic lack of leadership on display from that office throughout the pandemic, a reflection of the general feeling towards issues at the real heart of what is wrong in dentistry.", [["heart", "ANATOMY", 205, 210], ["heart", "ORGAN", 205, 210], ["heart", "ANATOMY", 205, 210]]], ["Dentistry does not escape this scrutiny.What happens next?Take patient charges and their annual increase, for example.", [["patient", "ORGANISM", 63, 70], ["patient", "SPECIES", 63, 70]]], ["In 2019 it was announced that patient charges would increase by an eye-watering 5% on the previous year's figures, increases that saw treatments stand at \u00a322.70 for a routine checkup in Band A, a filling cost \u00a362.10 in Band B and dentures cost \u00a3269.30 in Band C. These increases have served little more than providing cover for sustained cuts in state contributions to NHS dentistry.", [["patient", "ORGANISM", 30, 37], ["patient", "SPECIES", 30, 37], ["a filling cost", "TEST", 194, 208], ["Band B and dentures cost", "TREATMENT", 219, 243]]], ["Net government expenditure on services in England has fallen by nearly \u00a3550 million in real terms since 2010, while charges levels have increased by over 30% to plug the gap.What happens next?Charges for complex NHS treatment over the past five years have increased 4 times faster in England than in Wales.", [["plug the gap", "PROBLEM", 161, 173], ["complex NHS treatment", "TREATMENT", 204, 225], ["increased", "OBSERVATION_MODIFIER", 136, 145]]], ["Fees for treatments in Bands 2 and 3 have gone up by 23% since 2014/15 in England and are expected to rise by only 7% in the same period in Wales.What happens next?Nearly 1 in 5 patients have delayed treatment for reasons of cost, and studies show 380,000 patients with toothache are choosing to head to their GPs, who are not subject to charges but are unequipped to provide dental treatment.", [["toothache", "DISEASE", 270, 279], ["patients", "ORGANISM", 178, 186], ["patients", "ORGANISM", 256, 264], ["patients", "SPECIES", 178, 186], ["patients", "SPECIES", 256, 264], ["treatments in Bands", "TREATMENT", 9, 28], ["delayed treatment", "TREATMENT", 192, 209], ["studies", "TEST", 235, 242], ["toothache", "PROBLEM", 270, 279], ["dental treatment", "TREATMENT", 376, 392]]], ["The BDA estimated these appointments cost the NHS over \u00a320 million a year.", [["BDA", "SIMPLE_CHEMICAL", 4, 7]]], ["Some 135,000 patients per year are attending A&E units with dental problems, and an increasing number are resorting to DIY dentistry.What happens next?It is not beyond the realms of possibility to come to the conclusion these data show a ramping up of NHS dentistry privatisation.", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["dental problems", "PROBLEM", 60, 75], ["NHS dentistry privatisation", "TREATMENT", 252, 279]]], ["It's like a scene from a film where a secondary character is fighting to keep afloat, only for the main character to come along with a lifejacket, appearing to be the hero, when in fact all they plan to do is loom over them with a knowing look that they do not intend to help them one little bit.What happens next?Looking ahead for the next five years if we do not see an improved and better remunerated contract in England and better terms and working conditions for employed NHS dentists we will get to a point that many more dentists will only work privately or will seek careers outside of dentistry.", [["a film", "TEST", 23, 29]]], ["Those responsible cannot hide behind the pandemic chaos to justify inaction.What happens next?If the dental contract were an organ, it would be a failing heart awaiting a new transplant.", [["organ", "ANATOMY", 125, 130], ["heart", "ANATOMY", 154, 159], ["organ", "ORGAN", 125, 130], ["heart", "ORGAN", 154, 159], ["a new transplant", "TREATMENT", 169, 185], ["heart", "ANATOMY", 154, 159], ["transplant", "OBSERVATION", 175, 185]]], ["Without a new one, everything around it continues to fail.", [["new", "OBSERVATION_MODIFIER", 10, 13]]], ["Without a new approach, it will continue to suffer.", [["a new approach", "TREATMENT", 8, 22], ["new", "OBSERVATION_MODIFIER", 10, 13]]]], "PMC7132488": [["IntroductionType I interferon (IFN) production can be elicited by a wide variety of stimulants, including viruses, products of bacteria, plants and fungi.", [["Type I interferon", "GENE_OR_GENE_PRODUCT", 12, 29], ["IFN", "GENE_OR_GENE_PRODUCT", 31, 34], ["Type I interferon", "PROTEIN", 12, 29], ["IFN", "PROTEIN", 31, 34], ["IntroductionType I interferon (IFN) production", "TREATMENT", 0, 46], ["viruses", "PROBLEM", 106, 113], ["bacteria", "PROBLEM", 127, 135], ["fungi", "PROBLEM", 148, 153]]], ["Many cell types produce type I IFN following viral infection.", [["cell", "ANATOMY", 5, 9], ["viral infection", "DISEASE", 45, 60], ["cell", "CELL", 5, 9], ["type I IFN", "GENE_OR_GENE_PRODUCT", 24, 34], ["type I IFN", "PROTEIN", 24, 34], ["type I IFN", "PROBLEM", 24, 34], ["viral infection", "PROBLEM", 45, 60], ["cell types", "OBSERVATION", 5, 15], ["type I", "OBSERVATION_MODIFIER", 24, 30], ["viral", "OBSERVATION_MODIFIER", 45, 50], ["infection", "OBSERVATION", 51, 60]]], ["For example, influenza virus infection of monocytes (Ronni et al., 1995), macrophages (Roberts et al., 1979) and dendritic cells (DCs) (Cella et al., 1999b) activates the production of type I IFN in these cells and Sendai virus infection has been demonstrated to induce monocytes and macrophages to release IFN (Saksela et al., 1984).", [["monocytes", "ANATOMY", 42, 51], ["macrophages", "ANATOMY", 74, 85], ["dendritic cells", "ANATOMY", 113, 128], ["DCs", "ANATOMY", 130, 133], ["cells", "ANATOMY", 205, 210], ["monocytes", "ANATOMY", 270, 279], ["macrophages", "ANATOMY", 284, 295], ["influenza virus infection", "DISEASE", 13, 38], ["Sendai virus infection", "DISEASE", 215, 237], ["influenza virus", "ORGANISM", 13, 28], ["monocytes", "CELL", 42, 51], ["macrophages", "CELL", 74, 85], ["dendritic cells", "CELL", 113, 128], ["DCs", "CELL", 130, 133], ["type I IFN", "GENE_OR_GENE_PRODUCT", 185, 195], ["cells", "CELL", 205, 210], ["Sendai virus", "ORGANISM", 215, 227], ["monocytes", "CELL", 270, 279], ["macrophages", "CELL", 284, 295], ["IFN", "GENE_OR_GENE_PRODUCT", 307, 310], ["monocytes", "CELL_TYPE", 42, 51], ["macrophages", "CELL_TYPE", 74, 85], ["dendritic cells", "CELL_TYPE", 113, 128], ["DCs", "CELL_TYPE", 130, 133], ["type I IFN", "PROTEIN", 185, 195], ["monocytes", "CELL_TYPE", 270, 279], ["macrophages", "CELL_TYPE", 284, 295], ["IFN", "PROTEIN", 307, 310], ["influenza virus", "SPECIES", 13, 28], ["Sendai virus", "SPECIES", 215, 227], ["influenza virus", "SPECIES", 13, 28], ["Sendai virus", "SPECIES", 215, 227], ["influenza virus infection of monocytes", "PROBLEM", 13, 51], ["dendritic cells", "PROBLEM", 113, 128], ["type I IFN in these cells", "PROBLEM", 185, 210], ["Sendai virus infection", "PROBLEM", 215, 237], ["monocytes", "TEST", 270, 279], ["influenza virus", "OBSERVATION", 13, 28], ["macrophages", "ANATOMY", 74, 85], ["dendritic cells", "OBSERVATION", 113, 128], ["Sendai virus", "OBSERVATION", 215, 227]]], ["It is probable that in these cells double-stranded RNA (dsRNA) synthesized during the viral replicative cycle (Jacobs and Langland, 1996) is a trigger for type I IFN production, since synthetic dsRNA, e.g. polyinosinic\u2013polycytidylic acid (polyI:C), is known to be a potent inducer of type I IFN (De Clercq, 1981; Majde, 2000).IntroductionPlasmacytoid dendritic cells (pDCs), also known as natural interferon producing cells, (NIPCs), are major producers of type I IFN in response to stimulation with enveloped viruses and hence are key effectors in the innate immune system. pDCs are a rare cell population found in the peripheral blood, lymphoid organs, bone marrow, thymus, liver and lung (Asselin-Paturel et al., 2003; Blasius et al., 2004; de Heer et al., 2004; Demedts et al., 2005).", [["cells", "ANATOMY", 29, 34], ["Plasmacytoid dendritic cells", "ANATOMY", 338, 366], ["pDCs", "ANATOMY", 368, 372], ["cells", "ANATOMY", 418, 423], ["NIPCs", "ANATOMY", 426, 431], ["pDCs", "ANATOMY", 575, 579], ["cell", "ANATOMY", 591, 595], ["peripheral blood", "ANATOMY", 620, 636], ["lymphoid organs", "ANATOMY", 638, 653], ["bone marrow", "ANATOMY", 655, 666], ["thymus", "ANATOMY", 668, 674], ["liver", "ANATOMY", 676, 681], ["lung", "ANATOMY", 686, 690], ["polyinosinic\u2013polycytidylic acid", "CHEMICAL", 206, 237], ["polyI:C", "CHEMICAL", 239, 246], ["polyinosinic\u2013polycytidylic acid", "CHEMICAL", 206, 237], ["polyI:C", "CHEMICAL", 239, 246], ["cells", "CELL", 29, 34], ["type I IFN", "GENE_OR_GENE_PRODUCT", 155, 165], ["polyinosinic\u2013polycytidylic acid", "SIMPLE_CHEMICAL", 206, 237], ["polyI:C", "SIMPLE_CHEMICAL", 239, 246], ["type I IFN", "GENE_OR_GENE_PRODUCT", 284, 294], ["Plasmacytoid dendritic cells", "CELL", 338, 366], ["pDCs", "CELL", 368, 372], ["cells", "CELL", 418, 423], ["NIPCs", "CELL", 426, 431], ["type I IFN", "GENE_OR_GENE_PRODUCT", 457, 467], ["pDCs", "CELL", 575, 579], ["cell", "CELL", 591, 595], ["peripheral blood", "ORGANISM_SUBSTANCE", 620, 636], ["lymphoid organs", "MULTI-TISSUE_STRUCTURE", 638, 653], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 655, 666], ["thymus", "ORGAN", 668, 674], ["liver", "ORGAN", 676, 681], ["lung", "ORGAN", 686, 690], ["double-stranded RNA", "RNA", 35, 54], ["IFN", "PROTEIN", 162, 165], ["type I IFN", "PROTEIN", 284, 294], ["Plasmacytoid dendritic cells", "CELL_TYPE", 338, 366], ["pDCs", "CELL_TYPE", 368, 372], ["natural interferon producing cells", "CELL_TYPE", 389, 423], ["NIPCs", "CELL_TYPE", 426, 431], ["type I IFN", "PROTEIN", 457, 467], ["pDCs", "CELL_TYPE", 575, 579], ["double-stranded RNA (dsRNA)", "TREATMENT", 35, 62], ["type I IFN production", "PROBLEM", 155, 176], ["synthetic dsRNA", "PROBLEM", 184, 199], ["polyinosinic\u2013polycytidylic acid", "PROBLEM", 206, 237], ["IntroductionPlasmacytoid dendritic cells", "PROBLEM", 326, 366], ["natural interferon producing cells", "PROBLEM", 389, 423], ["type I IFN", "PROBLEM", 457, 467], ["stimulation", "TREATMENT", 483, 494], ["enveloped viruses", "PROBLEM", 500, 517], ["a rare cell population", "PROBLEM", 584, 606], ["probable that", "UNCERTAINTY", 6, 19], ["stranded RNA", "OBSERVATION_MODIFIER", 42, 54], ["Plasmacytoid dendritic cells", "OBSERVATION", 338, 366], ["viruses", "OBSERVATION", 510, 517], ["rare cell population", "OBSERVATION", 586, 606], ["peripheral", "ANATOMY_MODIFIER", 620, 630], ["blood", "ANATOMY", 631, 636], ["lymphoid organs", "OBSERVATION", 638, 653], ["bone marrow", "ANATOMY", 655, 666], ["thymus", "ANATOMY", 668, 674], ["liver", "ANATOMY", 676, 681], ["lung", "ANATOMY", 686, 690]]], ["In addition to their functional definition as the main type I IFN producing population in response to viruses they are defined by flow cytometry as CD11clowB220+CD11b\u2212Ly6C+ murine cells, or lineage\u2212HLA-DRhighCD11c\u2212CD123+ human cells (Asselin-Paturel et al., 2001; Cella et al., 1999a; Dzionek et al., 2000; Nakano et al., 2001).", [["CD11clowB220+CD11b\u2212Ly6C+ murine cells", "ANATOMY", 148, 185], ["HLA-DRhighCD11c\u2212CD123+ human cells", "ANATOMY", 198, 232], ["B220", "GENE_OR_GENE_PRODUCT", 156, 160], ["HLA", "GENE_OR_GENE_PRODUCT", 198, 201], ["IFN", "PROTEIN", 62, 65], ["B220", "PROTEIN", 156, 160], ["CD11b\u2212Ly6C+ murine cells", "CELL_LINE", 161, 185], ["HLA-DRhighCD11c\u2212CD123+ human cells", "CELL_LINE", 198, 232], ["murine", "SPECIES", 173, 179], ["human", "SPECIES", 221, 226], ["human", "SPECIES", 221, 226], ["viruses", "PROBLEM", 102, 109], ["flow cytometry", "TEST", 130, 144], ["CD11clo", "TEST", 148, 155], ["B220", "TEST", 156, 160], ["CD11", "TEST", 161, 165], ["b", "TEST", 165, 166], ["Ly6C", "TEST", 167, 171], ["murine cells", "TEST", 173, 185], ["HLA", "TEST", 198, 201], ["human cells", "TEST", 221, 232], ["Asselin", "TEST", 234, 241], ["murine cells", "OBSERVATION", 173, 185], ["human cells", "OBSERVATION", 221, 232]]], ["More recently developed monoclonal antibodies (mAb) such as 120G8, anti-mPDCA-1 and anti-BDCA-2, specific for the pDC, will ease identification of this cell type (Asselin-Paturel et al., 2003; Dzionek et al., 2000; Krug et al., 2004a).", [["pDC", "ANATOMY", 114, 117], ["cell", "ANATOMY", 152, 156], ["120G8", "SIMPLE_CHEMICAL", 60, 65], ["anti-mPDCA-1", "GENE_OR_GENE_PRODUCT", 67, 79], ["anti-BDCA-2", "GENE_OR_GENE_PRODUCT", 84, 95], ["pDC", "CELL", 114, 117], ["cell type", "CELL", 152, 161], ["monoclonal antibodies", "PROTEIN", 24, 45], ["mAb", "PROTEIN", 47, 50], ["120G8", "PROTEIN", 60, 65], ["anti-mPDCA", "PROTEIN", 67, 77], ["anti-BDCA", "PROTEIN", 84, 93], ["pDC", "CELL_TYPE", 114, 117], ["monoclonal antibodies (mAb", "TREATMENT", 24, 50], ["anti-mPDCA", "TEST", 67, 77], ["anti-BDCA", "TEST", 84, 93], ["monoclonal antibodies", "OBSERVATION", 24, 45]]], ["Virally stimulated pDCs can produce other cytokines in addition to type I IFN, but the mechanism of induction of the secretion of these factors is not fully understood to date (Piqueras et al., 2005).IntroductionAlthough replicative intermediates and viral genome are important for inducing type I IFN production, there is a complementary mechanism for the innate sensing of viral glycoproteins, which does not require infectious virus.", [["pDCs", "ANATOMY", 19, 23], ["pDCs", "CELL", 19, 23], ["type I IFN", "GENE_OR_GENE_PRODUCT", 67, 77], ["type I IFN", "GENE_OR_GENE_PRODUCT", 291, 301], ["infectious virus", "ORGANISM", 419, 435], ["pDCs", "CELL_TYPE", 19, 23], ["cytokines", "PROTEIN", 42, 51], ["type I IFN", "PROTEIN", 67, 77], ["viral genome", "DNA", 251, 263], ["IFN", "PROTEIN", 298, 301], ["viral glycoproteins", "PROTEIN", 375, 394], ["Virally stimulated pDCs", "PROBLEM", 0, 23], ["other cytokines", "PROBLEM", 36, 51], ["type I IFN", "PROBLEM", 67, 77], ["replicative intermediates", "PROBLEM", 221, 246], ["viral genome", "PROBLEM", 251, 263], ["type I IFN production", "PROBLEM", 291, 312], ["viral glycoproteins", "PROBLEM", 375, 394], ["infectious virus", "PROBLEM", 419, 435], ["viral genome", "OBSERVATION", 251, 263], ["viral glycoproteins", "OBSERVATION", 375, 394]]], ["In earlier work, human and porcine peripheral blood leukocytes and mouse spleen cells, and more recently human and murine pDCs specifically, have been shown to produce type I IFN in response to inactivated enveloped viruses, supporting the argument for an additional replication-independent viral recognition system.", [["peripheral blood leukocytes", "ANATOMY", 35, 62], ["spleen cells", "ANATOMY", 73, 85], ["pDCs", "ANATOMY", 122, 126], ["human", "ORGANISM", 17, 22], ["porcine", "ORGANISM", 27, 34], ["peripheral blood leukocytes", "CELL", 35, 62], ["mouse", "ORGANISM", 67, 72], ["spleen cells", "CELL", 73, 85], ["human", "ORGANISM", 105, 110], ["murine", "ORGANISM", 115, 121], ["pDCs", "CELL", 122, 126], ["type I IFN", "GENE_OR_GENE_PRODUCT", 168, 178], ["human and porcine peripheral blood leukocytes", "CELL_TYPE", 17, 62], ["mouse spleen cells", "CELL_TYPE", 67, 85], ["human and murine pDCs", "CELL_TYPE", 105, 126], ["type I IFN", "PROTEIN", 168, 178], ["human", "SPECIES", 17, 22], ["porcine", "SPECIES", 27, 34], ["mouse", "SPECIES", 67, 72], ["human", "SPECIES", 105, 110], ["murine", "SPECIES", 115, 121], ["human", "SPECIES", 17, 22], ["porcine", "SPECIES", 27, 34], ["mouse", "SPECIES", 67, 72], ["human", "SPECIES", 105, 110], ["porcine peripheral blood leukocytes", "TEST", 27, 62], ["mouse spleen cells", "PROBLEM", 67, 85], ["type I IFN", "PROBLEM", 168, 178], ["inactivated enveloped viruses", "PROBLEM", 194, 223], ["an additional replication", "TREATMENT", 253, 278], ["peripheral", "ANATOMY_MODIFIER", 35, 45], ["blood leukocytes", "ANATOMY", 46, 62], ["mouse spleen cells", "OBSERVATION", 67, 85], ["viruses", "OBSERVATION", 216, 223]]], ["This article will focus mainly on reviewing the evidence that viral glycoproteins can mediate type I IFN induction, in a mechanism which may be independent of the well-studied genome-mediated route.IntroductionA hitherto poorly studied issue is the search for the cellular receptors involved in viral glycoprotein recognition leading to type I IFN production.", [["cellular", "ANATOMY", 264, 272], ["type I IFN", "GENE_OR_GENE_PRODUCT", 94, 104], ["cellular", "CELL", 264, 272], ["type I IFN", "GENE_OR_GENE_PRODUCT", 337, 347], ["viral glycoproteins", "PROTEIN", 62, 81], ["type I IFN", "PROTEIN", 94, 104], ["cellular receptors", "PROTEIN", 264, 282], ["viral glycoprotein", "PROTEIN", 295, 313], ["IFN", "PROTEIN", 344, 347], ["viral glycoproteins", "PROBLEM", 62, 81], ["type I IFN induction", "TREATMENT", 94, 114], ["the cellular receptors", "PROBLEM", 260, 282], ["viral glycoprotein recognition", "PROBLEM", 295, 325], ["type I IFN production", "PROBLEM", 337, 358]]], ["Cell surface receptors regulate a range of functions, including differentiation, growth and survival, adhesion, migration, phagocytosis, activation and cytotoxicity.", [["Cell surface", "ANATOMY", 0, 12], ["Cell", "CELL", 0, 4], ["Cell surface receptors", "PROTEIN", 0, 22], ["Cell surface receptors", "TEST", 0, 22], ["adhesion", "PROBLEM", 102, 110], ["migration", "PROBLEM", 112, 121], ["phagocytosis", "PROBLEM", 123, 135], ["cytotoxicity", "PROBLEM", 152, 164]]], ["Identification of viral receptors is often difficult as many mediate only low affinity binding to surface viral proteins.", [["surface", "ANATOMY", 98, 105], ["viral receptors", "PROTEIN", 18, 33], ["surface viral proteins", "PROTEIN", 98, 120], ["viral receptors", "PROBLEM", 18, 33], ["low affinity binding", "PROBLEM", 74, 94], ["surface viral proteins", "PROBLEM", 98, 120], ["viral receptors", "OBSERVATION", 18, 33], ["low affinity", "OBSERVATION_MODIFIER", 74, 86]]], ["It has been difficult to identify the receptors specifically involved in glycoprotein-mediated IFN\u03b1/\u03b2 induction for both this reason and due to the rarity of pDCs.", [["pDCs", "ANATOMY", 158, 162], ["glycoprotein", "GENE_OR_GENE_PRODUCT", 73, 85], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 95, 99], ["\u03b2", "GENE_OR_GENE_PRODUCT", 100, 101], ["pDCs", "CELL", 158, 162], ["glycoprotein", "PROTEIN", 73, 85], ["IFN\u03b1", "PROTEIN", 95, 99], ["\u03b2", "PROTEIN", 100, 101], ["pDCs", "CELL_TYPE", 158, 162], ["pDCs", "PROBLEM", 158, 162]]], ["Surface receptors on DCs for microbial antigens include Toll-like receptors (TLRs), C-type lectin receptors and scavenger receptors.", [["DCs", "ANATOMY", 21, 24], ["DCs", "CELL", 21, 24], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 56, 75], ["TLRs", "GENE_OR_GENE_PRODUCT", 77, 81], ["C-type lectin receptors", "GENE_OR_GENE_PRODUCT", 84, 107], ["DCs", "CELL_TYPE", 21, 24], ["microbial antigens", "PROTEIN", 29, 47], ["Toll-like receptors", "PROTEIN", 56, 75], ["TLRs", "PROTEIN", 77, 81], ["C-type lectin receptors", "PROTEIN", 84, 107], ["scavenger receptors", "PROTEIN", 112, 131], ["Surface receptors", "TEST", 0, 17], ["DCs", "TEST", 21, 24], ["microbial antigens", "TREATMENT", 29, 47], ["C-type lectin receptors", "TREATMENT", 84, 107], ["scavenger receptors", "TREATMENT", 112, 131]]], ["The full repertoire of surface-expressed pDC receptors remains to be elucidated, however the list is growing as researchers try to understand how this important cell type recognizes and responds to pathogens.", [["surface", "ANATOMY", 23, 30], ["pDC", "ANATOMY", 41, 44], ["cell", "ANATOMY", 161, 165], ["surface", "CELLULAR_COMPONENT", 23, 30], ["pDC", "CELL", 41, 44], ["cell type", "CELL", 161, 170], ["pDC receptors", "PROTEIN", 41, 54], ["pathogens", "PROBLEM", 198, 207]]], ["In this review we highlight pattern recognition receptors (PRR) that bind or sense viral glycoproteins.", [["pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 28, 57], ["PRR", "GENE_OR_GENE_PRODUCT", 59, 62], ["pattern recognition receptors", "PROTEIN", 28, 57], ["PRR", "PROTEIN", 59, 62], ["viral glycoproteins", "PROTEIN", 83, 102], ["sense viral glycoproteins", "PROBLEM", 77, 102]]], ["Their expression on pDCs in particular, is not known in all cases.Viral recognition by endosomal sensors ::: Evidence for genome mediated induction of type I IFN by pDCsOligonucleotides have been proposed as type I IFN inducing ligands recognized by cytosolic and endosomal sensors in many cell types.", [["pDCs", "ANATOMY", 20, 24], ["endosomal", "ANATOMY", 87, 96], ["cytosolic", "ANATOMY", 250, 259], ["endosomal", "ANATOMY", 264, 273], ["cell", "ANATOMY", 290, 294], ["pDCs", "CELL", 20, 24], ["endosomal", "CELLULAR_COMPONENT", 87, 96], ["type I IFN", "GENE_OR_GENE_PRODUCT", 151, 161], ["pDCsOligonucleotides", "GENE_OR_GENE_PRODUCT", 165, 185], ["type I IFN", "GENE_OR_GENE_PRODUCT", 208, 218], ["cytosolic", "CELLULAR_COMPONENT", 250, 259], ["endosomal", "CELLULAR_COMPONENT", 264, 273], ["cell", "CELL", 290, 294], ["pDCs", "CELL_TYPE", 20, 24], ["type I IFN", "PROTEIN", 151, 161], ["pDCsOligonucleotides", "PROTEIN", 165, 185], ["IFN", "PROTEIN", 215, 218], ["genome mediated induction", "TREATMENT", 122, 147], ["type I IFN", "PROBLEM", 151, 161], ["pDCsOligonucleotides", "TREATMENT", 165, 185], ["type I IFN inducing ligands", "PROBLEM", 208, 235], ["cytosolic and endosomal sensors", "PROBLEM", 250, 281], ["endosomal sensors", "OBSERVATION", 264, 281], ["many cell types", "OBSERVATION", 285, 300]]], ["The mechanism of discrimination between self and non-self ligands is unclear, although compartmentalization of host ligands away from these receptors has been suggested (Barton et al., 2006).", [["discrimination between self and non-self ligands", "PROBLEM", 17, 65]]], ["Type I IFN induction by pDCs can be triggered through viral recognition via both TLR and non-TLR recognition of oligonucleotides. pDCs express high levels of TLRs 7 and 9 (Edwards et al., 2003), which have been shown to sense nucleic acids leading to type I IFN production.", [["pDCs", "ANATOMY", 24, 28], ["pDCs", "ANATOMY", 130, 134], ["nucleic acids", "CHEMICAL", 226, 239], ["Type I IFN", "GENE_OR_GENE_PRODUCT", 0, 10], ["pDCs", "CELL", 24, 28], ["TLR", "GENE_OR_GENE_PRODUCT", 81, 84], ["non-TLR", "GENE_OR_GENE_PRODUCT", 89, 96], ["pDCs", "CELL", 130, 134], ["TLRs 7", "GENE_OR_GENE_PRODUCT", 158, 164], ["type I IFN", "GENE_OR_GENE_PRODUCT", 251, 261], ["Type I IFN", "PROTEIN", 0, 10], ["pDCs", "CELL_TYPE", 24, 28], ["TLR", "PROTEIN", 81, 84], ["pDCs", "CELL_TYPE", 130, 134], ["TLRs 7 and 9", "PROTEIN", 158, 170], ["IFN", "PROTEIN", 258, 261], ["Type I IFN induction", "TREATMENT", 0, 20], ["non-TLR recognition of oligonucleotides", "TREATMENT", 89, 128], ["nucleic acids", "PROBLEM", 226, 239], ["type I IFN production", "PROBLEM", 251, 272], ["high", "OBSERVATION_MODIFIER", 143, 147]]], ["For example, TLR7 has been shown to mediate recognition of influenza virus genomic single-stranded RNA (ssRNA) (Diebold et al., 2004) and ssRNA from human immunodeficiency virus (HIV)-1 (Heil et al., 2004) while TLR9 senses mouse cytomegalovirus (MCMV) (Krug et al., 2004a; Tabeta et al., 2004).", [["TLR7", "CHEMICAL", 13, 17], ["human immunodeficiency virus", "DISEASE", 149, 177], ["TLR7", "GENE_OR_GENE_PRODUCT", 13, 17], ["influenza virus", "ORGANISM", 59, 74], ["human immunodeficiency virus", "ORGANISM", 149, 177], ["HIV)-1", "ORGANISM", 179, 185], ["TLR9", "GENE_OR_GENE_PRODUCT", 212, 216], ["mouse", "ORGANISM", 224, 229], ["cytomegalovirus", "ORGANISM", 230, 245], ["MCMV", "ORGANISM", 247, 251], ["TLR7", "PROTEIN", 13, 17], ["TLR9", "PROTEIN", 212, 216], ["influenza virus", "SPECIES", 59, 74], ["human immunodeficiency virus", "SPECIES", 149, 177], ["HIV", "SPECIES", 179, 182], ["mouse", "SPECIES", 224, 229], ["influenza virus", "SPECIES", 59, 74], ["human immunodeficiency virus", "SPECIES", 149, 177], ["HIV", "SPECIES", 179, 182], ["mouse cytomegalovirus", "SPECIES", 224, 245], ["MCMV", "SPECIES", 247, 251], ["influenza virus genomic single-stranded RNA (ssRNA)", "PROBLEM", 59, 110], ["ssRNA", "PROBLEM", 138, 143], ["human immunodeficiency virus", "PROBLEM", 149, 177], ["influenza virus", "OBSERVATION", 59, 74], ["stranded RNA", "OBSERVATION_MODIFIER", 90, 102]]], ["Purified ssRNA from influenza virus can stimulate bone marrow-derived DC cultures that contain pDCs to secrete IFN\u03b1; this was reduced to background levels using cells from TLR7\u2212/\u2212 mice (Diebold et al., 2004).", [["bone marrow", "ANATOMY", 50, 61], ["DC cultures", "ANATOMY", 70, 81], ["pDCs", "ANATOMY", 95, 99], ["cells", "ANATOMY", 161, 166], ["influenza virus", "ORGANISM", 20, 35], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 50, 61], ["-derived DC cultures", "CELL", 61, 81], ["pDCs", "CELL", 95, 99], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 111, 115], ["cells", "CELL", 161, 166], ["TLR7", "GENE_OR_GENE_PRODUCT", 172, 176], ["bone marrow-derived DC cultures", "CELL_LINE", 50, 81], ["pDCs", "CELL_TYPE", 95, 99], ["IFN\u03b1", "PROTEIN", 111, 115], ["TLR7", "PROTEIN", 172, 176], ["influenza virus", "SPECIES", 20, 35], ["mice", "SPECIES", 180, 184], ["influenza virus", "SPECIES", 20, 35], ["Purified ssRNA", "PROBLEM", 0, 14], ["influenza virus", "PROBLEM", 20, 35], ["bone marrow", "TEST", 50, 61], ["DC cultures", "TEST", 70, 81], ["pDCs", "PROBLEM", 95, 99], ["ssRNA", "OBSERVATION", 9, 14], ["influenza virus", "OBSERVATION", 20, 35]]], ["In addition, ssRNA derived from the HIV-1 genome stimulated human peripheral blood pDCs and murine bone marrow-derived pDCs to produce IFN\u03b1 in a TLR7-dependent manner (Heil et al., 2004).", [["peripheral blood pDCs", "ANATOMY", 66, 87], ["bone marrow", "ANATOMY", 99, 110], ["pDCs", "ANATOMY", 119, 123], ["HIV-1", "ORGANISM", 36, 41], ["human", "ORGANISM", 60, 65], ["peripheral blood pDCs", "CELL", 66, 87], ["murine", "ORGANISM", 92, 98], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 99, 110], ["-derived pDCs", "CELL", 110, 123], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 135, 139], ["TLR7", "GENE_OR_GENE_PRODUCT", 145, 149], ["HIV-1 genome", "DNA", 36, 48], ["human peripheral blood pDCs", "CELL_TYPE", 60, 87], ["murine bone marrow-derived pDCs", "CELL_TYPE", 92, 123], ["IFN\u03b1", "PROTEIN", 135, 139], ["TLR7", "PROTEIN", 145, 149], ["HIV-1", "SPECIES", 36, 41], ["human", "SPECIES", 60, 65], ["murine", "SPECIES", 92, 98], ["HIV-1", "SPECIES", 36, 41], ["human", "SPECIES", 60, 65], ["ssRNA", "PROBLEM", 13, 18], ["the HIV", "TEST", 32, 39], ["peripheral blood pDCs", "TEST", 66, 87], ["murine bone marrow", "TEST", 92, 110], ["bone", "ANATOMY", 99, 103]]], ["Similarly, it has been shown that splenic pDCs produce IFN\u03b1 in response to MCMV in a TLR9-dependent manner in experiments measuring IFN\u03b1 secretion by in vitro and in vivo stimulated murine splenic pDCs.", [["splenic pDCs", "ANATOMY", 34, 46], ["splenic pDCs", "ANATOMY", 189, 201], ["splenic pDCs", "CELL", 34, 46], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 55, 59], ["MCMV", "ORGANISM", 75, 79], ["TLR9", "GENE_OR_GENE_PRODUCT", 85, 89], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 132, 136], ["murine", "ORGANISM", 182, 188], ["splenic pDCs", "CELL", 189, 201], ["splenic pDCs", "CELL_TYPE", 34, 46], ["IFN\u03b1", "PROTEIN", 55, 59], ["TLR9", "PROTEIN", 85, 89], ["IFN\u03b1", "PROTEIN", 132, 136], ["murine splenic pDCs", "CELL_TYPE", 182, 201], ["murine", "SPECIES", 182, 188], ["MCMV", "SPECIES", 75, 79], ["splenic pDCs", "PROBLEM", 34, 46], ["MCMV", "TREATMENT", 75, 79], ["a TLR9-dependent manner", "TREATMENT", 83, 106], ["splenic", "ANATOMY", 34, 41], ["pDCs", "OBSERVATION", 42, 46], ["response to MCMV", "OBSERVATION", 63, 79], ["splenic", "ANATOMY", 189, 196]]], ["In this report the exact viral stimulus for TLR9 was not defined, but the double-stranded DNA genome of MCMV was implicated by studies using the TLR9 agonist unmethlylated CpG DNA (Krug et al., 2004a).", [["CpG", "CHEMICAL", 172, 175], ["TLR9", "GENE_OR_GENE_PRODUCT", 44, 48], ["DNA", "CELLULAR_COMPONENT", 90, 93], ["MCMV", "ORGANISM", 104, 108], ["TLR9", "GENE_OR_GENE_PRODUCT", 145, 149], ["DNA", "CELLULAR_COMPONENT", 176, 179], ["TLR9", "PROTEIN", 44, 48], ["double-stranded DNA genome", "DNA", 74, 100], ["TLR9", "PROTEIN", 145, 149], ["unmethlylated CpG DNA", "DNA", 158, 179], ["MCMV", "SPECIES", 104, 108], ["the double-stranded DNA genome of MCMV", "TREATMENT", 70, 108], ["the TLR9 agonist", "TREATMENT", 141, 157]]], ["The in vivo relevance for TLR9 in recognizing MCMV was confirmed in the same year when Tabeta et al. (2004) showed that mice with a point mutation in TLR9, which renders this receptor insensitive to its synthetic CpG DNA agonist, have higher MCMV titers in the spleen and reduced survival compared to control mice following MCMV infection.", [["spleen", "ANATOMY", 261, 267], ["MCMV infection", "DISEASE", 324, 338], ["CpG", "CHEMICAL", 213, 216], ["TLR9", "GENE_OR_GENE_PRODUCT", 26, 30], ["MCMV", "ORGANISM", 46, 50], ["mice", "ORGANISM", 120, 124], ["TLR9", "GENE_OR_GENE_PRODUCT", 150, 154], ["DNA", "CELLULAR_COMPONENT", 217, 220], ["MCMV", "ORGANISM", 242, 246], ["spleen", "ORGAN", 261, 267], ["mice", "ORGANISM", 309, 313], ["MCMV", "ORGANISM", 324, 328], ["TLR9", "PROTEIN", 26, 30], ["TLR9", "PROTEIN", 150, 154], ["mice", "SPECIES", 120, 124], ["mice", "SPECIES", 309, 313], ["MCMV", "SPECIES", 46, 50], ["mice", "SPECIES", 120, 124], ["MCMV", "SPECIES", 242, 246], ["mice", "SPECIES", 309, 313], ["MCMV", "SPECIES", 324, 328], ["TLR9 in recognizing MCMV", "TREATMENT", 26, 50], ["a point mutation in TLR9", "PROBLEM", 130, 154], ["its synthetic CpG DNA agonist", "TREATMENT", 199, 228], ["higher MCMV titers in the spleen", "PROBLEM", 235, 267], ["reduced survival", "TREATMENT", 272, 288], ["MCMV infection", "PROBLEM", 324, 338], ["higher", "OBSERVATION_MODIFIER", 235, 241], ["MCMV titers", "OBSERVATION", 242, 253], ["spleen", "ANATOMY", 261, 267], ["reduced", "OBSERVATION_MODIFIER", 272, 279], ["survival", "OBSERVATION_MODIFIER", 280, 288], ["infection", "OBSERVATION", 329, 338]]], ["In addition, these TLR9 mutant mice have reduced IFN\u03b1/\u03b2 in their serum following MCMV infection.", [["serum", "ANATOMY", 65, 70], ["infection", "DISEASE", 86, 95], ["TLR9", "GENE_OR_GENE_PRODUCT", 19, 23], ["mice", "ORGANISM", 31, 35], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 49, 53], ["\u03b2", "GENE_OR_GENE_PRODUCT", 54, 55], ["serum", "ORGANISM_SUBSTANCE", 65, 70], ["MCMV", "ORGANISM", 81, 85], ["TLR9", "PROTEIN", 19, 23], ["IFN\u03b1", "PROTEIN", 49, 53], ["\u03b2", "PROTEIN", 54, 55], ["mice", "SPECIES", 31, 35], ["mice", "SPECIES", 31, 35], ["MCMV", "SPECIES", 81, 85], ["reduced IFN\u03b1/\u03b2", "PROBLEM", 41, 55], ["MCMV infection", "PROBLEM", 81, 95], ["infection", "OBSERVATION", 86, 95]]], ["TLR3 senses dsRNA resulting in IFN\u03b1/\u03b2 induction, however it is not essential for IFN\u03b1/\u03b2 induction in virally infected cells (Honda et al., 2003) and neither human nor murine pDCs express this TLR (Colonna et al., 2004; Edwards et al., 2003).", [["cells", "ANATOMY", 118, 123], ["pDCs", "ANATOMY", 174, 178], ["virally infected", "DISEASE", 101, 117], ["TLR3", "GENE_OR_GENE_PRODUCT", 0, 4], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 31, 35], ["\u03b2", "GENE_OR_GENE_PRODUCT", 36, 37], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 81, 85], ["\u03b2", "GENE_OR_GENE_PRODUCT", 86, 87], ["virally", "ORGANISM", 101, 108], ["cells", "CELL", 118, 123], ["human", "ORGANISM", 157, 162], ["murine", "ORGANISM", 167, 173], ["pDCs", "CELL", 174, 178], ["TLR", "GENE_OR_GENE_PRODUCT", 192, 195], ["TLR3", "PROTEIN", 0, 4], ["IFN\u03b1", "PROTEIN", 31, 35], ["\u03b2", "PROTEIN", 36, 37], ["IFN\u03b1", "PROTEIN", 81, 85], ["\u03b2", "PROTEIN", 86, 87], ["virally infected cells", "CELL_TYPE", 101, 123], ["human nor murine pDCs", "CELL_TYPE", 157, 178], ["TLR", "PROTEIN", 192, 195], ["human", "SPECIES", 157, 162], ["murine", "SPECIES", 167, 173], ["human", "SPECIES", 157, 162], ["TLR3 senses dsRNA", "PROBLEM", 0, 17], ["IFN", "PROBLEM", 31, 34], ["IFN", "PROBLEM", 81, 84], ["senses dsRNA", "OBSERVATION", 5, 17]]], ["This evidence suggests that TLRs can play an important, and often necessary, role in viral sensing leading to type I IFN production; however, they are only expressed in a subset of cells and other receptors also sense viral ligands.Viral recognition by cytosolic sensors ::: Evidence for genome mediated induction of type I IFN by pDCsIn addition to endosomal TLR-mediated virus recognition, cytosolic pathways are also present.", [["cells", "ANATOMY", 181, 186], ["cytosolic", "ANATOMY", 253, 262], ["endosomal", "ANATOMY", 350, 359], ["cytosolic", "ANATOMY", 392, 401], ["TLRs", "GENE_OR_GENE_PRODUCT", 28, 32], ["type I IFN", "GENE_OR_GENE_PRODUCT", 110, 120], ["cells", "CELL", 181, 186], ["type I IFN", "GENE_OR_GENE_PRODUCT", 317, 327], ["pDCsIn", "GENE_OR_GENE_PRODUCT", 331, 337], ["endosomal", "CELLULAR_COMPONENT", 350, 359], ["TLR", "GENE_OR_GENE_PRODUCT", 360, 363], ["TLRs", "PROTEIN", 28, 32], ["IFN", "PROTEIN", 117, 120], ["type I IFN", "PROTEIN", 317, 327], ["pDCsIn", "PROTEIN", 331, 337], ["endosomal TLR", "PROTEIN", 350, 363], ["viral sensing", "PROBLEM", 85, 98], ["type I IFN production", "PROBLEM", 110, 131], ["type I IFN", "PROBLEM", 317, 327], ["endosomal TLR-mediated virus recognition", "TREATMENT", 350, 390], ["cytosolic pathways", "PROBLEM", 392, 410], ["viral ligands", "OBSERVATION", 218, 231]]], ["The cytoplasm of both innate immune cells and non-immune cells contains retinoic acid inducible gene-I (RIG-I) and melanoma differentiation-associated protein 5 (Mda5), which sense cytosolic virus-associated dsRNA leading to type I IFN production (Yoneyama et al., 2004, Yoneyama et al., 2005).", [["cytoplasm", "ANATOMY", 4, 13], ["immune cells", "ANATOMY", 29, 41], ["non-immune cells", "ANATOMY", 46, 62], ["cytosolic", "ANATOMY", 181, 190], ["retinoic acid", "CHEMICAL", 72, 85], ["cytoplasm", "ORGANISM_SUBSTANCE", 4, 13], ["innate immune cells", "CELL", 22, 41], ["non-immune cells", "CELL", 46, 62], ["retinoic acid inducible gene-I", "GENE_OR_GENE_PRODUCT", 72, 102], ["RIG-I", "GENE_OR_GENE_PRODUCT", 104, 109], ["melanoma differentiation-associated protein 5", "GENE_OR_GENE_PRODUCT", 115, 160], ["Mda5", "GENE_OR_GENE_PRODUCT", 162, 166], ["type I IFN", "GENE_OR_GENE_PRODUCT", 225, 235], ["innate immune cells", "CELL_TYPE", 22, 41], ["non-immune cells", "CELL_TYPE", 46, 62], ["retinoic acid inducible gene-I", "DNA", 72, 102], ["RIG-I", "DNA", 104, 109], ["melanoma differentiation-associated protein 5", "PROTEIN", 115, 160], ["Mda5", "PROTEIN", 162, 166], ["IFN", "PROTEIN", 232, 235], ["non-immune cells", "PROBLEM", 46, 62], ["retinoic acid inducible gene-I (RIG-I)", "PROBLEM", 72, 110], ["melanoma differentiation", "PROBLEM", 115, 139], ["associated protein", "PROBLEM", 140, 158], ["sense cytosolic virus", "PROBLEM", 175, 196], ["associated dsRNA", "PROBLEM", 197, 213], ["type I IFN production", "PROBLEM", 225, 246], ["both", "ANATOMY_MODIFIER", 17, 21], ["innate immune cells", "OBSERVATION", 22, 41], ["non-immune cells", "OBSERVATION", 46, 62], ["retinoic acid", "OBSERVATION", 72, 85], ["melanoma", "OBSERVATION", 115, 123], ["cytosolic virus", "OBSERVATION", 181, 196]]], ["Interestingly, studies comparing pDCs from RIG-I\u2212/\u2212 and MyD88\u2212/\u2212TRIF\u2212/\u2212 mice (which lack all known TLR-mediated activation signaling pathways) by Kato et al. (2005) demonstrated that the use of RIG-I or TLRs was cell type specific.", [["pDCs", "ANATOMY", 33, 37], ["cell", "ANATOMY", 212, 216], ["pDCs", "CELL", 33, 37], ["RIG-I\u2212", "GENE_OR_GENE_PRODUCT", 43, 49], ["\u2212", "GENE_OR_GENE_PRODUCT", 50, 51], ["MyD88\u2212", "GENE_OR_GENE_PRODUCT", 56, 62], ["TRIF", "GENE_OR_GENE_PRODUCT", 64, 68], ["TLR", "GENE_OR_GENE_PRODUCT", 99, 102], ["RIG-I", "GENE_OR_GENE_PRODUCT", 194, 199], ["TLRs", "GENE_OR_GENE_PRODUCT", 203, 207], ["cell", "CELL", 212, 216], ["pDCs", "CELL_TYPE", 33, 37], ["RIG", "PROTEIN", 43, 46], ["TRIF", "PROTEIN", 64, 68], ["TLR", "PROTEIN", 99, 102], ["RIG-I", "PROTEIN", 194, 199], ["TLRs", "PROTEIN", 203, 207], ["mice", "SPECIES", 72, 76], ["mice", "SPECIES", 72, 76], ["RIG", "TEST", 43, 46]]], ["While RIG-I seems to be required for IFN\u03b1/\u03b2 production in several cell types, TLRs remain the key pathway for innate recognition of RNA viruses in pDCs.", [["cell", "ANATOMY", 66, 70], ["pDCs", "ANATOMY", 147, 151], ["RIG-I", "GENE_OR_GENE_PRODUCT", 6, 11], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 37, 41], ["\u03b2", "GENE_OR_GENE_PRODUCT", 42, 43], ["cell", "CELL", 66, 70], ["TLRs", "GENE_OR_GENE_PRODUCT", 78, 82], ["pDCs", "CELL", 147, 151], ["RIG-I", "PROTEIN", 6, 11], ["IFN\u03b1", "PROTEIN", 37, 41], ["\u03b2", "PROTEIN", 42, 43], ["TLRs", "PROTEIN", 78, 82], ["pDCs", "CELL_TYPE", 147, 151], ["IFN", "PROBLEM", 37, 40], ["production", "PROBLEM", 44, 54], ["RNA viruses", "PROBLEM", 132, 143], ["several cell", "OBSERVATION_MODIFIER", 58, 70]]], ["Hence, pDCs from RIG-I\u2212/\u2212 mice showed equivalent IFN-\u03b1 production following Newcastle Disease virus (NDV) infection to that by wild-type mice, whereas pDCs from MyD88\u2212/\u2212 mice had a 4-fold reduction in IFN-\u03b1 production.", [["pDCs", "ANATOMY", 7, 11], ["pDCs", "ANATOMY", 151, 155], ["Newcastle Disease virus (NDV) infection", "DISEASE", 76, 115], ["pDCs", "CELL", 7, 11], ["RIG-I\u2212", "GENE_OR_GENE_PRODUCT", 17, 23], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 49, 54], ["Newcastle Disease virus", "ORGANISM", 76, 99], ["NDV", "ORGANISM", 101, 104], ["mice", "ORGANISM", 137, 141], ["pDCs", "CELL", 151, 155], ["MyD88", "GENE_OR_GENE_PRODUCT", 161, 166], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 201, 206], ["pDCs", "CELL_TYPE", 7, 11], ["RIG", "PROTEIN", 17, 20], ["IFN", "PROTEIN", 49, 52], ["pDCs", "CELL_TYPE", 151, 155], ["MyD88", "PROTEIN", 161, 166], ["IFN", "PROTEIN", 201, 204], ["mice", "SPECIES", 26, 30], ["mice", "SPECIES", 137, 141], ["mice", "SPECIES", 170, 174], ["mice", "SPECIES", 26, 30], ["Newcastle Disease virus", "SPECIES", 76, 99], ["NDV", "SPECIES", 101, 104], ["mice", "SPECIES", 137, 141], ["mice", "SPECIES", 170, 174], ["RIG", "TEST", 17, 20], ["equivalent IFN", "PROBLEM", 38, 52], ["Newcastle Disease virus (NDV) infection", "PROBLEM", 76, 115], ["MyD88", "TEST", 161, 166], ["a 4-fold reduction", "PROBLEM", 179, 197], ["IFN", "PROBLEM", 201, 204], ["4-fold", "OBSERVATION_MODIFIER", 181, 187], ["reduction", "OBSERVATION_MODIFIER", 188, 197]]], ["These two pathways of cytosolic dsRNA detection may have complementary functions; perhaps RIG-I sensing of cytosolic dsRNA may be important for an immediate detection of viral infection while TLR sensing of dsRNA in endosomal compartments may be more important for the systemic response to virus (Benedict and Ware, 2005; Levy and Marie, 2004).", [["cytosolic", "ANATOMY", 22, 31], ["cytosolic", "ANATOMY", 107, 116], ["endosomal compartments", "ANATOMY", 216, 238], ["infection", "DISEASE", 176, 185], ["cytosolic", "CELLULAR_COMPONENT", 22, 31], ["RIG-I", "GENE_OR_GENE_PRODUCT", 90, 95], ["TLR", "GENE_OR_GENE_PRODUCT", 192, 195], ["endosomal", "CELLULAR_COMPONENT", 216, 225], ["TLR", "PROTEIN", 192, 195], ["cytosolic dsRNA detection", "TREATMENT", 22, 47], ["cytosolic dsRNA", "TREATMENT", 107, 122], ["viral infection", "PROBLEM", 170, 185], ["dsRNA in endosomal compartments", "PROBLEM", 207, 238], ["cytosolic dsRNA", "OBSERVATION", 22, 37], ["cytosolic dsRNA", "OBSERVATION", 107, 122], ["viral", "OBSERVATION_MODIFIER", 170, 175], ["infection", "OBSERVATION", 176, 185], ["dsRNA", "OBSERVATION", 207, 212]]], ["Cells can also detect dsRNA through the dsRNA-dependent protein kinase R (PKR), which in response, inhibits host translation by phosphorylating the translation initiation factor eIF2\u03b1 and activates NF-\u03baB (Saunders and Barber, 2003).", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["dsRNA-dependent protein kinase R", "GENE_OR_GENE_PRODUCT", 40, 72], ["PKR", "GENE_OR_GENE_PRODUCT", 74, 77], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 178, 183], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 198, 203], ["protein kinase R", "PROTEIN", 56, 72], ["PKR", "PROTEIN", 74, 77], ["translation initiation factor", "PROTEIN", 148, 177], ["eIF2\u03b1", "PROTEIN", 178, 183], ["NF-\u03baB", "PROTEIN", 198, 203], ["dsRNA", "PROBLEM", 22, 27], ["the dsRNA", "TEST", 36, 45]]], ["Whether cells also have a mechanism for cytosolic recognition of ssRNA remains to be discovered.", [["cells", "ANATOMY", 8, 13], ["cytosolic", "ANATOMY", 40, 49], ["cells", "CELL", 8, 13], ["cytosolic", "CELLULAR_COMPONENT", 40, 49], ["cytosolic recognition of ssRNA", "PROBLEM", 40, 70], ["ssRNA", "OBSERVATION", 65, 70]]], ["Recently, a pathway by which the recognition of foreign cytosolic DNA leads to the production of type I IFN has been investigated in macrophages and DCs; however, the identity of the DNA sensor is not yet known, nor is whether DNA viruses may activate this pathway (Ishii et al., 2006; Stetson and Medzhitov, 2006).", [["cytosolic", "ANATOMY", 56, 65], ["macrophages", "ANATOMY", 133, 144], ["DCs", "ANATOMY", 149, 152], ["DNA", "CELLULAR_COMPONENT", 66, 69], ["type I IFN", "GENE_OR_GENE_PRODUCT", 97, 107], ["macrophages", "CELL", 133, 144], ["DCs", "CELL", 149, 152], ["DNA", "CELLULAR_COMPONENT", 183, 186], ["DNA", "CELLULAR_COMPONENT", 227, 230], ["type I IFN", "PROTEIN", 97, 107], ["macrophages", "CELL_TYPE", 133, 144], ["DCs", "CELL_TYPE", 149, 152], ["foreign cytosolic DNA", "PROBLEM", 48, 69], ["type I IFN", "PROBLEM", 97, 107], ["the DNA sensor", "TEST", 179, 193], ["DNA viruses", "PROBLEM", 227, 238], ["foreign cytosolic DNA", "OBSERVATION", 48, 69]]], ["Stetson and Medzhitov (2006) used infection by the intracellular bacterium Listeria monocytogenes as a source of cytosolic DNA, as well as DNA that lacks CpG motifs, to induce type I IFN production and this second source of DNA also induced potent induction of type I IFN when transfected into pDCs.", [["intracellular", "ANATOMY", 51, 64], ["cytosolic", "ANATOMY", 113, 122], ["pDCs", "ANATOMY", 294, 298], ["infection", "DISEASE", 34, 43], ["CpG", "CHEMICAL", 154, 157], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 51, 64], ["Listeria monocytogenes", "ORGANISM", 75, 97], ["cytosolic", "CELLULAR_COMPONENT", 113, 122], ["DNA", "CELLULAR_COMPONENT", 123, 126], ["DNA", "CELLULAR_COMPONENT", 139, 142], ["type I IFN", "GENE_OR_GENE_PRODUCT", 176, 186], ["DNA", "CELLULAR_COMPONENT", 224, 227], ["type I IFN", "GENE_OR_GENE_PRODUCT", 261, 271], ["pDCs", "CELL", 294, 298], ["cytosolic DNA", "DNA", 113, 126], ["CpG motifs", "DNA", 154, 164], ["IFN", "PROTEIN", 183, 186], ["type I IFN", "PROTEIN", 261, 271], ["pDCs", "CELL_TYPE", 294, 298], ["Listeria monocytogenes", "SPECIES", 75, 97], ["Listeria monocytogenes", "SPECIES", 75, 97], ["Medzhitov", "TREATMENT", 12, 21], ["infection", "PROBLEM", 34, 43], ["the intracellular bacterium Listeria monocytogenes", "PROBLEM", 47, 97], ["cytosolic DNA", "PROBLEM", 113, 126], ["CpG motifs", "TREATMENT", 154, 164], ["type I IFN production", "PROBLEM", 176, 197], ["DNA", "PROBLEM", 224, 227], ["type I IFN", "PROBLEM", 261, 271]]], ["Clearly, there is still more to learn about the cytosolic recognition of viral nucleic acids.Viral recognition by cytosolic sensors ::: Evidence for genome mediated induction of type I IFN by pDCsThe exact viral ligand binding to these receptors has not been unambiguously identified, although viral genome has been strongly implicated by the discovery of agonists of these receptors.", [["cytosolic", "ANATOMY", 48, 57], ["cytosolic", "ANATOMY", 114, 123], ["pDCs", "ANATOMY", 192, 196], ["nucleic acids", "CHEMICAL", 79, 92], ["type I IFN", "GENE_OR_GENE_PRODUCT", 178, 188], ["pDCs", "CELL", 192, 196], ["type I IFN", "PROTEIN", 178, 188], ["pDCs", "CELL_TYPE", 192, 196], ["viral genome", "DNA", 294, 306], ["viral nucleic acids", "TREATMENT", 73, 92], ["type I IFN", "PROBLEM", 178, 188], ["The exact viral ligand binding", "PROBLEM", 196, 226], ["viral genome", "PROBLEM", 294, 306], ["viral nucleic acids", "OBSERVATION", 73, 92], ["viral ligand", "OBSERVATION", 206, 218], ["viral genome", "OBSERVATION", 294, 306]]], ["It is conceivable that the viral ligand, such as dsRNA, ssRNA or DNA (whether it contains CpG or not), is recognized through another unidentified receptor and this brings the proposed ligand in contact with the known PRR (for example TLR) either by directing it to the correct cellular compartment or clustering the ligand in the vicinity of PRR, leading to the presentation of an array of ligands.", [["cellular compartment", "ANATOMY", 277, 297], ["CpG", "CHEMICAL", 90, 93], ["dsRNA", "GENE_OR_GENE_PRODUCT", 49, 54], ["DNA", "CELLULAR_COMPONENT", 65, 68], ["PRR", "GENE_OR_GENE_PRODUCT", 217, 220], ["TLR", "GENE_OR_GENE_PRODUCT", 234, 237], ["cellular", "CELL", 277, 285], ["PRR", "GENE_OR_GENE_PRODUCT", 342, 345], ["viral ligand", "PROTEIN", 27, 39], ["PRR", "PROTEIN", 217, 220], ["TLR", "PROTEIN", 234, 237], ["PRR", "PROTEIN", 342, 345], ["the viral ligand", "PROBLEM", 23, 39], ["dsRNA", "PROBLEM", 49, 54], ["ssRNA", "PROBLEM", 56, 61], ["DNA", "PROBLEM", 65, 68], ["viral ligand", "OBSERVATION", 27, 39]]], ["Alternatively, signaling via an additional co-receptor may be required or another ligand associated with the oligonucleotide may mediate binding to the PRR.Fixed virus-infected cells can stimulate IFN production ::: Evidence for glycoprotein mediated induction of type I IFNStudies using fixed virus-infected cells as stimuli for type I IFN induction suggest that IFN production is independent of virus entry into the producer cells.", [["cells", "ANATOMY", 177, 182], ["cells", "ANATOMY", 309, 314], ["cells", "ANATOMY", 427, 432], ["PRR", "GENE_OR_GENE_PRODUCT", 152, 155], ["Fixed virus", "ORGANISM", 156, 167], ["cells", "CELL", 177, 182], ["IFN", "GENE_OR_GENE_PRODUCT", 197, 200], ["type I IFNStudies", "GENE_OR_GENE_PRODUCT", 264, 281], ["fixed virus", "ORGANISM", 288, 299], ["cells", "CELL", 309, 314], ["type I IFN", "GENE_OR_GENE_PRODUCT", 330, 340], ["IFN", "GENE_OR_GENE_PRODUCT", 364, 367], ["cells", "CELL", 427, 432], ["PRR", "PROTEIN", 152, 155], ["IFN", "PROTEIN", 197, 200], ["glycoprotein", "PROTEIN", 229, 241], ["type I IFNStudies", "PROTEIN", 264, 281], ["IFN", "PROTEIN", 337, 340], ["IFN", "PROTEIN", 364, 367], ["producer cells", "CELL_TYPE", 418, 432], ["Fixed virus", "SPECIES", 156, 167], ["the oligonucleotide", "TREATMENT", 105, 124], ["Fixed virus", "PROBLEM", 156, 167], ["infected cells", "PROBLEM", 168, 182], ["glycoprotein mediated induction", "TREATMENT", 229, 260], ["type I IFNStudies", "PROBLEM", 264, 281], ["fixed virus", "PROBLEM", 288, 299], ["infected cells", "PROBLEM", 300, 314], ["type I IFN induction", "TREATMENT", 330, 350], ["IFN production", "PROBLEM", 364, 378], ["virus", "OBSERVATION", 162, 167], ["infected cells", "OBSERVATION", 168, 182], ["infected cells", "OBSERVATION", 300, 314]]], ["This has been demonstrated using fixed cells infected with herpes simplex virus (HSV)-1 (Capobianchi et al., 1985; Lebon, 1985), dengue virus (Kurane et al., 1986), transmissible gastroenteritis coronavirus (TGEV) (Charley and Laude, 1988), human parainfluenza virus (HPIV)-4A (Ito et al., 1994); and influenza virus (Miller and Anders, 2003).", [["cells", "ANATOMY", 39, 44], ["herpes simplex virus", "DISEASE", 59, 79], ["dengue virus", "DISEASE", 129, 141], ["transmissible gastroenteritis coronavirus", "DISEASE", 165, 206], ["TGEV", "DISEASE", 208, 212], ["human parainfluenza virus", "DISEASE", 241, 266], ["influenza virus", "DISEASE", 301, 316], ["cells", "CELL", 39, 44], ["herpes simplex virus", "ORGANISM", 59, 79], ["HSV)-1", "ORGANISM", 81, 87], ["dengue virus", "ORGANISM", 129, 141], ["transmissible gastroenteritis coronavirus", "ORGANISM", 165, 206], ["TGEV", "ORGANISM", 208, 212], ["human", "ORGANISM", 241, 246], ["parainfluenza virus", "ORGANISM", 247, 266], ["influenza virus", "ORGANISM", 301, 316], ["herpes simplex virus", "SPECIES", 59, 79], ["dengue virus", "SPECIES", 129, 141], ["transmissible gastroenteritis coronavirus", "SPECIES", 165, 206], ["TGEV", "SPECIES", 208, 212], ["human", "SPECIES", 241, 246], ["parainfluenza virus", "SPECIES", 247, 266], ["influenza virus", "SPECIES", 301, 316], ["herpes simplex virus", "SPECIES", 59, 79], ["HSV", "SPECIES", 81, 84], ["dengue virus", "SPECIES", 129, 141], ["transmissible gastroenteritis coronavirus", "SPECIES", 165, 206], ["TGEV", "SPECIES", 208, 212], ["human parainfluenza virus", "SPECIES", 241, 266], ["HPIV", "SPECIES", 268, 272], ["fixed cells infected", "PROBLEM", 33, 53], ["herpes simplex virus", "PROBLEM", 59, 79], ["HSV", "TEST", 81, 84], ["Lebon", "TEST", 115, 120], ["dengue virus", "PROBLEM", 129, 141], ["transmissible gastroenteritis coronavirus", "PROBLEM", 165, 206], ["human parainfluenza virus", "PROBLEM", 241, 266], ["influenza virus", "PROBLEM", 301, 316], ["fixed cells", "OBSERVATION", 33, 44], ["gastroenteritis coronavirus", "ANATOMY", 179, 206], ["parainfluenza virus", "OBSERVATION", 247, 266]]], ["These fixed virus-infected cells are thought to present arrays of viral glycoproteins at their surface, which would presumably be able to interact with receptors on the NIPC.", [["cells", "ANATOMY", 27, 32], ["surface", "ANATOMY", 95, 102], ["NIPC", "ANATOMY", 169, 173], ["cells", "CELL", 27, 32], ["surface", "CELLULAR_COMPONENT", 95, 102], ["viral glycoproteins", "PROTEIN", 66, 85], ["NIPC", "PROTEIN", 169, 173], ["These fixed virus", "PROBLEM", 0, 17], ["infected cells", "PROBLEM", 18, 32], ["viral glycoproteins", "PROBLEM", 66, 85], ["fixed", "OBSERVATION_MODIFIER", 6, 11], ["virus", "OBSERVATION", 12, 17], ["infected cells", "OBSERVATION", 18, 32], ["viral glycoproteins", "OBSERVATION", 66, 85]]], ["A number of these studies also implicated specific viral glycoproteins as necessary for IFN induction since mAb specific for the viral glycoprotein could block IFN induction.", [["IFN", "GENE_OR_GENE_PRODUCT", 88, 91], ["mAb", "GENE_OR_GENE_PRODUCT", 108, 111], ["IFN", "GENE_OR_GENE_PRODUCT", 160, 163], ["viral glycoproteins", "PROTEIN", 51, 70], ["IFN", "PROTEIN", 88, 91], ["mAb", "PROTEIN", 108, 111], ["viral glycoprotein", "PROTEIN", 129, 147], ["IFN", "PROTEIN", 160, 163], ["these studies", "TEST", 12, 25], ["specific viral glycoproteins", "PROBLEM", 42, 70], ["IFN induction", "TREATMENT", 88, 101], ["mAb", "TREATMENT", 108, 111], ["the viral glycoprotein", "TREATMENT", 125, 147], ["IFN induction", "TREATMENT", 160, 173]]], ["For example, in experiments by Charley et al. IFN induction by fixed TGEV-infected cells could be blocked by antibodies against the M (also known as E1) surface glycoprotein of TGEV (Charley and Laude, 1988).", [["cells", "ANATOMY", 83, 88], ["IFN", "CHEMICAL", 46, 49], ["IFN", "GENE_OR_GENE_PRODUCT", 46, 49], ["TGEV", "ORGANISM", 69, 73], ["cells", "CELL", 83, 88], ["E1", "GENE_OR_GENE_PRODUCT", 149, 151], ["TGEV", "ORGANISM", 177, 181], ["IFN", "PROTEIN", 46, 49], ["antibodies", "PROTEIN", 109, 119], ["E1", "PROTEIN", 149, 151], ["TGEV", "SPECIES", 69, 73], ["TGEV", "SPECIES", 177, 181], ["IFN induction", "TREATMENT", 46, 59], ["fixed TGEV", "PROBLEM", 63, 73], ["infected cells", "PROBLEM", 74, 88], ["infected cells", "OBSERVATION", 74, 88]]], ["Similarly, fixed HSV-1-infected cells induced IFN secretion by human PBMC, which was inhibited by the addition of mAb against HSV-1 envelope glycoprotein gD (Lebon, 1985).", [["cells", "ANATOMY", 32, 37], ["PBMC", "ANATOMY", 69, 73], ["HSV-1", "ORGANISM", 17, 22], ["cells", "CELL", 32, 37], ["IFN", "GENE_OR_GENE_PRODUCT", 46, 49], ["human", "ORGANISM", 63, 68], ["PBMC", "CELL", 69, 73], ["HSV-1", "ORGANISM", 126, 131], ["IFN", "PROTEIN", 46, 49], ["human PBMC", "CELL_TYPE", 63, 73], ["mAb", "PROTEIN", 114, 117], ["HSV-1 envelope glycoprotein gD", "PROTEIN", 126, 156], ["HSV-1", "SPECIES", 17, 22], ["human", "SPECIES", 63, 68], ["HSV-1", "SPECIES", 126, 131], ["HSV-1", "SPECIES", 17, 22], ["human", "SPECIES", 63, 68], ["HSV-1", "SPECIES", 126, 131], ["fixed HSV", "TEST", 11, 20], ["infected cells", "PROBLEM", 23, 37], ["IFN secretion", "PROBLEM", 46, 59], ["human PBMC", "TEST", 63, 73], ["mAb", "TREATMENT", 114, 117], ["HSV", "PROBLEM", 126, 129], ["fixed", "OBSERVATION_MODIFIER", 11, 16], ["HSV", "OBSERVATION", 17, 20], ["infected cells", "OBSERVATION", 23, 37]]], ["Fixed HPIV-4A-infected cells induced IFN production by mouse splenocytes and this could be inhibited by anti-HPIV-4A antiserum and mixtures of mAb against multiple epitopes on the HN glycoprotein (Ito et al., 1994).", [["cells", "ANATOMY", 23, 28], ["splenocytes", "ANATOMY", 61, 72], ["HPIV-4A", "CELL", 6, 13], ["cells", "CELL", 23, 28], ["IFN", "GENE_OR_GENE_PRODUCT", 37, 40], ["mouse", "ORGANISM", 55, 60], ["splenocytes", "CELL", 61, 72], ["anti-HPIV-4A", "GENE_OR_GENE_PRODUCT", 104, 116], ["antiserum", "ORGANISM_SUBSTANCE", 117, 126], ["mAb", "GENE_OR_GENE_PRODUCT", 143, 146], ["HN glycoprotein", "GENE_OR_GENE_PRODUCT", 180, 195], ["HPIV-4A-infected cells", "CELL_LINE", 6, 28], ["IFN", "PROTEIN", 37, 40], ["mouse splenocytes", "CELL_TYPE", 55, 72], ["anti-HPIV", "PROTEIN", 104, 113], ["mAb", "PROTEIN", 143, 146], ["epitopes", "PROTEIN", 164, 172], ["HN glycoprotein", "PROTEIN", 180, 195], ["mouse", "SPECIES", 55, 60], ["HPIV-4A", "SPECIES", 6, 13], ["mouse", "SPECIES", 55, 60], ["Fixed HPIV", "TEST", 0, 10], ["infected cells", "PROBLEM", 14, 28], ["IFN production", "PROBLEM", 37, 51], ["mouse splenocytes", "PROBLEM", 55, 72], ["anti-HPIV", "TEST", 104, 113], ["4A antiserum", "TREATMENT", 114, 126], ["mAb", "TREATMENT", 143, 146], ["multiple epitopes", "PROBLEM", 155, 172], ["infected cells", "OBSERVATION", 14, 28]]], ["Such systems of fixed virus infected-cells presumably have few or no free virions hence their ability to induce type I IFN is thought to be a consequence of interactions between viral envelope glycoproteins expressed on the surface membrane of the infected cells and receptors on the NIPC.", [["cells", "ANATOMY", 37, 42], ["surface membrane", "ANATOMY", 224, 240], ["cells", "ANATOMY", 257, 262], ["NIPC", "ANATOMY", 284, 288], ["fixed virus", "ORGANISM", 16, 27], ["-cells", "CELL", 36, 42], ["type I IFN", "GENE_OR_GENE_PRODUCT", 112, 122], ["surface membrane", "CELLULAR_COMPONENT", 224, 240], ["cells", "CELL", 257, 262], ["type I IFN", "PROTEIN", 112, 122], ["viral envelope glycoproteins", "PROTEIN", 178, 206], ["infected cells", "CELL_TYPE", 248, 262], ["NIPC", "CELL_TYPE", 284, 288], ["fixed virus infected-cells", "PROBLEM", 16, 42], ["free virions", "PROBLEM", 69, 81], ["type I IFN", "PROBLEM", 112, 122], ["viral envelope glycoproteins", "TREATMENT", 178, 206], ["the infected cells", "PROBLEM", 244, 262], ["fixed virus", "OBSERVATION", 16, 27], ["thought to be", "UNCERTAINTY", 126, 139], ["infected cells", "OBSERVATION", 248, 262]]], ["Alternatively the NIPC could recognize a cellular stress ligand induced upon viral infection.Cells transfected with viral glycoproteins can stimulate IFN production ::: Evidence for glycoprotein mediated induction of type I IFNThe use of cells transfected with viral glycoproteins allows researchers to ask whether induction is triggered by one or several viral glycoproteins, whether other viral components are necessary, or whether a cellular stress response to viral infection was also important.", [["cellular", "ANATOMY", 41, 49], ["Cells", "ANATOMY", 93, 98], ["cells", "ANATOMY", 238, 243], ["cellular", "ANATOMY", 436, 444], ["viral infection", "DISEASE", 77, 92], ["viral infection", "DISEASE", 464, 479], ["NIPC", "GENE_OR_GENE_PRODUCT", 18, 22], ["cellular", "CELL", 41, 49], ["Cells", "CELL", 93, 98], ["IFN", "GENE_OR_GENE_PRODUCT", 150, 153], ["type I IFN", "GENE_OR_GENE_PRODUCT", 217, 227], ["cells", "CELL", 238, 243], ["cellular", "CELL", 436, 444], ["NIPC", "PROTEIN", 18, 22], ["viral glycoproteins", "PROTEIN", 116, 135], ["IFN", "PROTEIN", 150, 153], ["glycoprotein", "PROTEIN", 182, 194], ["type I IFN", "PROTEIN", 217, 227], ["viral glycoproteins", "PROTEIN", 261, 280], ["viral glycoproteins", "PROTEIN", 356, 375], ["a cellular stress ligand", "PROBLEM", 39, 63], ["viral infection", "PROBLEM", 77, 92], ["viral glycoproteins", "TREATMENT", 116, 135], ["glycoprotein mediated induction", "TREATMENT", 182, 213], ["type I IFN", "PROBLEM", 217, 227], ["cells transfected", "TREATMENT", 238, 255], ["viral glycoproteins", "TREATMENT", 261, 280], ["several viral glycoproteins", "PROBLEM", 348, 375], ["other viral components", "PROBLEM", 385, 407], ["a cellular stress response", "PROBLEM", 434, 460], ["viral infection", "PROBLEM", 464, 479], ["cellular stress ligand", "OBSERVATION", 41, 63], ["viral", "OBSERVATION_MODIFIER", 77, 82], ["infection", "OBSERVATION", 83, 92], ["viral", "OBSERVATION_MODIFIER", 464, 469], ["infection", "OBSERVATION", 470, 479]]], ["In addition, systems using inactivated virus, or even virus-infected cells, as stimuli for type I IFN induction cannot rule out that viral nucleic acid may be present and capable of triggering type I IFN production.", [["cells", "ANATOMY", 69, 74], ["nucleic acid", "CHEMICAL", 139, 151], ["cells", "CELL", 69, 74], ["type I IFN", "GENE_OR_GENE_PRODUCT", 91, 101], ["type I IFN", "GENE_OR_GENE_PRODUCT", 193, 203], ["virus-infected cells", "CELL_TYPE", 54, 74], ["IFN", "PROTEIN", 98, 101], ["IFN", "PROTEIN", 200, 203], ["inactivated virus", "PROBLEM", 27, 44], ["even virus", "PROBLEM", 49, 59], ["infected cells", "PROBLEM", 60, 74], ["type I IFN induction", "TREATMENT", 91, 111], ["viral nucleic acid", "PROBLEM", 133, 151], ["triggering type I IFN production", "PROBLEM", 182, 214], ["infected cells", "OBSERVATION", 60, 74]]], ["Experiments where no viral genome is present most strongly suggest there is a genome-independent pathway of type I IFN induction, in which viral glycoproteins are recognized as the stimuli triggering IFN production.", [["type I IFN", "GENE_OR_GENE_PRODUCT", 108, 118], ["IFN", "GENE_OR_GENE_PRODUCT", 200, 203], ["viral genome", "DNA", 21, 33], ["IFN", "PROTEIN", 115, 118], ["viral glycoproteins", "PROTEIN", 139, 158], ["IFN", "PROTEIN", 200, 203], ["viral genome", "PROBLEM", 21, 33], ["type I IFN induction", "TREATMENT", 108, 128], ["viral glycoproteins", "PROBLEM", 139, 158], ["IFN production", "PROBLEM", 200, 214], ["no", "UNCERTAINTY", 18, 20], ["viral genome", "OBSERVATION", 21, 33]]], ["An example of this was seen when fixed insect cells transfected with the HSV-1 envelope glycoprotein gD, but not other HSV-1 glycoproteins (gB, gC, gE, gG and gI), induced strong type I IFN secretion by human PBMC (Ankel et al., 1998).", [["cells", "ANATOMY", 46, 51], ["PBMC", "ANATOMY", 209, 213], ["cells", "CELL", 46, 51], ["HSV-1", "ORGANISM", 73, 78], ["gD", "GENE_OR_GENE_PRODUCT", 101, 103], ["HSV-1 glycoproteins", "ORGANISM", 119, 138], ["gB", "GENE_OR_GENE_PRODUCT", 140, 142], ["gC", "GENE_OR_GENE_PRODUCT", 144, 146], ["gE", "GENE_OR_GENE_PRODUCT", 148, 150], ["gG", "GENE_OR_GENE_PRODUCT", 152, 154], ["gI", "GENE_OR_GENE_PRODUCT", 159, 161], ["type I IFN", "GENE_OR_GENE_PRODUCT", 179, 189], ["human", "ORGANISM", 203, 208], ["PBMC", "CELL", 209, 213], ["HSV-1 envelope glycoprotein gD", "PROTEIN", 73, 103], ["HSV-1 glycoproteins", "PROTEIN", 119, 138], ["gB", "PROTEIN", 140, 142], ["gC", "PROTEIN", 144, 146], ["gE", "PROTEIN", 148, 150], ["gG", "PROTEIN", 152, 154], ["gI", "PROTEIN", 159, 161], ["IFN", "PROTEIN", 186, 189], ["human PBMC", "CELL_TYPE", 203, 213], ["HSV-1", "SPECIES", 73, 78], ["HSV-1", "SPECIES", 119, 124], ["human", "SPECIES", 203, 208], ["HSV-1", "SPECIES", 73, 78], ["HSV-1", "SPECIES", 119, 124], ["human", "SPECIES", 203, 208], ["fixed insect cells", "PROBLEM", 33, 51], ["the HSV", "TEST", 69, 76], ["envelope glycoprotein gD", "TEST", 79, 103], ["other HSV", "TEST", 113, 122], ["gB", "TEST", 140, 142], ["gC", "TEST", 144, 146], ["gG", "TEST", 152, 154], ["gI", "TEST", 159, 161], ["induced strong type I IFN secretion", "PROBLEM", 164, 199], ["gI", "ANATOMY", 159, 161]]], ["IFN induction could be inhibited by mAb against gD, strengthening the argument for a role for gD in the induction of IFN\u03b1.", [["IFN", "CHEMICAL", 0, 3], ["IFN", "GENE_OR_GENE_PRODUCT", 0, 3], ["mAb", "GENE_OR_GENE_PRODUCT", 36, 39], ["gD", "GENE_OR_GENE_PRODUCT", 48, 50], ["gD", "GENE_OR_GENE_PRODUCT", 94, 96], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 117, 121], ["IFN", "PROTEIN", 0, 3], ["mAb", "PROTEIN", 36, 39], ["gD", "PROTEIN", 48, 50], ["gD", "PROTEIN", 94, 96], ["IFN\u03b1", "PROTEIN", 117, 121], ["IFN induction", "TREATMENT", 0, 13]]], ["In addition, Ito et al. showed that mouse spleen cells produced type I IFN when co-cultured with COS7 cells transfected with HPIV-4A virus HN glycoprotein, but not with COS7 transfected with vector alone (Ito et al., 1994).", [["spleen cells", "ANATOMY", 42, 54], ["COS7 cells", "ANATOMY", 97, 107], ["COS7", "ANATOMY", 169, 173], ["mouse", "ORGANISM", 36, 41], ["spleen cells", "CELL", 42, 54], ["type I IFN", "GENE_OR_GENE_PRODUCT", 64, 74], ["COS7 cells", "CELL", 97, 107], ["HPIV-4A virus", "ORGANISM", 125, 138], ["HN glycoprotein", "GENE_OR_GENE_PRODUCT", 139, 154], ["COS7", "CELL", 169, 173], ["mouse spleen cells", "CELL_TYPE", 36, 54], ["type I IFN", "PROTEIN", 64, 74], ["COS7 cells", "CELL_LINE", 97, 107], ["HPIV-4A virus HN glycoprotein", "PROTEIN", 125, 154], ["COS7", "PROTEIN", 169, 173], ["mouse", "SPECIES", 36, 41], ["mouse", "SPECIES", 36, 41], ["HPIV-4A virus", "SPECIES", 125, 138], ["mouse spleen cells", "PROBLEM", 36, 54], ["type I IFN", "PROBLEM", 64, 74], ["COS7 cells", "PROBLEM", 97, 107], ["HPIV", "TEST", 125, 129], ["4A virus HN glycoprotein", "TREATMENT", 130, 154], ["mouse spleen cells", "OBSERVATION", 36, 54]]], ["Thus, in the absence of any viral nucleic acid, viral glycoproteins expressed on the cell surface are sufficient for IFN induction to occur.Soluble viral glycoproteins can stimulate IFN production and other immune responses ::: Evidence for glycoprotein mediated induction of type I IFNSoluble viral glycoproteins can induce IFN\u03b1/\u03b2 production.", [["cell surface", "ANATOMY", 85, 97], ["nucleic acid", "CHEMICAL", 34, 46], ["cell surface", "CELLULAR_COMPONENT", 85, 97], ["IFN", "GENE_OR_GENE_PRODUCT", 117, 120], ["IFN", "GENE_OR_GENE_PRODUCT", 182, 185], ["type I IFNSoluble", "GENE_OR_GENE_PRODUCT", 276, 293], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 325, 329], ["\u03b2", "GENE_OR_GENE_PRODUCT", 330, 331], ["viral glycoproteins", "PROTEIN", 48, 67], ["IFN", "PROTEIN", 117, 120], ["Soluble viral glycoproteins", "PROTEIN", 140, 167], ["IFN", "PROTEIN", 182, 185], ["type I IFNSoluble viral glycoproteins", "PROTEIN", 276, 313], ["IFN\u03b1", "PROTEIN", 325, 329], ["\u03b2", "PROTEIN", 330, 331], ["any viral nucleic acid", "PROBLEM", 24, 46], ["viral glycoproteins", "PROBLEM", 48, 67], ["the cell surface", "TREATMENT", 81, 97], ["IFN induction", "TREATMENT", 117, 130], ["Soluble viral glycoproteins", "TREATMENT", 140, 167], ["glycoprotein mediated induction", "TREATMENT", 241, 272], ["type I IFNSoluble viral glycoproteins", "PROBLEM", 276, 313], ["IFN", "PROBLEM", 325, 328], ["nucleic acid", "OBSERVATION", 34, 46]]], ["For example, the recombinant extramembrane fragment of HSV-1 gD was sufficient to induce IFN\u03b1 production by human PBMC to a level comparable to that of intact virus (Ankel et al., 1998).", [["PBMC", "ANATOMY", 114, 118], ["HSV-1 gD", "ORGANISM", 55, 63], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 89, 93], ["human", "ORGANISM", 108, 113], ["PBMC", "CELL", 114, 118], ["recombinant extramembrane fragment", "PROTEIN", 17, 51], ["HSV-1 gD", "PROTEIN", 55, 63], ["IFN\u03b1", "PROTEIN", 89, 93], ["human PBMC", "CELL_TYPE", 108, 118], ["HSV-1", "SPECIES", 55, 60], ["human", "SPECIES", 108, 113], ["HSV-1", "SPECIES", 55, 60], ["human", "SPECIES", 108, 113], ["the recombinant extramembrane fragment of HSV", "PROBLEM", 13, 58], ["intact virus", "PROBLEM", 152, 164], ["recombinant", "OBSERVATION_MODIFIER", 17, 28], ["extramembrane", "OBSERVATION_MODIFIER", 29, 42], ["fragment", "OBSERVATION", 43, 51]]], ["In addition, soluble HN glycoprotein of HPIV-4A induced IFN production by murine splenocytes (Ito et al., 1994).", [["splenocytes", "ANATOMY", 81, 92], ["HPIV-4A", "GENE_OR_GENE_PRODUCT", 40, 47], ["IFN", "GENE_OR_GENE_PRODUCT", 56, 59], ["murine", "ORGANISM", 74, 80], ["splenocytes", "CELL", 81, 92], ["HN glycoprotein", "PROTEIN", 21, 36], ["HPIV", "PROTEIN", 40, 44], ["IFN", "PROTEIN", 56, 59], ["murine splenocytes", "CELL_TYPE", 74, 92], ["murine", "SPECIES", 74, 80], ["HPIV", "TEST", 40, 44]]], ["Since this work was done, pDCs have emerged as a cell type found in peripheral blood and spleen which produces the majority of type I IFN in response to viral stimulation.", [["pDCs", "ANATOMY", 26, 30], ["cell", "ANATOMY", 49, 53], ["peripheral blood", "ANATOMY", 68, 84], ["spleen", "ANATOMY", 89, 95], ["pDCs", "CELL", 26, 30], ["cell type", "CELL", 49, 58], ["peripheral blood", "ORGANISM_SUBSTANCE", 68, 84], ["spleen", "ORGAN", 89, 95], ["type I IFN", "GENE_OR_GENE_PRODUCT", 127, 137], ["pDCs", "CELL_TYPE", 26, 30], ["type I IFN", "PROTEIN", 127, 137], ["pDCs", "PROBLEM", 26, 30], ["a cell type", "TEST", 47, 58], ["peripheral blood and spleen", "PROBLEM", 68, 95], ["viral stimulation", "TREATMENT", 153, 170], ["peripheral", "ANATOMY_MODIFIER", 68, 78], ["blood", "ANATOMY", 79, 84], ["spleen", "ANATOMY", 89, 95], ["viral stimulation", "OBSERVATION", 153, 170]]], ["To our knowledge only one study to date has shown direct evidence that viral glycoproteins can stimulate pDCs to secrete type I IFN.", [["pDCs", "ANATOMY", 105, 109], ["pDCs", "CELL", 105, 109], ["type I IFN", "GENE_OR_GENE_PRODUCT", 121, 131], ["viral glycoproteins", "PROTEIN", 71, 90], ["pDCs", "CELL_TYPE", 105, 109], ["type I IFN", "PROTEIN", 121, 131], ["one study", "TEST", 22, 31], ["viral glycoproteins", "PROBLEM", 71, 90]]], ["In the study by del Corno et al. recombinant gp120 from R5 and X4 strains of HIV-1 stimulated pDCs enriched from human PBMC to secrete IFN\u03b1 (Del Corno et al., 2005).", [["pDCs", "ANATOMY", 94, 98], ["PBMC", "ANATOMY", 119, 123], ["gp120", "GENE_OR_GENE_PRODUCT", 45, 50], ["X4 strains", "ORGANISM", 63, 73], ["HIV-1", "ORGANISM", 77, 82], ["pDCs", "CELL", 94, 98], ["human", "ORGANISM", 113, 118], ["PBMC", "CELL", 119, 123], ["recombinant gp120", "PROTEIN", 33, 50], ["pDCs", "CELL_TYPE", 94, 98], ["human PBMC", "CELL_TYPE", 113, 123], ["IFN", "PROTEIN", 135, 138], ["HIV-1", "SPECIES", 77, 82], ["human", "SPECIES", 113, 118], ["HIV-1", "SPECIES", 77, 82], ["human", "SPECIES", 113, 118], ["the study", "TEST", 3, 12], ["HIV", "PROBLEM", 77, 80]]], ["Assuming there is no contamination of the glycoprotein samples with oligonucleotides, this work demonstrates a direct role of a viral glycoprotein in IFN\u03b1 induction by a purified pDC population.Soluble viral glycoproteins can stimulate IFN production and other immune responses ::: Evidence for glycoprotein mediated induction of type I IFNIn support of the argument that viral glycoproteins have a role in directly activating immune responses, viral glycoproteins have been shown to induce innate immune responses in B cells.", [["samples", "ANATOMY", 55, 62], ["pDC", "ANATOMY", 179, 182], ["B cells", "ANATOMY", 518, 525], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 150, 154], ["pDC", "CELL", 179, 182], ["IFN", "GENE_OR_GENE_PRODUCT", 236, 239], ["type I IFNIn", "GENE_OR_GENE_PRODUCT", 330, 342], ["B cells", "CELL", 518, 525], ["viral glycoprotein", "PROTEIN", 128, 146], ["IFN\u03b1", "PROTEIN", 150, 154], ["purified pDC population", "CELL_LINE", 170, 193], ["Soluble viral glycoproteins", "PROTEIN", 194, 221], ["IFN", "PROTEIN", 236, 239], ["glycoprotein", "PROTEIN", 295, 307], ["type I IFNIn", "PROTEIN", 330, 342], ["viral glycoproteins", "PROTEIN", 372, 391], ["viral glycoproteins", "PROTEIN", 445, 464], ["B cells", "CELL_TYPE", 518, 525], ["contamination of the glycoprotein samples", "PROBLEM", 21, 62], ["oligonucleotides", "TREATMENT", 68, 84], ["a viral glycoprotein", "TREATMENT", 126, 146], ["IFN\u03b1 induction", "TREATMENT", 150, 164], ["a purified pDC population", "TREATMENT", 168, 193], ["Soluble viral glycoproteins", "TREATMENT", 194, 221], ["glycoprotein mediated induction", "TREATMENT", 295, 326], ["type I IFNIn support", "TREATMENT", 330, 350], ["viral glycoproteins", "PROBLEM", 372, 391], ["viral glycoproteins", "PROBLEM", 445, 464], ["no", "UNCERTAINTY", 18, 20], ["contamination", "OBSERVATION", 21, 34]]], ["It has been shown that ultraviolet radiation-inactivated influenza virus of the H2 subtype and its purified haemagglutinin (HA) induced potent proliferation and upregulation of costimulatory molecules in human and murine B cells (Marshall-Clarke et al., 2006; Poumbourios et al., 1987).", [["B cells", "ANATOMY", 221, 228], ["ultraviolet", "CHEMICAL", 23, 34], ["HA", "CHEMICAL", 124, 126], ["influenza virus", "ORGANISM", 57, 72], ["haemagglutinin", "GENE_OR_GENE_PRODUCT", 108, 122], ["human", "ORGANISM", 204, 209], ["murine", "ORGANISM", 214, 220], ["B cells", "CELL", 221, 228], ["HA", "PROTEIN", 124, 126], ["costimulatory molecules", "PROTEIN", 177, 200], ["human and murine B cells", "CELL_TYPE", 204, 228], ["influenza virus", "SPECIES", 57, 72], ["human", "SPECIES", 204, 209], ["murine", "SPECIES", 214, 220], ["human", "SPECIES", 204, 209], ["ultraviolet radiation", "TREATMENT", 23, 44], ["inactivated influenza virus", "PROBLEM", 45, 72], ["the H2 subtype", "PROBLEM", 76, 90], ["its purified haemagglutinin (HA)", "TREATMENT", 95, 127], ["potent proliferation", "PROBLEM", 136, 156], ["upregulation of costimulatory molecules", "TREATMENT", 161, 200], ["H2 subtype", "OBSERVATION_MODIFIER", 80, 90], ["potent proliferation", "OBSERVATION", 136, 156], ["costimulatory molecules", "OBSERVATION", 177, 200]]], ["The induction of this response was dependent on cell surface MHC class II glycoprotein I-E expression by the B cells and was MyD88 dependent.", [["cell surface", "ANATOMY", 48, 60], ["B cells", "ANATOMY", 109, 116], ["cell", "CELL", 48, 52], ["MHC class II glycoprotein I-E", "GENE_OR_GENE_PRODUCT", 61, 90], ["B cells", "CELL", 109, 116], ["MyD88", "GENE_OR_GENE_PRODUCT", 125, 130], ["MHC class II glycoprotein I-E", "PROTEIN", 61, 90], ["B cells", "CELL_TYPE", 109, 116], ["MyD88", "PROTEIN", 125, 130], ["MyD88 dependent", "PROBLEM", 125, 140]]], ["The identity of the molecule involved in sensing the H2 HA is not known, but this study demonstrates that viral glycoproteins can be sensed by immune cells.Glycosylation on viral glycoproteins may be important in the induction of IFN ::: Evidence for glycoprotein mediated induction of type I IFNFurther investigations into identifying common patterns present on the many different viral glycoproteins that can induce type I IFN production have lead to the suggestion that sugar residues on viral glycoproteins can be recognized.", [["immune cells", "ANATOMY", 143, 155], ["sugar", "CHEMICAL", 473, 478], ["H2 HA", "GENE_OR_GENE_PRODUCT", 53, 58], ["immune cells", "CELL", 143, 155], ["type I IFNFurther", "GENE_OR_GENE_PRODUCT", 286, 303], ["type I IFN", "GENE_OR_GENE_PRODUCT", 418, 428], ["sugar", "SIMPLE_CHEMICAL", 473, 478], ["viral glycoproteins", "PROTEIN", 106, 125], ["immune cells", "CELL_TYPE", 143, 155], ["viral glycoproteins", "PROTEIN", 173, 192], ["IFN", "PROTEIN", 230, 233], ["glycoprotein", "PROTEIN", 251, 263], ["viral glycoproteins", "PROTEIN", 382, 401], ["IFN", "PROTEIN", 425, 428], ["viral glycoproteins", "PROTEIN", 491, 510], ["the molecule", "PROBLEM", 16, 28], ["sensing the H2 HA", "PROBLEM", 41, 58], ["this study", "TEST", 77, 87], ["viral glycoproteins", "PROBLEM", 106, 125], ["Glycosylation on viral glycoproteins", "TREATMENT", 156, 192], ["glycoprotein mediated induction", "TREATMENT", 251, 282], ["the many different viral glycoproteins", "PROBLEM", 363, 401], ["type I IFN production", "PROBLEM", 418, 439], ["sugar residues", "PROBLEM", 473, 487], ["viral glycoproteins", "PROBLEM", 491, 510], ["molecule", "OBSERVATION", 20, 28], ["immune cells", "OBSERVATION", 143, 155], ["viral glycoproteins", "OBSERVATION", 382, 401]]], ["Using genetically modified mouse hepatitis viruses (MHV) in which the abundant envelope glycoprotein, M, was either O- or N-glycosylated or not glycosylated at all, de Haan et al. (2003) studied the influence of M protein glycosylation on the IFN inducing capacity of the virus.", [["mouse hepatitis viruses", "DISEASE", 27, 50], ["O", "CHEMICAL", 116, 117], ["N", "CHEMICAL", 122, 123], ["mouse hepatitis viruses", "ORGANISM", 27, 50], ["MHV", "ORGANISM", 52, 55], ["envelope glycoprotein", "PROTEIN", 79, 100], ["M protein", "PROTEIN", 212, 221], ["IFN", "PROTEIN", 243, 246], ["mouse", "SPECIES", 27, 32], ["mouse hepatitis viruses", "SPECIES", 27, 50], ["MHV", "SPECIES", 52, 55], ["genetically modified mouse hepatitis viruses (MHV)", "TREATMENT", 6, 56], ["glycosylated", "TREATMENT", 124, 136], ["M protein glycosylation", "TREATMENT", 212, 235], ["the IFN", "TREATMENT", 239, 246], ["the virus", "PROBLEM", 268, 277], ["hepatitis viruses", "OBSERVATION", 33, 50]]], ["In this study, the differentially glycosylated M proteins were all expressed at similar levels on fixed cells infected with MHV, however, IFN induction by peripheral blood lymphocytes incubated with these infected cells was inhibited 30\u2013200-fold if virus lacked all glycosylation of its M glycoprotein.", [["cells", "ANATOMY", 104, 109], ["peripheral blood lymphocytes", "ANATOMY", 155, 183], ["cells", "ANATOMY", 214, 219], ["glycosylated M proteins", "GENE_OR_GENE_PRODUCT", 34, 57], ["cells", "CELL", 104, 109], ["MHV", "ORGANISM", 124, 127], ["IFN", "GENE_OR_GENE_PRODUCT", 138, 141], ["peripheral blood lymphocytes", "CELL", 155, 183], ["cells", "CELL", 214, 219], ["M glycoprotein", "GENE_OR_GENE_PRODUCT", 287, 301], ["M proteins", "PROTEIN", 47, 57], ["fixed cells", "CELL_TYPE", 98, 109], ["IFN", "PROTEIN", 138, 141], ["peripheral blood lymphocytes", "CELL_TYPE", 155, 183], ["infected cells", "CELL_TYPE", 205, 219], ["M glycoprotein", "PROTEIN", 287, 301], ["MHV", "SPECIES", 124, 127], ["this study", "TEST", 3, 13], ["the differentially glycosylated M proteins", "PROBLEM", 15, 57], ["fixed cells", "PROBLEM", 98, 109], ["MHV", "TREATMENT", 124, 127], ["IFN induction", "TREATMENT", 138, 151], ["peripheral blood lymphocytes", "TEST", 155, 183], ["these infected cells", "PROBLEM", 199, 219], ["virus", "PROBLEM", 249, 254]]], ["In addition, cells infected with mutant TGEV expressing partially or totally deglycosylated M were reduced in their ability to induce type I IFN production by PBMC in comparison with the parental virus, which again, suggested that glycosylation may be important in the induction of IFN (Laude et al., 1992).", [["cells", "ANATOMY", 13, 18], ["PBMC", "ANATOMY", 159, 163], ["cells", "CELL", 13, 18], ["mutant TGEV", "ORGANISM", 33, 44], ["type I IFN", "GENE_OR_GENE_PRODUCT", 134, 144], ["PBMC", "CELL", 159, 163], ["IFN", "GENE_OR_GENE_PRODUCT", 282, 285], ["IFN", "PROTEIN", 141, 144], ["PBMC", "CELL_TYPE", 159, 163], ["IFN", "PROTEIN", 282, 285], ["TGEV", "SPECIES", 40, 44], ["TGEV", "SPECIES", 40, 44], ["cells infected", "PROBLEM", 13, 27], ["mutant TGEV", "PROBLEM", 33, 44], ["totally deglycosylated M", "PROBLEM", 69, 93], ["type I IFN production", "PROBLEM", 134, 155], ["the parental virus", "PROBLEM", 183, 201], ["glycosylation", "TREATMENT", 231, 244]]], ["In a system of type I IFN induction in murine splenocytes by inactivated influenza virus where the main cell producing type I IFN was the pDC, mannan, known to block recognition of ligands by receptors with specificity for mannose, such as mannose receptor and DC-SIGN, inhibited the induction of IFN by inactivated influenza virus ((Miller and Anders, 2003) and unpublished data R.S and J.M).", [["splenocytes", "ANATOMY", 46, 57], ["cell", "ANATOMY", 104, 108], ["influenza virus", "DISEASE", 73, 88], ["influenza virus", "DISEASE", 316, 331], ["mannose", "CHEMICAL", 223, 230], ["mannose", "CHEMICAL", 240, 247], ["type I IFN", "GENE_OR_GENE_PRODUCT", 15, 25], ["murine", "ORGANISM", 39, 45], ["splenocytes", "CELL", 46, 57], ["influenza virus", "ORGANISM", 73, 88], ["cell", "CELL", 104, 108], ["type I IFN", "GENE_OR_GENE_PRODUCT", 119, 129], ["pDC", "CELL", 138, 141], ["mannan", "GENE_OR_GENE_PRODUCT", 143, 149], ["mannose", "SIMPLE_CHEMICAL", 223, 230], ["mannose receptor", "GENE_OR_GENE_PRODUCT", 240, 256], ["DC-SIGN", "SIMPLE_CHEMICAL", 261, 268], ["IFN", "GENE_OR_GENE_PRODUCT", 297, 300], ["influenza virus", "ORGANISM", 316, 331], ["IFN", "PROTEIN", 22, 25], ["murine splenocytes", "CELL_TYPE", 39, 57], ["type I IFN", "PROTEIN", 119, 129], ["pDC", "CELL_TYPE", 138, 141], ["mannan", "PROTEIN", 143, 149], ["mannose receptor", "PROTEIN", 240, 256], ["DC", "CELL_TYPE", 261, 263], ["SIGN", "PROTEIN", 264, 268], ["IFN", "PROTEIN", 297, 300], ["murine", "SPECIES", 39, 45], ["influenza virus", "SPECIES", 73, 88], ["influenza virus", "SPECIES", 316, 331], ["influenza virus", "SPECIES", 73, 88], ["type I IFN induction", "TREATMENT", 15, 35], ["murine splenocytes", "TREATMENT", 39, 57], ["inactivated influenza virus", "PROBLEM", 61, 88], ["mannose", "TREATMENT", 223, 230], ["mannose receptor", "TREATMENT", 240, 256], ["IFN", "TREATMENT", 297, 300], ["inactivated influenza virus", "PROBLEM", 304, 331], ["main cell", "OBSERVATION", 99, 108]]], ["Studies such as these implicate, but do not prove, the involvement of viral glycoproteins in IFN\u03b1/\u03b2 induction and suggest recognition by a lectin-like receptor on the NIPC.TLRs sensing viral glycoproteins ::: Receptors recognizing viral envelope glycoproteinsIn addition to activating the response to nucleic acids, some TLRs can mediate responses to viral proteins.", [["NIPC", "ANATOMY", 167, 171], ["nucleic acids", "CHEMICAL", 301, 314], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 93, 97], ["\u03b2", "GENE_OR_GENE_PRODUCT", 98, 99], ["lectin-like receptor", "GENE_OR_GENE_PRODUCT", 139, 159], ["NIPC", "CANCER", 167, 171], ["TLRs", "GENE_OR_GENE_PRODUCT", 172, 176], ["TLRs", "GENE_OR_GENE_PRODUCT", 321, 325], ["viral glycoproteins", "PROTEIN", 70, 89], ["IFN\u03b1", "PROTEIN", 93, 97], ["\u03b2", "PROTEIN", 98, 99], ["lectin-like receptor", "PROTEIN", 139, 159], ["TLRs", "PROTEIN", 172, 176], ["viral glycoproteins", "PROTEIN", 185, 204], ["viral envelope glycoproteins", "PROTEIN", 231, 259], ["TLRs", "PROTEIN", 321, 325], ["viral proteins", "PROTEIN", 351, 365], ["Studies", "TEST", 0, 7], ["viral glycoproteins", "PROBLEM", 70, 89], ["viral envelope glycoproteins", "PROBLEM", 231, 259], ["nucleic acids", "TREATMENT", 301, 314], ["viral proteins", "PROBLEM", 351, 365], ["viral glycoproteins", "OBSERVATION", 70, 89], ["viral envelope glycoproteins", "OBSERVATION", 231, 259]]], ["Respiratory syncytial virus (RSV) F protein is an example of a viral envelope glycoprotein which can be sensed by TLR4 and CD14 (Kurt-Jones et al., 2000).", [["Respiratory syncytial virus", "DISEASE", 0, 27], ["Respiratory syncytial virus", "ORGANISM", 0, 27], ["RSV", "ORGANISM", 29, 32], ["TLR4", "GENE_OR_GENE_PRODUCT", 114, 118], ["CD14", "GENE_OR_GENE_PRODUCT", 123, 127], ["Respiratory syncytial virus (RSV) F protein", "PROTEIN", 0, 43], ["viral envelope glycoprotein", "PROTEIN", 63, 90], ["TLR4", "PROTEIN", 114, 118], ["CD14", "PROTEIN", 123, 127], ["Respiratory syncytial virus", "SPECIES", 0, 27], ["Respiratory syncytial virus", "SPECIES", 0, 27], ["RSV", "SPECIES", 29, 32], ["Respiratory syncytial virus", "PROBLEM", 0, 27], ["a viral envelope glycoprotein", "PROBLEM", 61, 90], ["syncytial virus", "OBSERVATION", 12, 27]]], ["F protein can induce IL-6 secretion from purified human monocytes in a manner that could be blocked by anti-CD14 mAb.", [["monocytes", "ANATOMY", 56, 65], ["F protein", "GENE_OR_GENE_PRODUCT", 0, 9], ["IL-6", "GENE_OR_GENE_PRODUCT", 21, 25], ["human", "ORGANISM", 50, 55], ["monocytes", "CELL", 56, 65], ["anti-CD14 mAb", "GENE_OR_GENE_PRODUCT", 103, 116], ["F protein", "PROTEIN", 0, 9], ["IL-6", "PROTEIN", 21, 25], ["purified human monocytes", "CELL_TYPE", 41, 65], ["anti-CD14 mAb", "PROTEIN", 103, 116], ["human", "SPECIES", 50, 55], ["human", "SPECIES", 50, 55], ["F protein", "TEST", 0, 9], ["IL", "TEST", 21, 23], ["anti-CD14 mAb", "TREATMENT", 103, 116], ["human monocytes", "OBSERVATION_MODIFIER", 50, 65]]], ["In addition, F protein could not stimulate macrophages from CD14\u2212/\u2212 or TLR4\u2212/\u2212 mice to produce IL-6.", [["macrophages", "ANATOMY", 43, 54], ["CD14\u2212/\u2212", "ANATOMY", 60, 67], ["F protein", "GENE_OR_GENE_PRODUCT", 13, 22], ["macrophages", "CELL", 43, 54], ["CD14", "GENE_OR_GENE_PRODUCT", 60, 64], ["\u2212", "GENE_OR_GENE_PRODUCT", 66, 67], ["TLR4\u2212", "GENE_OR_GENE_PRODUCT", 71, 76], ["IL-6", "GENE_OR_GENE_PRODUCT", 95, 99], ["F protein", "PROTEIN", 13, 22], ["macrophages", "CELL_TYPE", 43, 54], ["CD14", "PROTEIN", 60, 64], ["IL-6", "PROTEIN", 95, 99], ["mice", "SPECIES", 79, 83], ["mice", "SPECIES", 79, 83], ["CD14", "TEST", 60, 64], ["IL", "TEST", 95, 97]]], ["The envelope proteins of murine retroviruses also activate TLR4 (Rassa et al., 2002).", [["murine", "ORGANISM", 25, 31], ["retroviruses", "ORGANISM", 32, 44], ["TLR4", "GENE_OR_GENE_PRODUCT", 59, 63], ["envelope proteins", "PROTEIN", 4, 21], ["TLR4", "PROTEIN", 59, 63], ["murine", "SPECIES", 25, 31], ["The envelope proteins of murine retroviruses", "TREATMENT", 0, 44], ["murine retroviruses", "OBSERVATION", 25, 44]]], ["Similarly, TLR2 and CD14 can recognize an undefined human cytomegalovirus (HCMV) structure, likely to be an envelope glycoprotein (Compton et al., 2003).", [["TLR2", "GENE_OR_GENE_PRODUCT", 11, 15], ["CD14", "GENE_OR_GENE_PRODUCT", 20, 24], ["human", "ORGANISM", 52, 57], ["cytomegalovirus", "ORGANISM", 58, 73], ["HCMV", "ORGANISM", 75, 79], ["TLR2", "PROTEIN", 11, 15], ["CD14", "PROTEIN", 20, 24], ["envelope glycoprotein", "PROTEIN", 108, 129], ["human", "SPECIES", 52, 57], ["human cytomegalovirus", "SPECIES", 52, 73], ["HCMV", "SPECIES", 75, 79], ["an undefined human cytomegalovirus (HCMV) structure", "PROBLEM", 39, 90], ["cytomegalovirus", "OBSERVATION", 58, 73], ["likely to be", "UNCERTAINTY", 92, 104]]], ["HCMV dense bodies (which contain envelope and tegument, but lack capsid and nucleic acid) can induce human PBMC to secrete IL-8 and IL-6 in a manner that could be inhibited by antibodies against CD14.", [["dense bodies", "ANATOMY", 5, 17], ["tegument", "ANATOMY", 46, 54], ["PBMC", "ANATOMY", 107, 111], ["nucleic acid", "CHEMICAL", 76, 88], ["HCMV", "ORGANISM", 0, 4], ["tegument", "CELLULAR_COMPONENT", 46, 54], ["human", "ORGANISM", 101, 106], ["PBMC", "CELL", 107, 111], ["IL-8", "GENE_OR_GENE_PRODUCT", 123, 127], ["IL-6", "GENE_OR_GENE_PRODUCT", 132, 136], ["CD14", "GENE_OR_GENE_PRODUCT", 195, 199], ["human PBMC", "CELL_TYPE", 101, 111], ["IL-8", "PROTEIN", 123, 127], ["IL-6", "PROTEIN", 132, 136], ["antibodies", "PROTEIN", 176, 186], ["CD14", "PROTEIN", 195, 199], ["human", "SPECIES", 101, 106], ["HCMV", "SPECIES", 0, 4], ["human", "SPECIES", 101, 106], ["HCMV dense bodies", "PROBLEM", 0, 17], ["lack capsid and nucleic acid", "TREATMENT", 60, 88], ["secrete IL", "TEST", 115, 125], ["CD14", "PROBLEM", 195, 199], ["dense", "OBSERVATION_MODIFIER", 5, 10], ["bodies", "OBSERVATION", 11, 17]]], ["Human embryonic kidney (HEK) cells transfected with TLR2 produced IL-8 in response to inactivated virus and inactivated HCMV could stimulate NF-\u03baB driven reporter gene expression in these cells.", [["embryonic kidney (HEK) cells", "ANATOMY", 6, 34], ["cells", "ANATOMY", 188, 193], ["Human", "ORGANISM", 0, 5], ["embryonic kidney (HEK) cells", "CELL", 6, 34], ["TLR2", "GENE_OR_GENE_PRODUCT", 52, 56], ["IL-8", "GENE_OR_GENE_PRODUCT", 66, 70], ["HCMV", "ORGANISM", 120, 124], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 141, 146], ["cells", "CELL", 188, 193], ["Human embryonic kidney (HEK) cells", "CELL_LINE", 0, 34], ["TLR2", "PROTEIN", 52, 56], ["IL-8", "PROTEIN", 66, 70], ["NF-\u03baB", "PROTEIN", 141, 146], ["reporter gene", "DNA", 154, 167], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["HCMV", "SPECIES", 120, 124], ["Human embryonic kidney (HEK) cells", "PROBLEM", 0, 34], ["TLR2 produced IL", "TREATMENT", 52, 68], ["inactivated virus", "PROBLEM", 86, 103], ["HCMV", "PROBLEM", 120, 124], ["kidney", "ANATOMY", 16, 22]]], ["The levels of IL-8 secreted and NF-\u03baB driven gene expression by TLR2 expressing HEK were enhanced when CD14 was co-expressed.", [["HEK", "ANATOMY", 80, 83], ["IL-8", "GENE_OR_GENE_PRODUCT", 14, 18], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 32, 37], ["TLR2", "GENE_OR_GENE_PRODUCT", 64, 68], ["HEK", "CELL", 80, 83], ["CD14", "GENE_OR_GENE_PRODUCT", 103, 107], ["IL-8", "PROTEIN", 14, 18], ["NF-\u03baB", "PROTEIN", 32, 37], ["TLR2", "PROTEIN", 64, 68], ["HEK", "CELL_LINE", 80, 83], ["CD14", "PROTEIN", 103, 107], ["The levels", "TEST", 0, 10], ["IL", "TEST", 14, 16], ["CD14", "TEST", 103, 107]]], ["In addition, thioglycolate-elicited macrophages from TLR2\u2212/\u2212 mice did not secrete IL-6 in response to HCMV.", [["macrophages", "ANATOMY", 36, 47], ["thioglycolate", "CHEMICAL", 13, 26], ["thioglycolate", "CHEMICAL", 13, 26], ["thioglycolate", "SIMPLE_CHEMICAL", 13, 26], ["macrophages", "CELL", 36, 47], ["TLR2\u2212", "GENE_OR_GENE_PRODUCT", 53, 58], ["IL-6", "GENE_OR_GENE_PRODUCT", 82, 86], ["HCMV", "ORGANISM", 102, 106], ["macrophages", "CELL_TYPE", 36, 47], ["IL-6", "PROTEIN", 82, 86], ["mice", "SPECIES", 61, 65], ["mice", "SPECIES", 61, 65], ["HCMV", "SPECIES", 102, 106], ["thioglycolate", "TREATMENT", 13, 26], ["macrophages", "TEST", 36, 47], ["TLR2\u2212/\u2212 mice", "TREATMENT", 53, 65], ["HCMV", "PROBLEM", 102, 106], ["HCMV", "OBSERVATION", 102, 106]]], ["The haemagglutinin (H) protein of measles virus wild-type strains also triggers TLR2 activation in a way that is enhanced by CD14 expression but independent of the measles virus receptors CD46 and CD150 (Bieback et al., 2002).", [["haemagglutinin (H)", "GENE_OR_GENE_PRODUCT", 4, 22], ["measles virus", "ORGANISM", 34, 47], ["TLR2", "GENE_OR_GENE_PRODUCT", 80, 84], ["CD14", "GENE_OR_GENE_PRODUCT", 125, 129], ["measles virus", "ORGANISM", 164, 177], ["CD46", "GENE_OR_GENE_PRODUCT", 188, 192], ["CD150", "GENE_OR_GENE_PRODUCT", 197, 202], ["haemagglutinin (H) protein", "PROTEIN", 4, 30], ["TLR2", "PROTEIN", 80, 84], ["CD14", "PROTEIN", 125, 129], ["measles virus receptors", "PROTEIN", 164, 187], ["CD46", "PROTEIN", 188, 192], ["CD150", "PROTEIN", 197, 202], ["measles virus", "SPECIES", 34, 47], ["measles virus", "SPECIES", 34, 47], ["measles virus", "SPECIES", 164, 177], ["The haemagglutinin (H) protein", "TEST", 0, 30], ["measles virus", "PROBLEM", 34, 47], ["type strains", "PROBLEM", 53, 65], ["TLR2 activation", "PROBLEM", 80, 95], ["TLR2 activation", "OBSERVATION", 80, 95]]], ["This demonstrates that TLRs can sense not only viral genome, but also viral glycoproteins leading to responses including cytokine secretion.", [["TLRs", "GENE_OR_GENE_PRODUCT", 23, 27], ["TLRs", "PROTEIN", 23, 27], ["viral genome", "DNA", 47, 59], ["viral glycoproteins", "PROTEIN", 70, 89], ["cytokine", "PROTEIN", 121, 129], ["viral genome", "PROBLEM", 47, 59], ["viral glycoproteins", "PROBLEM", 70, 89], ["cytokine secretion", "PROBLEM", 121, 139], ["viral genome", "OBSERVATION", 47, 59]]], ["It is interesting to note that in much of the work implicating viral nucleic acid as being sensed by the TLR, viral glycoprotein is also present.C-type lectins sensing viral glycoproteins ::: Receptors recognizing viral envelope glycoproteinsA number of C-type lectin receptors, including DC-SIGN, Langerin and the mannose receptor (MR) are important for the binding of HIV-1 envelope proteins to epithelial DCs and macrophages which express these molecules (Turville et al., 2003).", [["epithelial DCs", "ANATOMY", 397, 411], ["macrophages", "ANATOMY", 416, 427], ["nucleic acid", "CHEMICAL", 69, 81], ["mannose", "CHEMICAL", 315, 322], ["TLR", "GENE_OR_GENE_PRODUCT", 105, 108], ["C-type lectins", "GENE_OR_GENE_PRODUCT", 145, 159], ["C-type lectin receptors", "GENE_OR_GENE_PRODUCT", 254, 277], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 289, 296], ["Langerin", "GENE_OR_GENE_PRODUCT", 298, 306], ["mannose receptor", "GENE_OR_GENE_PRODUCT", 315, 331], ["HIV-1", "ORGANISM", 370, 375], ["epithelial DCs", "CELL", 397, 411], ["macrophages", "CELL", 416, 427], ["TLR", "PROTEIN", 105, 108], ["viral glycoprotein", "PROTEIN", 110, 128], ["C-type lectins", "PROTEIN", 145, 159], ["viral glycoproteins", "PROTEIN", 168, 187], ["viral envelope glycoproteins", "PROTEIN", 214, 242], ["C-type lectin receptors", "PROTEIN", 254, 277], ["DC", "PROTEIN", 289, 291], ["SIGN", "PROTEIN", 292, 296], ["Langerin", "PROTEIN", 298, 306], ["mannose receptor", "PROTEIN", 315, 331], ["MR", "PROTEIN", 333, 335], ["HIV-1 envelope proteins", "PROTEIN", 370, 393], ["epithelial DCs", "CELL_TYPE", 397, 411], ["macrophages", "CELL_TYPE", 416, 427], ["HIV-1", "SPECIES", 370, 375], ["HIV-1", "SPECIES", 370, 375], ["viral nucleic acid", "PROBLEM", 63, 81], ["viral glycoprotein", "TREATMENT", 110, 128], ["Receptors", "TEST", 192, 201], ["viral envelope glycoproteins", "PROBLEM", 214, 242], ["HIV", "PROBLEM", 370, 373], ["epithelial DCs", "TEST", 397, 411], ["nucleic acid", "OBSERVATION", 69, 81], ["viral glycoprotein", "OBSERVATION", 110, 128], ["viral envelope", "OBSERVATION", 214, 228], ["epithelial DCs", "OBSERVATION", 397, 411]]], ["The extent of glycosylation of gp120 allows HIV-1 to bind to at least three different C-type lectin receptors on cells within the stratified squamous epithelium in what is often a mannose-specific manner (Turville et al., 2002).", [["cells", "ANATOMY", 113, 118], ["squamous epithelium", "ANATOMY", 141, 160], ["mannose", "CHEMICAL", 180, 187], ["gp120", "GENE_OR_GENE_PRODUCT", 31, 36], ["HIV-1", "ORGANISM", 44, 49], ["C-type lectin receptors", "GENE_OR_GENE_PRODUCT", 86, 109], ["cells", "CELL", 113, 118], ["squamous epithelium", "TISSUE", 141, 160], ["mannose", "SIMPLE_CHEMICAL", 180, 187], ["gp120", "PROTEIN", 31, 36], ["C-type lectin receptors", "PROTEIN", 86, 109], ["HIV-1", "SPECIES", 44, 49], ["HIV-1", "SPECIES", 44, 49], ["glycosylation of gp120", "TREATMENT", 14, 36], ["HIV", "PROBLEM", 44, 47], ["glycosylation", "OBSERVATION", 14, 27], ["squamous epithelium", "OBSERVATION", 141, 160]]], ["HIV-1 whole virus particle binding to monocyte-derived macrophages can be inhibited by mannan, EDTA, d-mannose or mannose-binding lectin (MBL) (Nguyen and Hildreth, 2003) and binding of gp120 to some DC subsets can be inhibited by mannan (Turville et al., 2002).", [["monocyte", "ANATOMY", 38, 46], ["macrophages", "ANATOMY", 55, 66], ["DC", "ANATOMY", 200, 202], ["EDTA", "CHEMICAL", 95, 99], ["d-mannose", "CHEMICAL", 101, 110], ["mannose", "CHEMICAL", 114, 121], ["EDTA", "CHEMICAL", 95, 99], ["d-mannose", "CHEMICAL", 101, 110], ["mannose", "CHEMICAL", 114, 121], ["HIV-1", "ORGANISM", 0, 5], ["whole virus", "ORGANISM", 6, 17], ["monocyte", "CELL", 38, 46], ["macrophages", "CELL", 55, 66], ["mannan", "SIMPLE_CHEMICAL", 87, 93], ["EDTA", "SIMPLE_CHEMICAL", 95, 99], ["d-mannose", "SIMPLE_CHEMICAL", 101, 110], ["mannose-binding lectin", "SIMPLE_CHEMICAL", 114, 136], ["MBL", "GENE_OR_GENE_PRODUCT", 138, 141], ["gp120", "GENE_OR_GENE_PRODUCT", 186, 191], ["mannan", "SIMPLE_CHEMICAL", 231, 237], ["monocyte-derived macrophages", "CELL_TYPE", 38, 66], ["mannose-binding lectin", "PROTEIN", 114, 136], ["MBL", "PROTEIN", 138, 141], ["gp120", "PROTEIN", 186, 191], ["DC subsets", "CELL_TYPE", 200, 210], ["HIV-1", "SPECIES", 0, 5], ["HIV-1", "SPECIES", 0, 5], ["HIV", "PROBLEM", 0, 3], ["whole virus particle binding", "PROBLEM", 6, 34], ["monocyte", "TEST", 38, 46], ["d-mannose", "TREATMENT", 101, 110], ["mannose", "TEST", 114, 121], ["some DC subsets", "TREATMENT", 195, 210]]], ["In addition gp120 also binds to an astroglial cell line expressing MR more than an untransfected control and this can be inhibited by deglycosylation of gp120 and addition of EGTA (Liu et al., 2004).", [["astroglial cell line", "ANATOMY", 35, 55], ["EGTA", "CHEMICAL", 175, 179], ["EGTA", "CHEMICAL", 175, 179], ["gp120", "GENE_OR_GENE_PRODUCT", 12, 17], ["astroglial cell line", "CELL", 35, 55], ["gp120", "GENE_OR_GENE_PRODUCT", 153, 158], ["EGTA", "SIMPLE_CHEMICAL", 175, 179], ["gp120", "PROTEIN", 12, 17], ["astroglial cell line", "CELL_LINE", 35, 55], ["MR", "PROTEIN", 67, 69], ["gp120", "PROTEIN", 153, 158], ["an astroglial cell line", "TREATMENT", 32, 55], ["MR", "PROBLEM", 67, 69], ["an untransfected control", "TREATMENT", 80, 104], ["deglycosylation of gp120", "TREATMENT", 134, 158], ["EGTA", "TREATMENT", 175, 179], ["astroglial cell line", "OBSERVATION", 35, 55]]], ["A functional role for MR in HIV-1 infection is suggested by findings that expression of MR in astroglial cells increased their infectivity by HIV-1.", [["astroglial cells", "ANATOMY", 94, 110], ["HIV-1 infection", "DISEASE", 28, 43], ["HIV-1", "ORGANISM", 28, 33], ["astroglial cells", "CELL", 94, 110], ["HIV-1", "ORGANISM", 142, 147], ["MR", "PROTEIN", 22, 24], ["MR", "PROTEIN", 88, 90], ["astroglial cells", "CELL_TYPE", 94, 110], ["HIV-1", "SPECIES", 28, 33], ["HIV-1", "SPECIES", 142, 147], ["HIV-1", "SPECIES", 28, 33], ["HIV-1", "SPECIES", 142, 147], ["MR", "PROBLEM", 22, 24], ["HIV", "PROBLEM", 28, 31], ["1 infection", "PROBLEM", 32, 43], ["MR in astroglial cells", "PROBLEM", 88, 110], ["infection", "OBSERVATION", 34, 43], ["astroglial cells", "OBSERVATION", 94, 110]]], ["This effect could be inhibited by anti-MR serum, mannan and mannose.", [["serum", "ANATOMY", 42, 47], ["mannose", "CHEMICAL", 60, 67], ["mannose", "CHEMICAL", 60, 67], ["serum", "ORGANISM_SUBSTANCE", 42, 47], ["mannan", "SIMPLE_CHEMICAL", 49, 55], ["mannose", "SIMPLE_CHEMICAL", 60, 67], ["MR", "PROTEIN", 39, 41], ["anti-MR serum", "TEST", 34, 47]]], ["In the same way the infection of primary human astrocytes by HIV-1 was inhibited by anti-MR serum and small interfering RNA (siRNA) against MR. Together this research defines a mannose-dependent binding mechanism of HIV-1 to some cell types and suggests a role for MR in infection.", [["astrocytes", "ANATOMY", 47, 57], ["serum", "ANATOMY", 92, 97], ["cell", "ANATOMY", 230, 234], ["infection", "DISEASE", 20, 29], ["infection", "DISEASE", 271, 280], ["mannose", "CHEMICAL", 177, 184], ["human", "ORGANISM", 41, 46], ["astrocytes", "CELL", 47, 57], ["HIV-1", "ORGANISM", 61, 66], ["anti-MR", "GENE_OR_GENE_PRODUCT", 84, 91], ["serum", "ORGANISM_SUBSTANCE", 92, 97], ["mannose", "SIMPLE_CHEMICAL", 177, 184], ["HIV-1", "ORGANISM", 216, 221], ["cell", "CELL", 230, 234], ["primary human astrocytes", "CELL_TYPE", 33, 57], ["MR", "PROTEIN", 89, 91], ["small interfering RNA", "RNA", 102, 123], ["MR", "PROTEIN", 265, 267], ["human", "SPECIES", 41, 46], ["HIV-1", "SPECIES", 61, 66], ["HIV-1", "SPECIES", 216, 221], ["human", "SPECIES", 41, 46], ["HIV-1", "SPECIES", 61, 66], ["HIV-1", "SPECIES", 216, 221], ["the infection of primary human astrocytes", "PROBLEM", 16, 57], ["anti-MR serum", "TEST", 84, 97], ["small interfering RNA", "PROBLEM", 102, 123], ["a mannose-dependent binding mechanism", "PROBLEM", 175, 212], ["HIV", "PROBLEM", 216, 219], ["some cell types", "PROBLEM", 225, 240], ["MR in infection", "PROBLEM", 265, 280], ["infection", "OBSERVATION", 20, 29], ["small", "OBSERVATION_MODIFIER", 102, 107], ["interfering RNA", "OBSERVATION", 108, 123], ["cell types", "OBSERVATION", 230, 240], ["infection", "OBSERVATION", 271, 280]]], ["Interestingly, MR has also been reported as being important for the induction of IFN\u03b1 in response to several viruses including HIV-1 (Milone and Fitzgerald-Bocarsly, 1998).C-type lectins sensing viral glycoproteins ::: Receptors recognizing viral envelope glycoproteinsThese studies with HIV-1 do not demonstrate direct binding of viral glycoproteins to a defined PRR.", [["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 81, 85], ["HIV-1", "ORGANISM", 127, 132], ["C-type lectins", "GENE_OR_GENE_PRODUCT", 172, 186], ["HIV-1", "ORGANISM", 288, 293], ["PRR", "GENE_OR_GENE_PRODUCT", 364, 367], ["MR", "PROTEIN", 15, 17], ["IFN\u03b1", "PROTEIN", 81, 85], ["C-type lectins", "PROTEIN", 172, 186], ["viral glycoproteins", "PROTEIN", 195, 214], ["viral envelope glycoproteins", "PROTEIN", 241, 269], ["viral glycoproteins", "PROTEIN", 331, 350], ["PRR", "PROTEIN", 364, 367], ["HIV-1", "SPECIES", 127, 132], ["HIV-1", "SPECIES", 288, 293], ["HIV-1", "SPECIES", 127, 132], ["HIV-1", "SPECIES", 288, 293], ["MR", "TEST", 15, 17], ["IFN", "TREATMENT", 81, 84], ["HIV", "TEST", 127, 130], ["viral envelope glycoproteins", "PROBLEM", 241, 269], ["These studies", "TEST", 269, 282], ["HIV", "TEST", 288, 291], ["viral glycoproteins", "PROBLEM", 331, 350], ["viral envelope glycoproteins", "OBSERVATION", 241, 269], ["viral glycoproteins", "OBSERVATION", 331, 350]]], ["Although other PRR have been shown to bind viral glycoproteins, conclusive evidence is often lacking for a functional response to recognition.", [["PRR", "GENE_OR_GENE_PRODUCT", 15, 18], ["PRR", "PROTEIN", 15, 18], ["viral glycoproteins", "PROTEIN", 43, 62], ["bind viral glycoproteins", "PROBLEM", 38, 62]]], ["For example, DC-SIGN and DC-SIGNR have been shown to recognize several viruses including; HIV-1, HIV-2, simian immunodeficiency virus (SIV), Ebola virus and dengue virus (Alvarez et al., 2002; Curtis et al., 1992; Geijtenbeek et al., 2000; Navarro-Sanchez et al., 2003; Pohlmann et al., 2001a, Pohlmann et al., 2001b; Tassaneetrithep et al., 2003).", [["DC", "ANATOMY", 13, 15], ["DC", "ANATOMY", 25, 27], ["simian immunodeficiency virus (SIV), Ebola virus and dengue virus", "DISEASE", 104, 169], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 13, 20], ["DC-SIGNR", "GENE_OR_GENE_PRODUCT", 25, 33], ["HIV-1", "ORGANISM", 90, 95], ["HIV-2", "ORGANISM", 97, 102], ["simian immunodeficiency virus", "ORGANISM", 104, 133], ["SIV", "ORGANISM", 135, 138], ["Ebola virus", "ORGANISM", 141, 152], ["dengue virus", "ORGANISM", 157, 169], ["DC", "CELL_TYPE", 13, 15], ["SIGN", "PROTEIN", 16, 20], ["DC", "CELL_TYPE", 25, 27], ["SIGNR", "PROTEIN", 28, 33], ["HIV-1", "SPECIES", 90, 95], ["HIV-2", "SPECIES", 97, 102], ["simian immunodeficiency virus", "SPECIES", 104, 133], ["Ebola virus and dengue virus", "SPECIES", 141, 169], ["HIV-1", "SPECIES", 90, 95], ["HIV-2", "SPECIES", 97, 102], ["simian immunodeficiency virus", "SPECIES", 104, 133], ["SIV", "SPECIES", 135, 138], ["Ebola virus", "SPECIES", 141, 152], ["dengue virus", "SPECIES", 157, 169], ["several viruses", "PROBLEM", 63, 78], ["HIV", "TEST", 90, 93], ["HIV", "TEST", 97, 100], ["simian immunodeficiency virus", "PROBLEM", 104, 133], ["Ebola virus", "PROBLEM", 141, 152], ["dengue virus", "PROBLEM", 157, 169], ["viruses", "OBSERVATION", 71, 78]]], ["In another example, a cell line expressing either DC-SIGN or DC-SIGNR bound more beads coated with gp120 of HIV-1 than the untransfected control.", [["cell line", "ANATOMY", 22, 31], ["DC", "ANATOMY", 50, 52], ["DC", "ANATOMY", 61, 63], ["cell line", "CELL", 22, 31], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 50, 57], ["DC-SIGNR", "GENE_OR_GENE_PRODUCT", 61, 69], ["HIV-1", "ORGANISM", 108, 113], ["cell line", "CELL_LINE", 22, 31], ["DC", "CELL_TYPE", 50, 52], ["SIGN", "PROTEIN", 53, 57], ["DC", "CELL_TYPE", 61, 63], ["SIGNR", "PROTEIN", 64, 69], ["gp120", "PROTEIN", 99, 104], ["HIV-1", "SPECIES", 108, 113], ["HIV-1", "SPECIES", 108, 113], ["a cell line", "TREATMENT", 20, 31], ["SIGNR bound", "PROBLEM", 64, 75], ["HIV", "PROBLEM", 108, 111], ["the untransfected control", "TREATMENT", 119, 144], ["cell line", "OBSERVATION", 22, 31]]], ["This binding could be partially inhibited by Fab fragments against DC-SIGN or DC-SIGNR (Dakappagari et al., 2006) or anti-DC-SIGN and DC-SIGNR mAb, mannan and EDTA (Bashirova et al., 2001).", [["DC", "ANATOMY", 67, 69], ["DC", "ANATOMY", 78, 80], ["EDTA", "CHEMICAL", 159, 163], ["Fab", "GENE_OR_GENE_PRODUCT", 45, 48], ["anti-DC-SIGN", "SIMPLE_CHEMICAL", 117, 129], ["mannan", "SIMPLE_CHEMICAL", 148, 154], ["EDTA", "SIMPLE_CHEMICAL", 159, 163], ["Fab fragments", "PROTEIN", 45, 58], ["DC", "CELL_TYPE", 67, 69], ["DC", "CELL_TYPE", 78, 80], ["anti-DC", "PROTEIN", 117, 124], ["SIGN", "PROTEIN", 125, 129], ["DC", "CELL_TYPE", 134, 136], ["SIGNR mAb", "PROTEIN", 137, 146]]], ["This demonstrates that viral glycoproteins can bind PRR, although evidence linking this to a functional response is limited.Collectins sensing viral glycoproteins ::: Receptors recognizing viral envelope glycoproteinsCollectins are a group of soluble collagenous lectins which have a carbohydrate recognition domain that binds mannose residues.", [["carbohydrate", "CHEMICAL", 284, 296], ["mannose", "CHEMICAL", 327, 334], ["PRR", "GENE_OR_GENE_PRODUCT", 52, 55], ["mannose residues", "SIMPLE_CHEMICAL", 327, 343], ["viral glycoproteins", "PROTEIN", 23, 42], ["PRR", "PROTEIN", 52, 55], ["Collectins sensing viral glycoproteins", "PROTEIN", 124, 162], ["viral envelope glycoproteins", "PROTEIN", 189, 217], ["Collectins", "PROTEIN", 217, 227], ["soluble collagenous lectins", "PROTEIN", 243, 270], ["carbohydrate recognition domain", "PROTEIN", 284, 315], ["viral glycoproteins", "PROBLEM", 23, 42], ["viral envelope glycoproteinsCollectins", "PROBLEM", 189, 227], ["a group of soluble collagenous lectins", "TREATMENT", 232, 270], ["viral glycoproteins", "OBSERVATION", 23, 42], ["viral glycoproteins", "OBSERVATION", 143, 162], ["mannose residues", "OBSERVATION", 327, 343]]], ["Several human collectins have been implicated in viral recognition, including surfactant protein (SP)-D, SP-A and MBL.", [["human", "ORGANISM", 8, 13], ["collectins", "GENE_OR_GENE_PRODUCT", 14, 24], ["surfactant protein (SP)-D", "GENE_OR_GENE_PRODUCT", 78, 103], ["SP-A", "GENE_OR_GENE_PRODUCT", 105, 109], ["MBL", "GENE_OR_GENE_PRODUCT", 114, 117], ["human collectins", "PROTEIN", 8, 24], ["surfactant protein (SP)-D", "PROTEIN", 78, 103], ["SP", "PROTEIN", 105, 107], ["MBL", "PROTEIN", 114, 117], ["human", "SPECIES", 8, 13], ["human", "SPECIES", 8, 13], ["Several human collectins", "PROBLEM", 0, 24], ["viral recognition", "TEST", 49, 66], ["surfactant protein", "TEST", 78, 96], ["MBL", "PROBLEM", 114, 117]]], ["For example SP-D binds HA and neuraminidase (NA) of influenza virus and binding was destroyed when influenza virus was deglycosylated (Hartshorn et al., 2000; Reading et al., 1997).", [["SP-D", "CHEMICAL", 12, 16], ["NA", "CHEMICAL", 45, 47], ["SP-D", "SIMPLE_CHEMICAL", 12, 16], ["HA", "GENE_OR_GENE_PRODUCT", 23, 25], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 30, 43], ["influenza virus", "ORGANISM", 52, 67], ["influenza virus", "ORGANISM", 99, 114], ["SP", "PROTEIN", 12, 14], ["HA", "PROTEIN", 23, 25], ["neuraminidase", "PROTEIN", 30, 43], ["influenza virus", "SPECIES", 52, 67], ["influenza virus", "SPECIES", 52, 67], ["influenza virus", "SPECIES", 99, 114], ["SP-D binds HA", "PROBLEM", 12, 25], ["neuraminidase", "PROBLEM", 30, 43], ["influenza virus", "PROBLEM", 52, 67], ["influenza virus", "PROBLEM", 99, 114], ["influenza virus", "OBSERVATION", 52, 67]]], ["SP-A and MBL bind influenza virus and can inhibit the haemagglutination activity of influenza virus (Malhotra et al., 1994).", [["SP-A", "CHEMICAL", 0, 4], ["influenza virus", "DISEASE", 18, 33], ["influenza virus", "DISEASE", 84, 99], ["SP-A", "GENE_OR_GENE_PRODUCT", 0, 4], ["MBL", "GENE_OR_GENE_PRODUCT", 9, 12], ["influenza virus", "ORGANISM", 18, 33], ["influenza virus", "ORGANISM", 84, 99], ["SP", "PROTEIN", 0, 2], ["MBL", "PROTEIN", 9, 12], ["influenza virus", "SPECIES", 18, 33], ["influenza virus", "SPECIES", 84, 99], ["influenza virus", "SPECIES", 18, 33], ["A and MBL bind influenza virus", "PROBLEM", 3, 33], ["influenza virus", "PROBLEM", 84, 99], ["influenza virus", "OBSERVATION", 18, 33]]], ["Collectins are soluble proteins thought to opsonise viral particles to aid their uptake by phagocytes though binding to a cellular receptor.", [["phagocytes", "ANATOMY", 91, 101], ["cellular", "ANATOMY", 122, 130], ["phagocytes", "CELL", 91, 101], ["cellular", "CELL", 122, 130], ["soluble proteins", "PROTEIN", 15, 31], ["phagocytes", "CELL_TYPE", 91, 101], ["cellular receptor", "PROTEIN", 122, 139], ["soluble proteins", "TREATMENT", 15, 31], ["viral particles", "PROBLEM", 52, 67]]], ["The binding of SP-D, SP-A and MBL to influenza virus demonstrates the recognition of viral carbohydrate by soluble PRR; this could bring the virus particle closer to an innate immune cell and by clustering cellular receptors could initiate signaling.Scavenger receptors sensing viral glycoproteins ::: Receptors recognizing viral envelope glycoproteinsIn addition to C-type lectins, scavenger receptors have been shown to bind viruses.", [["immune cell", "ANATOMY", 176, 187], ["cellular", "ANATOMY", 206, 214], ["SP-D", "CHEMICAL", 15, 19], ["SP-A", "CHEMICAL", 21, 25], ["carbohydrate", "CHEMICAL", 91, 103], ["SP-D", "SIMPLE_CHEMICAL", 15, 19], ["SP-A", "GENE_OR_GENE_PRODUCT", 21, 25], ["MBL", "GENE_OR_GENE_PRODUCT", 30, 33], ["influenza virus", "ORGANISM", 37, 52], ["PRR", "GENE_OR_GENE_PRODUCT", 115, 118], ["immune cell", "CELL", 176, 187], ["cellular", "CELL", 206, 214], ["C-type lectins", "GENE_OR_GENE_PRODUCT", 367, 381], ["scavenger receptors", "GENE_OR_GENE_PRODUCT", 383, 402], ["SP", "PROTEIN", 15, 17], ["SP", "PROTEIN", 21, 23], ["MBL", "PROTEIN", 30, 33], ["PRR", "PROTEIN", 115, 118], ["cellular receptors", "PROTEIN", 206, 224], ["Scavenger receptors", "PROTEIN", 250, 269], ["viral glycoproteins", "PROTEIN", 278, 297], ["viral envelope glycoproteins", "PROTEIN", 324, 352], ["C-type lectins", "PROTEIN", 367, 381], ["scavenger receptors", "PROTEIN", 383, 402], ["influenza virus", "SPECIES", 37, 52], ["influenza virus", "SPECIES", 37, 52], ["SP", "PROBLEM", 15, 17], ["SP", "PROBLEM", 21, 23], ["influenza virus", "PROBLEM", 37, 52], ["viral carbohydrate by soluble PRR", "PROBLEM", 85, 118], ["the virus particle", "TREATMENT", 137, 155], ["an innate immune cell", "TREATMENT", 166, 187], ["viral envelope glycoproteins", "PROBLEM", 324, 352], ["C-type lectins", "TREATMENT", 367, 381], ["scavenger receptors", "TREATMENT", 383, 402], ["immune cell", "OBSERVATION", 176, 187], ["viral glycoproteins", "OBSERVATION", 278, 297], ["viral envelope glycoproteins", "OBSERVATION", 324, 352], ["viruses", "OBSERVATION", 427, 434]]], ["For example, the human class B scavenger receptor SR-BI, also known as CLA-1, binds hepatitis C virus (HCV) glycoprotein E2 (Scarselli et al., 2002).", [["hepatitis C", "DISEASE", 84, 95], ["human", "ORGANISM", 17, 22], ["class B scavenger receptor", "GENE_OR_GENE_PRODUCT", 23, 49], ["SR-BI", "GENE_OR_GENE_PRODUCT", 50, 55], ["CLA-1", "GENE_OR_GENE_PRODUCT", 71, 76], ["hepatitis C virus", "ORGANISM", 84, 101], ["HCV", "ORGANISM", 103, 106], ["human class B scavenger receptor", "PROTEIN", 17, 49], ["SR", "PROTEIN", 50, 52], ["BI", "PROTEIN", 53, 55], ["CLA-1", "PROTEIN", 71, 76], ["human", "SPECIES", 17, 22], ["hepatitis C virus", "SPECIES", 84, 101], ["human", "SPECIES", 17, 22], ["hepatitis C virus", "SPECIES", 84, 101], ["HCV", "SPECIES", 103, 106], ["CLA", "TEST", 71, 74], ["binds hepatitis C virus (HCV) glycoprotein E2", "PROBLEM", 78, 123], ["CLA", "ANATOMY", 71, 74]]], ["Similarly, the salivary agglutinin gp340 binds gp120 of HIV-1 and inhibits HIV-1 infectivity (Wu et al., 2003).", [["salivary agglutinin", "GENE_OR_GENE_PRODUCT", 15, 34], ["gp120", "GENE_OR_GENE_PRODUCT", 47, 52], ["HIV-1", "ORGANISM", 56, 61], ["HIV-1", "ORGANISM", 75, 80], ["salivary agglutinin gp340", "PROTEIN", 15, 40], ["gp120", "PROTEIN", 47, 52], ["HIV-1", "SPECIES", 56, 61], ["HIV-1", "SPECIES", 75, 80], ["HIV-1", "SPECIES", 56, 61], ["HIV-1", "SPECIES", 75, 80], ["the salivary agglutinin", "TEST", 11, 34], ["HIV", "TEST", 56, 59], ["HIV", "PROBLEM", 75, 78]]], ["In an in vivo study, Suzuki et al. (1997) showed that types I and II class A scavenger receptor (SR-A) knock-out mice display an increased susceptibility to HSV-1 infection, suggesting a role for SR-A in the development of the immune response against HSV-1.", [["HSV-1 infection", "DISEASE", 157, 172], ["class A scavenger receptor", "GENE_OR_GENE_PRODUCT", 69, 95], ["SR-A", "GENE_OR_GENE_PRODUCT", 97, 101], ["mice", "ORGANISM", 113, 117], ["HSV-1", "ORGANISM", 157, 162], ["SR-A", "GENE_OR_GENE_PRODUCT", 196, 200], ["HSV-1", "ORGANISM", 251, 256], ["SR", "PROTEIN", 97, 99], ["SR-A", "PROTEIN", 196, 200], ["mice", "SPECIES", 113, 117], ["HSV-1", "SPECIES", 157, 162], ["HSV-1", "SPECIES", 157, 162], ["HSV-1", "SPECIES", 251, 256], ["A scavenger receptor", "TEST", 75, 95], ["an increased susceptibility to HSV", "PROBLEM", 126, 160], ["1 infection", "PROBLEM", 161, 172], ["HSV", "PROBLEM", 251, 254], ["increased", "OBSERVATION_MODIFIER", 129, 138], ["infection", "OBSERVATION", 163, 172]]], ["This work demonstrates that different families of PRR can interact with viral glycoproteins.ConclusionsThe exact molecular basis for the induction of type I IFN by viruses remains to be determined, although in addition to the recognition of viral genome, viral glycoproteins are clearly sensed in a manner that can depend on glycosylation.", [["PRR", "GENE_OR_GENE_PRODUCT", 50, 53], ["type I IFN", "GENE_OR_GENE_PRODUCT", 150, 160], ["PRR", "PROTEIN", 50, 53], ["viral glycoproteins", "PROTEIN", 72, 91], ["type I IFN", "PROTEIN", 150, 160], ["viral genome", "DNA", 241, 253], ["viral glycoproteins", "PROTEIN", 255, 274], ["viral glycoproteins", "PROBLEM", 72, 91], ["type I IFN", "PROBLEM", 150, 160], ["viruses", "PROBLEM", 164, 171], ["viral genome", "PROBLEM", 241, 253], ["viral glycoproteins", "PROBLEM", 255, 274], ["glycosylation", "TREATMENT", 325, 338], ["viral genome", "OBSERVATION", 241, 253]]], ["Nucleic acid or viral glycoproteins are unlikely to be sensed in isolation; therefore it is more likely that recognition of several viral components occurs sequentially or simultaneously in a redundant manner reminiscent of the innate recognition of bacterial and fungal pathogens.", [["viral glycoproteins", "PROTEIN", 16, 35], ["Nucleic acid", "TEST", 0, 12], ["viral glycoproteins", "PROBLEM", 16, 35], ["several viral components", "PROBLEM", 124, 148], ["bacterial and fungal pathogens", "PROBLEM", 250, 280], ["viral glycoproteins", "OBSERVATION", 16, 35], ["more likely", "UNCERTAINTY", 92, 103], ["several", "OBSERVATION_MODIFIER", 124, 131], ["viral", "OBSERVATION", 132, 137], ["bacterial", "OBSERVATION_MODIFIER", 250, 259], ["fungal pathogens", "OBSERVATION", 264, 280]]], ["Hence, the receptors for both viral oligonucleotides and glycoproteins are likely to contribute to detection of viral infection and may contribute synergistically to the subsequent induction of the innate immune response.ConclusionsAlthough receptors mediating viral genome recognition have been proposed, good candidate receptors for signaling by viral glycoproteins have yet to emerge.", [["viral infection", "DISEASE", 112, 127], ["viral glycoproteins", "PROTEIN", 348, 367], ["both viral oligonucleotides and glycoproteins", "PROBLEM", 25, 70], ["viral infection", "PROBLEM", 112, 127], ["receptors mediating viral genome recognition", "PROBLEM", 241, 285], ["viral glycoproteins", "PROBLEM", 348, 367], ["viral oligonucleotides", "OBSERVATION", 30, 52], ["viral", "OBSERVATION_MODIFIER", 112, 117], ["infection", "OBSERVATION", 118, 127]]], ["Viral glycoproteins interact with PRR from a range of families (e.g. TLRs, C-type lectins, scavenger receptors and collectins); however, PRR expression on pDCs has yet to be extensively characterized.", [["pDCs", "ANATOMY", 155, 159], ["PRR", "GENE_OR_GENE_PRODUCT", 34, 37], ["TLRs", "GENE_OR_GENE_PRODUCT", 69, 73], ["C-type lectins", "GENE_OR_GENE_PRODUCT", 75, 89], ["scavenger receptors", "GENE_OR_GENE_PRODUCT", 91, 110], ["collectins", "GENE_OR_GENE_PRODUCT", 115, 125], ["PRR", "GENE_OR_GENE_PRODUCT", 137, 140], ["pDCs", "CELL", 155, 159], ["Viral glycoproteins", "PROTEIN", 0, 19], ["PRR", "PROTEIN", 34, 37], ["TLRs", "PROTEIN", 69, 73], ["C-type lectins", "PROTEIN", 75, 89], ["scavenger receptors", "PROTEIN", 91, 110], ["collectins", "PROTEIN", 115, 125], ["PRR", "PROTEIN", 137, 140], ["pDCs", "CELL_TYPE", 155, 159], ["Viral glycoproteins", "PROBLEM", 0, 19], ["PRR", "TREATMENT", 34, 37], ["scavenger receptors", "TREATMENT", 91, 110], ["PRR expression on pDCs", "PROBLEM", 137, 159]]], ["Nevertheless, pDCs do express BDCA-2 and Siglec-H, members of the C-type lectin and siglec families, and although the exact function of these proteins has yet to be elucidated, these receptor families contain members involved in pathogen recognition.", [["pDCs", "ANATOMY", 14, 18], ["pDCs", "CELL", 14, 18], ["BDCA-2", "GENE_OR_GENE_PRODUCT", 30, 36], ["Siglec-H", "GENE_OR_GENE_PRODUCT", 41, 49], ["C-type lectin", "GENE_OR_GENE_PRODUCT", 66, 79], ["siglec", "GENE_OR_GENE_PRODUCT", 84, 90], ["pDCs", "CELL_TYPE", 14, 18], ["BDCA", "PROTEIN", 30, 34], ["Siglec-H", "PROTEIN", 41, 49], ["C-type lectin", "PROTEIN", 66, 79], ["siglec families", "PROTEIN", 84, 99], ["BDCA", "TEST", 30, 34]]], ["It will be interesting in the future to see what PRR pDCs express and whether these play a role in viral recognition and the induction of type I IFN.ConclusionsThe identification of the specific cellular and viral molecules responsible for induction of type I IFN production by both viral genome and glycoprotein will be of value in the development of antiviral therapies and design of effective vaccines as we learn how to stimulate the innate immune system.", [["pDCs", "ANATOMY", 53, 57], ["cellular", "ANATOMY", 195, 203], ["PRR pDCs", "CELL", 49, 57], ["type I IFN", "GENE_OR_GENE_PRODUCT", 138, 148], ["cellular", "CELL", 195, 203], ["type I IFN", "GENE_OR_GENE_PRODUCT", 253, 263], ["PRR pDCs", "CELL_TYPE", 49, 57], ["type I IFN", "PROTEIN", 138, 148], ["cellular and viral molecules", "PROTEIN", 195, 223], ["type I IFN", "PROTEIN", 253, 263], ["viral genome", "DNA", 283, 295], ["glycoprotein", "PROTEIN", 300, 312], ["the specific cellular and viral molecules", "PROBLEM", 182, 223], ["induction of type I IFN production", "TREATMENT", 240, 274], ["both viral genome", "PROBLEM", 278, 295], ["glycoprotein", "TREATMENT", 300, 312], ["antiviral therapies", "TREATMENT", 352, 371], ["effective vaccines", "TREATMENT", 386, 404], ["viral molecules", "OBSERVATION", 208, 223], ["viral genome", "OBSERVATION", 283, 295], ["antiviral therapies", "OBSERVATION", 352, 371]]]], "3f54f654ba3ada324d842633518108997a592228": [["IntroductionIn 1963 EOR Reynolds concluded that 'oxygen therapy is vitally important in bronchiolitis and there is little convincing evidence that any other therapy is consistently or even occasionally useful'.", [["oxygen", "CHEMICAL", 49, 55], ["bronchiolitis", "DISEASE", 88, 101], ["oxygen", "CHEMICAL", 49, 55], ["oxygen", "SIMPLE_CHEMICAL", 49, 55], ["'oxygen therapy", "TREATMENT", 48, 63], ["bronchiolitis", "PROBLEM", 88, 101], ["oxygen therapy", "OBSERVATION", 49, 63], ["bronchiolitis", "OBSERVATION", 88, 101], ["little convincing evidence", "UNCERTAINTY", 115, 141]]], ["It is arguable that there has been little progress in the subsequent 46 years.", [["little", "OBSERVATION_MODIFIER", 35, 41], ["progress", "OBSERVATION_MODIFIER", 42, 50]]], ["Treatments that might be effective include nebulized 3% hypertonic saline mixed with a bronchodilator, and ventilatory support for respiratory failure.", [["respiratory", "ANATOMY", 131, 142], ["respiratory failure", "DISEASE", 131, 150], ["Treatments", "TREATMENT", 0, 10], ["nebulized 3% hypertonic saline", "TREATMENT", 43, 73], ["a bronchodilator", "TREATMENT", 85, 101], ["ventilatory support", "TREATMENT", 107, 126], ["respiratory failure", "PROBLEM", 131, 150], ["respiratory failure", "OBSERVATION", 131, 150]]], ["For the majority of patients, however, supportive management is the mainstay, with emphasis on treating insufficient fluid intake and hypoxia.EpidemiologyBronchiolitis is the commonest cause of hospitalization in infancy.", [["fluid", "ANATOMY", 117, 122], ["hypoxia", "DISEASE", 134, 141], ["Bronchiolitis", "DISEASE", 154, 167], ["patients", "ORGANISM", 20, 28], ["fluid", "ORGANISM_SUBSTANCE", 117, 122], ["patients", "SPECIES", 20, 28], ["supportive management", "TREATMENT", 39, 60], ["insufficient fluid intake", "PROBLEM", 104, 129], ["hypoxia", "PROBLEM", 134, 141], ["EpidemiologyBronchiolitis", "PROBLEM", 142, 167], ["hypoxia", "OBSERVATION", 134, 141], ["Bronchiolitis", "OBSERVATION", 154, 167]]], ["It usually affects infants aged 1-6 months, although it can occur up to 2 years of age, and is usually a mild self-limiting illness that does not require medical intervention.", [["infants", "ORGANISM", 19, 26], ["infants", "SPECIES", 19, 26], ["a mild self-limiting illness", "PROBLEM", 103, 131], ["medical intervention", "TREATMENT", 154, 174], ["mild", "OBSERVATION_MODIFIER", 105, 109]]], ["It is a clinical syndrome characterized initially by coryzal symptoms followed Madeleine Adams MRCPCH by onset of harsh cough, tachypnoea and wheezing.", [["coryzal", "ANATOMY", 53, 60], ["MRCPCH", "DISEASE", 95, 101], ["cough", "DISEASE", 120, 125], ["tachypnoea", "DISEASE", 127, 137], ["wheezing", "DISEASE", 142, 150], ["a clinical syndrome", "PROBLEM", 6, 25], ["coryzal symptoms", "PROBLEM", 53, 69], ["harsh cough", "PROBLEM", 114, 125], ["tachypnoea", "PROBLEM", 127, 137], ["wheezing", "PROBLEM", 142, 150], ["harsh", "OBSERVATION_MODIFIER", 114, 119], ["cough", "OBSERVATION", 120, 125], ["tachypnoea", "OBSERVATION", 127, 137], ["wheezing", "OBSERVATION", 142, 150]]], ["On examination there may be chest hyperinflation with costal recession, and fine inspiratory crackles and polyphonic expiratory wheeze on auscultation.EpidemiologyA significant contributor to confusion over the management of bronchiolitis is the absence of an internationally agreed common definition.", [["chest", "ANATOMY", 28, 33], ["costal", "ANATOMY", 54, 60], ["confusion", "DISEASE", 192, 201], ["bronchiolitis", "DISEASE", 225, 238], ["chest", "ORGANISM_SUBDIVISION", 28, 33], ["costal", "ORGAN", 54, 60], ["examination", "TEST", 3, 14], ["chest hyperinflation", "PROBLEM", 28, 48], ["costal recession", "PROBLEM", 54, 70], ["fine inspiratory crackles", "PROBLEM", 76, 101], ["polyphonic expiratory wheeze", "PROBLEM", 106, 134], ["auscultation", "TEST", 138, 150], ["confusion", "PROBLEM", 192, 201], ["bronchiolitis", "PROBLEM", 225, 238], ["may be", "UNCERTAINTY", 21, 27], ["chest", "ANATOMY", 28, 33], ["hyperinflation", "OBSERVATION", 34, 48], ["costal", "ANATOMY", 54, 60], ["recession", "OBSERVATION", 61, 70], ["fine", "OBSERVATION_MODIFIER", 76, 80], ["inspiratory crackles", "OBSERVATION", 81, 101], ["polyphonic", "OBSERVATION_MODIFIER", 106, 116], ["expiratory wheeze", "OBSERVATION", 117, 134], ["bronchiolitis", "OBSERVATION", 225, 238]]], ["In the United Kingdom, Australasia, and parts of Europe, bronchiolitis is interpreted as the presence of tachypnoea, hyperinflation of the chest, and characteristically widespread fine end inspiratory crackles on auscultation.", [["chest", "ANATOMY", 139, 144], ["bronchiolitis", "DISEASE", 57, 70], ["tachypnoea", "DISEASE", 105, 115], ["chest", "ORGAN", 139, 144], ["Australasia", "PROBLEM", 23, 34], ["bronchiolitis", "PROBLEM", 57, 70], ["tachypnoea", "PROBLEM", 105, 115], ["hyperinflation of the chest", "PROBLEM", 117, 144], ["characteristically widespread fine end inspiratory crackles", "PROBLEM", 150, 209], ["auscultation", "TEST", 213, 225], ["Kingdom", "OBSERVATION_MODIFIER", 14, 21], ["Australasia", "OBSERVATION", 23, 34], ["bronchiolitis", "OBSERVATION", 57, 70], ["tachypnoea", "OBSERVATION", 105, 115], ["hyperinflation", "OBSERVATION", 117, 131], ["chest", "ANATOMY", 139, 144], ["characteristically", "OBSERVATION_MODIFIER", 150, 168], ["widespread", "OBSERVATION_MODIFIER", 169, 179], ["fine", "OBSERVATION_MODIFIER", 180, 184], ["end", "OBSERVATION_MODIFIER", 185, 188], ["inspiratory", "OBSERVATION_MODIFIER", 189, 200], ["crackles", "OBSERVATION", 201, 209]]], ["Wheeze is commonly but not invariably present.", [["Wheeze", "DISEASE", 0, 6], ["Wheeze", "PROBLEM", 0, 6], ["not", "UNCERTAINTY", 23, 26], ["invariably", "OBSERVATION_MODIFIER", 27, 37]]], ["The pattern of illness is virtually always seen in the first year of life, most commonly in the first 6 months of life.", [["illness", "DISEASE", 15, 22], ["illness", "PROBLEM", 15, 22], ["illness", "OBSERVATION", 15, 22]]], ["In contrast, in North America and other parts of Europe, bronchiolitis is a term for any viral infection of the lower respiratory tract in the first 2 years of life, and may include children with recurrent wheeze.", [["lower respiratory tract", "ANATOMY", 112, 135], ["bronchiolitis", "DISEASE", 57, 70], ["viral infection of the lower respiratory tract", "DISEASE", 89, 135], ["wheeze", "DISEASE", 206, 212], ["lower", "ORGANISM_SUBDIVISION", 112, 117], ["respiratory tract", "ORGANISM_SUBDIVISION", 118, 135], ["children", "ORGANISM", 182, 190], ["children", "SPECIES", 182, 190], ["bronchiolitis", "PROBLEM", 57, 70], ["any viral infection of the lower respiratory tract", "PROBLEM", 85, 135], ["recurrent wheeze", "PROBLEM", 196, 212], ["bronchiolitis", "OBSERVATION", 57, 70], ["viral", "OBSERVATION_MODIFIER", 89, 94], ["infection", "OBSERVATION", 95, 104], ["lower", "ANATOMY_MODIFIER", 112, 117], ["respiratory tract", "ANATOMY", 118, 135], ["wheeze", "OBSERVATION", 206, 212]]], ["The confusion over definition is compounded by different types of study; many studies in inpatients will be closer to the UK and Australasian definition, while many studies in outpatients will include mostly children corresponding to the North American and European definition.", [["confusion", "DISEASE", 4, 13], ["outpatients", "ORGANISM", 176, 187], ["children", "ORGANISM", 208, 216], ["children", "SPECIES", 208, 216], ["The confusion", "PROBLEM", 0, 13], ["study", "TEST", 66, 71], ["many studies", "TEST", 73, 85], ["confusion", "OBSERVATION", 4, 13]]], ["Furthermore there is no widely accepted validated scoring system to measure illness severity, making comparisons between studies difficult.", [["illness", "DISEASE", 76, 83], ["illness severity", "PROBLEM", 76, 92], ["comparisons between studies", "TEST", 101, 128], ["no", "UNCERTAINTY", 21, 23], ["widely", "OBSERVATION_MODIFIER", 24, 30]]], ["Commonly, outcome measures in interventional studies will include summation scores of symptoms and signs, oxygen saturations, respiratory rate, and length of stay in hospital.EpidemiologyApproximately 1-3% of infants will be hospitalized with bronchiolitis, of whom 1-2% will require ventilation for either respiratory failure or apnoeas.", [["respiratory", "ANATOMY", 307, 318], ["oxygen", "CHEMICAL", 106, 112], ["bronchiolitis", "DISEASE", 243, 256], ["respiratory failure", "DISEASE", 307, 326], ["apnoeas", "DISEASE", 330, 337], ["oxygen", "CHEMICAL", 106, 112], ["oxygen", "SIMPLE_CHEMICAL", 106, 112], ["infants", "ORGANISM", 209, 216], ["infants", "SPECIES", 209, 216], ["interventional studies", "TEST", 30, 52], ["symptoms", "PROBLEM", 86, 94], ["signs", "TEST", 99, 104], ["oxygen saturations", "TEST", 106, 124], ["respiratory rate", "TEST", 126, 142], ["EpidemiologyApproximately", "TEST", 175, 200], ["bronchiolitis", "PROBLEM", 243, 256], ["ventilation", "TREATMENT", 284, 295], ["either respiratory failure", "PROBLEM", 300, 326], ["apnoeas", "PROBLEM", 330, 337], ["bronchiolitis", "OBSERVATION", 243, 256], ["respiratory", "ANATOMY", 307, 318], ["failure", "OBSERVATION", 319, 326], ["apnoeas", "OBSERVATION", 330, 337]]], ["Hospitalization for bronchiolitis is commoner in boys and in lower socioeconomic groups.", [["bronchiolitis", "DISEASE", 20, 33], ["boys", "SPECIES", 49, 53], ["bronchiolitis", "PROBLEM", 20, 33], ["bronchiolitis", "OBSERVATION", 20, 33], ["lower", "ANATOMY_MODIFIER", 61, 66]]], ["Preterm infants (less than 32 weeks) and infants with chronic lung disease, congenital cardiac abnormalities, or immune deficiencies are at higher risk of severe disease.", [["lung", "ANATOMY", 62, 66], ["cardiac", "ANATOMY", 87, 94], ["chronic lung disease", "DISEASE", 54, 74], ["congenital cardiac abnormalities", "DISEASE", 76, 108], ["immune deficiencies", "DISEASE", 113, 132], ["infants", "ORGANISM", 8, 15], ["infants", "ORGANISM", 41, 48], ["lung", "ORGAN", 62, 66], ["cardiac", "ORGAN", 87, 94], ["infants", "SPECIES", 8, 15], ["infants", "SPECIES", 41, 48], ["Preterm infants", "PROBLEM", 0, 15], ["chronic lung disease", "PROBLEM", 54, 74], ["congenital cardiac abnormalities", "PROBLEM", 76, 108], ["immune deficiencies", "PROBLEM", 113, 132], ["severe disease", "PROBLEM", 155, 169], ["chronic", "OBSERVATION_MODIFIER", 54, 61], ["lung", "ANATOMY", 62, 66], ["disease", "OBSERVATION", 67, 74], ["cardiac", "ANATOMY", 87, 94], ["abnormalities", "OBSERVATION", 95, 108], ["immune deficiencies", "OBSERVATION", 113, 132], ["severe", "OBSERVATION_MODIFIER", 155, 161], ["disease", "OBSERVATION", 162, 169]]], ["Mortality rates in hospitalized infants are 0.5-1.7%.", [["infants", "ORGANISM", 32, 39], ["infants", "SPECIES", 32, 39], ["Mortality rates", "TEST", 0, 15]]], ["Respiratory syncytial virus (RSV) accounts for 50-90% of cases of bronchiolitis resulting in approximately 20000 UK admissions per year.", [["Respiratory syncytial virus", "DISEASE", 0, 27], ["RSV", "DISEASE", 29, 32], ["bronchiolitis", "DISEASE", 66, 79], ["Respiratory syncytial virus", "ORGANISM", 0, 27], ["RSV", "ORGANISM", 29, 32], ["Respiratory syncytial virus", "SPECIES", 0, 27], ["Respiratory syncytial virus", "SPECIES", 0, 27], ["RSV", "SPECIES", 29, 32], ["Respiratory syncytial virus", "PROBLEM", 0, 27], ["bronchiolitis", "PROBLEM", 66, 79], ["syncytial virus", "OBSERVATION", 12, 27], ["bronchiolitis", "OBSERVATION", 66, 79]]], ["Annual epidemics of RSV occur between late autumn and spring (October to March in the northern hemisphere).", [["RSV", "DISEASE", 20, 23], ["RSV", "ORGANISM", 20, 23], ["RSV", "SPECIES", 20, 23], ["RSV", "PROBLEM", 20, 23], ["RSV", "OBSERVATION", 20, 23], ["late", "OBSERVATION_MODIFIER", 38, 42], ["autumn", "OBSERVATION", 43, 49], ["northern hemisphere", "ANATOMY", 86, 105]]], ["The virus rapidly infects the respiratory tract epithelium, causing epithelial necrosis and destruction of the cilia.", [["respiratory tract epithelium", "ANATOMY", 30, 58], ["epithelial", "ANATOMY", 68, 78], ["cilia", "ANATOMY", 111, 116], ["necrosis", "DISEASE", 79, 87], ["respiratory tract epithelium", "TISSUE", 30, 58], ["epithelial", "TISSUE", 68, 78], ["cilia", "CELLULAR_COMPONENT", 111, 116], ["The virus rapidly infects the respiratory tract epithelium", "PROBLEM", 0, 58], ["epithelial necrosis", "PROBLEM", 68, 87], ["destruction of the cilia", "PROBLEM", 92, 116], ["virus", "OBSERVATION", 4, 9], ["respiratory tract", "ANATOMY", 30, 47], ["epithelial", "ANATOMY_MODIFIER", 68, 78], ["necrosis", "OBSERVATION", 79, 87], ["destruction", "OBSERVATION", 92, 103], ["cilia", "ANATOMY_MODIFIER", 111, 116]]], ["There is a florid inflammatory response with neutrophil and lymphocytic cellular infiltration and oedema of the submucosa, and an imbalance in cytokines with an excess of TH type II over type I cytokines demonstrated by high interleukin 4 (IL4)/interferon \u03b3 ratio.", [["neutrophil", "ANATOMY", 45, 55], ["lymphocytic cellular", "ANATOMY", 60, 80], ["submucosa", "ANATOMY", 112, 121], ["oedema", "DISEASE", 98, 104], ["neutrophil", "CELL", 45, 55], ["lymphocytic cellular", "CELL", 60, 80], ["submucosa", "MULTI-TISSUE_STRUCTURE", 112, 121], ["TH type II", "GENE_OR_GENE_PRODUCT", 171, 181], ["interleukin 4", "GENE_OR_GENE_PRODUCT", 225, 238], ["IL4", "GENE_OR_GENE_PRODUCT", 240, 243], ["interferon \u03b3", "GENE_OR_GENE_PRODUCT", 245, 257], ["cytokines", "PROTEIN", 143, 152], ["TH type II", "PROTEIN", 171, 181], ["type I cytokines", "PROTEIN", 187, 203], ["interleukin 4", "PROTEIN", 225, 238], ["IL4", "PROTEIN", 240, 243], ["interferon \u03b3", "PROTEIN", 245, 257], ["a florid inflammatory response", "PROBLEM", 9, 39], ["neutrophil", "PROBLEM", 45, 55], ["lymphocytic cellular infiltration", "PROBLEM", 60, 93], ["oedema of the submucosa", "PROBLEM", 98, 121], ["an imbalance in cytokines", "PROBLEM", 127, 152], ["type I cytokines", "PROBLEM", 187, 203], ["high interleukin 4 (IL4)/interferon \u03b3 ratio", "TREATMENT", 220, 263], ["florid", "OBSERVATION_MODIFIER", 11, 17], ["inflammatory", "OBSERVATION_MODIFIER", 18, 30], ["neutrophil", "OBSERVATION_MODIFIER", 45, 55], ["lymphocytic cellular infiltration", "OBSERVATION", 60, 93], ["oedema", "OBSERVATION", 98, 104], ["submucosa", "ANATOMY", 112, 121], ["imbalance", "OBSERVATION", 130, 139], ["cytokines", "OBSERVATION_MODIFIER", 143, 152], ["excess", "OBSERVATION_MODIFIER", 161, 167], ["high", "OBSERVATION_MODIFIER", 220, 224]]], ["There is increased mucus production from goblet cells which, in combination with the decimated epithelial cells, results in mucus plugging.", [["mucus", "ANATOMY", 19, 24], ["goblet cells", "ANATOMY", 41, 53], ["epithelial cells", "ANATOMY", 95, 111], ["mucus", "ANATOMY", 124, 129], ["mucus", "ORGANISM_SUBSTANCE", 19, 24], ["goblet cells", "CELL", 41, 53], ["epithelial cells", "CELL", 95, 111], ["mucus", "TISSUE", 124, 129], ["goblet cells", "CELL_TYPE", 41, 53], ["decimated epithelial cells", "CELL_TYPE", 85, 111], ["increased mucus production", "PROBLEM", 9, 35], ["goblet cells", "PROBLEM", 41, 53], ["the decimated epithelial cells", "PROBLEM", 81, 111], ["mucus plugging", "PROBLEM", 124, 138], ["increased", "OBSERVATION_MODIFIER", 9, 18], ["mucus production", "OBSERVATION", 19, 35], ["goblet cells", "OBSERVATION", 41, 53], ["epithelial cells", "OBSERVATION", 95, 111], ["mucus plugging", "OBSERVATION", 124, 138]]], ["Mucus plugging causes obstruction of bronchioles with resultant air trapping leading to areas of hyperinflation and airway collapse.", [["Mucus", "ANATOMY", 0, 5], ["bronchioles", "ANATOMY", 37, 48], ["airway", "ANATOMY", 116, 122], ["hyperinflation", "DISEASE", 97, 111], ["airway collapse", "DISEASE", 116, 131], ["Mucus", "MULTI-TISSUE_STRUCTURE", 0, 5], ["bronchioles", "MULTI-TISSUE_STRUCTURE", 37, 48], ["airway", "MULTI-TISSUE_STRUCTURE", 116, 122], ["Mucus plugging", "PROBLEM", 0, 14], ["obstruction of bronchioles", "PROBLEM", 22, 48], ["resultant air trapping", "PROBLEM", 54, 76], ["hyperinflation", "PROBLEM", 97, 111], ["airway collapse", "PROBLEM", 116, 131], ["plugging", "OBSERVATION", 6, 14], ["obstruction", "OBSERVATION", 22, 33], ["bronchioles", "ANATOMY", 37, 48], ["resultant", "OBSERVATION_MODIFIER", 54, 63], ["air trapping", "OBSERVATION", 64, 76], ["areas", "OBSERVATION_MODIFIER", 88, 93], ["hyperinflation", "OBSERVATION", 97, 111], ["airway", "ANATOMY", 116, 122], ["collapse", "OBSERVATION", 123, 131]]], ["As the respiratory epithelium regenerates, the new non-ciliated cells are poorly equipped to clear the inflammatory debris.", [["respiratory epithelium", "ANATOMY", 7, 29], ["cells", "ANATOMY", 64, 69], ["respiratory epithelium", "TISSUE", 7, 29], ["cells", "CELL", 64, 69], ["non-ciliated cells", "CELL_TYPE", 51, 69], ["the respiratory epithelium regenerates", "PROBLEM", 3, 41], ["the new non-ciliated cells", "PROBLEM", 43, 69], ["the inflammatory debris", "PROBLEM", 99, 122], ["respiratory epithelium regenerates", "OBSERVATION", 7, 41], ["new", "OBSERVATION_MODIFIER", 47, 50], ["non-ciliated cells", "OBSERVATION", 51, 69], ["inflammatory", "OBSERVATION_MODIFIER", 103, 115], ["debris", "OBSERVATION", 116, 122]]], ["Hypoxaemia is primarily due to ventilation/perfusion mismatch, and hypercapnoea is a relatively late phenomenon.EpidemiologyAfter RSV, the next most frequent cause is probably human metapneumovirus (hMPV) which causes a similar clinical picture as RSV, although dual infection with both RSV and hMPV may cause more severe disease.", [["Hypoxaemia", "DISEASE", 0, 10], ["hypercapnoea", "DISEASE", 67, 79], ["human metapneumovirus (hMPV)", "DISEASE", 176, 204], ["RSV", "DISEASE", 248, 251], ["infection", "DISEASE", 267, 276], ["hMPV", "DISEASE", 295, 299], ["RSV", "ORGANISM", 130, 133], ["human", "ORGANISM", 176, 181], ["metapneumovirus", "ORGANISM", 182, 197], ["hMPV", "ORGANISM", 199, 203], ["RSV", "ORGANISM", 248, 251], ["RSV", "ORGANISM", 287, 290], ["hMPV", "ORGANISM", 295, 299], ["human", "SPECIES", 176, 181], ["metapneumovirus", "SPECIES", 182, 197], ["RSV", "SPECIES", 130, 133], ["human metapneumovirus", "SPECIES", 176, 197], ["hMPV", "SPECIES", 199, 203], ["RSV", "SPECIES", 248, 251], ["RSV", "SPECIES", 287, 290], ["hMPV", "SPECIES", 295, 299], ["Hypoxaemia", "PROBLEM", 0, 10], ["ventilation/perfusion mismatch", "PROBLEM", 31, 61], ["hypercapnoea", "PROBLEM", 67, 79], ["a relatively late phenomenon", "PROBLEM", 83, 111], ["EpidemiologyAfter RSV", "PROBLEM", 112, 133], ["human metapneumovirus (hMPV", "PROBLEM", 176, 203], ["RSV", "PROBLEM", 248, 251], ["dual infection", "PROBLEM", 262, 276], ["RSV", "PROBLEM", 287, 290], ["hMPV", "PROBLEM", 295, 299], ["more severe disease", "PROBLEM", 310, 329], ["primarily due to", "UNCERTAINTY", 14, 30], ["ventilation", "OBSERVATION", 31, 42], ["perfusion mismatch", "OBSERVATION", 43, 61], ["relatively", "OBSERVATION_MODIFIER", 85, 95], ["late", "OBSERVATION_MODIFIER", 96, 100], ["phenomenon", "OBSERVATION", 101, 111], ["metapneumovirus", "OBSERVATION", 182, 197], ["infection", "OBSERVATION", 267, 276], ["RSV", "OBSERVATION", 287, 290], ["severe", "OBSERVATION_MODIFIER", 315, 321], ["disease", "OBSERVATION", 322, 329]]], ["Rhinovirus may be a commoner cause in older infants, and less frequent causes include adenovirus, parainfluenza, influenza, coronavirus, and the more recently identified bocavirus.", [["Rhinovirus", "CHEMICAL", 0, 10], ["adenovirus, parainfluenza, influenza, coronavirus", "DISEASE", 86, 135], ["infants", "ORGANISM", 44, 51], ["adenovirus", "ORGANISM", 86, 96], ["parainfluenza", "ORGANISM", 98, 111], ["bocavirus", "CANCER", 170, 179], ["infants", "SPECIES", 44, 51], ["parainfluenza", "SPECIES", 98, 111], ["Rhinovirus", "PROBLEM", 0, 10], ["adenovirus", "PROBLEM", 86, 96], ["parainfluenza", "PROBLEM", 98, 111], ["influenza", "PROBLEM", 113, 122], ["coronavirus", "PROBLEM", 124, 135], ["bocavirus", "PROBLEM", 170, 179], ["parainfluenza", "OBSERVATION", 98, 111], ["bocavirus", "OBSERVATION", 170, 179]]], ["It is possible that bacterial superinfection is associated with increased severity of disease.ManagementInterventions can be classed as supportive, therapeutic or preventative.Supportive managementThe current management of bronchiolitis is primarily supportive, concentrating on the major effects of the condition, namely inadequate feeding, respiratory distress and apnoeas.", [["respiratory", "ANATOMY", 342, 353], ["bacterial superinfection", "DISEASE", 20, 44], ["bronchiolitis", "DISEASE", 223, 236], ["respiratory distress", "DISEASE", 342, 362], ["apnoeas", "DISEASE", 367, 374], ["bacterial superinfection", "PROBLEM", 20, 44], ["increased severity of disease", "PROBLEM", 64, 93], ["ManagementInterventions", "TREATMENT", 94, 117], ["Supportive management", "TREATMENT", 176, 197], ["bronchiolitis", "PROBLEM", 223, 236], ["respiratory distress", "PROBLEM", 342, 362], ["apnoeas", "PROBLEM", 367, 374], ["possible", "UNCERTAINTY", 6, 14], ["bacterial", "OBSERVATION_MODIFIER", 20, 29], ["superinfection", "OBSERVATION", 30, 44], ["associated with", "UNCERTAINTY", 48, 63], ["increased", "OBSERVATION_MODIFIER", 64, 73], ["severity", "OBSERVATION_MODIFIER", 74, 82], ["disease", "OBSERVATION", 86, 93], ["bronchiolitis", "OBSERVATION", 223, 236], ["respiratory distress", "OBSERVATION", 342, 362], ["apnoeas", "OBSERVATION", 367, 374]]], ["Inadequate feeding is usually secondary to respiratory distress and the consequent increased work of breathing.", [["respiratory", "ANATOMY", 43, 54], ["respiratory distress", "DISEASE", 43, 63], ["respiratory distress", "PROBLEM", 43, 63], ["the consequent increased work of breathing", "PROBLEM", 68, 110], ["respiratory distress", "OBSERVATION", 43, 63], ["consequent", "OBSERVATION_MODIFIER", 72, 82], ["increased", "OBSERVATION_MODIFIER", 83, 92], ["work of breathing", "OBSERVATION", 93, 110]]], ["The infant will be tachypnoeic, may have bouts of coughing with increased upper airway secretions, and thus may struggle to feed adequately.", [["airway", "ANATOMY", 80, 86], ["coughing", "DISEASE", 50, 58], ["infant", "ORGANISM", 4, 10], ["upper airway", "ORGANISM_SUBDIVISION", 74, 86], ["secretions", "ORGANISM_SUBSTANCE", 87, 97], ["infant", "SPECIES", 4, 10], ["tachypnoeic", "PROBLEM", 19, 30], ["coughing", "PROBLEM", 50, 58], ["increased upper airway secretions", "PROBLEM", 64, 97], ["coughing", "OBSERVATION", 50, 58], ["upper", "ANATOMY_MODIFIER", 74, 79], ["airway", "ANATOMY", 80, 86], ["secretions", "OBSERVATION", 87, 97]]], ["Tachypnoea increases fluid loss, and so the infant can easily become dehydrated.Supportive managementInfants with bronchiolitis are generally intolerant of interventions, and so minimal handling is recommended.", [["fluid", "ANATOMY", 21, 26], ["Tachypnoea", "DISEASE", 0, 10], ["fluid loss", "DISEASE", 21, 31], ["bronchiolitis", "DISEASE", 114, 127], ["Tachypnoea", "SIMPLE_CHEMICAL", 0, 10], ["fluid", "ORGANISM_SUBSTANCE", 21, 26], ["infant", "ORGANISM", 44, 50], ["Infants", "ORGANISM", 101, 108], ["infant", "SPECIES", 44, 50], ["Infants", "SPECIES", 101, 108], ["Tachypnoea", "PROBLEM", 0, 10], ["fluid loss", "PROBLEM", 21, 31], ["dehydrated", "PROBLEM", 69, 79], ["Supportive management", "TREATMENT", 80, 101], ["bronchiolitis", "PROBLEM", 114, 127], ["interventions", "TREATMENT", 156, 169], ["fluid loss", "OBSERVATION", 21, 31], ["dehydrated", "OBSERVATION", 69, 79], ["bronchiolitis", "OBSERVATION", 114, 127]]], ["For milder cases giving small volumes of feed at regular intervals may be sufficient.", [["milder cases", "PROBLEM", 4, 16], ["small volumes of feed", "TREATMENT", 24, 45], ["small", "OBSERVATION_MODIFIER", 24, 29]]], ["Administration of oxygen may be enough to decrease work of breathing, so allowing regular fluid intake.", [["fluid", "ANATOMY", 90, 95], ["oxygen", "CHEMICAL", 18, 24], ["oxygen", "CHEMICAL", 18, 24], ["oxygen", "SIMPLE_CHEMICAL", 18, 24], ["fluid", "ORGANISM_SUBSTANCE", 90, 95], ["Administration of oxygen", "TREATMENT", 0, 24]]], ["If this proves inadequate, a nasogastric tube can be passed to administer enteral fluids -initially bolus feeds, but if this worsens respiratory distress, by continuous feeding.", [["nasogastric tube", "ANATOMY", 29, 45], ["respiratory", "ANATOMY", 133, 144], ["respiratory distress", "DISEASE", 133, 153], ["tube", "TISSUE", 41, 45], ["a nasogastric tube", "TREATMENT", 27, 45], ["enteral fluids", "TREATMENT", 74, 88], ["bolus feeds", "TREATMENT", 100, 111], ["respiratory distress", "PROBLEM", 133, 153], ["nasogastric tube", "OBSERVATION", 29, 45]]], ["Ultimately if the infant is unable to tolerate enteral feeds, fluids can be administered intravenously.", [["intravenously", "ANATOMY", 89, 102], ["infant", "ORGANISM", 18, 24], ["intravenously", "IMMATERIAL_ANATOMICAL_ENTITY", 89, 102], ["infant", "SPECIES", 18, 24], ["enteral feeds", "TREATMENT", 47, 60], ["fluids", "TREATMENT", 62, 68]]], ["RSV infection can result in inappropriate syndrome of inappropriate antidiuretic hormone secretion (SIADH), and so after determining serum electrolytes, intravenous fluids are usually restricted to 75% of maintenance requirements.Respiratory supportThe ventilation/perfusion mismatch characteristic of bronchiolitis results in hypoxia and increased work of breathing.", [["serum", "ANATOMY", 133, 138], ["intravenous", "ANATOMY", 153, 164], ["RSV infection", "DISEASE", 0, 13], ["inappropriate antidiuretic hormone secretion", "DISEASE", 54, 98], ["SIADH", "DISEASE", 100, 105], ["bronchiolitis", "DISEASE", 302, 315], ["hypoxia", "DISEASE", 327, 334], ["RSV", "ORGANISM", 0, 3], ["antidiuretic hormone", "GENE_OR_GENE_PRODUCT", 68, 88], ["serum", "ORGANISM_SUBSTANCE", 133, 138], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 153, 164], ["RSV", "SPECIES", 0, 3], ["RSV infection", "PROBLEM", 0, 13], ["inappropriate syndrome", "PROBLEM", 28, 50], ["inappropriate antidiuretic hormone secretion", "PROBLEM", 54, 98], ["SIADH", "PROBLEM", 100, 105], ["serum electrolytes", "TEST", 133, 151], ["intravenous fluids", "TREATMENT", 153, 171], ["maintenance requirements", "TREATMENT", 205, 229], ["Respiratory support", "TREATMENT", 230, 249], ["The ventilation/perfusion mismatch", "TEST", 249, 283], ["bronchiolitis", "PROBLEM", 302, 315], ["hypoxia", "PROBLEM", 327, 334], ["increased work of breathing", "PROBLEM", 339, 366], ["infection", "OBSERVATION", 4, 13], ["antidiuretic hormone", "OBSERVATION", 68, 88], ["perfusion mismatch", "OBSERVATION", 265, 283], ["bronchiolitis", "OBSERVATION", 302, 315], ["hypoxia", "OBSERVATION", 327, 334], ["increased", "OBSERVATION_MODIFIER", 339, 348], ["work of breathing", "OBSERVATION", 349, 366]]], ["Oxygen is the mainstay of treatment for respiratory distress, and is usually administered via head-box to minimize handling.", [["respiratory", "ANATOMY", 40, 51], ["head", "ANATOMY", 94, 98], ["Oxygen", "CHEMICAL", 0, 6], ["respiratory distress", "DISEASE", 40, 60], ["Oxygen", "CHEMICAL", 0, 6], ["Oxygen", "SIMPLE_CHEMICAL", 0, 6], ["head", "ORGANISM_SUBDIVISION", 94, 98], ["Oxygen", "TREATMENT", 0, 6], ["treatment", "TREATMENT", 26, 35], ["respiratory distress", "PROBLEM", 40, 60]]], ["For higher concentrations, a combination of head box and facemask or rebreathing bag may be used, although this usually implies significant respiratory failure and often precedes respiratory collapse.", [["head", "ANATOMY", 44, 48], ["respiratory", "ANATOMY", 140, 151], ["respiratory", "ANATOMY", 179, 190], ["respiratory failure", "DISEASE", 140, 159], ["respiratory collapse", "DISEASE", 179, 199], ["head", "ORGANISM_SUBDIVISION", 44, 48], ["higher concentrations", "PROBLEM", 4, 25], ["head box", "TREATMENT", 44, 52], ["facemask", "TREATMENT", 57, 65], ["rebreathing bag", "TREATMENT", 69, 84], ["significant respiratory failure", "PROBLEM", 128, 159], ["respiratory collapse", "PROBLEM", 179, 199], ["significant", "OBSERVATION_MODIFIER", 128, 139], ["respiratory failure", "OBSERVATION", 140, 159], ["respiratory collapse", "OBSERVATION", 179, 199]]], ["Increasing impairment of gas exchange will result in hypoxia unresponsive to head-box oxygen and hypercarbia, eventually leading to physical exhaustion and complete respiratory failure.Ventilatory supportBetween 2% and 5% of bronchiolitis admissions will have respiratory failure, and increasingly non-invasive ventilation is used to offer continuous positive airway pressure (CPAP) support, usually via nasal prongs to decrease the need for intubation and sedation.", [["respiratory", "ANATOMY", 165, 176], ["respiratory", "ANATOMY", 260, 271], ["airway", "ANATOMY", 360, 366], ["nasal", "ANATOMY", 404, 409], ["hypoxia", "DISEASE", 53, 60], ["oxygen", "CHEMICAL", 86, 92], ["hypercarbia", "DISEASE", 97, 108], ["respiratory failure", "DISEASE", 165, 184], ["bronchiolitis", "DISEASE", 225, 238], ["respiratory failure", "DISEASE", 260, 279], ["oxygen", "CHEMICAL", 86, 92], ["head-box oxygen", "SIMPLE_CHEMICAL", 77, 92], ["airway", "MULTI-TISSUE_STRUCTURE", 360, 366], ["Increasing impairment of gas exchange", "PROBLEM", 0, 37], ["hypoxia", "PROBLEM", 53, 60], ["head-box oxygen", "TREATMENT", 77, 92], ["hypercarbia", "PROBLEM", 97, 108], ["physical exhaustion", "PROBLEM", 132, 151], ["complete respiratory failure", "PROBLEM", 156, 184], ["Ventilatory supportBetween", "TREATMENT", 185, 211], ["bronchiolitis", "PROBLEM", 225, 238], ["respiratory failure", "PROBLEM", 260, 279], ["increasingly non-invasive ventilation", "TREATMENT", 285, 322], ["continuous positive airway pressure", "TREATMENT", 340, 375], ["CPAP) support", "TREATMENT", 377, 390], ["nasal prongs", "TREATMENT", 404, 416], ["intubation", "TREATMENT", 442, 452], ["sedation", "TREATMENT", 457, 465], ["impairment", "OBSERVATION", 11, 21], ["gas exchange", "OBSERVATION", 25, 37], ["hypercarbia", "OBSERVATION", 97, 108], ["respiratory failure", "OBSERVATION", 165, 184], ["bronchiolitis", "OBSERVATION", 225, 238], ["respiratory failure", "OBSERVATION", 260, 279]]], ["It is thought that the action of CPAP is through prevention of airway collapse during the respiratory cycle, so preserving ventilation and decreasing ventilation/perfusion mismatch.", [["airway", "ANATOMY", 63, 69], ["respiratory", "ANATOMY", 90, 101], ["CPAP", "CHEMICAL", 33, 37], ["airway", "MULTI-TISSUE_STRUCTURE", 63, 69], ["CPAP", "TREATMENT", 33, 37], ["airway collapse", "PROBLEM", 63, 78], ["the respiratory cycle", "TREATMENT", 86, 107], ["preserving ventilation", "TREATMENT", 112, 134], ["decreasing ventilation/perfusion mismatch", "TREATMENT", 139, 180], ["airway", "ANATOMY", 63, 69], ["collapse", "OBSERVATION", 70, 78], ["respiratory cycle", "OBSERVATION", 90, 107], ["perfusion mismatch", "OBSERVATION", 162, 180]]], ["Observational studies suggest that in bronchiolitis CPAP decreases the respiratory rate, pulse rate, and partial pressure of carbon dioxide, and so decreases the intubation rate and consequently the rate of ventilator-associated pneumonia.", [["respiratory", "ANATOMY", 71, 82], ["bronchiolitis", "DISEASE", 38, 51], ["carbon dioxide", "CHEMICAL", 125, 139], ["pneumonia", "DISEASE", 229, 238], ["carbon dioxide", "CHEMICAL", 125, 139], ["carbon dioxide", "SIMPLE_CHEMICAL", 125, 139], ["Observational studies", "TEST", 0, 21], ["bronchiolitis CPAP", "TREATMENT", 38, 56], ["the respiratory rate", "TEST", 67, 87], ["pulse rate", "TEST", 89, 99], ["partial pressure of carbon dioxide", "TREATMENT", 105, 139], ["the intubation rate", "TREATMENT", 158, 177], ["pneumonia", "PROBLEM", 229, 238], ["bronchiolitis", "OBSERVATION", 38, 51], ["respiratory rate", "OBSERVATION", 71, 87], ["carbon dioxide", "OBSERVATION", 125, 139], ["pneumonia", "OBSERVATION", 229, 238]]], ["CPAP does not appear to affect length of hospital stay or duration of ventilation.", [["CPAP", "CHEMICAL", 0, 4], ["CPAP", "TREATMENT", 0, 4], ["ventilation", "TREATMENT", 70, 81]]], ["A controlled study demonstrated that if initiated early, nasal CPAP resulted in a significant decrease in PCO 2 and was well tolerated without any significant complications, suggesting that earlier intervention would improve outcome.", [["nasal", "ANATOMY", 57, 62], ["CPAP", "CHEMICAL", 63, 67], ["nasal", "ORGANISM_SUBDIVISION", 57, 62], ["A controlled study", "TEST", 0, 18], ["nasal CPAP", "TREATMENT", 57, 67], ["a significant decrease in PCO 2", "PROBLEM", 80, 111], ["any significant complications", "PROBLEM", 143, 172], ["earlier intervention", "TREATMENT", 190, 210], ["significant", "OBSERVATION_MODIFIER", 82, 93], ["decrease", "OBSERVATION_MODIFIER", 94, 102]]], ["If respiratory failure continues despite nasal CPAP, full intubation and ventilation is warranted.", [["respiratory", "ANATOMY", 3, 14], ["nasal", "ANATOMY", 41, 46], ["respiratory failure", "DISEASE", 3, 22], ["nasal", "ORGANISM_SUBDIVISION", 41, 46], ["respiratory failure", "PROBLEM", 3, 22], ["nasal CPAP", "TREATMENT", 41, 51], ["full intubation", "TREATMENT", 53, 68], ["ventilation", "TREATMENT", 73, 84], ["respiratory", "ANATOMY", 3, 14], ["failure", "OBSERVATION", 15, 22], ["nasal CPAP", "OBSERVATION", 41, 51]]], ["In those that are mechanically ventilated, administration of exogenous surfactant may decrease duration of mechanical ventilation.", [["mechanically ventilated", "TREATMENT", 18, 41], ["exogenous surfactant", "TREATMENT", 61, 81], ["mechanical ventilation", "TREATMENT", 107, 129], ["mechanically", "OBSERVATION_MODIFIER", 18, 30], ["ventilated", "OBSERVATION", 31, 41], ["mechanical ventilation", "OBSERVATION", 107, 129]]], ["If mechanical ventilation is ineffective, there may be a role for extracorporeal membrane oxygenation (ECMO).Therapeutic interventions BronchodilatorsInterpretation of the evidence for the efficacy of bronchodilators in bronchiolitis is hampered by the heterogeneity of the inclusion criteria in different studies.", [["extracorporeal membrane", "ANATOMY", 66, 89], ["bronchiolitis", "DISEASE", 220, 233], ["mechanical ventilation", "TREATMENT", 3, 25], ["extracorporeal membrane oxygenation", "TREATMENT", 66, 101], ["Therapeutic interventions", "TREATMENT", 109, 134], ["Bronchodilators", "TREATMENT", 135, 150], ["bronchodilators", "TREATMENT", 201, 216], ["bronchiolitis", "PROBLEM", 220, 233], ["different studies", "TEST", 296, 313], ["mechanical ventilation", "OBSERVATION", 3, 25], ["bronchiolitis", "OBSERVATION", 220, 233]]], ["Many studies, particularly if outpatient-based, will include infants up to 2 years old with recurrent wheeze, and it is arguable that many of these infants may have an asthma phenotype.", [["wheeze", "DISEASE", 102, 108], ["asthma", "DISEASE", 168, 174], ["infants", "ORGANISM", 61, 68], ["infants", "ORGANISM", 148, 155], ["infants", "SPECIES", 61, 68], ["infants", "SPECIES", 148, 155], ["Many studies", "TEST", 0, 12], ["recurrent wheeze", "PROBLEM", 92, 108], ["an asthma phenotype", "PROBLEM", 165, 184], ["wheeze", "OBSERVATION", 102, 108], ["asthma", "OBSERVATION", 168, 174]]], ["Three classes of bronchodilators have been trialled in bronchiolitis: \u03b2 2 agonists, ipratropium, and adrenergic agents, all of which have shown benefit in asthmatics.\u03b2 2 agonistsBronchodilators are the treatment of choice for acute asthma in older children and adults, and there is some evidence that bronchodilators may produce short-term improvement in clinical scores in outpatient-based studies of bronchiolitis.", [["bronchiolitis", "DISEASE", 55, 68], ["ipratropium", "CHEMICAL", 84, 95], ["Bronchodilators", "CHEMICAL", 178, 193], ["asthma", "DISEASE", 232, 238], ["bronchiolitis", "DISEASE", 402, 415], ["ipratropium", "CHEMICAL", 84, 95], ["\u03b2 2 agonists", "SIMPLE_CHEMICAL", 70, 82], ["ipratropium", "SIMPLE_CHEMICAL", 84, 95], ["adrenergic agents", "SIMPLE_CHEMICAL", 101, 118], [".\u03b2 2", "SIMPLE_CHEMICAL", 165, 169], ["Bronchodilators", "SIMPLE_CHEMICAL", 178, 193], ["children", "ORGANISM", 248, 256], ["children", "SPECIES", 248, 256], ["bronchodilators", "TREATMENT", 17, 32], ["bronchiolitis", "PROBLEM", 55, 68], ["2 agonists", "TREATMENT", 72, 82], ["ipratropium", "TREATMENT", 84, 95], ["adrenergic agents", "TREATMENT", 101, 118], ["asthmatics", "PROBLEM", 155, 165], ["Bronchodilators", "TREATMENT", 178, 193], ["the treatment", "TREATMENT", 198, 211], ["acute asthma", "PROBLEM", 226, 238], ["bronchodilators", "TREATMENT", 301, 316], ["bronchiolitis", "PROBLEM", 402, 415], ["bronchodilators", "OBSERVATION", 17, 32], ["bronchiolitis", "OBSERVATION", 55, 68], ["acute", "OBSERVATION_MODIFIER", 226, 231], ["asthma", "OBSERVATION", 232, 238], ["short-term", "OBSERVATION_MODIFIER", 329, 339], ["bronchiolitis", "OBSERVATION", 402, 415]]], ["An earlier meta-analysis by Flores and Horwitz concluded that \u03b2 2 agonists had a statistically significant but clinically insignificant effect on oxygen saturations and heart rate when used in milder cases in an outpatient setting, but had no significant effect on hospitalizations.", [["heart", "ANATOMY", 169, 174], ["oxygen", "CHEMICAL", 146, 152], ["oxygen", "CHEMICAL", 146, 152], ["\u03b2 2 agonists", "GENE_OR_GENE_PRODUCT", 62, 74], ["oxygen", "SIMPLE_CHEMICAL", 146, 152], ["heart", "ORGAN", 169, 174], ["An earlier meta-analysis", "TEST", 0, 24], ["oxygen saturations", "TEST", 146, 164], ["heart rate", "TEST", 169, 179], ["oxygen saturations", "OBSERVATION", 146, 164], ["heart", "ANATOMY", 169, 174]]], ["A later systematic review of all pharmacological treatments concluded that \u03b2 2 agonists had no significant beneficial effects.", [["\u03b2 2 agonists", "GENE_OR_GENE_PRODUCT", 75, 87], ["all pharmacological treatments", "TREATMENT", 29, 59]]], ["The most recent Cochrane review of 22 trials involving 1428 infants with bronchiolitis who received inhaled bronchodilators (including \u03b2 2 agonists, ipratropium and adrenergic agents) reported a significant improvement in overall average clinical score, but had no effect on either pulse oximetry measurements or on risk of hospitalization.", [["bronchiolitis", "DISEASE", 73, 86], ["ipratropium", "CHEMICAL", 149, 160], ["ipratropium", "CHEMICAL", 149, 160], ["infants", "ORGANISM", 60, 67], ["\u03b2 2 agonists", "SIMPLE_CHEMICAL", 135, 147], ["ipratropium", "SIMPLE_CHEMICAL", 149, 160], ["adrenergic agents", "SIMPLE_CHEMICAL", 165, 182], ["infants", "SPECIES", 60, 67], ["bronchiolitis", "PROBLEM", 73, 86], ["inhaled bronchodilators", "TREATMENT", 100, 123], ["\u03b2 2 agonists", "TREATMENT", 135, 147], ["ipratropium", "TREATMENT", 149, 160], ["adrenergic agents", "TREATMENT", 165, 182], ["pulse oximetry measurements", "TEST", 282, 309], ["bronchiolitis", "OBSERVATION", 73, 86], ["significant", "OBSERVATION_MODIFIER", 195, 206], ["improvement", "OBSERVATION_MODIFIER", 207, 218]]], ["However, the inclusion criteria for many of the studies allowed children with recurrent wheezing up to 24 months of age, and subgroup analysis suggested that benefit was primarily in outpatient studies of shorter duration, suggesting that many of those who showed benefit may have had recurrent wheeze rather than isolated bronchiolitis.IpratropiumAn earlier systematic review identified four studies assessing the use of nebulized ipratropium bromide in bronchiolitis and concluded that there was no significant benefit.", [["wheezing", "DISEASE", 88, 96], ["wheeze", "DISEASE", 295, 301], ["bronchiolitis", "DISEASE", 323, 336], ["ipratropium bromide", "CHEMICAL", 432, 451], ["bronchiolitis", "DISEASE", 455, 468], ["IpratropiumAn", "CHEMICAL", 337, 350], ["ipratropium bromide", "CHEMICAL", 432, 451], ["children", "ORGANISM", 64, 72], ["IpratropiumAn", "SIMPLE_CHEMICAL", 337, 350], ["ipratropium bromide", "SIMPLE_CHEMICAL", 432, 451], ["children", "SPECIES", 64, 72], ["the studies", "TEST", 44, 55], ["recurrent wheezing", "PROBLEM", 78, 96], ["subgroup analysis", "TEST", 125, 142], ["recurrent wheeze", "PROBLEM", 285, 301], ["isolated bronchiolitis", "PROBLEM", 314, 336], ["four studies", "TEST", 388, 400], ["nebulized ipratropium bromide", "TREATMENT", 422, 451], ["bronchiolitis", "PROBLEM", 455, 468], ["wheeze", "OBSERVATION", 295, 301], ["bronchiolitis", "OBSERVATION", 323, 336], ["bronchiolitis", "OBSERVATION", 455, 468]]], ["A subsequent Cochrane analysis reached similar conclusions.", [["A subsequent Cochrane analysis", "TEST", 0, 30]]], ["It is likely that ipratropium has a role in young infants with recurrent wheeze.Adrenergic agentsAdrenergic agents such as epinephrine appear attractive as they combine the \u03b2-adrenergic effects of bronchodilation with the \u03b1-adrenergic effects of vasoconstriction of the bronchiolar vasculature.", [["bronchiolar vasculature", "ANATOMY", 270, 293], ["ipratropium", "CHEMICAL", 18, 29], ["wheeze", "DISEASE", 73, 79], ["epinephrine", "CHEMICAL", 123, 134], ["ipratropium", "CHEMICAL", 18, 29], ["epinephrine", "CHEMICAL", 123, 134], ["ipratropium", "SIMPLE_CHEMICAL", 18, 29], ["infants", "ORGANISM", 50, 57], ["epinephrine", "SIMPLE_CHEMICAL", 123, 134], ["bronchiolar vasculature", "MULTI-TISSUE_STRUCTURE", 270, 293], ["infants", "SPECIES", 50, 57], ["ipratropium", "TREATMENT", 18, 29], ["recurrent wheeze", "PROBLEM", 63, 79], ["Adrenergic agents", "TREATMENT", 80, 97], ["Adrenergic agents", "TREATMENT", 97, 114], ["epinephrine", "TREATMENT", 123, 134], ["bronchodilation", "TREATMENT", 197, 212], ["vasoconstriction of the bronchiolar vasculature", "PROBLEM", 246, 293], ["likely", "UNCERTAINTY", 6, 12], ["wheeze", "OBSERVATION", 73, 79], ["vasoconstriction", "OBSERVATION", 246, 262], ["bronchiolar", "ANATOMY_MODIFIER", 270, 281], ["vasculature", "ANATOMY", 282, 293]]], ["The vasoconstrictive action in particular could potentially decrease the characteristic mucosal oedema and mucus hyper-secretion.", [["mucosal", "ANATOMY", 88, 95], ["mucus", "ANATOMY", 107, 112], ["oedema", "DISEASE", 96, 102], ["mucosal oedema", "PATHOLOGICAL_FORMATION", 88, 102], ["mucus", "ORGANISM_SUBSTANCE", 107, 112], ["The vasoconstrictive action", "TREATMENT", 0, 27], ["the characteristic mucosal oedema", "PROBLEM", 69, 102], ["mucus hyper-secretion", "PROBLEM", 107, 128], ["vasoconstrictive", "OBSERVATION", 4, 20], ["characteristic", "OBSERVATION_MODIFIER", 73, 87], ["mucosal", "ANATOMY", 88, 95], ["oedema", "OBSERVATION", 96, 102], ["mucus hyper", "OBSERVATION", 107, 118]]], ["A meta-analysis of 14 studies concluded that nebulized epinephrine had beneficial effects compared to either placebo or salbutamol, but the effects were short-term.", [["epinephrine", "CHEMICAL", 55, 66], ["salbutamol", "CHEMICAL", 120, 130], ["epinephrine", "CHEMICAL", 55, 66], ["salbutamol", "CHEMICAL", 120, 130], ["epinephrine", "SIMPLE_CHEMICAL", 55, 66], ["salbutamol", "SIMPLE_CHEMICAL", 120, 130], ["A meta-analysis of 14 studies", "TEST", 0, 29], ["nebulized epinephrine", "TREATMENT", 45, 66], ["placebo", "TREATMENT", 109, 116], ["salbutamol", "TREATMENT", 120, 130]]], ["In studies of inpatients, when compared to placebo epinephrine resulted in a significantly better clinical score at 60 minutes, and when compared to salbutamol resulted in a significantly lower respiratory rate after 30 minutes.", [["respiratory", "ANATOMY", 194, 205], ["epinephrine", "CHEMICAL", 51, 62], ["salbutamol", "CHEMICAL", 149, 159], ["epinephrine", "CHEMICAL", 51, 62], ["salbutamol", "CHEMICAL", 149, 159], ["epinephrine", "SIMPLE_CHEMICAL", 51, 62], ["salbutamol", "SIMPLE_CHEMICAL", 149, 159], ["placebo epinephrine", "TREATMENT", 43, 62], ["salbutamol", "TREATMENT", 149, 159], ["a significantly lower respiratory rate", "PROBLEM", 172, 210], ["respiratory rate", "OBSERVATION", 194, 210]]], ["Short-term benefits were more pronounced in outpatient studies, but the benefits lasted less than 60 minutes and had no effect on hospitalization rates.Adrenergic agentsThus in summary there is very little evidence of benefit for any bronchodilators in bronchiolitis.", [["bronchiolitis", "DISEASE", 253, 266], ["outpatient studies", "TEST", 44, 62], ["Adrenergic agents", "TREATMENT", 152, 169], ["any bronchodilators", "TREATMENT", 230, 249], ["bronchiolitis", "PROBLEM", 253, 266], ["very little evidence of", "UNCERTAINTY", 194, 217], ["bronchiolitis", "OBSERVATION", 253, 266]]], ["What evidence there is of very short-term benefit from epinephrine, mostly in the outpatient setting, which may reflect benefit in infants with recurrent wheeze phenotypes.MontelukastThe leukotriene receptor antagonist montelukast may be beneficial in young children and infants when started early in acute (mostly virus-induced) asthma/wheezing.", [["epinephrine", "CHEMICAL", 55, 66], ["Montelukast", "CHEMICAL", 172, 183], ["leukotriene", "CHEMICAL", 187, 198], ["montelukast", "CHEMICAL", 219, 230], ["asthma", "DISEASE", 330, 336], ["wheezing", "DISEASE", 337, 345], ["epinephrine", "CHEMICAL", 55, 66], ["Montelukast", "CHEMICAL", 172, 183], ["montelukast", "CHEMICAL", 219, 230], ["epinephrine", "SIMPLE_CHEMICAL", 55, 66], ["infants", "ORGANISM", 131, 138], ["Montelukast", "SIMPLE_CHEMICAL", 172, 183], ["leukotriene receptor", "GENE_OR_GENE_PRODUCT", 187, 207], ["montelukast", "SIMPLE_CHEMICAL", 219, 230], ["children", "ORGANISM", 258, 266], ["infants", "ORGANISM", 271, 278], ["infants", "SPECIES", 131, 138], ["children", "SPECIES", 258, 266], ["infants", "SPECIES", 271, 278], ["epinephrine", "TREATMENT", 55, 66], ["recurrent wheeze phenotypes", "PROBLEM", 144, 171], ["Montelukast", "TREATMENT", 172, 183], ["The leukotriene receptor antagonist montelukast", "TREATMENT", 183, 230], ["acute (mostly virus", "PROBLEM", 301, 320], ["asthma", "PROBLEM", 330, 336], ["wheezing", "PROBLEM", 337, 345], ["very", "OBSERVATION_MODIFIER", 26, 30], ["short-term", "OBSERVATION_MODIFIER", 31, 41], ["may reflect", "UNCERTAINTY", 108, 119], ["wheezing", "OBSERVATION", 337, 345]]], ["However, a recent placebo-controlled study of montelukast in 53 infants with a first episode of bronchiolitis demonstrated absence of benefit, with no significant differences in length of hospitalization, clinical severity score, or inflammatory mediators between the two groups.CorticosteroidsCorticosteroids would appear to be an attractive therapy for bronchiolitis; bronchiolitis is characterized by a florid inflammatory response, and the anti-inflammatory actions of corticosteroids are beneficial in older children and adults with asthma.", [["montelukast", "CHEMICAL", 46, 57], ["bronchiolitis", "DISEASE", 96, 109], ["bronchiolitis", "DISEASE", 355, 368], ["bronchiolitis", "DISEASE", 370, 383], ["corticosteroids", "CHEMICAL", 473, 488], ["asthma", "DISEASE", 538, 544], ["montelukast", "CHEMICAL", 46, 57], ["corticosteroids", "CHEMICAL", 473, 488], ["montelukast", "SIMPLE_CHEMICAL", 46, 57], ["infants", "ORGANISM", 64, 71], ["corticosteroids", "SIMPLE_CHEMICAL", 473, 488], ["children", "ORGANISM", 513, 521], ["inflammatory mediators", "PROTEIN", 233, 255], ["infants", "SPECIES", 64, 71], ["children", "SPECIES", 513, 521], ["montelukast", "TREATMENT", 46, 57], ["bronchiolitis", "PROBLEM", 96, 109], ["clinical severity score", "PROBLEM", 205, 228], ["inflammatory mediators", "PROBLEM", 233, 255], ["CorticosteroidsCorticosteroids", "TREATMENT", 279, 309], ["an attractive therapy", "TREATMENT", 329, 350], ["bronchiolitis", "PROBLEM", 355, 368], ["bronchiolitis", "PROBLEM", 370, 383], ["a florid inflammatory response", "PROBLEM", 404, 434], ["corticosteroids", "TREATMENT", 473, 488], ["asthma", "PROBLEM", 538, 544], ["bronchiolitis", "OBSERVATION", 96, 109], ["inflammatory", "OBSERVATION_MODIFIER", 233, 245], ["bronchiolitis", "OBSERVATION", 355, 368], ["bronchiolitis", "OBSERVATION", 370, 383], ["florid", "OBSERVATION_MODIFIER", 406, 412], ["inflammatory response", "OBSERVATION", 413, 434], ["anti-inflammatory", "OBSERVATION_MODIFIER", 444, 461], ["asthma", "OBSERVATION", 538, 544]]], ["Unfortunately there is a large body of evidence for their lack of benefit in bronchiolitis.", [["bronchiolitis", "DISEASE", 77, 90], ["bronchiolitis", "PROBLEM", 77, 90], ["large", "OBSERVATION_MODIFIER", 25, 30], ["bronchiolitis", "OBSERVATION", 77, 90]]], ["The most recent Cochrane review of 13 trials included nearly 1200 children aged 0-30 months who had received the equivalent of 0.5-10 mg/kg of systemic prednisone for 2-7 days.", [["prednisone", "CHEMICAL", 152, 162], ["prednisone", "CHEMICAL", 152, 162], ["children", "ORGANISM", 66, 74], ["prednisone", "SIMPLE_CHEMICAL", 152, 162], ["children", "SPECIES", 66, 74], ["systemic prednisone", "TREATMENT", 143, 162]]], ["Although the length of hospitalization was 0.38 days shorter in the steroid-treated group, the difference was not significant, and there was a similar lack of significant differences in respiratory rate, oxygen saturations, need for supplemental oxygen, need for supportive fluids, and need for bronchodilators.", [["respiratory", "ANATOMY", 186, 197], ["steroid", "CHEMICAL", 68, 75], ["oxygen", "CHEMICAL", 204, 210], ["oxygen", "CHEMICAL", 246, 252], ["steroid", "CHEMICAL", 68, 75], ["oxygen", "CHEMICAL", 204, 210], ["oxygen", "CHEMICAL", 246, 252], ["steroid", "SIMPLE_CHEMICAL", 68, 75], ["oxygen", "SIMPLE_CHEMICAL", 204, 210], ["oxygen", "SIMPLE_CHEMICAL", 246, 252], ["significant differences in respiratory rate", "PROBLEM", 159, 202], ["oxygen saturations", "TEST", 204, 222], ["supplemental oxygen", "TREATMENT", 233, 252], ["supportive fluids", "TREATMENT", 263, 280], ["bronchodilators", "TREATMENT", 295, 310], ["length", "OBSERVATION_MODIFIER", 13, 19], ["significant", "OBSERVATION_MODIFIER", 114, 125], ["significant", "OBSERVATION_MODIFIER", 159, 170], ["respiratory rate", "OBSERVATION", 186, 202]]], ["Furthermore corticosteroids showed no significant benefits even in subgroup analyses of infants who were less than 12 months of age, had confirmed respiratory syncytial virus (RSV) infection, or had no previous history of wheezing.", [["corticosteroids", "CHEMICAL", 12, 27], ["respiratory syncytial virus (RSV) infection", "DISEASE", 147, 190], ["wheezing", "DISEASE", 222, 230], ["corticosteroids", "CHEMICAL", 12, 27], ["infants", "ORGANISM", 88, 95], ["respiratory syncytial virus", "ORGANISM", 147, 174], ["RSV", "ORGANISM", 176, 179], ["infants", "SPECIES", 88, 95], ["respiratory syncytial virus", "SPECIES", 147, 174], ["RSV", "SPECIES", 176, 179], ["Furthermore corticosteroids", "TREATMENT", 0, 27], ["respiratory syncytial virus (RSV) infection", "PROBLEM", 147, 190], ["wheezing", "PROBLEM", 222, 230], ["no", "UNCERTAINTY", 35, 37], ["significant", "OBSERVATION_MODIFIER", 38, 49], ["respiratory", "ANATOMY", 147, 158], ["syncytial virus", "OBSERVATION", 159, 174], ["wheezing", "OBSERVATION", 222, 230]]], ["It is interesting to note that a recent large trial of oral corticosteroids in older preschool children with acute wheeze also demonstrated no benefit.Hypertonic salineThe mode of action of hypertonic saline (HS) in bronchiolitis is unclear.", [["oral", "ANATOMY", 55, 59], ["corticosteroids", "CHEMICAL", 60, 75], ["bronchiolitis", "DISEASE", 216, 229], ["corticosteroids", "CHEMICAL", 60, 75], ["oral", "ORGANISM_SUBDIVISION", 55, 59], ["children", "ORGANISM", 95, 103], ["Hypertonic saline", "SIMPLE_CHEMICAL", 151, 168], ["hypertonic saline", "SIMPLE_CHEMICAL", 190, 207], ["children", "SPECIES", 95, 103], ["oral corticosteroids", "TREATMENT", 55, 75], ["acute wheeze", "PROBLEM", 109, 121], ["Hypertonic saline", "TREATMENT", 151, 168], ["hypertonic saline (HS)", "TREATMENT", 190, 212], ["bronchiolitis", "PROBLEM", 216, 229], ["large", "OBSERVATION_MODIFIER", 40, 45], ["acute", "OBSERVATION_MODIFIER", 109, 114], ["wheeze", "OBSERVATION", 115, 121], ["no", "UNCERTAINTY", 140, 142], ["saline", "OBSERVATION", 162, 168], ["bronchiolitis", "OBSERVATION", 216, 229]]], ["In vitro, HS increases the airway surface liquid (ASL) height in an epithelial cell line model, and in vivo HS increases the mucociliary clearance of radiolabelled aerosol in both normal controls and asthmatics.", [["airway surface", "ANATOMY", 27, 41], ["epithelial cell line", "ANATOMY", 68, 88], ["mucociliary", "ANATOMY", 125, 136], ["epithelial cell line", "CELL", 68, 88], ["mucociliary", "MULTI-TISSUE_STRUCTURE", 125, 136], ["epithelial cell line model", "CELL_LINE", 68, 94], ["an epithelial cell line model", "TREATMENT", 65, 94], ["radiolabelled aerosol", "TREATMENT", 150, 171], ["asthmatics", "PROBLEM", 200, 210], ["airway", "ANATOMY", 27, 33], ["epithelial cell line", "OBSERVATION", 68, 88], ["mucociliary clearance", "OBSERVATION", 125, 146], ["normal controls", "OBSERVATION", 180, 195]]], ["Hypertonic saline is increasingly utilized in cystic fibrosis (CF) where it increases mucociliary clearance for at least 8 hours in a dose-dependent manner, and increases sputum expectoration.", [["cystic", "ANATOMY", 46, 52], ["mucociliary", "ANATOMY", 86, 97], ["sputum", "ANATOMY", 171, 177], ["cystic fibrosis", "DISEASE", 46, 61], ["CF", "DISEASE", 63, 65], ["sputum expectoration", "DISEASE", 171, 191], ["Hypertonic saline", "SIMPLE_CHEMICAL", 0, 17], ["cystic fibrosis", "PATHOLOGICAL_FORMATION", 46, 61], ["mucociliary", "ORGAN", 86, 97], ["Hypertonic saline", "TREATMENT", 0, 17], ["cystic fibrosis", "PROBLEM", 46, 61], ["mucociliary clearance", "TREATMENT", 86, 107], ["increases sputum expectoration", "PROBLEM", 161, 191], ["saline", "OBSERVATION", 11, 17], ["cystic", "OBSERVATION_MODIFIER", 46, 52], ["fibrosis", "OBSERVATION", 53, 61], ["mucociliary clearance", "OBSERVATION", 86, 107], ["increases", "OBSERVATION_MODIFIER", 161, 170], ["sputum expectoration", "OBSERVATION", 171, 191]]], ["In a randomized placebo-controlled study 4 ml of 7% HS administered twice daily via a nebulizer resulted in significant decreases in the number of both mild and severe respiratory exacerbations, in the days antibiotics received per year; and in the number of days absent from work or school.", [["respiratory", "ANATOMY", 168, 179], ["respiratory exacerbations", "DISEASE", 168, 193], ["a randomized placebo-controlled study", "TREATMENT", 3, 40], ["a nebulizer", "TREATMENT", 84, 95], ["both mild and severe respiratory exacerbations", "PROBLEM", 147, 193], ["the days antibiotics", "TREATMENT", 198, 218], ["significant", "OBSERVATION_MODIFIER", 108, 119], ["decreases", "OBSERVATION_MODIFIER", 120, 129], ["both", "OBSERVATION_MODIFIER", 147, 151], ["mild", "OBSERVATION_MODIFIER", 152, 156], ["severe", "OBSERVATION_MODIFIER", 161, 167], ["respiratory exacerbations", "OBSERVATION", 168, 193]]], ["HS can induce bronchospasm even in normal adults, and so in CF it is recommended that HS is only administered after a bronchodilator.Hypertonic salineThere is increasing evidence that disease pathogenesis in CF is due to increased sodium absorption from the airway surface, leading to airway dehydration and subsequent loss of the normal ASL volume and thus decreased ciliary clearance.", [["airway surface", "ANATOMY", 258, 272], ["airway", "ANATOMY", 285, 291], ["ASL", "ANATOMY", 338, 341], ["ciliary", "ANATOMY", 368, 375], ["bronchospasm", "DISEASE", 14, 26], ["CF", "DISEASE", 208, 210], ["sodium", "CHEMICAL", 231, 237], ["airway dehydration", "DISEASE", 285, 303], ["sodium", "CHEMICAL", 231, 237], ["Hypertonic saline", "SIMPLE_CHEMICAL", 133, 150], ["sodium", "SIMPLE_CHEMICAL", 231, 237], ["airway surface", "CELLULAR_COMPONENT", 258, 272], ["airway", "MULTI-TISSUE_STRUCTURE", 285, 291], ["ASL", "MULTI-TISSUE_STRUCTURE", 338, 341], ["ciliary", "MULTI-TISSUE_STRUCTURE", 368, 375], ["bronchospasm", "PROBLEM", 14, 26], ["a bronchodilator", "TREATMENT", 116, 132], ["Hypertonic saline", "TREATMENT", 133, 150], ["disease pathogenesis in CF", "PROBLEM", 184, 210], ["increased sodium absorption from the airway surface", "PROBLEM", 221, 272], ["airway dehydration", "PROBLEM", 285, 303], ["subsequent loss of the normal ASL volume", "PROBLEM", 308, 348], ["decreased ciliary clearance", "PROBLEM", 358, 385], ["bronchospasm", "OBSERVATION", 14, 26], ["saline", "OBSERVATION", 144, 150], ["increasing", "OBSERVATION_MODIFIER", 159, 169], ["disease", "OBSERVATION", 184, 191], ["increased", "OBSERVATION_MODIFIER", 221, 230], ["sodium absorption", "OBSERVATION", 231, 248], ["airway", "ANATOMY", 258, 264], ["surface", "ANATOMY_MODIFIER", 265, 272], ["airway", "ANATOMY", 285, 291], ["dehydration", "OBSERVATION", 292, 303], ["loss", "OBSERVATION_MODIFIER", 319, 323], ["normal", "OBSERVATION", 331, 337], ["ASL volume", "OBSERVATION", 338, 348], ["decreased", "OBSERVATION_MODIFIER", 358, 367], ["ciliary clearance", "OBSERVATION", 368, 385]]], ["Administration of HS is thought to attract water into the airway, so increasing ASL volume and ciliary clearance.", [["airway", "ANATOMY", 58, 64], ["ciliary", "ANATOMY", 95, 102], ["airway", "MULTI-TISSUE_STRUCTURE", 58, 64], ["ASL", "MULTI-TISSUE_STRUCTURE", 80, 83], ["ciliary", "MULTI-TISSUE_STRUCTURE", 95, 102], ["HS", "TREATMENT", 18, 20], ["increasing ASL volume", "TREATMENT", 69, 90], ["ciliary clearance", "TREATMENT", 95, 112], ["airway", "ANATOMY", 58, 64], ["ciliary clearance", "OBSERVATION", 95, 112]]], ["Other agents that attract water into the airway, such as the sugar alcohol mannitol, have similar effects.", [["airway", "ANATOMY", 41, 47], ["mannitol", "CHEMICAL", 75, 83], ["sugar alcohol", "CHEMICAL", 61, 74], ["mannitol", "CHEMICAL", 75, 83], ["airway", "MULTI-TISSUE_STRUCTURE", 41, 47], ["sugar alcohol", "SIMPLE_CHEMICAL", 61, 74], ["mannitol", "SIMPLE_CHEMICAL", 75, 83], ["Other agents", "TREATMENT", 0, 12], ["the sugar alcohol mannitol", "TREATMENT", 57, 83], ["airway", "ANATOMY", 41, 47]]], ["It is unclear whether a similar mode of action is applicable to bronchiolitis, and other postulated modes of action include breakdown of ionic bonds within airway mucus, resulting in decreased mucus viscosity and so easing clearance of airway secretions, and increased prostaglandin E 2 release which stimulates ciliary beat frequency; or possibly HS simply induces coughing, even in normal subjects, and so some of its action could be simply through its tussive effect.Hypertonic salineA Cochrane review of four trials of HS in 254 infants with bronchiolitis demonstrated significantly decreased duration of hospitalization.", [["airway mucus", "ANATOMY", 156, 168], ["mucus", "ANATOMY", 193, 198], ["airway", "ANATOMY", 236, 242], ["ciliary", "ANATOMY", 312, 319], ["bronchiolitis", "DISEASE", 64, 77], ["prostaglandin E", "CHEMICAL", 269, 284], ["coughing", "DISEASE", 366, 374], ["salineA", "CHEMICAL", 481, 488], ["bronchiolitis", "DISEASE", 546, 559], ["prostaglandin E 2", "CHEMICAL", 269, 286], ["airway mucus", "TISSUE", 156, 168], ["mucus", "TISSUE", 193, 198], ["prostaglandin E 2", "GENE_OR_GENE_PRODUCT", 269, 286], ["Hypertonic salineA", "SIMPLE_CHEMICAL", 470, 488], ["infants", "ORGANISM", 533, 540], ["infants", "SPECIES", 533, 540], ["bronchiolitis", "PROBLEM", 64, 77], ["breakdown of ionic bonds within airway mucus", "PROBLEM", 124, 168], ["decreased mucus viscosity", "PROBLEM", 183, 208], ["airway secretions", "PROBLEM", 236, 253], ["increased prostaglandin E", "TREATMENT", 259, 284], ["ciliary beat frequency", "PROBLEM", 312, 334], ["coughing", "PROBLEM", 366, 374], ["Hypertonic salineA", "TREATMENT", 470, 488], ["HS", "TREATMENT", 523, 525], ["bronchiolitis", "PROBLEM", 546, 559], ["bronchiolitis", "OBSERVATION", 64, 77], ["airway", "ANATOMY", 156, 162], ["mucus", "OBSERVATION", 163, 168], ["decreased", "OBSERVATION_MODIFIER", 183, 192], ["mucus viscosity", "OBSERVATION", 193, 208], ["airway", "ANATOMY", 236, 242], ["secretions", "OBSERVATION", 243, 253], ["coughing", "OBSERVATION", 366, 374], ["normal", "OBSERVATION", 384, 390], ["salineA", "OBSERVATION", 481, 488], ["bronchiolitis", "OBSERVATION", 546, 559], ["significantly", "OBSERVATION_MODIFIER", 573, 586], ["decreased", "OBSERVATION_MODIFIER", 587, 596]]], ["Three trials were from the same group of investigators, and used a similar treatment protocol of administering 4 ml of 3% HS every 8 hours, mixed with either 1.5 mg of epinephrine or 5 mg of terbutaline.", [["epinephrine", "CHEMICAL", 168, 179], ["terbutaline", "CHEMICAL", 191, 202], ["epinephrine", "CHEMICAL", 168, 179], ["terbutaline", "CHEMICAL", 191, 202], ["epinephrine", "SIMPLE_CHEMICAL", 168, 179], ["terbutaline", "SIMPLE_CHEMICAL", 191, 202], ["a similar treatment protocol", "TREATMENT", 65, 93], ["epinephrine", "TREATMENT", 168, 179], ["terbutaline", "TREATMENT", 191, 202]]], ["Although administration of a bronchodilator was not essential in the other trial, the majority of subjects concomitantly received a bronchodilator.", [["subjects", "ORGANISM", 98, 106], ["a bronchodilator", "TREATMENT", 27, 43], ["a bronchodilator", "TREATMENT", 130, 146]]], ["The pooled data suggested that 3% HS decreased the median duration of stay by 0.94 days (95% confidence Interval: \u22121.48 to \u22120.4, P = 0.0006) compared to nebulized 0.9% saline, although there was no significant effect on hospitalization rate.Antiviral agentsA controlled trial of the antiviral agent ribavirin via aerosol in infants receiving mechanical ventilation for severe RSV infection initially showed significant benefit, although there were concerns over the choice of aerosolized water as the control.", [["ribavirin", "CHEMICAL", 299, 308], ["RSV infection", "DISEASE", 376, 389], ["ribavirin", "CHEMICAL", 299, 308], ["saline", "SIMPLE_CHEMICAL", 168, 174], ["ribavirin", "SIMPLE_CHEMICAL", 299, 308], ["infants", "ORGANISM", 324, 331], ["RSV", "ORGANISM", 376, 379], ["infants", "SPECIES", 324, 331], ["RSV", "SPECIES", 376, 379], ["The pooled data", "TEST", 0, 15], ["P", "TEST", 129, 130], ["nebulized 0.9% saline", "TREATMENT", 153, 174], ["hospitalization rate", "TEST", 220, 240], ["Antiviral agents", "TREATMENT", 241, 257], ["the antiviral agent ribavirin", "TREATMENT", 279, 308], ["aerosol", "TREATMENT", 313, 320], ["mechanical ventilation", "TREATMENT", 342, 364], ["severe RSV infection", "PROBLEM", 369, 389], ["aerosolized water", "TREATMENT", 476, 493], ["no", "UNCERTAINTY", 195, 197], ["significant", "OBSERVATION_MODIFIER", 198, 209], ["effect", "OBSERVATION_MODIFIER", 210, 216], ["severe", "OBSERVATION_MODIFIER", 369, 375], ["RSV", "OBSERVATION", 376, 379]]], ["A repeat study using aerosolized saline as control demonstrated no benefit, and a subsequent meta-analysis of all controlled trials concluded that there was no significant benefit from aerosolized ribavirin, although there may be a slight reduction in the duration of mechanical ventilation.", [["ribavirin", "CHEMICAL", 197, 206], ["ribavirin", "CHEMICAL", 197, 206], ["saline", "SIMPLE_CHEMICAL", 33, 39], ["ribavirin", "SIMPLE_CHEMICAL", 197, 206], ["A repeat study", "TEST", 0, 14], ["aerosolized saline", "TREATMENT", 21, 39], ["aerosolized ribavirin", "TREATMENT", 185, 206], ["a slight reduction", "PROBLEM", 230, 248], ["mechanical ventilation", "TREATMENT", 268, 290], ["no", "UNCERTAINTY", 64, 66], ["no significant", "UNCERTAINTY", 157, 171], ["aerosolized ribavirin", "OBSERVATION", 185, 206], ["may be", "UNCERTAINTY", 223, 229], ["slight", "OBSERVATION_MODIFIER", 232, 238], ["reduction", "OBSERVATION_MODIFIER", 239, 248], ["mechanical ventilation", "OBSERVATION", 268, 290]]], ["There may however be a role for intravenous ribavirin in severe disease in immunocompromised patients.", [["intravenous", "ANATOMY", 32, 43], ["ribavirin", "CHEMICAL", 44, 53], ["ribavirin", "CHEMICAL", 44, 53], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 32, 43], ["ribavirin", "SIMPLE_CHEMICAL", 44, 53], ["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101], ["intravenous ribavirin", "TREATMENT", 32, 53], ["severe disease in immunocompromised patients", "PROBLEM", 57, 101], ["severe", "OBSERVATION_MODIFIER", 57, 63], ["disease", "OBSERVATION", 64, 71], ["immunocompromised", "OBSERVATION", 75, 92]]], ["Intravenous RSV immune globulin is ineffective in the acute treatment of RSV lower respiratory tract infection.Other treatmentsOther treatments that have shown no benefit in acute bronchiolitis include nebulized deoxyribonuclease, chest physiotherapy, and antibiotics.PreventionInfants known to be at risk of severe bronchiolitis can receive passive immunization against RSV, either with RSV immunoglobulin (RSVIG) by monthly intravenous injections or with monthly intramuscular injections of the humanized monoclonal antibody palivizumab.", [["lower respiratory tract", "ANATOMY", 77, 100], ["chest", "ANATOMY", 231, 236], ["intravenous", "ANATOMY", 426, 437], ["intramuscular", "ANATOMY", 465, 478], ["RSV lower respiratory tract infection", "DISEASE", 73, 110], ["bronchiolitis", "DISEASE", 180, 193], ["bronchiolitis", "DISEASE", 316, 329], ["RSV", "DISEASE", 371, 374], ["palivizumab", "CHEMICAL", 527, 538], ["RSV", "ORGANISM", 12, 15], ["RSV", "ORGANISM", 73, 76], ["tract", "ORGANISM_SUBDIVISION", 95, 100], ["deoxyribonuclease", "GENE_OR_GENE_PRODUCT", 212, 229], ["chest", "ORGANISM_SUBDIVISION", 231, 236], ["RSV", "ORGANISM", 371, 374], ["RSV", "ORGANISM", 388, 391], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 392, 406], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 426, 437], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 465, 478], ["deoxyribonuclease", "PROTEIN", 212, 229], ["RSV immunoglobulin", "PROTEIN", 388, 406], ["humanized monoclonal antibody", "PROTEIN", 497, 526], ["Infants", "SPECIES", 278, 285], ["RSV", "SPECIES", 12, 15], ["RSV", "SPECIES", 73, 76], ["RSV", "SPECIES", 371, 374], ["RSV", "SPECIES", 388, 391], ["Intravenous RSV immune globulin", "TREATMENT", 0, 31], ["the acute treatment", "TREATMENT", 50, 69], ["RSV lower respiratory tract infection", "PROBLEM", 73, 110], ["Other treatments", "TREATMENT", 111, 127], ["Other treatments", "TREATMENT", 127, 143], ["acute bronchiolitis", "PROBLEM", 174, 193], ["nebulized deoxyribonuclease", "TREATMENT", 202, 229], ["chest physiotherapy", "TREATMENT", 231, 250], ["antibiotics", "TREATMENT", 256, 267], ["severe bronchiolitis", "PROBLEM", 309, 329], ["passive immunization", "TREATMENT", 342, 362], ["RSV", "PROBLEM", 371, 374], ["RSV immunoglobulin (RSVIG", "TREATMENT", 388, 413], ["intravenous injections", "TREATMENT", 426, 448], ["monthly intramuscular injections", "TREATMENT", 457, 489], ["the humanized monoclonal antibody palivizumab", "TREATMENT", 493, 538], ["RSV immune globulin", "OBSERVATION", 12, 31], ["acute", "OBSERVATION_MODIFIER", 54, 59], ["RSV", "OBSERVATION", 73, 76], ["lower", "ANATOMY_MODIFIER", 77, 82], ["respiratory tract", "ANATOMY", 83, 100], ["infection", "OBSERVATION", 101, 110], ["no benefit", "UNCERTAINTY", 160, 170], ["acute", "OBSERVATION_MODIFIER", 174, 179], ["bronchiolitis", "OBSERVATION", 180, 193], ["chest", "ANATOMY", 231, 236], ["severe", "OBSERVATION_MODIFIER", 309, 315], ["bronchiolitis", "OBSERVATION", 316, 329]]], ["Neither has any risk of RSV transmission, and neither interferes with the routine childhood vaccination schedule.RSV immunoglobulinThe PREVENT study was a randomized double-blind comparison of RSV immunoglobulin prophylaxis every 30 days versus placebo in over 500 premature infants and infants with bronchopulmonary dysplasia; it demonstrated a significant reduction of hospitalization for RSV and duration of hospitalization, but demonstrated no significant effect on the need for mechanical ventilation, days on intensive care, or mortality.", [["bronchopulmonary dysplasia", "ANATOMY", 300, 326], ["bronchopulmonary dysplasia", "DISEASE", 300, 326], ["RSV", "DISEASE", 391, 394], ["RSV", "ORGANISM", 24, 27], ["RSV", "ORGANISM", 113, 116], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 117, 131], ["RSV", "ORGANISM", 193, 196], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 197, 211], ["infants", "ORGANISM", 275, 282], ["infants", "ORGANISM", 287, 294], ["bronchopulmonary dysplasia", "PATHOLOGICAL_FORMATION", 300, 326], ["RSV", "ORGANISM", 391, 394], ["RSV immunoglobulin", "PROTEIN", 113, 131], ["RSV immunoglobulin", "PROTEIN", 193, 211], ["infants", "SPECIES", 275, 282], ["infants", "SPECIES", 287, 294], ["RSV", "SPECIES", 24, 27], ["RSV", "SPECIES", 113, 116], ["RSV", "SPECIES", 193, 196], ["RSV", "SPECIES", 391, 394], ["RSV transmission", "PROBLEM", 24, 40], ["the routine childhood vaccination schedule", "TREATMENT", 70, 112], ["RSV immunoglobulin", "TEST", 113, 131], ["RSV immunoglobulin prophylaxis", "TREATMENT", 193, 223], ["placebo", "TREATMENT", 245, 252], ["bronchopulmonary dysplasia", "PROBLEM", 300, 326], ["RSV", "PROBLEM", 391, 394], ["mechanical ventilation", "TREATMENT", 483, 505], ["intensive care", "TREATMENT", 515, 529], ["RSV", "OBSERVATION", 24, 27], ["bronchopulmonary", "ANATOMY", 300, 316], ["dysplasia", "OBSERVATION", 317, 326], ["significant", "OBSERVATION_MODIFIER", 346, 357], ["reduction", "OBSERVATION_MODIFIER", 358, 367], ["no", "UNCERTAINTY", 445, 447], ["significant", "OBSERVATION_MODIFIER", 448, 459], ["effect", "OBSERVATION", 460, 466]]], ["RSVIG is no longer used because of the need for monthly intravenous infusions and the small theoretical risk of viral transmission.Humanized monoclonal antibodyThere is probably no agent that divides neonatologists and respiratory paediatricians as much as palivizumab.", [["intravenous", "ANATOMY", 56, 67], ["palivizumab", "CHEMICAL", 257, 268], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 56, 67], ["Humanized monoclonal antibody", "PROTEIN", 131, 160], ["RSVIG", "TEST", 0, 5], ["monthly intravenous infusions", "TREATMENT", 48, 77], ["viral transmission", "PROBLEM", 112, 130], ["Humanized monoclonal antibody", "TEST", 131, 160], ["palivizumab", "TREATMENT", 257, 268], ["no longer", "UNCERTAINTY", 9, 18], ["small", "OBSERVATION_MODIFIER", 86, 91], ["viral transmission", "OBSERVATION", 112, 130], ["probably no", "UNCERTAINTY", 169, 180]]], ["Palivizumab is a humanized immunoglobulin G1 that binds to the RSV fusion protein, and in the cotton rat model it is 50-100 more potent than RSV immunoglobulin.", [["Palivizumab", "CHEMICAL", 0, 11], ["Palivizumab", "CHEMICAL", 0, 11], ["Palivizumab", "SIMPLE_CHEMICAL", 0, 11], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 27, 41], ["RSV", "ORGANISM", 63, 66], ["rat", "ORGANISM", 101, 104], ["RSV", "ORGANISM", 141, 144], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 145, 159], ["humanized immunoglobulin G1", "PROTEIN", 17, 44], ["RSV fusion protein", "PROTEIN", 63, 81], ["RSV immunoglobulin", "PROTEIN", 141, 159], ["rat", "SPECIES", 101, 104], ["RSV", "SPECIES", 63, 66], ["rat", "SPECIES", 101, 104], ["RSV", "SPECIES", 141, 144], ["Palivizumab", "TREATMENT", 0, 11], ["a humanized immunoglobulin G1", "TREATMENT", 15, 44], ["the RSV fusion protein", "TEST", 59, 81], ["the cotton rat model", "TEST", 90, 110], ["RSV immunoglobulin", "TREATMENT", 141, 159], ["RSV fusion", "OBSERVATION", 63, 73]]], ["It prevents entry of RSV into the cells lining the respiratory tract, and when administered intramuscularly has a half life of 18-20 days.", [["cells", "ANATOMY", 34, 39], ["respiratory tract", "ANATOMY", 51, 68], ["RSV", "ORGANISM", 21, 24], ["cells", "CELL", 34, 39], ["respiratory tract", "ORGANISM_SUBDIVISION", 51, 68], ["RSV", "SPECIES", 21, 24], ["RSV", "OBSERVATION", 21, 24], ["respiratory tract", "ANATOMY", 51, 68]]], ["It is administered by monthly intramuscular injections during the RSV season, and is currently licensed for use in preterm infants (less than 35 weeks' gestation) who are less than 6 months old at the start of the bronchiolitis season, any child under 2 years of age who has received treatment for bronchopulmonary dysplasia in the previous 6 months, or in children with haemodynamically significant heart disease.Humanized monoclonal antibodyThe Impact study was a placebo-controlled trial of intramuscular palivizumab every 30 days in over 1500 high-risk infants; the infants were either born at or earlier than 35 weeks' gestation and were less than 6 months of age, or were less than 2 years of age and had had a clinical diagnosis of bronchopulmonary dysplasia which required treatment (oxygen, corticosteroids, bronchodilators or diuretics) in the preceding 6 months.", [["intramuscular", "ANATOMY", 30, 43], ["bronchopulmonary dysplasia", "ANATOMY", 298, 324], ["heart", "ANATOMY", 400, 405], ["bronchopulmonary dysplasia", "ANATOMY", 739, 765], ["bronchiolitis", "DISEASE", 214, 227], ["bronchopulmonary dysplasia", "DISEASE", 298, 324], ["heart disease", "DISEASE", 400, 413], ["palivizumab", "CHEMICAL", 508, 519], ["bronchopulmonary dysplasia", "DISEASE", 739, 765], ["oxygen", "CHEMICAL", 792, 798], ["oxygen", "CHEMICAL", 792, 798], ["corticosteroids", "CHEMICAL", 800, 815], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 30, 43], ["RSV", "ORGANISM", 66, 69], ["infants", "ORGANISM", 123, 130], ["bronchopulmonary dysplasia", "PATHOLOGICAL_FORMATION", 298, 324], ["children", "ORGANISM", 357, 365], ["heart", "ORGAN", 400, 405], ["infants", "ORGANISM", 557, 564], ["infants", "ORGANISM", 570, 577], ["bronchopulmonary dysplasia", "PATHOLOGICAL_FORMATION", 739, 765], ["oxygen", "SIMPLE_CHEMICAL", 792, 798], ["Humanized monoclonal antibody", "PROTEIN", 414, 443], ["infants", "SPECIES", 123, 130], ["children", "SPECIES", 357, 365], ["infants", "SPECIES", 557, 564], ["infants", "SPECIES", 570, 577], ["RSV", "SPECIES", 66, 69], ["monthly intramuscular injections", "TREATMENT", 22, 54], ["treatment", "TREATMENT", 284, 293], ["bronchopulmonary dysplasia", "PROBLEM", 298, 324], ["haemodynamically significant heart disease", "PROBLEM", 371, 413], ["Humanized monoclonal antibody", "TEST", 414, 443], ["a placebo-controlled trial of intramuscular palivizumab", "TREATMENT", 464, 519], ["bronchopulmonary dysplasia", "PROBLEM", 739, 765], ["treatment (oxygen", "TREATMENT", 781, 798], ["corticosteroids", "TREATMENT", 800, 815], ["bronchodilators", "TREATMENT", 817, 832], ["diuretics", "TREATMENT", 836, 845], ["bronchiolitis", "OBSERVATION", 214, 227], ["bronchopulmonary", "ANATOMY", 298, 314], ["dysplasia", "OBSERVATION", 315, 324], ["significant", "OBSERVATION_MODIFIER", 388, 399], ["heart", "ANATOMY", 400, 405], ["disease", "OBSERVATION", 406, 413], ["bronchopulmonary", "ANATOMY", 739, 755], ["dysplasia", "OBSERVATION", 756, 765]]], ["Palivizumab significantly decreased the risk of hospitalization, duration of hospitalization, and the need for intensive care, although it had no significant effect on either the need for ventilation or death.Humanized monoclonal antibodyAlthough the relative effect was striking, the absolute effect was much less so, and the calculated number needed to treat (NNT) was 17.", [["Palivizumab", "CHEMICAL", 0, 11], ["death", "DISEASE", 203, 208], ["Palivizumab", "CHEMICAL", 0, 11], ["Palivizumab", "SIMPLE_CHEMICAL", 0, 11], ["Humanized monoclonal antibody", "PROTEIN", 209, 238], ["Palivizumab", "TREATMENT", 0, 11], ["intensive care", "TREATMENT", 111, 125], ["ventilation", "TREATMENT", 188, 199], ["death", "PROBLEM", 203, 208], ["Humanized monoclonal antibody", "TEST", 209, 238], ["effect", "OBSERVATION_MODIFIER", 260, 266]]], ["Due to its high cost, its economic value has been questioned, with an estimated cost of preventing one hospital admission of \u00a343,000.", [["high", "OBSERVATION_MODIFIER", 11, 15]]], ["In 2005 the Joint Committee for Vaccinations and Immunizations (JCVI) recommended that palivuzimab should be given to all children less than 2 years of age who had previously been treated with home oxygen for chronic lung disease, or those with haemodynamically significant congenital heart disease, pulmonary hypertension, or severe congenital immune deficiency.", [["lung", "ANATOMY", 217, 221], ["heart", "ANATOMY", 285, 290], ["pulmonary", "ANATOMY", 300, 309], ["palivuzimab", "CHEMICAL", 87, 98], ["oxygen", "CHEMICAL", 198, 204], ["chronic lung disease", "DISEASE", 209, 229], ["congenital heart disease", "DISEASE", 274, 298], ["pulmonary hypertension", "DISEASE", 300, 322], ["congenital immune deficiency", "DISEASE", 334, 362], ["palivuzimab", "CHEMICAL", 87, 98], ["oxygen", "CHEMICAL", 198, 204], ["palivuzimab", "SIMPLE_CHEMICAL", 87, 98], ["children", "ORGANISM", 122, 130], ["oxygen", "SIMPLE_CHEMICAL", 198, 204], ["lung", "ORGAN", 217, 221], ["heart", "ORGAN", 285, 290], ["pulmonary", "ORGAN", 300, 309], ["children", "SPECIES", 122, 130], ["Vaccinations", "TREATMENT", 32, 44], ["Immunizations (JCVI)", "TREATMENT", 49, 69], ["palivuzimab", "TREATMENT", 87, 98], ["home oxygen", "TREATMENT", 193, 204], ["chronic lung disease", "PROBLEM", 209, 229], ["haemodynamically significant congenital heart disease", "PROBLEM", 245, 298], ["pulmonary hypertension", "PROBLEM", 300, 322], ["severe congenital immune deficiency", "PROBLEM", 327, 362], ["Joint", "ANATOMY", 12, 17], ["chronic", "OBSERVATION_MODIFIER", 209, 216], ["lung", "ANATOMY", 217, 221], ["disease", "OBSERVATION", 222, 229], ["significant", "OBSERVATION_MODIFIER", 262, 273], ["congenital", "OBSERVATION", 274, 284], ["heart", "ANATOMY", 285, 290], ["disease", "OBSERVATION", 291, 298], ["pulmonary", "ANATOMY", 300, 309], ["hypertension", "OBSERVATION", 310, 322], ["severe", "OBSERVATION_MODIFIER", 327, 333], ["congenital", "OBSERVATION_MODIFIER", 334, 344], ["immune deficiency", "OBSERVATION", 345, 362]]], ["Despite these recommendations, the use of Palivuzimab varies greatly in different areas of the UK.VaccinationAt present there is no effective vaccine for bronchiolitis.", [["Palivuzimab", "CHEMICAL", 42, 53], ["bronchiolitis", "DISEASE", 154, 167], ["Palivuzimab", "CHEMICAL", 42, 53], ["Palivuzimab", "SIMPLE_CHEMICAL", 42, 53], ["UK", "GENE_OR_GENE_PRODUCT", 95, 97], ["Palivuzimab", "TREATMENT", 42, 53], ["Vaccination", "TREATMENT", 98, 109], ["effective vaccine", "TREATMENT", 132, 149], ["bronchiolitis", "PROBLEM", 154, 167], ["no effective", "UNCERTAINTY", 129, 141], ["bronchiolitis", "OBSERVATION", 154, 167]]], ["Attempts have been made to develop a vaccine against RSV; however, when this vaccine was entered into clinical trials patients given the vaccine went on to develop more severe symptoms than those not vaccinated.", [["RSV", "DISEASE", 53, 56], ["RSV", "ORGANISM", 53, 56], ["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 118, 126], ["RSV", "SPECIES", 53, 56], ["a vaccine", "TREATMENT", 35, 44], ["RSV", "PROBLEM", 53, 56], ["this vaccine", "TREATMENT", 72, 84], ["the vaccine", "TREATMENT", 133, 144], ["more severe symptoms", "PROBLEM", 164, 184]]], ["Current efforts to develop a vaccine suitable for human trials focus on using non-animal-derived materials to obtain viral plasmid DNA; at present the efficiency of viral recovery is 30-100%.ConclusionsFluids and oxygen are the mainstays of management.", [["plasmid", "ANATOMY", 123, 130], ["oxygen", "CHEMICAL", 213, 219], ["oxygen", "CHEMICAL", 213, 219], ["human", "ORGANISM", 50, 55], ["DNA", "CELLULAR_COMPONENT", 131, 134], ["oxygen", "SIMPLE_CHEMICAL", 213, 219], ["viral plasmid DNA", "DNA", 117, 134], ["human", "SPECIES", 50, 55], ["human", "SPECIES", 50, 55], ["a vaccine", "TREATMENT", 27, 36], ["human trials", "TREATMENT", 50, 62], ["non-animal-derived materials", "TREATMENT", 78, 106], ["viral plasmid DNA", "TREATMENT", 117, 134], ["Fluids", "TREATMENT", 202, 208], ["oxygen", "TREATMENT", 213, 219], ["management", "TREATMENT", 241, 251], ["viral recovery", "OBSERVATION", 165, 179]]], ["There is increasing evidence for the role of nebulized 3% hypertonic saline administered with a bronchodilator.", [["saline", "SIMPLE_CHEMICAL", 69, 75], ["nebulized 3% hypertonic saline", "TREATMENT", 45, 75], ["a bronchodilator", "TREATMENT", 94, 110], ["increasing", "OBSERVATION_MODIFIER", 9, 19]]], ["CPAP and if necessary mechanical ventilation are effective for respiratory failure.", [["respiratory", "ANATOMY", 63, 74], ["respiratory failure", "DISEASE", 63, 82], ["CPAP", "CHEMICAL", 0, 4], ["CPAP", "TREATMENT", 0, 4], ["mechanical ventilation", "TREATMENT", 22, 44], ["respiratory failure", "PROBLEM", 63, 82], ["failure", "OBSERVATION", 75, 82]]], ["Palivizumab decreases the risk of hospitalizations in high-risk infants, although there is controversy over its benefits. \u25c6 wheezing with chest hyperinflation with costal recession on examination, and fine inspiratory crackles and polyphonic expiratory wheeze on auscultation \u2022 rSV accounts for 50-90% of cases of bronchiolitis -other causative agents include Human metapneumovirus (hmpV), rhinovirus and less frequently adenovirus, parainfluenza, influenza, coronavirus and the more recently identified bocavirus \u2022 management of bronchiolitis is primarily supportive, concentrating on the major complications of inadequate feeding, respiratory distress and apnoeas.", [["chest", "ANATOMY", 138, 143], ["costal", "ANATOMY", 164, 170], ["respiratory", "ANATOMY", 633, 644], ["Palivizumab", "CHEMICAL", 0, 11], ["wheezing", "DISEASE", 124, 132], ["chest hyperinflation", "DISEASE", 138, 158], ["expiratory wheeze", "DISEASE", 242, 259], ["bronchiolitis", "DISEASE", 314, 327], ["Human metapneumovirus (hmpV), rhinovirus", "DISEASE", 360, 400], ["parainfluenza", "DISEASE", 433, 446], ["influenza", "DISEASE", 448, 457], ["coronavirus", "DISEASE", 459, 470], ["bronchiolitis", "DISEASE", 530, 543], ["respiratory distress", "DISEASE", 633, 653], ["apnoeas", "DISEASE", 658, 665], ["Palivizumab", "CHEMICAL", 0, 11], ["Palivizumab", "SIMPLE_CHEMICAL", 0, 11], ["infants", "ORGANISM", 64, 71], ["chest", "ORGANISM_SUBDIVISION", 138, 143], ["Human metapneumovirus", "ORGANISM", 360, 381], ["hmpV", "ORGANISM", 383, 387], ["rhinovirus", "ORGANISM", 390, 400], ["adenovirus", "ORGANISM", 421, 431], ["parainfluenza", "ORGANISM", 433, 446], ["coronavirus", "ORGANISM", 459, 470], ["infants", "SPECIES", 64, 71], ["Human metapneumovirus", "SPECIES", 360, 381], ["parainfluenza", "SPECIES", 433, 446], ["coronavirus", "SPECIES", 459, 470], ["Human metapneumovirus", "SPECIES", 360, 381], ["hmpV", "SPECIES", 383, 387], ["Palivizumab", "TREATMENT", 0, 11], ["wheezing", "PROBLEM", 124, 132], ["chest hyperinflation", "PROBLEM", 138, 158], ["costal recession", "PROBLEM", 164, 180], ["examination", "TEST", 184, 195], ["fine inspiratory crackles", "PROBLEM", 201, 226], ["polyphonic expiratory wheeze", "PROBLEM", 231, 259], ["auscultation", "TEST", 263, 275], ["rSV", "PROBLEM", 278, 281], ["bronchiolitis", "PROBLEM", 314, 327], ["Human metapneumovirus (hmpV)", "PROBLEM", 360, 388], ["rhinovirus", "PROBLEM", 390, 400], ["less frequently adenovirus", "PROBLEM", 405, 431], ["parainfluenza", "PROBLEM", 433, 446], ["influenza", "PROBLEM", 448, 457], ["coronavirus", "PROBLEM", 459, 470], ["bocavirus \u2022 management", "TREATMENT", 504, 526], ["bronchiolitis", "PROBLEM", 530, 543], ["inadequate feeding", "PROBLEM", 613, 631], ["respiratory distress", "PROBLEM", 633, 653], ["apnoeas", "PROBLEM", 658, 665], ["wheezing", "OBSERVATION", 124, 132], ["chest", "ANATOMY", 138, 143], ["hyperinflation", "OBSERVATION", 144, 158], ["costal", "ANATOMY", 164, 170], ["recession", "OBSERVATION", 171, 180], ["fine", "OBSERVATION_MODIFIER", 201, 205], ["inspiratory", "OBSERVATION_MODIFIER", 206, 217], ["crackles", "OBSERVATION", 218, 226], ["expiratory wheeze", "OBSERVATION", 242, 259], ["bronchiolitis", "OBSERVATION", 314, 327], ["bronchiolitis", "OBSERVATION", 530, 543], ["respiratory distress", "OBSERVATION", 633, 653], ["apnoeas", "OBSERVATION", 658, 665]]], ["Fluids (either enteral or parenteral) and oxygen are the mainstays, although cpap or mechanical ventilation are effective for respiratory failure \u2022 there is no role for bronchodilators, corticosteroids, antiviral agents, physiotherapy, nebulized dnase or antibiotics, but nebulized 3% hypertonic saline administered with a bronchodilator may decrease length of stay in hospitalConclusions\u2022 preventative strategies such as rSV immunoglobulin or the anti-rSV monoclonal antibody palivuzimab can decrease disease severity and need for hospitalization, although there is controversy over their benefits", [["respiratory", "ANATOMY", 126, 137], ["Fluids", "CHEMICAL", 0, 6], ["oxygen", "CHEMICAL", 42, 48], ["respiratory failure", "DISEASE", 126, 145], ["palivuzimab", "CHEMICAL", 477, 488], ["oxygen", "CHEMICAL", 42, 48], ["oxygen", "SIMPLE_CHEMICAL", 42, 48], ["hypertonic saline", "SIMPLE_CHEMICAL", 285, 302], ["rSV immunoglobulin", "GENE_OR_GENE_PRODUCT", 422, 440], ["rSV immunoglobulin", "PROTEIN", 422, 440], ["anti-rSV monoclonal antibody", "PROTEIN", 448, 476], ["rSV", "SPECIES", 422, 425], ["anti-rSV", "SPECIES", 448, 456], ["Fluids (either enteral or parenteral)", "TREATMENT", 0, 37], ["oxygen", "TREATMENT", 42, 48], ["the mainstays", "TREATMENT", 53, 66], ["cpap", "TREATMENT", 77, 81], ["mechanical ventilation", "TREATMENT", 85, 107], ["respiratory failure", "PROBLEM", 126, 145], ["bronchodilators", "TREATMENT", 169, 184], ["corticosteroids", "TREATMENT", 186, 201], ["antiviral agents", "TREATMENT", 203, 219], ["physiotherapy", "TREATMENT", 221, 234], ["nebulized dnase", "TREATMENT", 236, 251], ["antibiotics", "TREATMENT", 255, 266], ["nebulized 3% hypertonic saline", "TREATMENT", 272, 302], ["a bronchodilator", "TREATMENT", 321, 337], ["preventative strategies", "TREATMENT", 390, 413], ["rSV immunoglobulin", "TREATMENT", 422, 440], ["the anti-rSV monoclonal antibody palivuzimab", "TREATMENT", 444, 488], ["disease severity", "PROBLEM", 502, 518], ["hospitalization", "TREATMENT", 532, 547], ["no role for", "UNCERTAINTY", 157, 168]]]], "2aec20c10785448b3d01e9de635004cb61d89b46": [["IntroductionA novel coronavirus disease, designated as COVID-19, has become a pandemic worldwide.", [["coronavirus disease", "DISEASE", 20, 39], ["COVID-19", "CHEMICAL", 55, 63], ["coronavirus", "ORGANISM", 20, 31], ["IntroductionA novel coronavirus disease", "PROBLEM", 0, 39], ["COVID", "TEST", 55, 60], ["coronavirus disease", "OBSERVATION", 20, 39], ["pandemic", "OBSERVATION", 78, 86]]], ["As of March 29, 2020, there were 634,835 confirmed COVID-19 cases and 29,957 deaths reported worldwide.", [["deaths", "DISEASE", 77, 83], ["COVID", "TEST", 51, 56]]], ["2 The incubation period is defined as the time from infection to symptom onset.", [["infection", "DISEASE", 52, 61], ["infection", "PROBLEM", 52, 61], ["infection", "OBSERVATION", 52, 61]]], ["It is a key indicator that helps to depict the transmission dynamics of infectious diseases.", [["infectious diseases", "DISEASE", 72, 91], ["infectious diseases", "PROBLEM", 72, 91], ["infectious", "OBSERVATION", 72, 82]]], ["3 It can also help to determine the quarantine period for suspicious cases.", [["suspicious cases", "PROBLEM", 58, 74]]], ["4, 5 Thus far, several studies have estimated the incubation period of COVID-19.", [["COVID-19", "CHEMICAL", 71, 79], ["several studies", "TEST", 15, 30], ["COVID", "TEST", 71, 76]]], ["The reported mean incubation period for COVID-19 varied from 4 days to 10.9 days.", [["COVID", "TEST", 40, 45]]], ["[6] [7] [8] [9] However, the above-mentioned studies have been limited by their small sample sizes and/or the fact that they were based on publicly reported data.", [["[6] [7] [8] [9", "SIMPLE_CHEMICAL", 0, 14], ["the above-mentioned studies", "TEST", 25, 52]]], ["As a result, sampling bias and selection bias may have been introduced into the estimates.", [["sampling bias", "TEST", 13, 26], ["selection bias", "TREATMENT", 31, 45]]], ["10 Moreover, factors associated with the incubation period of COVID-19 are not fully known.IntroductionTo obtain reliable estimates of the incubation period for COVID-19, we collected data in a municipality in Hubei province during a full outbreak period.", [["COVID-19", "CHEMICAL", 62, 70], ["COVID-19", "CHEMICAL", 62, 70], ["COVID", "TEST", 62, 67], ["COVID", "TEST", 161, 166]]], ["Our aim was to further assess the incubation period of COVID-19, and to explore whether there were different incubation periods among different age groups.Study Setting BackgroundOn 20 January 2020, the Shiyan Center for Disease Control and Prevention in Hubei province identified the first COVID-19 case and began active surveillance of people returning from Wuhan and its surrounding areas in Hubei province.", [["COVID-19", "CELL", 55, 63], ["people", "ORGANISM", 338, 344], ["people", "SPECIES", 338, 344], ["Disease Control", "TREATMENT", 221, 236]]], ["The surveillance program was then expanded to people who had recently returned from Wuhan regardless of symptoms; patients in hospitals or clinics; and individuals detected by fever screening in communities.", [["fever", "DISEASE", 176, 181], ["people", "ORGANISM", 46, 52], ["patients", "ORGANISM", 114, 122], ["people", "SPECIES", 46, 52], ["patients", "SPECIES", 114, 122], ["symptoms", "PROBLEM", 104, 112], ["fever screening", "TEST", 176, 191]]], ["Epidemiological surveys were conducted for each confirmed case, using a standard format.Data CollectionWe collected data for cases with confirmed COVID-19 in Shiyan based on the epidemiological survey reports.", [["Epidemiological surveys", "TEST", 0, 23], ["COVID", "TEST", 146, 151]]], ["Information collected included each case's sex, age, source of infection (imported from Wuhan, or locally infected), date of exposure (entry into and exit from Wuhan, or the earliest and latest date of close contact with a Wuhanimported/locally infected case), date of symptom onset, and date of diagnosis.Data CollectionThe symptom onset of COVID-19 patients was defined as one or more of the following symptoms: cough, dyspnea, fever, chest congestion, muscle soreness, chills, fatigue, and diarrhea.", [["chest", "ANATOMY", 437, 442], ["muscle", "ANATOMY", 455, 461], ["infection", "DISEASE", 63, 72], ["COVID", "DISEASE", 342, 347], ["cough", "DISEASE", 414, 419], ["dyspnea", "DISEASE", 421, 428], ["fever", "DISEASE", 430, 435], ["chest congestion", "DISEASE", 437, 453], ["muscle soreness", "DISEASE", 455, 470], ["chills", "DISEASE", 472, 478], ["fatigue", "DISEASE", 480, 487], ["diarrhea", "DISEASE", 493, 501], ["patients", "ORGANISM", 351, 359], ["chest", "ORGANISM_SUBDIVISION", 437, 442], ["muscle", "ORGAN", 455, 461], ["patients", "SPECIES", 351, 359], ["infection", "PROBLEM", 63, 72], ["Data Collection", "TEST", 306, 321], ["COVID", "TEST", 342, 347], ["the following symptoms", "PROBLEM", 390, 412], ["cough", "PROBLEM", 414, 419], ["dyspnea", "PROBLEM", 421, 428], ["fever", "PROBLEM", 430, 435], ["chest congestion", "PROBLEM", 437, 453], ["muscle soreness", "PROBLEM", 455, 470], ["chills", "PROBLEM", 472, 478], ["fatigue", "PROBLEM", 480, 487], ["diarrhea", "PROBLEM", 493, 501], ["infection", "OBSERVATION", 63, 72], ["cough", "OBSERVATION", 414, 419], ["chest", "ANATOMY", 437, 442], ["congestion", "OBSERVATION", 443, 453], ["muscle", "ANATOMY", 455, 461], ["soreness", "OBSERVATION", 462, 470], ["chills", "OBSERVATION", 472, 478]]], ["To estimate the incubation period for COVID-19, the exposure periods were inferred from the history of travel in Wuhan and/or history of exposure to confirmed cases, as follows: (i) If a patient had a history of travel in Wuhan two weeks before symptom onset and stayed no more than one week in Wuhan, the left and right endpoints of the windows of possible date of infection were set as the date of entry into and exit from Wuhan, respectively; (ii) If a patient did not have a history of travel to Wuhan two weeks before symptom onset and had a well-defined contact period with a confirmed case, the left and right endpoints of the windows of possible date of infection were set as the initial contact date and the last contact date, respectively; and (iii) If a patient had a history of staying in Wuhan for more than one week, or if there was no clear contact information about a confirmed case, or if the contact period with a confirmed case was not clear or was longer than one week, the exposed period was not recorded.Statistical AnalysisFrequency counts and percentages were used in the descriptive analysis.", [["left", "ANATOMY", 306, 310], ["left", "ANATOMY", 602, 606], ["infection", "DISEASE", 366, 375], ["infection", "DISEASE", 662, 671], ["patient", "ORGANISM", 187, 194], ["patient", "ORGANISM", 456, 463], ["patient", "ORGANISM", 765, 772], ["patient", "SPECIES", 187, 194], ["patient", "SPECIES", 456, 463], ["patient", "SPECIES", 765, 772], ["COVID", "TEST", 38, 43], ["infection", "PROBLEM", 366, 375], ["infection", "PROBLEM", 662, 671], ["Statistical AnalysisFrequency counts", "TEST", 1026, 1062], ["percentages", "TEST", 1067, 1078], ["the descriptive analysis", "TEST", 1092, 1116], ["left", "ANATOMY_MODIFIER", 306, 310], ["right", "ANATOMY_MODIFIER", 315, 320], ["infection", "OBSERVATION", 366, 375], ["left", "ANATOMY_MODIFIER", 602, 606], ["right", "ANATOMY_MODIFIER", 611, 616], ["infection", "OBSERVATION", 662, 671]]], ["All of the analyses were performed using R software, version 3.6.1.", [["the analyses", "TEST", 7, 19], ["version", "TEST", 53, 60]]], ["11 For each case, the date of infection was between two possible dates, while the date of symptom onset was definite.", [["infection", "DISEASE", 30, 39], ["infection", "PROBLEM", 30, 39], ["symptom onset", "PROBLEM", 90, 103], ["infection", "OBSERVATION", 30, 39]]], ["12 We estimated incubation period using the algorithm described by Reich et al implemented in the coarseDataTools R package.", [["the algorithm", "TREATMENT", 40, 53], ["DataTools R package", "TREATMENT", 104, 123]]], ["Finally, we applied a multivariate regression using the best fit model to examine the difference in incubation periods for different age groups.Ethics StatementThis study was approved by the Research Ethics Committee of Hubei University of Medicine to access the database and analyze the data.", [["a multivariate regression", "TREATMENT", 20, 45], ["the database", "TEST", 259, 271], ["the data", "TEST", 284, 292]]], ["Analytic datasets were constructed in an anonymized fashion.", [["Analytic datasets", "TEST", 0, 17]]], ["The names and identification numbers of all patients were encrypted before use to ensure confidentiality.", [["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52]]], ["Approval to conduct the study was done in compliance with the Declaration of Helsinki.Patients' CharacteristicsBetween 20 January 2020 and 29 February 2020, 672 COVID-19 cases were detected and diagnosed in Shiyan, Hubei province.", [["Patients", "ORGANISM", 86, 94], ["Patients", "SPECIES", 86, 94], ["the study", "TEST", 20, 29], ["COVID", "TEST", 161, 166]]], ["We identified 180 cases with a welldefined period of exposure and date of symptom onset.", [["symptom onset", "PROBLEM", 74, 87]]], ["Of the 180 cases, the mean age was 46.1 years with a standard deviation of 15.3 years; 83 (46.1%) were female and 97 (53.9%) were male; 57 (31.7%) had a history of staying in Wuhan no more than one week prior to onset or diagnosis, and 123 (68.3%) were locally infected.", [["locally infected", "PROBLEM", 253, 269], ["infected", "OBSERVATION", 261, 269]]], ["The length of exposure intervals ranged from 0 to 7 days with a mean of 2.3 days and a standard deviation of 2.4 days.", [["length", "OBSERVATION_MODIFIER", 4, 10]]], ["The parameters and specific quantiles of Weibull distributions fitted to incubation periods for different age groups are shown in Table 2 .", [["Weibull distributions", "PROBLEM", 41, 62], ["incubation periods", "TREATMENT", 73, 91]]], ["The shape and scale parameters of the corresponding distributions increase as the age group changes from the youngest to the eldest.", [["shape", "OBSERVATION_MODIFIER", 4, 9], ["scale", "OBSERVATION_MODIFIER", 14, 19], ["distributions", "OBSERVATION_MODIFIER", 52, 65], ["increase", "OBSERVATION_MODIFIER", 66, 74]]], ["Figure 2 shows the corresponding probability density distributions and cumulative density distributions of incubation periods for the three age groups.", [["the corresponding probability density distributions", "PROBLEM", 15, 66], ["probability", "OBSERVATION_MODIFIER", 33, 44], ["density", "OBSERVATION_MODIFIER", 45, 52], ["distributions", "OBSERVATION_MODIFIER", 53, 66], ["cumulative", "OBSERVATION_MODIFIER", 71, 81], ["density", "OBSERVATION_MODIFIER", 82, 89], ["distributions", "OBSERVATION_MODIFIER", 90, 103], ["incubation", "OBSERVATION_MODIFIER", 107, 117], ["periods", "OBSERVATION_MODIFIER", 118, 125]]], ["The incubation periods have an increasing trend from the youngest to the eldest cases.", [["increasing", "OBSERVATION_MODIFIER", 31, 41], ["trend", "OBSERVATION_MODIFIER", 42, 47]]], ["The median incubation period was estimated at 4.0 days (95% CI: 3.5-4.4) for cases aged under 30, 5.8 days (95% CI: 5.6-6.0) for cases aged between 30 and 59, and 7.7 days (95% CI: 6.9-8.4) for cases aged greater than or equal to 60.", [["CI", "TEST", 60, 62], ["CI", "TEST", 112, 114], ["cases", "TEST", 129, 134], ["CI", "TEST", 177, 179], ["cases", "TEST", 194, 199]]], ["The three distribution curves are almost superimposed in the right tails after 16 days.", [["right tails", "ANATOMY", 61, 72], ["three", "OBSERVATION_MODIFIER", 4, 9], ["distribution", "OBSERVATION_MODIFIER", 10, 22], ["curves", "OBSERVATION_MODIFIER", 23, 29], ["almost", "OBSERVATION_MODIFIER", 34, 40], ["superimposed", "OBSERVATION_MODIFIER", 41, 53], ["right", "ANATOMY_MODIFIER", 61, 66], ["tails", "ANATOMY_MODIFIER", 67, 72]]], ["Of those symptomatic cases, 95% cases aged less than 30 showed symptoms within 12.3 days (95% CI: 11.7-12.8) after infection, while 14.4 days (95% CI: 14.2-14.7) for cases aged between 30 and 59, and 14.1 days (95% CI: 13.2-15.0) for cases aged greater than or equal to 60.Incubation Period DistributionIn the multivariate Weibull regression model (Table 3) , sex and source of infection were not found to be significantly associated with the incubation period.", [["infection", "DISEASE", 115, 124], ["infection", "DISEASE", 378, 387], ["symptoms", "PROBLEM", 63, 71], ["CI", "TEST", 94, 96], ["infection", "PROBLEM", 115, 124], ["CI", "TEST", 147, 149], ["cases", "TEST", 166, 171], ["CI", "TEST", 215, 217], ["cases", "TEST", 234, 239], ["infection", "PROBLEM", 378, 387], ["symptomatic", "OBSERVATION_MODIFIER", 9, 20], ["infection", "OBSERVATION", 115, 124], ["infection", "OBSERVATION", 378, 387]]], ["The incubation periods for elderly cases and middle-age cases were longer than those for young cases, though only the elderly showed a significant longer incubation period than the young cases (P = 0.013).", [["The incubation periods", "TREATMENT", 0, 22], ["elderly cases", "PROBLEM", 27, 40]]], ["After adjusting for sex and source of infection, the incubation period for cases above 60 years was 1.5 times (95% CI: 1.09-2.05) longer than that of cases aged less than 30 on average.DiscussionUsing contact tracing data accounting for interval censoring of exposures, our estimate of incubation period for COVID-19 follows a Weibull distribution with a median of 5.8 days.", [["infection", "DISEASE", 38, 47], ["infection", "PROBLEM", 38, 47], ["CI", "TEST", 115, 117], ["COVID", "TEST", 308, 313], ["infection", "OBSERVATION", 38, 47]]], ["Our estimated median incubation period is longer than the values from two studies conducted during the early outbreak of COVID-19, which were 5.2 days 17 and 4.8 days, 18 respectively.", [["two studies", "TEST", 70, 81], ["COVID", "TEST", 121, 126]]], ["These two studies set the date of leaving Wuhan as the exposure time.", [["These two studies", "TEST", 0, 17]]], ["However, infectees may have been exposed several days prior to leaving Wuhan.", [["infectees", "PROBLEM", 9, 18]]], ["This might result in an underestimate of the incubation period.DiscussionTime of infection is critical in estimating the incubation period.", [["infection", "DISEASE", 81, 90], ["infection", "PROBLEM", 81, 90], ["infection", "OBSERVATION", 81, 90]]], ["However, many of its manufacturing plants are still in Shiyan.", [["manufacturing plants", "OBSERVATION", 21, 41]]], ["As a result, there is more frequent population mobility between these two cities than other cities in the province.", [["more", "OBSERVATION_MODIFIER", 22, 26], ["frequent", "OBSERVATION_MODIFIER", 27, 35], ["population", "OBSERVATION_MODIFIER", 36, 46], ["mobility", "OBSERVATION_MODIFIER", 47, 55]]], ["This facilitated our ability to estimate the time of infection in cases with a history of short stay in Wuhan before symptom onset.", [["infection", "DISEASE", 53, 62], ["infection", "PROBLEM", 53, 62], ["infection", "OBSERVATION", 53, 62]]], ["Besides, because of the lockdown of the communities in the city, most transmissions of COVID-19 occurred within families or neighborhoods.", [["COVID-19", "CHEMICAL", 87, 95], ["COVID", "TEST", 87, 92]]], ["Therefore, for those had close contacts with Wuhanimported cases, we could infer source of infection with high accuracy.", [["infection", "DISEASE", 91, 100], ["infection", "PROBLEM", 91, 100], ["infection", "OBSERVATION", 91, 100]]], ["As a result, we can obtain the time interval of infection from the earliest and last contact time.", [["infection", "DISEASE", 48, 57], ["infection", "PROBLEM", 48, 57], ["infection", "OBSERVATION", 48, 57]]], ["For these reasons, our estimate of the incubation period should be more justifiable than those in previously published studies.DiscussionAlthough the incubation period distributions of different age groups are significantly different, the distribution curves are almost superimposed in the right tails.", [["right tails", "ANATOMY", 290, 301], ["significantly different", "OBSERVATION_MODIFIER", 210, 233], ["right", "ANATOMY_MODIFIER", 290, 295], ["tails", "ANATOMY_MODIFIER", 296, 301]]], ["Of symptomatic cases in any age group, about 95% will show symptoms within 14 days.", [["symptomatic cases", "PROBLEM", 3, 20], ["symptoms", "PROBLEM", 59, 67], ["symptomatic", "OBSERVATION_MODIFIER", 3, 14], ["cases", "OBSERVATION", 15, 20]]], ["However, considering that nearly 5% of patients still require an incubation period of more than 14 days, a 1-5-day extension of the quarantine period may be necessary.DiscussionOur results suggest that older people infected with SARS-CoV-2 have longer incubation period than that of younger people.", [["SARS", "DISEASE", 229, 233], ["patients", "ORGANISM", 39, 47], ["people", "ORGANISM", 208, 214], ["SARS-CoV-2", "ORGANISM", 229, 239], ["people", "ORGANISM", 291, 297], ["patients", "SPECIES", 39, 47], ["people", "SPECIES", 208, 214], ["people", "SPECIES", 291, 297], ["SARS-CoV", "SPECIES", 229, 237]]], ["The more responsive the host's immune system is to a respiratory virus, the shorter the incubation period.", [["immune system", "ANATOMICAL_SYSTEM", 31, 44], ["a respiratory virus", "PROBLEM", 51, 70], ["more responsive", "OBSERVATION_MODIFIER", 4, 19], ["respiratory virus", "OBSERVATION", 53, 70]]], ["19 Elderly people display a marked increase in the proportion of highly differentiated effector and memory T cells due to a lifetime of exposure to a variety of pathogens.", [["effector", "ANATOMY", 87, 95], ["memory T cells", "ANATOMY", 100, 114], ["people", "ORGANISM", 11, 17], ["effector", "CELL", 87, 95], ["memory T cells", "CELL", 100, 114], ["highly differentiated effector and memory T cells", "CELL_TYPE", 65, 114], ["people", "SPECIES", 11, 17], ["a marked increase", "PROBLEM", 26, 43], ["memory T cells", "PROBLEM", 100, 114], ["pathogens", "PROBLEM", 161, 170], ["marked", "OBSERVATION_MODIFIER", 28, 34], ["increase", "OBSERVATION_MODIFIER", 35, 43], ["highly differentiated", "OBSERVATION_MODIFIER", 65, 86]]], ["20 A significant proportion of T cells of elderly loses the expression of costimulatory molecules, [20] [21] [22] which may lead to delay in the transmission of defense information by the immune system.", [["T cells", "ANATOMY", 31, 38], ["immune system", "ANATOMY", 188, 201], ["T cells", "CELL", 31, 38], ["immune system", "ANATOMICAL_SYSTEM", 188, 201], ["T cells", "CELL_TYPE", 31, 38], ["costimulatory molecules", "PROTEIN", 74, 97]]], ["When the host's immune system is not yet activated, the virus can replicate in large amount in the incubation period.", [["the virus", "PROBLEM", 52, 61], ["large", "OBSERVATION_MODIFIER", 79, 84], ["amount", "OBSERVATION_MODIFIER", 85, 91]]], ["This might explain that the proportion of severe cases in elder age was significantly higher than in the young.", [["severe", "OBSERVATION_MODIFIER", 42, 48], ["cases", "OBSERVATION", 49, 54], ["higher", "OBSERVATION_MODIFIER", 86, 92]]], ["This need to be proven by another epidemiological study.DiscussionThe present study has several limitations.", [["another epidemiological study", "TEST", 26, 55], ["The present study", "TEST", 66, 83]]], ["Patients returned from Wuhan may have delayed reporting their symptoms to avoid discrimination.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["their symptoms", "PROBLEM", 56, 70]]], ["It is possible that the time of infection is more inclined to the left or right endpoint of the interval, depending on the transmission of SARS-CoV2.", [["left", "ANATOMY", 66, 70], ["infection", "DISEASE", 32, 41], ["SARS", "DISEASE", 139, 143], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 139, 148], ["infection", "PROBLEM", 32, 41], ["SARS", "PROBLEM", 139, 143], ["infection", "OBSERVATION", 32, 41], ["left", "ANATOMY_MODIFIER", 66, 70], ["right", "ANATOMY_MODIFIER", 74, 79]]], ["A large proportion of Wuhan residences were excluded.", [["large", "OBSERVATION_MODIFIER", 2, 7], ["proportion", "OBSERVATION_MODIFIER", 8, 18]]], ["Third, we only had information on confirmed cases and may have missed some cases with very mild symptoms.", [["very mild symptoms", "PROBLEM", 86, 104]]], ["In view of the large sample size, it is unlikely that these biases could have influenced the estimation very much.DiscussionIn conclusion, our results contribute to a better understanding of COVID-19 and provide useful parameters for modeling the dynamics of disease transmission.", [["COVID-19", "CELL", 191, 199], ["COVID-19", "DNA", 191, 199], ["the large sample size", "PROBLEM", 11, 32], ["COVID", "TEST", 191, 196], ["disease transmission", "PROBLEM", 259, 279], ["large", "OBSERVATION_MODIFIER", 15, 20], ["sample", "OBSERVATION_MODIFIER", 21, 27], ["size", "OBSERVATION_MODIFIER", 28, 32], ["is unlikely", "UNCERTAINTY", 37, 48]]], ["However, more attention should be paid to asymptomatic elderly people who had a history of exposure.Publish your work in this journalRisk Management and Healthcare Policy is an international, peerreviewed, open access journal focusing on all aspects of public health, policy, and preventative measures to promote good health and improve morbidity and mortality in the population.", [["people", "ORGANISM", 63, 69], ["people", "SPECIES", 63, 69], ["preventative measures", "TREATMENT", 280, 301]]], ["The journal welcomes submitted papers covering original research, basic science, clinical & epidemiological studies, reviews and evaluations, guidelines, expert opinion and commentary, case reports and extended reports.", [["evaluations", "TEST", 129, 140]]], ["The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use.", [["The manuscript management system", "TREATMENT", 0, 32]]]], "PMC7419640": [["IntroductionObesity is a major public health threat in the 21st century.", [["IntroductionObesity", "DISEASE", 0, 19]]], ["Globally, about 2.1 billion adults are obese.1 Obesity is characterized by excessive or abnormal fat storage and is influenced by genetic and environmental factors.2 Additionally, it is associated with several cardiometabolic diseases, such as type 2 diabetes, hypertension, and coronary heart diseases.3,4 However, the presence of metabolic disturbances varies among subjects with the same body mass index (BMI).", [["fat", "ANATOMY", 97, 100], ["coronary", "ANATOMY", 279, 287], ["heart", "ANATOMY", 288, 293], ["body", "ANATOMY", 391, 395], ["Obesity", "DISEASE", 47, 54], ["cardiometabolic diseases", "DISEASE", 210, 234], ["type 2 diabetes", "DISEASE", 244, 259], ["hypertension", "DISEASE", 261, 273], ["coronary heart diseases", "DISEASE", 279, 302], ["metabolic disturbances", "DISEASE", 332, 354], ["adults", "ORGANISM", 28, 34], ["fat", "TISSUE", 97, 100], ["heart", "ORGAN", 288, 293], ["body", "ORGANISM_SUBDIVISION", 391, 395], ["obese", "PROBLEM", 39, 44], ["Obesity", "PROBLEM", 47, 54], ["excessive or abnormal fat storage", "PROBLEM", 75, 108], ["several cardiometabolic diseases", "PROBLEM", 202, 234], ["type 2 diabetes", "PROBLEM", 244, 259], ["hypertension", "PROBLEM", 261, 273], ["coronary heart diseases", "PROBLEM", 279, 302], ["metabolic disturbances", "PROBLEM", 332, 354], ["the same body mass index", "PROBLEM", 382, 406], ["obese", "OBSERVATION", 39, 44], ["excessive", "OBSERVATION_MODIFIER", 75, 84], ["abnormal", "OBSERVATION_MODIFIER", 88, 96], ["fat storage", "OBSERVATION", 97, 108], ["associated with", "UNCERTAINTY", 186, 201], ["several", "OBSERVATION_MODIFIER", 202, 209], ["cardiometabolic", "OBSERVATION_MODIFIER", 210, 225], ["diseases", "OBSERVATION", 226, 234], ["diabetes", "OBSERVATION", 251, 259], ["hypertension", "OBSERVATION", 261, 273], ["coronary heart", "ANATOMY", 279, 293], ["diseases", "OBSERVATION", 294, 302], ["metabolic disturbances", "OBSERVATION", 332, 354], ["mass", "OBSERVATION", 396, 400]]], ["Some obese individuals will never have obesity-related metabolic abnormalities in their lifetime, which is defined as metabolically healthy obese (MHO) subject.5 Unlike subjects with a metabolically unhealthy obese (MUO), MHO subjects are at a lower risk of cardiometabolic diseases.6 Meanwhile, individuals with normal BMI but abnormal metabolic status are defined as metabolically unhealthy normal-weight (MUNW) subjects.7 The above examples show that the definition of obesity by BMI alone cannot accurately reflect the obesity-related metabolic status and susceptibility to metabolic diseases.", [["obesity", "DISEASE", 39, 46], ["metabolic abnormalities", "DISEASE", 55, 78], ["metabolically unhealthy obese", "DISEASE", 185, 214], ["cardiometabolic diseases", "DISEASE", 258, 282], ["obesity", "DISEASE", 472, 479], ["obesity", "DISEASE", 523, 530], ["metabolic diseases", "DISEASE", 578, 596], ["individuals", "ORGANISM", 11, 22], ["individuals", "ORGANISM", 296, 307], ["Some obese individuals", "PROBLEM", 0, 22], ["obesity", "PROBLEM", 39, 46], ["metabolic abnormalities", "PROBLEM", 55, 78], ["cardiometabolic diseases", "PROBLEM", 258, 282], ["abnormal metabolic status", "PROBLEM", 328, 353], ["obesity", "PROBLEM", 472, 479], ["the obesity", "PROBLEM", 519, 530], ["metabolic diseases", "PROBLEM", 578, 596], ["obese", "OBSERVATION", 5, 10], ["metabolic abnormalities", "OBSERVATION", 55, 78], ["cardiometabolic diseases", "OBSERVATION", 258, 282], ["obesity", "OBSERVATION", 472, 479], ["obesity", "OBSERVATION", 523, 530], ["metabolic status", "OBSERVATION", 539, 555], ["metabolic diseases", "OBSERVATION", 578, 596]]], ["Hence, there is an urgent requirement to identify novel obesity biomarkers that can distinguish between the different obese phenotypes.IntroductionIt is now generally accepted that anatomic and physiologic derangements of adipocyte and adipose tissue are central to the pathology of different phenotypes of obesity and obesity-associated metabolic complications.8,9 Excessive triglycerides cause adipocyte hypertrophy and proliferation, which results in the accumulation of unhealthy fat and decreased blood supply.10 Under hypoxia, adipocytes and adipose tissue recruit fat cells and macrophages that release inflammatory cytokines.11 Hypertrophic adipocytes produce a wide range of pro-inflammatory adipokines, leading to insulin resistance.12 Studies have indicated that the pathological state of the adipose tissue plays an important role in the development of obesity-associated metabolic diseases.", [["adipocyte", "ANATOMY", 222, 231], ["adipose tissue", "ANATOMY", 236, 250], ["adipocyte", "ANATOMY", 396, 405], ["fat", "ANATOMY", 484, 487], ["blood", "ANATOMY", 502, 507], ["adipocytes", "ANATOMY", 533, 543], ["adipose tissue", "ANATOMY", 548, 562], ["fat cells", "ANATOMY", 571, 580], ["macrophages", "ANATOMY", 585, 596], ["adipocytes", "ANATOMY", 649, 659], ["adipose tissue", "ANATOMY", 804, 818], ["obesity", "DISEASE", 56, 63], ["obesity", "DISEASE", 307, 314], ["obesity", "DISEASE", 319, 326], ["metabolic complications", "DISEASE", 338, 361], ["triglycerides", "CHEMICAL", 376, 389], ["hypertrophy", "DISEASE", 406, 417], ["hypoxia", "DISEASE", 524, 531], ["obesity", "DISEASE", 865, 872], ["metabolic diseases", "DISEASE", 884, 902], ["triglycerides", "CHEMICAL", 376, 389], ["adipocyte", "CELL", 222, 231], ["adipose tissue", "TISSUE", 236, 250], ["triglycerides", "SIMPLE_CHEMICAL", 376, 389], ["adipocyte", "CELL", 396, 405], ["fat", "TISSUE", 484, 487], ["blood", "ORGANISM_SUBSTANCE", 502, 507], ["adipocytes", "CELL", 533, 543], ["adipose tissue", "TISSUE", 548, 562], ["fat cells", "CELL", 571, 580], ["macrophages", "CELL", 585, 596], ["adipocytes", "CELL", 649, 659], ["insulin", "GENE_OR_GENE_PRODUCT", 724, 731], ["adipose tissue", "TISSUE", 804, 818], ["adipocyte", "CELL_TYPE", 222, 231], ["adipocytes", "CELL_TYPE", 533, 543], ["fat cells", "CELL_TYPE", 571, 580], ["macrophages", "CELL_TYPE", 585, 596], ["inflammatory cytokines", "PROTEIN", 610, 632], ["Hypertrophic adipocytes", "CELL_TYPE", 636, 659], ["pro-inflammatory adipokines", "PROTEIN", 684, 711], ["an urgent requirement", "PROBLEM", 16, 37], ["novel obesity biomarkers", "PROBLEM", 50, 74], ["the different obese phenotypes", "PROBLEM", 104, 134], ["anatomic and physiologic derangements of adipocyte and adipose tissue", "PROBLEM", 181, 250], ["obesity", "PROBLEM", 307, 314], ["obesity", "PROBLEM", 319, 326], ["associated metabolic complications", "PROBLEM", 327, 361], ["Excessive triglycerides", "PROBLEM", 366, 389], ["adipocyte hypertrophy", "PROBLEM", 396, 417], ["proliferation", "PROBLEM", 422, 435], ["unhealthy fat", "PROBLEM", 474, 487], ["decreased blood supply", "PROBLEM", 492, 514], ["hypoxia", "PROBLEM", 524, 531], ["adipocytes", "PROBLEM", 533, 543], ["adipose tissue recruit fat cells", "TREATMENT", 548, 580], ["macrophages", "PROBLEM", 585, 596], ["inflammatory cytokines", "PROBLEM", 610, 632], ["Hypertrophic adipocytes", "PROBLEM", 636, 659], ["pro-inflammatory adipokines", "TREATMENT", 684, 711], ["insulin resistance", "PROBLEM", 724, 742], ["12 Studies", "TEST", 743, 753], ["obesity", "PROBLEM", 865, 872], ["associated metabolic diseases", "PROBLEM", 873, 902], ["obesity", "OBSERVATION", 56, 63], ["different", "OBSERVATION_MODIFIER", 108, 117], ["obese phenotypes", "OBSERVATION", 118, 134], ["physiologic", "OBSERVATION_MODIFIER", 194, 205], ["derangements", "OBSERVATION", 206, 218], ["adipocyte", "ANATOMY", 222, 231], ["adipose tissue", "OBSERVATION", 236, 250], ["obesity", "OBSERVATION", 307, 314], ["obesity", "OBSERVATION", 319, 326], ["metabolic complications", "OBSERVATION", 338, 361], ["adipocyte", "ANATOMY", 396, 405], ["hypertrophy", "OBSERVATION", 406, 417], ["proliferation", "OBSERVATION_MODIFIER", 422, 435], ["accumulation", "OBSERVATION_MODIFIER", 458, 470], ["unhealthy fat", "OBSERVATION", 474, 487], ["decreased", "OBSERVATION_MODIFIER", 492, 501], ["blood supply", "OBSERVATION", 502, 514], ["hypoxia", "OBSERVATION", 524, 531], ["adipocytes", "ANATOMY", 533, 543], ["adipose tissue", "OBSERVATION", 548, 562], ["fat cells", "OBSERVATION", 571, 580], ["inflammatory cytokines", "OBSERVATION", 610, 632], ["Hypertrophic adipocytes", "OBSERVATION", 636, 659], ["wide", "OBSERVATION_MODIFIER", 670, 674], ["pro-inflammatory adipokines", "OBSERVATION", 684, 711], ["insulin resistance", "OBSERVATION", 724, 742], ["adipose tissue", "OBSERVATION", 804, 818], ["obesity", "OBSERVATION", 865, 872], ["metabolic diseases", "OBSERVATION", 884, 902]]], ["Except for the above mentioned inflammatory cytokines and adipokines, the pathological state of the adipose tissue is regulated by other factors such as hormone and resistin.", [["adipose tissue", "ANATOMY", 100, 114], ["adipose tissue", "TISSUE", 100, 114], ["resistin", "GENE_OR_GENE_PRODUCT", 165, 173], ["inflammatory cytokines", "PROTEIN", 31, 53], ["adipokines", "PROTEIN", 58, 68], ["resistin", "PROTEIN", 165, 173], ["inflammatory cytokines", "PROBLEM", 31, 53], ["adipokines", "TREATMENT", 58, 68], ["the adipose tissue", "PROBLEM", 96, 114], ["hormone and resistin", "TREATMENT", 153, 173], ["inflammatory", "OBSERVATION_MODIFIER", 31, 43], ["cytokines", "OBSERVATION", 44, 53], ["adipose tissue", "ANATOMY", 100, 114]]], ["More and more studies have shown that epigenetic regulation also plays important roles in the pathophysiological processes of adipose tissue.13 In our previous study, we identified miR-503 as the differential expressed gene in insulin receptor substrate-1 (IRS-1) KO mice with a decrease in fat mass.14 And bone morphogenetic proteins receptor type 1A (BMPR1a), the target gene of miR-503, whose express was synchronously declined in IRS-1 KO mice.15 We further confirmed this finding by transfecting primary preadipocytes with BMPR1A-specific small interfering RNAs (siRNAs), and the results showed a significant disruption of adipogenesis.16 Hence, we hypothesise that miR-503 and BMPR1a might be important biomarkers for obesity and set to investigate their association with different obese phenotypes.IntroductionMicro-RNAs (miRNAs) are small, non-coding RNAs that negatively regulate gene expression at the post-transcriptional level.17 They are crucial in maintaining metabolic homeostasis18 and exhibit typical characteristics of a good biomarker.19 Studies have revealed that there are significant differences between the levels of several miRNAs (miR-142-3p, miR-140-5p, miR-15a, miR-520c-3c, and miR-423-5p) in morbidly obese men, suggesting that they may serve as novel biomarkers for risk estimation and classification of morbidly obese patients.20IntroductionBMPR1A is the receptor of bone morphogenetic proteins (BMPs) which belong to the transforming growth factor-\u03b2 superfamily.21 BMP signaling plays a key role in adipose biology.22,23 Among the different isoforms of BMP receptors, BMPR1A mediates most of the effects of BMP2/4 and BMP6/721 and has been linked to adipose development and metabolism in both mice and human studies.", [["adipose tissue", "ANATOMY", 126, 140], ["fat mass", "ANATOMY", 291, 299], ["preadipocytes", "ANATOMY", 509, 522], ["bone", "ANATOMY", 1398, 1402], ["adipose", "ANATOMY", 1531, 1538], ["adipose", "ANATOMY", 1682, 1689], ["obesity", "DISEASE", 724, 731], ["morbidly obese", "DISEASE", 1334, 1348], ["adipose tissue", "TISSUE", 126, 140], ["miR-503", "GENE_OR_GENE_PRODUCT", 181, 188], ["insulin receptor substrate-1", "GENE_OR_GENE_PRODUCT", 227, 255], ["IRS-1", "GENE_OR_GENE_PRODUCT", 257, 262], ["fat", "TISSUE", 291, 294], ["bone morphogenetic proteins receptor type 1A", "GENE_OR_GENE_PRODUCT", 307, 351], ["BMPR1a", "GENE_OR_GENE_PRODUCT", 353, 359], ["miR-503", "GENE_OR_GENE_PRODUCT", 381, 388], ["IRS-1", "GENE_OR_GENE_PRODUCT", 434, 439], ["preadipocytes", "CELL", 509, 522], ["BMPR1A", "GENE_OR_GENE_PRODUCT", 528, 534], ["small interfering RNAs", "GENE_OR_GENE_PRODUCT", 544, 566], ["miR-503", "GENE_OR_GENE_PRODUCT", 671, 678], ["BMPR1a", "GENE_OR_GENE_PRODUCT", 683, 689], ["IntroductionMicro-RNAs", "GENE_OR_GENE_PRODUCT", 805, 827], ["miR-142-3p", "GENE_OR_GENE_PRODUCT", 1156, 1166], ["miR-140-5p", "GENE_OR_GENE_PRODUCT", 1168, 1178], ["miR-15a", "GENE_OR_GENE_PRODUCT", 1180, 1187], ["miR-520c-3c", "GENE_OR_GENE_PRODUCT", 1189, 1200], ["miR-423-5", "GENE_OR_GENE_PRODUCT", 1206, 1215], ["men", "ORGANISM", 1236, 1239], ["patients", "ORGANISM", 1349, 1357], ["20IntroductionBMPR1A", "GENE_OR_GENE_PRODUCT", 1358, 1378], ["bone", "TISSUE", 1398, 1402], ["transforming growth factor-\u03b2", "GENE_OR_GENE_PRODUCT", 1453, 1481], ["BMP", "GENE_OR_GENE_PRODUCT", 1497, 1500], ["adipose", "TISSUE", 1531, 1538], ["BMP receptors", "GENE_OR_GENE_PRODUCT", 1585, 1598], ["BMPR1A", "GENE_OR_GENE_PRODUCT", 1600, 1606], ["BMP2/4", "GENE_OR_GENE_PRODUCT", 1639, 1645], ["BMP6", "GENE_OR_GENE_PRODUCT", 1650, 1654], ["721", "GENE_OR_GENE_PRODUCT", 1655, 1658], ["adipose", "TISSUE", 1682, 1689], ["mice", "ORGANISM", 1725, 1729], ["human", "ORGANISM", 1734, 1739], ["miR-503", "DNA", 181, 188], ["insulin receptor substrate-1 (IRS-1", "PROTEIN", 227, 262], ["bone morphogenetic proteins receptor type 1A", "PROTEIN", 307, 351], ["BMPR1a", "PROTEIN", 353, 359], ["miR-503", "DNA", 381, 388], ["IRS", "PROTEIN", 434, 437], ["primary preadipocytes", "CELL_TYPE", 501, 522], ["BMPR1A", "PROTEIN", 528, 534], ["small interfering RNAs", "RNA", 544, 566], ["BMPR1a", "PROTEIN", 683, 689], ["IntroductionMicro-RNAs", "RNA", 805, 827], ["miRNAs", "DNA", 829, 835], ["small, non-coding RNAs", "RNA", 841, 863], ["miR", "DNA", 1168, 1171], ["miR", "DNA", 1180, 1183], ["miR", "DNA", 1189, 1192], ["miR", "DNA", 1206, 1209], ["20IntroductionBMPR1A", "PROTEIN", 1358, 1378], ["bone morphogenetic proteins", "PROTEIN", 1398, 1425], ["BMPs", "PROTEIN", 1427, 1431], ["transforming growth factor-\u03b2 superfamily", "PROTEIN", 1453, 1493], ["BMP", "PROTEIN", 1497, 1500], ["BMP receptors", "PROTEIN", 1585, 1598], ["BMPR1A", "PROTEIN", 1600, 1606], ["BMP2/4", "PROTEIN", 1639, 1645], ["BMP6", "PROTEIN", 1650, 1654], ["mice", "SPECIES", 267, 271], ["mice", "SPECIES", 443, 447], ["men", "SPECIES", 1236, 1239], ["patients", "SPECIES", 1349, 1357], ["mice", "SPECIES", 1725, 1729], ["human", "SPECIES", 1734, 1739], ["mice", "SPECIES", 267, 271], ["mice", "SPECIES", 443, 447], ["mice", "SPECIES", 1725, 1729], ["human", "SPECIES", 1734, 1739], ["epigenetic regulation", "PROBLEM", 38, 59], ["adipose tissue", "PROBLEM", 126, 140], ["insulin receptor substrate", "TREATMENT", 227, 253], ["IRS", "TEST", 257, 260], ["a decrease in fat mass", "PROBLEM", 277, 299], ["bone morphogenetic proteins", "TEST", 307, 334], ["BMPR1A", "TEST", 528, 534], ["specific small interfering RNAs (siRNAs)", "PROBLEM", 535, 575], ["a significant disruption of adipogenesis", "PROBLEM", 600, 640], ["BMPR1a", "PROBLEM", 683, 689], ["obesity", "PROBLEM", 724, 731], ["different obese phenotypes", "PROBLEM", 778, 804], ["small, non-coding RNAs", "PROBLEM", 841, 863], ["miR", "TEST", 1156, 1159], ["miR", "TEST", 1168, 1171], ["miR", "TEST", 1180, 1183], ["miR", "TEST", 1189, 1192], ["miR", "TEST", 1206, 1209], ["novel biomarkers", "TEST", 1275, 1291], ["risk estimation", "TEST", 1296, 1311], ["morbidly obese patients", "PROBLEM", 1334, 1357], ["bone morphogenetic proteins (BMPs", "PROBLEM", 1398, 1431], ["BMP receptors", "TREATMENT", 1585, 1598], ["BMPR1A mediates", "TREATMENT", 1600, 1615], ["BMP2/4 and BMP6", "TREATMENT", 1639, 1654], ["human studies", "TEST", 1734, 1747], ["adipose tissue", "OBSERVATION", 126, 140], ["decrease", "OBSERVATION_MODIFIER", 279, 287], ["fat mass", "OBSERVATION", 291, 299], ["bone", "ANATOMY", 307, 311], ["small", "OBSERVATION_MODIFIER", 544, 549], ["interfering RNAs", "OBSERVATION", 550, 566], ["significant", "OBSERVATION_MODIFIER", 602, 613], ["disruption", "OBSERVATION", 614, 624], ["adipogenesis", "OBSERVATION", 628, 640], ["small", "OBSERVATION_MODIFIER", 841, 846], ["non-coding RNAs", "OBSERVATION", 848, 863], ["gene expression", "OBSERVATION", 889, 904], ["metabolic homeostasis18", "OBSERVATION", 974, 997], ["good", "OBSERVATION_MODIFIER", 1039, 1043], ["significant", "OBSERVATION_MODIFIER", 1094, 1105], ["differences", "OBSERVATION", 1106, 1117], ["obese", "OBSERVATION", 1230, 1235], ["bone", "ANATOMY", 1398, 1402]]], ["A cohort study indicated that BMPR1A expression in the adipose tissue of overweight and obese individuals was higher than that in lean subjects, and its level was correlated with the occurrence of type 2 diabetes.20 In a conditional myogenic factor 5-BMPR1A knockout (KO) model, in which BMPR1A expression was blocked in the brown adipogenic progenitor cells, these mice displayed a significant reduction in the amount of constitutive brown adipose tissue at the embryonic stage.24 Through the database of the European Bioinformatics Institute, we found BMPR1A can express in blood.", [["adipose tissue", "ANATOMY", 55, 69], ["brown adipogenic progenitor cells", "ANATOMY", 325, 358], ["brown adipose tissue", "ANATOMY", 435, 455], ["embryonic", "ANATOMY", 463, 472], ["blood", "ANATOMY", 576, 581], ["type 2 diabetes", "DISEASE", 197, 212], ["BMPR1A", "GENE_OR_GENE_PRODUCT", 30, 36], ["adipose tissue", "TISSUE", 55, 69], ["5", "GENE_OR_GENE_PRODUCT", 249, 250], ["BMPR1A", "GENE_OR_GENE_PRODUCT", 251, 257], ["BMPR1A", "GENE_OR_GENE_PRODUCT", 288, 294], ["brown adipogenic progenitor cells", "CELL", 325, 358], ["mice", "ORGANISM", 366, 370], ["brown adipose tissue", "TISSUE", 435, 455], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 463, 472], ["BMPR1A", "GENE_OR_GENE_PRODUCT", 554, 560], ["blood", "ORGANISM_SUBSTANCE", 576, 581], ["BMPR1A", "PROTEIN", 30, 36], ["BMPR1A", "PROTEIN", 251, 257], ["BMPR1A", "PROTEIN", 288, 294], ["brown adipogenic progenitor cells", "CELL_TYPE", 325, 358], ["BMPR1A", "PROTEIN", 554, 560], ["mice", "SPECIES", 366, 370], ["A cohort study", "TEST", 0, 14], ["BMPR1A expression", "PROBLEM", 30, 47], ["obese individuals", "PROBLEM", 88, 105], ["type 2 diabetes", "PROBLEM", 197, 212], ["a conditional myogenic factor", "TEST", 219, 248], ["a significant reduction", "PROBLEM", 381, 404], ["constitutive brown adipose tissue", "PROBLEM", 422, 455], ["BMPR1A", "PROBLEM", 554, 560], ["BMPR1A", "OBSERVATION", 30, 36], ["adipose tissue", "ANATOMY", 55, 69], ["obese", "OBSERVATION", 88, 93], ["higher", "OBSERVATION_MODIFIER", 110, 116], ["diabetes", "OBSERVATION", 204, 212], ["brown adipogenic progenitor cells", "OBSERVATION", 325, 358], ["significant", "OBSERVATION_MODIFIER", 383, 394], ["reduction", "OBSERVATION_MODIFIER", 395, 404], ["amount", "OBSERVATION_MODIFIER", 412, 418], ["constitutive", "OBSERVATION", 422, 434], ["brown adipose tissue", "OBSERVATION", 435, 455], ["embryonic stage", "OBSERVATION", 463, 478], ["BMPR1A", "OBSERVATION", 554, 560]]], ["Hence, these data suggested that BMPR1A is likely to participate in the metabolic disturbances caused by adipose tissue and serves as a potential marker to differentiate between different types of obesity.IntroductionIn this study, we aimed to evaluate the expression of BMPR1A and miR-503 in the serum samples of subjects with different obese phenotypes and metabolic statuses, and investigate whether their expression is correlated with the different phenotypes of obesity.", [["adipose tissue", "ANATOMY", 105, 119], ["serum samples", "ANATOMY", 297, 310], ["metabolic disturbances", "DISEASE", 72, 94], ["obesity", "DISEASE", 197, 204], ["miR-503", "CHEMICAL", 282, 289], ["obesity", "DISEASE", 467, 474], ["BMPR1A", "GENE_OR_GENE_PRODUCT", 33, 39], ["adipose tissue", "TISSUE", 105, 119], ["BMPR1A", "GENE_OR_GENE_PRODUCT", 271, 277], ["miR-503", "GENE_OR_GENE_PRODUCT", 282, 289], ["serum samples", "ORGANISM_SUBSTANCE", 297, 310], ["BMPR1A", "PROTEIN", 33, 39], ["BMPR1A", "PROTEIN", 271, 277], ["miR-503", "PROTEIN", 282, 289], ["BMPR1A", "PROBLEM", 33, 39], ["the metabolic disturbances", "PROBLEM", 68, 94], ["adipose tissue", "PROBLEM", 105, 119], ["obesity", "PROBLEM", 197, 204], ["this study", "TEST", 220, 230], ["BMPR1A", "TEST", 271, 277], ["miR", "TEST", 282, 285], ["the serum samples", "TEST", 293, 310], ["different obese phenotypes", "PROBLEM", 328, 354], ["obesity", "PROBLEM", 467, 474], ["BMPR1A", "OBSERVATION", 33, 39], ["adipose tissue", "OBSERVATION", 105, 119], ["obesity", "OBSERVATION", 197, 204], ["metabolic statuses", "OBSERVATION", 359, 377], ["obesity", "OBSERVATION", 467, 474]]], ["Our findings provide insights into potential biomarkers that can help differentiate between different obesity types, with or without metabolic abnormalities.Study Population and Participants ::: Materials and MethodsA cross-sectional case\u2013control study was undertaken from 2014 to 2015 in the Health Management Center of the Second Xiangya Hospital, Central South University.", [["obesity", "DISEASE", 102, 109], ["metabolic abnormalities", "DISEASE", 133, 156], ["Participants", "SPECIES", 178, 190], ["potential biomarkers", "TEST", 35, 55], ["different obesity types", "PROBLEM", 92, 115], ["metabolic abnormalities", "PROBLEM", 133, 156], ["MethodsA cross-sectional case\u2013control study", "TEST", 209, 252], ["obesity", "OBSERVATION", 102, 109]]], ["Eligible participants were Chinese adult individuals above the age of 18 (either sex) with overweight/obesity (BMI\u226524 kg/m2) and their respective paired controls (BMI < 24 kg/m2).25 Individuals with the following diseases, conditions or indulgences were excluded: BMI > 40 kg/m2,26 severe liver and kidney disorders, regular drinkers, pregnancy, and malignancy, and secondary obesity caused by other diseases, such as bulimia or Cushing\u2019s syndrome.", [["liver", "ANATOMY", 289, 294], ["kidney", "ANATOMY", 299, 305], ["overweight/obesity", "DISEASE", 91, 109], ["liver and kidney disorders", "DISEASE", 289, 315], ["malignancy", "DISEASE", 350, 360], ["obesity", "DISEASE", 376, 383], ["bulimia", "DISEASE", 418, 425], ["Cushing\u2019s syndrome", "DISEASE", 429, 447], ["individuals", "ORGANISM", 41, 52], ["liver", "ORGAN", 289, 294], ["kidney", "ORGAN", 299, 305], ["participants", "SPECIES", 9, 21], ["overweight/obesity", "PROBLEM", 91, 109], ["the following diseases", "PROBLEM", 199, 221], ["indulgences", "PROBLEM", 237, 248], ["BMI", "TEST", 264, 267], ["severe liver and kidney disorders", "PROBLEM", 282, 315], ["pregnancy", "PROBLEM", 335, 344], ["malignancy", "PROBLEM", 350, 360], ["secondary obesity", "PROBLEM", 366, 383], ["other diseases", "PROBLEM", 394, 408], ["bulimia", "PROBLEM", 418, 425], ["Cushing\u2019s syndrome", "PROBLEM", 429, 447], ["liver", "ANATOMY", 289, 294], ["kidney", "ANATOMY", 299, 305], ["disorders", "OBSERVATION", 306, 315], ["malignancy", "OBSERVATION", 350, 360], ["secondary obesity", "OBSERVATION", 366, 383]]], ["Additionally, individuals using steroid hormones or drugs (aspirin, isoniazid, or rifampicin) that might cause weight change and glycemic and lipid metabolism imbalance in the past 6 months were excluded.", [["steroid", "CHEMICAL", 32, 39], ["aspirin", "CHEMICAL", 59, 66], ["isoniazid", "CHEMICAL", 68, 77], ["rifampicin", "CHEMICAL", 82, 92], ["steroid", "CHEMICAL", 32, 39], ["aspirin", "CHEMICAL", 59, 66], ["isoniazid", "CHEMICAL", 68, 77], ["rifampicin", "CHEMICAL", 82, 92], ["aspirin", "SIMPLE_CHEMICAL", 59, 66], ["isoniazid", "SIMPLE_CHEMICAL", 68, 77], ["rifampicin", "SIMPLE_CHEMICAL", 82, 92], ["lipid", "SIMPLE_CHEMICAL", 142, 147], ["steroid hormones", "TREATMENT", 32, 48], ["drugs", "TREATMENT", 52, 57], ["aspirin", "TREATMENT", 59, 66], ["isoniazid", "TREATMENT", 68, 77], ["rifampicin", "TREATMENT", 82, 92], ["weight change", "PROBLEM", 111, 124], ["glycemic and lipid metabolism imbalance", "PROBLEM", 129, 168], ["metabolism imbalance", "OBSERVATION", 148, 168]]], ["Individuals were divided into the following three groups based on body weight and metabolic status: metabolically healthy normal weight (MHNW), MHO and MUO subjects, and the control is MHNW group.", [["body", "ANATOMY", 66, 70], ["body", "ORGANISM_SUBDIVISION", 66, 70], ["MHNW", "CANCER", 185, 189], ["body weight", "TEST", 66, 77]]], ["The MHO and MUO groups were matched by BMI, while the MHNW and overweight/obesity groups were matched by age.", [["obesity", "DISEASE", 74, 81], ["MUO groups", "TREATMENT", 12, 22], ["overweight/obesity groups", "PROBLEM", 63, 88]]], ["Considering the World Health Organization (WHO) proposed BMI cut-off points for Asian populations, normal weight was defined as BMI 18.5\u201323.9 kg/m2, overweight as BMI 24.0\u201327.9 kg/m2, and obesity as BMI \u226528 kg/m2.25 Due to the limited sample size and many overweight people already had metabolic abnormalities in China, this study combined overweight and obese people into one group, and BMI \u2265 24 kg/m2 was used to define overweight/obesity.", [["overweight", "DISEASE", 149, 159], ["obesity", "DISEASE", 188, 195], ["overweight", "DISEASE", 256, 266], ["metabolic abnormalities", "DISEASE", 286, 309], ["overweight", "DISEASE", 422, 432], ["obesity", "DISEASE", 433, 440], ["people", "ORGANISM", 267, 273], ["people", "ORGANISM", 361, 367], ["people", "SPECIES", 267, 273], ["people", "SPECIES", 361, 367], ["BMI", "TEST", 128, 131], ["overweight", "TEST", 149, 159], ["BMI", "TEST", 163, 166], ["obesity", "PROBLEM", 188, 195], ["BMI", "TEST", 199, 202], ["the limited sample size", "PROBLEM", 223, 246], ["metabolic abnormalities in China", "PROBLEM", 286, 318], ["this study", "TEST", 320, 330], ["obesity", "PROBLEM", 433, 440], ["obesity", "OBSERVATION", 188, 195], ["size", "OBSERVATION_MODIFIER", 242, 246], ["metabolic abnormalities", "OBSERVATION", 286, 309], ["obesity", "OBSERVATION", 433, 440]]], ["Metabolic status, which is associated with numerous components of metabolic syndrome, was determined according to the 2007 Joint Committee for Developing Chinese Guidelines (JCDCG2007).27 Subjects defined as metabolically unhealthy had more than two of the following cardiometabolic abnormalities: 1) WC \u2265 90 cm for men and \u2265 85 cm for women, 2) serum triglyceride (TG) \u2265 1.7 mmol/L or specific treatment for dyslipidemia, 3) high-density lipoprotein cholesterol (HDL-C) < 1.04 mmol/L or specific treatment for dyslipidemia, 4) BP \u2265 130/85 mm Hg or use of any antihypertensive agents, and 5) fasting plasma glucose (FPG) \u2265 6.1 mmol/L and/or 2 h plasma glucose \u2265 7.8 mmol/L and/or diagnosed diabetic mellitus and undergoing therapy.", [["serum", "ANATOMY", 346, 351], ["plasma", "ANATOMY", 600, 606], ["plasma", "ANATOMY", 645, 651], ["metabolic syndrome", "DISEASE", 66, 84], ["cardiometabolic abnormalities", "DISEASE", 267, 296], ["triglyceride", "CHEMICAL", 352, 364], ["TG", "DISEASE", 366, 368], ["dyslipidemia", "DISEASE", 409, 421], ["cholesterol", "CHEMICAL", 451, 462], ["HDL-C", "CHEMICAL", 464, 469], ["dyslipidemia", "DISEASE", 511, 523], ["glucose", "CHEMICAL", 607, 614], ["glucose", "CHEMICAL", 652, 659], ["diabetic mellitus", "DISEASE", 690, 707], ["WC", "CHEMICAL", 301, 303], ["triglyceride", "CHEMICAL", 352, 364], ["cholesterol", "CHEMICAL", 451, 462], ["Hg", "CHEMICAL", 543, 545], ["glucose", "CHEMICAL", 607, 614], ["glucose", "CHEMICAL", 652, 659], ["men", "ORGANISM", 316, 319], ["women", "ORGANISM", 336, 341], ["serum", "ORGANISM_SUBSTANCE", 346, 351], ["triglyceride", "SIMPLE_CHEMICAL", 352, 364], ["TG", "SIMPLE_CHEMICAL", 366, 368], ["high-density lipoprotein cholesterol", "SIMPLE_CHEMICAL", 426, 462], ["HDL-C", "SIMPLE_CHEMICAL", 464, 469], ["plasma", "ORGANISM_SUBSTANCE", 600, 606], ["glucose", "SIMPLE_CHEMICAL", 607, 614], ["FPG", "SIMPLE_CHEMICAL", 616, 619], ["plasma", "ORGANISM_SUBSTANCE", 645, 651], ["glucose", "SIMPLE_CHEMICAL", 652, 659], ["HDL", "PROTEIN", 464, 467], ["men", "SPECIES", 316, 319], ["women", "SPECIES", 336, 341], ["metabolic syndrome", "PROBLEM", 66, 84], ["WC", "TEST", 301, 303], ["men", "TEST", 316, 319], ["women", "TEST", 336, 341], ["serum triglyceride", "TEST", 346, 364], ["TG", "TEST", 366, 368], ["mmol", "TEST", 376, 380], ["specific treatment", "TREATMENT", 386, 404], ["dyslipidemia", "PROBLEM", 409, 421], ["high-density lipoprotein cholesterol", "TEST", 426, 462], ["HDL", "TEST", 464, 467], ["specific treatment", "TREATMENT", 488, 506], ["dyslipidemia", "PROBLEM", 511, 523], ["BP", "TEST", 528, 530], ["mm Hg", "TEST", 540, 545], ["any antihypertensive agents", "TREATMENT", 556, 583], ["fasting plasma glucose", "TEST", 592, 614], ["FPG", "TEST", 616, 619], ["plasma glucose", "TEST", 645, 659], ["diabetic mellitus", "PROBLEM", 690, 707], ["therapy", "TREATMENT", 723, 730], ["associated with", "UNCERTAINTY", 27, 42], ["numerous", "OBSERVATION_MODIFIER", 43, 51], ["components", "OBSERVATION_MODIFIER", 52, 62], ["metabolic syndrome", "OBSERVATION", 66, 84], ["Joint", "ANATOMY", 123, 128], ["diabetic mellitus", "OBSERVATION", 690, 707]]], ["All subjects signed a written consent form prior to their participation in the study.", [["the study", "TEST", 75, 84]]], ["All experimental protocols were performed in accordance with the guidelines of the World Medical Association Declaration of Helsinki for human subjects.", [["human", "ORGANISM", 137, 142], ["human", "SPECIES", 137, 142], ["human", "SPECIES", 137, 142], ["All experimental protocols", "TREATMENT", 0, 26]]], ["This study was approved by the Ethics Committee of National Clinical Research Center for Metabolic Disease, the Second Xiangya Hospital of Central South University.", [["Metabolic Disease", "DISEASE", 89, 106], ["This study", "TEST", 0, 10], ["Metabolic Disease", "PROBLEM", 89, 106], ["Metabolic Disease", "OBSERVATION", 89, 106]]], ["Clinical trial registration number: ChiCTR-EOC-16,010,194.", [["ChiCTR", "TEST", 36, 42], ["EOC", "TEST", 43, 46]]], ["We deposited all data and related metadata of our research in the public repository (ResMan, http://www.medresman.org/pub/cn/proj/projectshow.aspx? proj=2139).Clinical Data Collection ::: Materials and MethodsAll recruited subjects completed a detailed questionnaire about their basic information with the help of specialists.", [["Methods", "TREATMENT", 202, 209]]], ["The sample size was obtained by online sample size calculators (https://www.sample-size.net/) and decided according to the difference of serum miR-503 levels between MHNW and overweight/obese subjects (considering the facts in our study, S = 1.09, \u03b1= 0.05, \u03b4 = 0.1).", [["serum", "ANATOMY", 137, 142], ["miR-503", "CHEMICAL", 143, 150], ["overweight/obese", "DISEASE", 175, 191], ["serum", "ORGANISM_SUBSTANCE", 137, 142], ["miR-503", "GENE_OR_GENE_PRODUCT", 143, 150], ["The sample size", "TEST", 0, 15], ["serum miR", "TEST", 137, 146], ["overweight/obese subjects", "PROBLEM", 175, 200], ["our study", "TEST", 227, 236], ["S", "TEST", 238, 239], ["size", "OBSERVATION_MODIFIER", 11, 15]]], ["To reduce the bias caused by clinical diagnosis, each participant was evaluated by three experienced physicians based on established protocol.", [["participant", "SPECIES", 54, 65]]], ["Anthropometric variables (body weight and height) were measured using an ultrasonic height and weight scale (Shanghe Electronic Technology Co. Ltd, Zhengzhou, China) in subjects in a quiet and fasting state, wearing light clothing and no shoes.", [["body", "ANATOMY", 26, 30], ["body", "ORGANISM_SUBDIVISION", 26, 30], ["Anthropometric variables", "TEST", 0, 24], ["body weight and height)", "TEST", 26, 49], ["an ultrasonic height", "TEST", 70, 90], ["light clothing", "TREATMENT", 216, 230]]], ["BMI was calculated using the following formula: weight (kg)/height (m2).", [["BMI", "TEST", 0, 3], ["weight", "TEST", 48, 54], ["height", "TEST", 60, 66]]], ["Waist circumference (WC) was measured during the end of exhalation, with a steel tape halfway between the lower rib margin and iliac crest in a horizontal plane.", [["Waist", "ANATOMY", 0, 5], ["lower rib margin", "ANATOMY", 106, 122], ["iliac crest", "ANATOMY", 127, 138], ["Waist", "TISSUE", 0, 5], ["rib margin", "MULTI-TISSUE_STRUCTURE", 112, 122], ["iliac crest", "MULTI-TISSUE_STRUCTURE", 127, 138], ["Waist circumference", "TEST", 0, 19], ["WC", "TEST", 21, 23], ["a steel tape", "TREATMENT", 73, 85], ["lower", "ANATOMY_MODIFIER", 106, 111], ["rib", "ANATOMY", 112, 115], ["margin", "ANATOMY_MODIFIER", 116, 122], ["iliac", "ANATOMY", 127, 132], ["crest", "ANATOMY_MODIFIER", 133, 138]]], ["Hip circumference (HC) was measured at the widest part of the buttocks.", [["Hip", "ANATOMY", 0, 3], ["buttocks", "ANATOMY", 62, 70], ["Hip", "ORGANISM_SUBDIVISION", 0, 3], ["buttocks", "ORGANISM_SUBDIVISION", 62, 70], ["Hip circumference (HC)", "TEST", 0, 22], ["widest", "OBSERVATION_MODIFIER", 43, 49], ["buttocks", "ANATOMY", 62, 70]]], ["Blood pressure (BP) was recorded three times with a standard electronic sphygmomanometer after the subject rested for 15 min in a seated position; the average of three readings was used in the analysis.Blood Collection and Biochemical Analysis ::: Materials and MethodsFollowing an overnight fast of about 8 to 10 hours, venous blood was collected by venipuncture from all participants for biochemical tests and other analyses.", [["Blood", "ANATOMY", 0, 5], ["Blood", "ANATOMY", 202, 207], ["venous blood", "ANATOMY", 321, 333], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["Blood", "ORGANISM_SUBSTANCE", 202, 207], ["venous blood", "ORGANISM_SUBSTANCE", 321, 333], ["participants", "SPECIES", 373, 385], ["Blood pressure", "TEST", 0, 14], ["BP", "TEST", 16, 18], ["the analysis", "TEST", 189, 201], ["Blood Collection", "TEST", 202, 218], ["Biochemical Analysis", "TEST", 223, 243], ["Methods", "TREATMENT", 262, 269], ["venous blood", "TEST", 321, 333], ["biochemical tests", "TEST", 390, 407], ["other analyses", "TEST", 412, 426], ["pressure", "OBSERVATION_MODIFIER", 6, 14], ["venous", "ANATOMY", 321, 327]]], ["We measured FPG using the hexokinase enzymatic method (Ningbo Medical System Biotechnology Co. Ltd., Zhejiang, China).", [["FPG", "SIMPLE_CHEMICAL", 12, 15], ["hexokinase", "GENE_OR_GENE_PRODUCT", 26, 36], ["FPG", "PROTEIN", 12, 15], ["hexokinase", "PROTEIN", 26, 36], ["FPG", "TEST", 12, 15], ["the hexokinase enzymatic method", "TREATMENT", 22, 53]]], ["TG, low-density lipoprotein cholesterol (LDL-C), HDL-C, and total cholesterol (TC) levels were measured using an automated analyzer (Architect c8000 Chemistry System, Abbott Diagnostics, USA).Enzyme-Linked Immunosorbent Assay (ELISA) ::: Materials and MethodsFor the determination of BMPR1A concentration, blood samples were kept for 30 min at room temperature before centrifugation for 15 min at 1000 x g.", [["blood samples", "ANATOMY", 306, 319], ["TG", "DISEASE", 0, 2], ["cholesterol", "CHEMICAL", 28, 39], ["cholesterol", "CHEMICAL", 66, 77], ["TC", "CHEMICAL", 79, 81], ["cholesterol", "CHEMICAL", 28, 39], ["cholesterol", "CHEMICAL", 66, 77], ["TG", "SIMPLE_CHEMICAL", 0, 2], ["low-density lipoprotein cholesterol", "SIMPLE_CHEMICAL", 4, 39], ["LDL-C", "SIMPLE_CHEMICAL", 41, 46], ["HDL-C", "SIMPLE_CHEMICAL", 49, 54], ["cholesterol", "SIMPLE_CHEMICAL", 66, 77], ["TC", "SIMPLE_CHEMICAL", 79, 81], ["BMPR1A", "GENE_OR_GENE_PRODUCT", 284, 290], ["blood samples", "ORGANISM_SUBSTANCE", 306, 319], ["LDL", "PROTEIN", 41, 44], ["HDL", "PROTEIN", 49, 52], ["BMPR1A", "PROTEIN", 284, 290], ["TG", "TEST", 0, 2], ["low-density lipoprotein cholesterol", "TEST", 4, 39], ["LDL", "TEST", 41, 44], ["HDL", "TEST", 49, 52], ["total cholesterol", "TEST", 60, 77], ["an automated analyzer", "TEST", 110, 131], ["Enzyme", "TEST", 192, 198], ["Immunosorbent Assay", "TEST", 206, 225], ["Methods", "TREATMENT", 252, 259], ["BMPR1A concentration", "TREATMENT", 284, 304], ["blood samples", "TEST", 306, 319], ["low-density", "OBSERVATION_MODIFIER", 4, 15]]], ["Serum aliquots were stored at \u201380\u00b0C until analyzed.", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["Serum aliquots", "TEST", 0, 14]]], ["For the detection of BMPR1A protein concentrations, sandwich ELISA was performed using a commercially available quantitative reagent kit (Cusabio Biotech Co., Ltd., Wuhan, China) according to the manufacturer\u2019s protocol.RNA Isolation and Quantitative Real-Time PCR ::: Materials and MethodsTotal RNA was isolated using TRIzol LS reagent according to the manufacturer\u2019s instructions (Invitrogen), and then reverse-transcribed with the Reverse Transcription kit (Takara) to generate first-strand miRNA-cDNA PCR templates.", [["BMPR1A", "GENE_OR_GENE_PRODUCT", 21, 27], ["BMPR1A", "PROTEIN", 21, 27], ["MethodsTotal RNA", "RNA", 283, 299], ["cDNA PCR templates", "DNA", 500, 518], ["BMPR1A protein concentrations", "PROBLEM", 21, 50], ["sandwich ELISA", "TEST", 52, 66], ["RNA Isolation", "TEST", 220, 233], ["MethodsTotal RNA", "TREATMENT", 283, 299], ["TRIzol LS reagent", "TREATMENT", 319, 336], ["strand miRNA-cDNA PCR templates", "TREATMENT", 487, 518]]], ["Quantitative real-time PCR was performed using SYBR Premix Ex Taq II kit (Takara, Otsu, Japan) on the LightCycler 480 Instrument II Real-time PCR System (Roche, Basel, Switzerland).", [["Quantitative real-time PCR", "TEST", 0, 26]]], ["All PCR experiments were performed in triplicate.", [["All PCR experiments", "TEST", 0, 19]]], ["Primers specific for human miR-503 were used, and miR-39 was used as an internal control.", [["human", "ORGANISM", 21, 26], ["miR-503", "GENE_OR_GENE_PRODUCT", 27, 34], ["miR-39", "GENE_OR_GENE_PRODUCT", 50, 56], ["human miR-503", "DNA", 21, 34], ["miR-39", "DNA", 50, 56], ["human", "SPECIES", 21, 26], ["human", "SPECIES", 21, 26], ["human miR", "TEST", 21, 30], ["an internal control", "TREATMENT", 69, 88]]], ["Relative miRNA expression was quantified with the \u2013\u0394\u0394Ct method, and the fold-change was determined using the formula 2\u2013\u0394\u0394Ct.28Statistical Analysis ::: Materials and MethodsAll statistical analyses were performed using SPSS software version 19.0 (SPSS, Inc., Chicago, USA).", [["the \u2013\u0394\u0394Ct method", "TREATMENT", 46, 62], ["All statistical analyses", "TEST", 172, 196], ["SPSS software version", "TEST", 218, 239], ["SPSS", "TEST", 246, 250], ["miRNA expression", "OBSERVATION", 9, 25]]], ["A P value < 0.05 was considered statistically significant.", [["A P value", "TEST", 0, 9]]], ["Continuous variables with normal distribution are expressed as mean \u00b1 standard deviation (SD), data transformation was used to normalize the distribution of variables with minor skewed distribution, and comparisons between different groups were made using one-way analysis of variance (ANOVA).", [["mean \u00b1 standard deviation (SD), data transformation", "PROBLEM", 63, 114], ["normal", "OBSERVATION", 26, 32], ["distribution", "OBSERVATION_MODIFIER", 33, 45], ["minor", "OBSERVATION_MODIFIER", 172, 177], ["skewed", "OBSERVATION_MODIFIER", 178, 184], ["distribution", "OBSERVATION_MODIFIER", 185, 197]]], ["Categorical variables are expressed as percentages (%), and comparisons between different groups were made using the Chi-square test.", [["Categorical variables", "TEST", 0, 21], ["the Chi-square test", "TEST", 113, 132]]], ["Age-and sex-adjusted partial correlation analysis was used to analyze the correlation between serum BMPR1A, miR-503, and anthropometric and metabolic characteristics.", [["serum", "ANATOMY", 94, 99], ["serum", "ORGANISM_SUBSTANCE", 94, 99], ["BMPR1A", "GENE_OR_GENE_PRODUCT", 100, 106], ["miR-503", "GENE_OR_GENE_PRODUCT", 108, 115], ["serum BMPR1A", "PROTEIN", 94, 106], ["sex-adjusted partial correlation analysis", "TEST", 8, 49], ["serum BMPR1A", "TEST", 94, 106], ["miR", "TEST", 108, 111], ["metabolic characteristics", "OBSERVATION", 140, 165]]], ["Receiver operating characteristic (ROC) curve analysis was performed to determine the predictive value of BMPR1A and miR-503 in subjects with different body weights and metabolic status.", [["body", "ANATOMY", 152, 156], ["miR-503", "CHEMICAL", 117, 124], ["BMPR1A", "GENE_OR_GENE_PRODUCT", 106, 112], ["miR-503", "GENE_OR_GENE_PRODUCT", 117, 124], ["body", "ORGANISM_SUBDIVISION", 152, 156], ["BMPR1A", "PROTEIN", 106, 112], ["miR-503", "DNA", 117, 124], ["curve analysis", "TEST", 40, 54], ["BMPR1A", "TEST", 106, 112], ["miR", "TEST", 117, 120], ["different body weights", "TEST", 142, 164], ["metabolic status", "OBSERVATION", 169, 185]]], ["Logistic regression analysis was used to evaluate potential risk and related factors associated with different obesity phenotypes and metabolic status, especially to identify related factors with the presence of the MUO phenotype (coded 1) in overweight/obese subjects.", [["obesity", "DISEASE", 111, 118], ["overweight/obese", "DISEASE", 243, 259], ["Logistic regression analysis", "TEST", 0, 28], ["related factors", "PROBLEM", 69, 84], ["different obesity phenotypes", "PROBLEM", 101, 129], ["obesity", "OBSERVATION", 111, 118], ["obese", "OBSERVATION", 254, 259]]], ["In MHNW and MHO groups, MHO was coded 1, while in MHNW and MUO groups, MUO was coded 1.Baseline Characteristics of the Study Subjects ::: ResultsWe recruited 136 subjects, 3 were unwilling to sign the informed consent, and 23 were excluded according to the exclusion criteria, and 2 were in the MUNW group which was not discussed in this research, the final sample size was 98.", [["MHNW", "ANATOMY", 3, 7], ["MHNW", "CANCER", 3, 7], ["MUNW", "CANCER", 295, 299], ["the final sample size", "TEST", 348, 369], ["size", "OBSERVATION_MODIFIER", 365, 369]]], ["Of the 55 subjects in the overweight/obesity group, 27 were overweight and 28 were obese.", [["obesity", "DISEASE", 37, 44], ["overweight", "DISEASE", 60, 70], ["obese", "PROBLEM", 83, 88], ["obesity", "OBSERVATION", 37, 44], ["obese", "OBSERVATION", 83, 88]]], ["After square transformation for TG, HDL-C, BMPR1a and log transformation for FPG, every variable is normally distributed.", [["TG", "DISEASE", 32, 34], ["TG", "SIMPLE_CHEMICAL", 32, 34], ["HDL-C", "SIMPLE_CHEMICAL", 36, 41], ["BMPR1a", "GENE_OR_GENE_PRODUCT", 43, 49], ["FPG", "GENE_OR_GENE_PRODUCT", 77, 80], ["TG", "PROTEIN", 32, 34], ["HDL", "PROTEIN", 36, 39], ["BMPR1a", "PROTEIN", 43, 49], ["FPG", "PROTEIN", 77, 80], ["TG", "TEST", 32, 34], ["HDL", "TEST", 36, 39], ["BMPR1a", "PROBLEM", 43, 49], ["FPG", "TEST", 77, 80], ["normally", "OBSERVATION_MODIFIER", 100, 108], ["distributed", "OBSERVATION_MODIFIER", 109, 120]]], ["The characteristics of the overall study population are listed in Table 1, 98 participants aged 36 to 57 years were divided into three groups, 43 in MHNW group, 34 in MHO group and 21 in MUO group.", [["MHNW", "CANCER", 149, 153], ["MHO", "CANCER", 167, 170], ["MUO", "CANCER", 187, 190], ["participants", "SPECIES", 78, 90]]], ["Based on their BMI, 43 (43.9%) subjects were classified as normal weight, and 55 (56.1%) were classified as overweight/obesity.", [["overweight", "DISEASE", 108, 118], ["obesity", "DISEASE", 119, 126], ["subjects", "ORGANISM", 31, 39], ["their BMI", "TEST", 9, 18], ["obesity", "PROBLEM", 119, 126], ["obesity", "OBSERVATION", 119, 126]]], ["Approximately 34.7% (n = 34) of the total participants were metabolically healthy obese.", [["participants", "ORGANISM", 42, 54], ["participants", "SPECIES", 42, 54]]], ["There were no differences in age, sex and BMI between the MHO and MUO groups.", [["no", "UNCERTAINTY", 11, 13], ["differences", "OBSERVATION_MODIFIER", 14, 25]]], ["As expected, the MUO group displayed higher BP, higher levels of TG and TC, and lower levels of HDL-C compared with the MHO group.", [["MUO", "CANCER", 17, 20], ["TG", "SIMPLE_CHEMICAL", 65, 67], ["TC", "SIMPLE_CHEMICAL", 72, 74], ["HDL-C", "SIMPLE_CHEMICAL", 96, 101], ["MHO", "CANCER", 120, 123], ["BP", "PROTEIN", 44, 46], ["TG", "PROTEIN", 65, 67], ["HDL", "PROTEIN", 96, 99], ["higher BP", "TEST", 37, 46], ["TG", "TEST", 65, 67], ["TC", "TEST", 72, 74], ["HDL", "TEST", 96, 99]]], ["Compared with the MHNW group, the MHO group had lower levels of HDL-C and higher BMI, WC, and waist\u2013hip ratio (WHR).", [["MHNW", "CANCER", 18, 22], ["MHO", "CANCER", 34, 37], ["HDL-C", "SIMPLE_CHEMICAL", 64, 69], ["waist\u2013hip", "SIMPLE_CHEMICAL", 94, 103], ["HDL", "PROTEIN", 64, 67], ["HDL", "TEST", 64, 67], ["higher BMI", "TEST", 74, 84], ["WC", "TEST", 86, 88]]]], "38669631d3cd27b417c1986b2ccce75a724321ae": [["Avian influenza A/H5N1 has threatened human health for nearly 2 decades.", [["Avian influenza A/H5N1", "DISEASE", 0, 22], ["Avian influenza A/H5N1", "ORGANISM", 0, 22], ["human", "ORGANISM", 38, 43], ["Avian influenza A/H5N1", "SPECIES", 0, 22], ["human", "SPECIES", 38, 43], ["Avian influenza A/H5N1", "SPECIES", 0, 22], ["human", "SPECIES", 38, 43]]], ["Avian influenza A vaccine without adjuvant is poorly immunogenic.", [["Avian influenza A", "ORGANISM", 0, 17], ["Avian influenza A vaccine", "SPECIES", 0, 25], ["Avian influenza A vaccine", "TREATMENT", 0, 25], ["adjuvant", "TREATMENT", 34, 42]]], ["A flexible rapid tactic for mass vaccination will be needed if a pandemic occurs.", [["A flexible rapid tactic", "TREATMENT", 0, 23], ["mass vaccination", "TREATMENT", 28, 44], ["a pandemic", "PROBLEM", 63, 73]]]], "PMC7114224": [["IntroductionBovine respiratory disease (BRD) is a multifactorial disease in cattle caused by a variety of pathogens.", [["IntroductionBovine respiratory disease", "DISEASE", 0, 38], ["BRD", "DISEASE", 40, 43], ["cattle", "ORGANISM", 76, 82], ["cattle", "SPECIES", 76, 82], ["BRD", "SPECIES", 40, 43], ["cattle", "SPECIES", 76, 82], ["IntroductionBovine respiratory disease", "PROBLEM", 0, 38], ["BRD", "PROBLEM", 40, 43], ["a multifactorial disease", "PROBLEM", 48, 72], ["pathogens", "PROBLEM", 106, 115], ["respiratory disease", "OBSERVATION", 19, 38], ["multifactorial", "OBSERVATION_MODIFIER", 50, 64], ["disease", "OBSERVATION", 65, 72], ["pathogens", "OBSERVATION", 106, 115]]], ["It affects both the upper and lower respiratory tract and the lungs of cattle (Poulsen and McGuirk, 2009).", [["upper", "ANATOMY", 20, 25], ["lower respiratory tract", "ANATOMY", 30, 53], ["lungs", "ANATOMY", 62, 67], ["upper", "ORGANISM_SUBDIVISION", 20, 25], ["lower respiratory", "ORGANISM_SUBDIVISION", 30, 47], ["tract", "ORGANISM_SUBDIVISION", 48, 53], ["lungs", "ORGAN", 62, 67], ["cattle", "SPECIES", 71, 77], ["cattle", "SPECIES", 71, 77], ["both", "ANATOMY_MODIFIER", 11, 15], ["upper", "ANATOMY_MODIFIER", 20, 25], ["lower", "ANATOMY_MODIFIER", 30, 35], ["respiratory tract", "ANATOMY", 36, 53], ["lungs", "ANATOMY", 62, 67]]], ["BRD involves a wide variety of infectious agents.", [["BRD", "DISEASE", 0, 3], ["BRD", "PROBLEM", 0, 3], ["infectious agents", "TREATMENT", 31, 48], ["infectious", "OBSERVATION", 31, 41]]], ["These include viruses such as bovine respiratory syncytial virus (BRSV), parainfluenza type 3 virus (PI3), bovine coronavirus, bovine viral diarrhoea virus and bovine herpes virus 1 (BHV-1), as well as bacteria such as Mannheimia haemolytica, Histophilus somni, Pasteurella multocida and Mycoplasma bovis.", [["respiratory syncytial virus", "DISEASE", 37, 64], ["parainfluenza type 3 virus", "DISEASE", 73, 99], ["bovine coronavirus", "DISEASE", 107, 125], ["bovine viral diarrhoea", "DISEASE", 127, 149], ["bovine herpes virus", "DISEASE", 160, 179], ["bovine", "ORGANISM", 30, 36], ["respiratory syncytial virus", "ORGANISM", 37, 64], ["BRSV", "ORGANISM", 66, 70], ["parainfluenza type 3 virus", "ORGANISM", 73, 99], ["PI3", "GENE_OR_GENE_PRODUCT", 101, 104], ["bovine coronavirus", "ORGANISM", 107, 125], ["bovine viral diarrhoea virus", "ORGANISM", 127, 155], ["bovine herpes virus 1", "ORGANISM", 160, 181], ["BHV-1", "ORGANISM", 183, 188], ["Mannheimia haemolytica", "ORGANISM", 219, 241], ["Histophilus somni", "ORGANISM", 243, 260], ["Pasteurella multocida", "ORGANISM", 262, 283], ["Mycoplasma bovis", "ORGANISM", 288, 304], ["bovine", "SPECIES", 30, 36], ["respiratory syncytial virus", "SPECIES", 37, 64], ["BRSV", "SPECIES", 66, 70], ["parainfluenza type 3 virus", "SPECIES", 73, 99], ["bovine", "SPECIES", 107, 113], ["coronavirus", "SPECIES", 114, 125], ["bovine", "SPECIES", 127, 133], ["viral diarrhoea virus", "SPECIES", 134, 155], ["bovine", "SPECIES", 160, 166], ["herpes virus 1", "SPECIES", 167, 181], ["BHV-1", "SPECIES", 183, 188], ["Mannheimia haemolytica", "SPECIES", 219, 241], ["Histophilus somni", "SPECIES", 243, 260], ["Pasteurella multocida", "SPECIES", 262, 283], ["Mycoplasma bovis", "SPECIES", 288, 304], ["bovine respiratory syncytial virus", "SPECIES", 30, 64], ["BRSV", "SPECIES", 66, 70], ["parainfluenza type 3 virus", "SPECIES", 73, 99], ["bovine coronavirus", "SPECIES", 107, 125], ["bovine viral diarrhoea virus", "SPECIES", 127, 155], ["bovine herpes virus 1", "SPECIES", 160, 181], ["BHV-1", "SPECIES", 183, 188], ["Mannheimia haemolytica", "SPECIES", 219, 241], ["Histophilus somni", "SPECIES", 243, 260], ["Pasteurella multocida", "SPECIES", 262, 283], ["Mycoplasma bovis", "SPECIES", 288, 304], ["viruses", "PROBLEM", 14, 21], ["bovine respiratory syncytial virus", "PROBLEM", 30, 64], ["parainfluenza type 3 virus (PI3", "PROBLEM", 73, 104], ["bovine coronavirus", "PROBLEM", 107, 125], ["bovine viral diarrhoea virus", "PROBLEM", 127, 155], ["bovine herpes virus", "PROBLEM", 160, 179], ["BHV", "TEST", 183, 186], ["bacteria", "PROBLEM", 202, 210], ["Mannheimia haemolytica", "TEST", 219, 241], ["Histophilus somni", "PROBLEM", 243, 260], ["Pasteurella multocida", "PROBLEM", 262, 283], ["Mycoplasma bovis", "PROBLEM", 288, 304], ["viruses", "OBSERVATION", 14, 21], ["respiratory syncytial", "ANATOMY", 37, 58], ["Mycoplasma bovis", "OBSERVATION", 288, 304]]], ["BRD is a significant cause of morbidity and mortality in calves (Busato et al., 1997, Dutil et al., 1999, Windeyer et al., 2014).", [["BRD", "DISEASE", 0, 3], ["calves", "ORGANISM", 57, 63], ["calves", "SPECIES", 57, 63], ["BRD", "PROBLEM", 0, 3], ["morbidity", "PROBLEM", 30, 39], ["significant", "OBSERVATION_MODIFIER", 9, 20], ["morbidity", "OBSERVATION", 30, 39]]], ["Busato et al. (1997) monitored 100 Swiss suckler beef herds from birth to weaning, in one generation of calves, and reported a pre-weaning calf mortality rate of five per cent.", [["calves", "ORGANISM", 104, 110], ["calf", "ORGANISM_SUBDIVISION", 139, 143], ["beef", "SPECIES", 49, 53], ["calves", "SPECIES", 104, 110], ["calf", "SPECIES", 139, 143], ["beef", "SPECIES", 49, 53], ["a pre-weaning calf mortality rate", "TREATMENT", 125, 158]]], ["Over 50% of these mortalities were due to respiratory disease.", [["respiratory", "ANATOMY", 42, 53], ["respiratory disease", "DISEASE", 42, 61], ["respiratory disease", "PROBLEM", 42, 61], ["respiratory disease", "OBSERVATION", 42, 61]]], ["Similarly, in a study of 467 suckler beef herds in Canada, Dutil et al. (1999) reported a pre-weaning calf mortality rate of 5.4% in herds with less than 40 females, and 5.6% in herds with 40 or more females.", [["calf", "ORGANISM_SUBDIVISION", 102, 106], ["beef", "SPECIES", 37, 41], ["calf", "SPECIES", 102, 106], ["beef", "SPECIES", 37, 41], ["a study", "TEST", 14, 21], ["a pre-weaning calf mortality rate", "TEST", 88, 121]]], ["Of these recorded cases of mortality, 12.8\u201317.5% was due to respiratory disease.", [["respiratory", "ANATOMY", 60, 71], ["respiratory disease", "DISEASE", 60, 79], ["mortality", "TEST", 27, 36], ["respiratory disease", "PROBLEM", 60, 79], ["respiratory disease", "OBSERVATION", 60, 79]]], ["Windeyer et al. (2014) observed a case fatality risk for BRD of 7.1% in dairy heifer calves on commercial dairy farms in Minnesota and Ontario.", [["BRD", "DISEASE", 57, 60], ["calves", "ORGANISM", 85, 91], ["calves", "SPECIES", 85, 91], ["BRD", "PROBLEM", 57, 60]]], ["In the Republic of Ireland, respiratory disease is the main cause of mortality in calves from one to three months of age.", [["respiratory", "ANATOMY", 28, 39], ["respiratory disease", "DISEASE", 28, 47], ["calves", "ORGANISM", 82, 88], ["calves", "SPECIES", 82, 88], ["respiratory disease", "PROBLEM", 28, 47], ["respiratory disease", "OBSERVATION", 28, 47], ["main", "OBSERVATION_MODIFIER", 55, 59], ["mortality", "OBSERVATION", 69, 78]]], ["Almost 30% of calves between one and three months of age submitted to the Veterinary Laboratory Service in 2012 for necropsy died as a result of respiratory disease (All-Ireland Animal Disease Surveillance Report, 2012).", [["respiratory", "ANATOMY", 145, 156], ["respiratory disease", "DISEASE", 145, 164], ["calves", "ORGANISM", 14, 20], ["calves", "SPECIES", 14, 20], ["respiratory disease", "PROBLEM", 145, 164], ["respiratory disease", "OBSERVATION", 145, 164]]], ["Recognised risk factors for dairy calf mortality during the rearing period include calf birth weight, colostrum intake, milk feeding practices, housing, age at weaning and exposure to infectious disease (Brickell et al., 2009a, Brickell et al., 2009b, Sivula et al., 1996, Speicher and Hepp, 1973).", [["colostrum", "ANATOMY", 102, 111], ["milk", "ANATOMY", 120, 124], ["infectious disease", "DISEASE", 184, 202], ["calf", "ORGANISM_SUBDIVISION", 34, 38], ["calf", "ORGANISM_SUBDIVISION", 83, 87], ["colostrum", "ORGANISM_SUBDIVISION", 102, 111], ["milk", "ORGANISM_SUBDIVISION", 120, 124], ["calf", "SPECIES", 34, 38], ["calf", "SPECIES", 83, 87], ["dairy calf mortality", "PROBLEM", 28, 48], ["calf birth weight", "PROBLEM", 83, 100], ["infectious", "OBSERVATION_MODIFIER", 184, 194]]], ["However, the impact of these risk factors on calf mortality is often inconsistent across studies (Brickell et al., 2009a, Brickell et al., 2009b).IntroductionThe BRD complex causes major economic and welfare losses (Healy et al., 1993, Stanton et al., 2012).", [["calf", "ORGANISM_SUBDIVISION", 45, 49], ["BRD complex", "PROTEIN", 162, 173], ["calf", "SPECIES", 45, 49], ["these risk factors on calf mortality", "PROBLEM", 23, 59], ["BRD complex", "OBSERVATION_MODIFIER", 162, 173], ["major", "OBSERVATION_MODIFIER", 181, 186], ["economic", "OBSERVATION_MODIFIER", 187, 195]]], ["There are substantial costs associated with mortality, antibiotics and/or anti-inflammatory treatment, and poor life-time performance of affected calves.", [["calves", "ORGANISM", 146, 152], ["calves", "SPECIES", 146, 152], ["mortality", "TREATMENT", 44, 53], ["antibiotics", "TREATMENT", 55, 66], ["anti-inflammatory treatment", "TREATMENT", 74, 101], ["affected calves", "PROBLEM", 137, 152], ["substantial", "OBSERVATION_MODIFIER", 10, 21], ["costs", "OBSERVATION", 22, 27]]], ["An economic model from 2001 estimated the average loss for a typical Dutch farm with 60% of the heifers affected by BRD at \u20ac31.20 per animal (van der Fels-Klerx et al., 2001).IntroductionIn general calves diagnosed with BRD are treated with antibiotics and/or anti-inflammatory drugs.", [["BRD", "DISEASE", 116, 119], ["BRD", "DISEASE", 220, 223], ["calves", "ORGANISM", 198, 204], ["calves", "SPECIES", 198, 204], ["BRD", "SPECIES", 116, 119], ["BRD", "SPECIES", 220, 223], ["BRD", "PROBLEM", 116, 119], ["BRD", "PROBLEM", 220, 223], ["antibiotics", "TREATMENT", 241, 252], ["anti-inflammatory drugs", "TREATMENT", 260, 283]]], ["Recovery following treatment depends on how early the disease is diagnosed and treated (Cusack et al., 2003).", [["treatment", "TREATMENT", 19, 28], ["disease", "OBSERVATION", 54, 61]]], ["Earlier recognition of BRD would reduce the severity of the disease and decrease the costs for the Stockperson.", [["BRD", "DISEASE", 23, 26], ["BRD", "PROBLEM", 23, 26], ["the disease", "PROBLEM", 56, 67], ["disease", "OBSERVATION", 60, 67], ["decrease", "OBSERVATION_MODIFIER", 72, 80]]], ["Currently, BRD is detected by means of clinical signs including increased rectal temperature, abnormal breathing patterns, reduced feed intake, coughing, nasal or eye discharge (Poulsen and McGuirk, 2009).", [["rectal", "ANATOMY", 74, 80], ["nasal", "ANATOMY", 154, 159], ["eye", "ANATOMY", 163, 166], ["BRD", "DISEASE", 11, 14], ["coughing", "DISEASE", 144, 152], ["rectal", "ORGANISM_SUBDIVISION", 74, 80], ["nasal", "ORGANISM_SUBDIVISION", 154, 159], ["eye", "ORGAN", 163, 166], ["BRD", "PROBLEM", 11, 14], ["clinical signs", "TEST", 39, 53], ["increased rectal temperature", "PROBLEM", 64, 92], ["abnormal breathing patterns", "PROBLEM", 94, 121], ["reduced feed intake", "PROBLEM", 123, 142], ["coughing", "PROBLEM", 144, 152], ["nasal or eye discharge", "PROBLEM", 154, 176], ["BRD", "OBSERVATION", 11, 14], ["rectal", "ANATOMY", 74, 80], ["nasal", "ANATOMY", 154, 159], ["eye", "ANATOMY", 163, 166]]], ["Treatment with antibiotics is normally initiated as soon as these symptoms are observed.", [["antibiotics", "TREATMENT", 15, 26], ["these symptoms", "PROBLEM", 60, 74]]], ["However, detecting the disease in an earlier state, before the appearance of clinical symptoms, is more difficult.IntroductionAutomated and continuous monitoring of calves through Precision Livestock Farming (PLF) (Berckmans, 2008, Berckmans, 2013, Wathes et al., 2008) technology is an approach that has potential for recognition of BRD before the appearance of clinical manifestations of the disease.", [["BRD", "DISEASE", 334, 337], ["calves", "ORGANISM", 165, 171], ["calves", "SPECIES", 165, 171], ["BRD", "SPECIES", 334, 337], ["the disease", "PROBLEM", 19, 30], ["clinical symptoms", "PROBLEM", 77, 94], ["continuous monitoring", "TEST", 140, 161], ["BRD", "PROBLEM", 334, 337], ["the disease", "PROBLEM", 390, 401], ["disease", "OBSERVATION", 23, 30], ["disease", "OBSERVATION", 394, 401]]], ["Infrared thermography has been used to detect the onset of BRD in calves (Schaefer et al., 2012) and image analysis has been used for the detection of lame cows (Viazzi et al., 2014) and disease in pigs (Kashiha et al., 2013, Weixing et al., 2009).IntroductionA cough sound monitor has previously been used for the detection of respiratory disease in pigs (Van Hirtum et al., 1999, Van Hirtum and Berckmans, 2003).", [["respiratory", "ANATOMY", 328, 339], ["BRD", "DISEASE", 59, 62], ["respiratory disease", "DISEASE", 328, 347], ["calves", "ORGANISM", 66, 72], ["pigs", "ORGANISM", 198, 202], ["pigs", "ORGANISM", 351, 355], ["calves", "SPECIES", 66, 72], ["cows", "SPECIES", 156, 160], ["pigs", "SPECIES", 198, 202], ["pigs", "SPECIES", 351, 355], ["BRD", "SPECIES", 59, 62], ["pigs", "SPECIES", 198, 202], ["pigs", "SPECIES", 351, 355], ["Infrared thermography", "TEST", 0, 21], ["BRD in calves", "PROBLEM", 59, 72], ["image analysis", "TEST", 101, 115], ["lame cows", "PROBLEM", 151, 160], ["disease", "PROBLEM", 187, 194], ["IntroductionA cough sound monitor", "TEST", 248, 281], ["respiratory disease", "PROBLEM", 328, 347], ["BRD", "OBSERVATION", 59, 62], ["calves", "ANATOMY", 66, 72], ["respiratory", "ANATOMY", 328, 339], ["disease", "OBSERVATION", 340, 347]]], ["Further studies reported the use of an online, cough monitoring system (Exadaktylos et al., 2008, Guarino et al., 2008), demonstrated that coughing sources could be localised (Silva et al., 2008) and that the cough monitor could be used for the detection of respiratory diseases in pigs (Finger et al., 2014).", [["respiratory", "ANATOMY", 258, 269], ["cough", "DISEASE", 209, 214], ["respiratory diseases", "DISEASE", 258, 278], ["pigs", "ORGANISM", 282, 286], ["pigs", "SPECIES", 282, 286], ["pigs", "SPECIES", 282, 286], ["Further studies", "TEST", 0, 15], ["cough monitoring system", "TEST", 47, 70], ["coughing sources", "PROBLEM", 139, 155], ["the cough monitor", "TEST", 205, 222], ["respiratory diseases", "PROBLEM", 258, 278], ["respiratory", "ANATOMY", 258, 269], ["diseases", "OBSERVATION", 270, 278]]], ["However, this technology has not been evaluated to date for calves, although it has been shown that it is possible to differentiate between mechanical and calf cough sounds (Ferrari et al., 2010).", [["cough", "DISEASE", 160, 165], ["calves", "ORGANISM", 60, 66], ["calf", "ORGANISM_SUBDIVISION", 155, 159], ["calves", "SPECIES", 60, 66], ["calf", "SPECIES", 155, 159], ["calves", "PROBLEM", 60, 66], ["mechanical and calf cough sounds", "PROBLEM", 140, 172], ["calf", "ANATOMY", 155, 159], ["cough", "OBSERVATION", 160, 165]]], ["Thus PLF technologies offer great potential in adding value to the Stockperson by reducing the severity of BRD and associated costs through earlier intervention.IntroductionOther approaches of PLF specifically with sound analysis worth mentioning are for instance, the detection and counting of screams in pigs for stress assessment (Sch\u00f6n et al., 2004, Moura et al., 2008a, Vandermeulen et al., 2015).", [["BRD", "DISEASE", 107, 110], ["pigs", "ORGANISM", 306, 310], ["pigs", "SPECIES", 306, 310], ["BRD", "SPECIES", 107, 110], ["pigs", "SPECIES", 306, 310], ["PLF technologies", "TREATMENT", 5, 21], ["BRD", "PROBLEM", 107, 110], ["earlier intervention", "TREATMENT", 140, 160], ["IntroductionOther approaches of PLF", "TREATMENT", 161, 196], ["sound analysis", "TEST", 215, 229], ["the detection", "TEST", 265, 278], ["stress assessment", "TEST", 315, 332], ["BRD", "OBSERVATION", 107, 110]]], ["Acoustic monitoring was also used to estimate the dry matter intake of grazing sheep (Galli et al., 2011).", [["sheep", "ORGANISM", 79, 84], ["sheep", "SPECIES", 79, 84], ["sheep", "SPECIES", 79, 84], ["Acoustic monitoring", "TEST", 0, 19]]], ["Techniques used in human speech processing were applied to recognise different cow calls (Jahns, 2008).", [["human", "ORGANISM", 19, 24], ["cow", "ORGANISM", 79, 82], ["human", "SPECIES", 19, 24], ["human", "SPECIES", 19, 24], ["human speech processing", "TREATMENT", 19, 42]]], ["Sound analysis deduced the thermal comfort of chicks (Moura et al., 2008b) and the differences in sound between a feather pecking flock and a non-feather pecking flock (Bright, 2008).IntroductionThe objective of this study was to develop a cough monitor for calves to provide a warning system for early recognition of BRD.", [["BRD", "DISEASE", 318, 321], ["calves", "ORGANISM", 258, 264], ["calves", "SPECIES", 258, 264], ["Sound analysis", "TEST", 0, 14], ["a feather pecking flock", "TREATMENT", 112, 135], ["this study", "TEST", 212, 222], ["a cough monitor", "TEST", 238, 253], ["calves", "PROBLEM", 258, 264], ["a warning system", "TREATMENT", 276, 292], ["BRD", "PROBLEM", 318, 321], ["thermal", "OBSERVATION_MODIFIER", 27, 34]]], ["The approach involved; (1), constructing a cough monitor algorithm based on sound data recorded during calf rearing over a 60 day period in three separate calf houses; (2), assessing the algorithm performance with sensitivity and specificity metrics; (3), comparing the algorithm outcome with a gold standard for BRD using the Wisconsin clinical respiratory score (Lago et al., 2006) combined with rectal temperature.", [["rectal", "ANATOMY", 398, 404], ["BRD", "DISEASE", 313, 316], ["calf", "ORGANISM_SUBDIVISION", 103, 107], ["rectal", "ORGAN", 398, 404], ["calf", "SPECIES", 103, 107], ["calf", "SPECIES", 155, 159], ["BRD", "SPECIES", 313, 316], ["a cough monitor algorithm", "TEST", 41, 66], ["sound data", "TEST", 76, 86], ["the algorithm performance", "TEST", 183, 208], ["BRD", "PROBLEM", 313, 316], ["rectal temperature", "TEST", 398, 416], ["calf", "ANATOMY", 103, 107], ["calf", "ANATOMY", 155, 159], ["rectal", "ANATOMY", 398, 404]]], ["A further objective was to evaluate the algorithm outcome in terms of an early warning system and compare it with the timing of treatment of calves presenting with BRD by the veterinarian.Animal and housing ::: Material and methodsA total of sixty-two male Holstein\u2013Friesian (H-F) and Jersey (J) calves were housed in mixed groups in three calf houses with sawdust covered floors at Teagasc, AGRIC, Grange, from the 21st of March to the 11th of June 2013 (82 days).", [["BRD", "DISEASE", 164, 167], ["calves", "ORGANISM", 141, 147], ["H-F", "CELL", 276, 279], ["calves", "ORGANISM", 296, 302], ["calves", "SPECIES", 141, 147], ["calves", "SPECIES", 296, 302], ["calf", "SPECIES", 340, 344], ["BRD", "SPECIES", 164, 167], ["treatment of calves", "TREATMENT", 128, 147], ["BRD", "PROBLEM", 164, 167], ["calves", "OBSERVATION", 141, 147], ["calf", "ANATOMY", 340, 344]]], ["The number, age and weight of calves, per breed, at the start of the study, in each respective house are shown in Table 1.Animal and housing ::: Material and methodsEach house was an open-fronted shed with three solid walls and a galvanised monopitch roof and measured 6.77 m (length) by 4.56 m (width).", [["calves", "ORGANISM", 30, 36], ["calves", "SPECIES", 30, 36], ["the study", "TEST", 65, 74], ["a galvanised monopitch roof", "TREATMENT", 228, 255], ["solid", "ANATOMY_MODIFIER", 212, 217], ["walls", "ANATOMY_MODIFIER", 218, 223], ["roof", "ANATOMY_MODIFIER", 251, 255], ["6.77 m", "OBSERVATION_MODIFIER", 269, 275]]], ["Fig. 1shows a picture of the house, calves and microphone.", [["calves", "ORGANISM", 36, 42], ["calves", "SPECIES", 36, 42], ["microphone", "TREATMENT", 47, 57]]], ["The recording microphone was positioned in the centre of each house at a height of 2.75 m above the sawdust covered floor of each house.", [["The recording microphone", "TREATMENT", 0, 24]]], ["The houses were adjacent to each other; house 1 was adjacent to house 2 and house 2 was adjacent to house 3.Animal and housing ::: Material and methodsCalves were fed a diet with a 23% crude protein (CP), 18% lipid, milk replacer (MR) (Blossom Easymix; Volac, Co. Cavan, Ireland) and concentrate (26.5% barley, 25% soya, 15% maize, 12.5% beet pulp, 12.5% soya hulls, 5% molasses, 2.5% minerals, 1% vegetable oil (18.8% CP, 22.4% neutral detergent fibre)) using an electronic feeding system (Foster-Tecknik SA 2000, Engen, Germany).Animal and housing ::: Material and methodsDuring the weaning phase, MR was gradually reduced from its previous allocation over a 14 d period (d \u221213 to d 0).", [["pulp", "ANATOMY", 343, 347], ["vegetable oil", "ANATOMY", 398, 411], ["CP", "CHEMICAL", 200, 202], ["minerals", "CHEMICAL", 385, 393], ["CP", "CHEMICAL", 419, 421], ["Calves", "ORGANISM", 151, 157], ["lipid", "SIMPLE_CHEMICAL", 209, 214], ["milk", "ORGANISM_SUBSTANCE", 216, 220], ["replacer", "ORGANISM_SUBDIVISION", 221, 229], ["pulp", "TISSUE", 343, 347], ["MR", "PROTEIN", 600, 602], ["Calves", "SPECIES", 151, 157], ["barley", "SPECIES", 303, 309], ["maize", "SPECIES", 325, 330], ["beet", "SPECIES", 338, 342], ["a 23% crude protein (CP)", "TREATMENT", 179, 203], ["18% lipid, milk replacer", "TREATMENT", 205, 229], ["MR", "TEST", 231, 233], ["5% molasses", "TREATMENT", 367, 378], ["neutral detergent fibre)", "TREATMENT", 429, 453], ["an electronic feeding system", "TREATMENT", 461, 489], ["MR", "TEST", 600, 602], ["reduced", "OBSERVATION_MODIFIER", 617, 624]]], ["By d \u22121, all calves were consuming at least 1 kg of concentrate daily for three consecutive days.", [["calves", "ORGANISM", 13, 19], ["calves", "SPECIES", 13, 19]]], ["On d 0, MR was eliminated from the diet of all calves.Vaccination of calves ::: Material and methodsCalves were immunised on arrival at Teagasc, AGRIC, Grange against BHV-1, PI-3, BRSV, Mannheimia haemolytica serotypes A1 and A6 and Salmonella dublin and Salmonella typhimurium using Rispoval IBR-Marker live, Bovipast RSP and Bovivac S vaccines, respectively.", [["calves", "ORGANISM", 47, 53], ["calves", "ORGANISM", 69, 75], ["Calves", "ORGANISM", 100, 106], ["BHV-1", "ORGANISM", 167, 172], ["PI-3", "ORGANISM", 174, 178], ["BRSV", "ORGANISM", 180, 184], ["Mannheimia haemolytica serotypes A1", "ORGANISM", 186, 221], ["A6", "CELL", 226, 228], ["Salmonella dublin", "ORGANISM", 233, 250], ["Salmonella typhimurium", "ORGANISM", 255, 277], ["MR", "PROTEIN", 8, 10], ["calves", "SPECIES", 47, 53], ["calves", "SPECIES", 69, 75], ["Calves", "SPECIES", 100, 106], ["BRSV", "SPECIES", 180, 184], ["Mannheimia haemolytica", "SPECIES", 186, 208], ["Salmonella dublin", "SPECIES", 233, 250], ["Salmonella typhimurium", "SPECIES", 255, 277], ["BHV-1", "SPECIES", 167, 172], ["BRSV", "SPECIES", 180, 184], ["Mannheimia haemolytica", "SPECIES", 186, 208], ["Salmonella dublin", "SPECIES", 233, 250], ["Salmonella typhimurium", "SPECIES", 255, 277], ["MR", "TEST", 8, 10], ["methodsCalves", "TREATMENT", 93, 106], ["AGRIC", "TEST", 145, 150], ["BHV", "TEST", 167, 170], ["PI", "TEST", 174, 176], ["BRSV", "PROBLEM", 180, 184], ["Mannheimia haemolytica serotypes", "TEST", 186, 218], ["Salmonella dublin", "TREATMENT", 233, 250], ["Salmonella typhimurium", "TREATMENT", 255, 277], ["Rispoval IBR", "TREATMENT", 284, 296], ["Bovipast RSP", "TREATMENT", 310, 322], ["Bovivac S vaccines", "TREATMENT", 327, 345], ["all calves", "ANATOMY", 43, 53], ["calves", "ANATOMY", 69, 75]]], ["Calves received a second booster vaccination with Bovipast RSP four weeks after arrival as per manufacturer\u2019s instructions.Clinical assessment of calves \u2013 Gold standard 1 ::: Material and methodsClinical assessments were performed by a trained human observer on all calves at least twice a week during the pre-weaning period and once per week during the post-weaning period.", [["Calves", "ORGANISM", 0, 6], ["calves", "ORGANISM", 146, 152], ["human", "ORGANISM", 244, 249], ["calves", "ORGANISM", 266, 272], ["Calves", "SPECIES", 0, 6], ["calves", "SPECIES", 146, 152], ["human", "SPECIES", 244, 249], ["calves", "SPECIES", 266, 272], ["human", "SPECIES", 244, 249], ["a second booster vaccination", "TREATMENT", 16, 44], ["Clinical assessment", "TEST", 123, 142], ["Clinical assessments", "TEST", 195, 215], ["the post-weaning period", "TREATMENT", 350, 373]]], ["These assessments included the monitoring and recording of; rectal temperature, presence of a cough (none, induced, spontaneous cough or repeated induced coughs, repeated spontaneous coughs), ear position (normal, ear flick or head shake, unilateral droop, head tilt or bilateral droop), presence of nasal discharge (none, small amount of unilateral discharge, bilateral or excessive discharge, copious bilateral discharge) and presence of ocular discharges (none, small amount, moderate amount of bilateral discharge, heavy discharge).", [["rectal", "ANATOMY", 60, 66], ["ear", "ANATOMY", 192, 195], ["ear", "ANATOMY", 214, 217], ["head", "ANATOMY", 227, 231], ["droop", "ANATOMY", 250, 255], ["head", "ANATOMY", 257, 261], ["nasal", "ANATOMY", 300, 305], ["ocular", "ANATOMY", 440, 446], ["cough", "DISEASE", 94, 99], ["cough", "DISEASE", 128, 133], ["coughs", "DISEASE", 154, 160], ["coughs", "DISEASE", 183, 189], ["ocular discharges", "DISEASE", 440, 457], ["rectal", "ORGANISM_SUBDIVISION", 60, 66], ["ear", "ORGAN", 192, 195], ["ear", "ORGAN", 214, 217], ["head", "ORGANISM_SUBDIVISION", 227, 231], ["head", "ORGANISM_SUBDIVISION", 257, 261], ["nasal", "ORGANISM_SUBDIVISION", 300, 305], ["These assessments", "TEST", 0, 17], ["the monitoring", "TEST", 27, 41], ["rectal temperature", "TEST", 60, 78], ["a cough", "PROBLEM", 92, 99], ["spontaneous cough", "PROBLEM", 116, 133], ["repeated induced coughs", "PROBLEM", 137, 160], ["repeated spontaneous coughs", "PROBLEM", 162, 189], ["head shake", "PROBLEM", 227, 237], ["unilateral droop", "PROBLEM", 239, 255], ["head tilt", "PROBLEM", 257, 266], ["bilateral droop", "PROBLEM", 270, 285], ["nasal discharge", "PROBLEM", 300, 315], ["unilateral discharge", "PROBLEM", 339, 359], ["bilateral or excessive discharge", "PROBLEM", 361, 393], ["copious bilateral discharge", "PROBLEM", 395, 422], ["ocular discharges", "PROBLEM", 440, 457], ["bilateral discharge", "PROBLEM", 498, 517], ["rectal", "ANATOMY", 60, 66], ["cough", "OBSERVATION", 94, 99], ["head", "ANATOMY", 257, 261], ["bilateral", "ANATOMY_MODIFIER", 270, 279], ["nasal", "ANATOMY", 300, 305], ["bilateral", "ANATOMY_MODIFIER", 361, 370], ["ocular", "ANATOMY", 440, 446], ["discharges", "OBSERVATION", 447, 457], ["moderate", "OBSERVATION_MODIFIER", 479, 487], ["amount", "OBSERVATION_MODIFIER", 488, 494], ["bilateral", "ANATOMY_MODIFIER", 498, 507]]], ["The Wisconsin health scoring criteria were used to create a cumulative respiratory score (RS) from the results of the calves\u2019 clinical assessments (Fig. 2).", [["calves", "ORGANISM", 118, 124], ["calves", "SPECIES", 118, 124], ["a cumulative respiratory score", "PROBLEM", 58, 88], ["clinical assessments", "TEST", 126, 146]]], ["Then RS was devised from the cumulative score for nasal discharge, eye or ear score (whichever was greatest), cough and rectal temperature.", [["nasal", "ANATOMY", 50, 55], ["eye", "ANATOMY", 67, 70], ["ear", "ANATOMY", 74, 77], ["rectal", "ANATOMY", 120, 126], ["cough", "DISEASE", 110, 115], ["nasal", "ORGANISM_SUBDIVISION", 50, 55], ["eye", "ORGAN", 67, 70], ["ear", "ORGAN", 74, 77], ["rectal", "ORGANISM_SUBDIVISION", 120, 126], ["nasal discharge", "PROBLEM", 50, 65], ["eye or ear score", "PROBLEM", 67, 83], ["cough", "PROBLEM", 110, 115], ["rectal temperature", "TEST", 120, 138], ["nasal", "ANATOMY", 50, 55], ["eye", "ANATOMY", 67, 70], ["ear", "ANATOMY", 74, 77], ["rectal", "ANATOMY", 120, 126]]], ["These respiratory disease assessment criteria were approved by the University of Wisconsin Research Animal Resources Centre Animal Care and Use Committee (Lago et al., 2006).", [["respiratory", "ANATOMY", 6, 17], ["respiratory disease", "DISEASE", 6, 25], ["These respiratory disease assessment criteria", "PROBLEM", 0, 45], ["respiratory", "ANATOMY", 6, 17], ["disease", "OBSERVATION", 18, 25]]], ["A calf was considered to have respiratory disease if it had an RS of 5 or higher, and a rectal temperature of at least 39.5 \u00b0C. In this study the combined RS and rectal temperature were regarded as gold standard one (GS1) for positive identification of calves with BRD.Blood sampling of calves \u2013 Gold standard 2 ::: Material and methodsOn d \u221214, \u22126, \u22123, 0, 1, 3, 8, and, 14 relative to weaning (d 0), calves were blood sampled via jugular venepuncture for subsequent haematological analysis of neutrophil profiles.", [["respiratory", "ANATOMY", 30, 41], ["rectal", "ANATOMY", 88, 94], ["rectal", "ANATOMY", 162, 168], ["Blood", "ANATOMY", 269, 274], ["blood", "ANATOMY", 413, 418], ["jugular", "ANATOMY", 431, 438], ["neutrophil", "ANATOMY", 494, 504], ["respiratory disease", "DISEASE", 30, 49], ["BRD", "DISEASE", 265, 268], ["calf", "ORGANISM", 2, 6], ["rectal", "ORGAN", 88, 94], ["rectal", "ORGAN", 162, 168], ["calves", "ORGANISM", 253, 259], ["Blood", "ORGANISM_SUBSTANCE", 269, 274], ["calves", "ORGANISM", 287, 293], ["calves", "ORGANISM", 401, 407], ["blood", "ORGANISM_SUBSTANCE", 413, 418], ["jugular venepuncture", "MULTI-TISSUE_STRUCTURE", 431, 451], ["neutrophil", "CELL", 494, 504], ["calf", "SPECIES", 2, 6], ["calves", "SPECIES", 253, 259], ["calves", "SPECIES", 287, 293], ["calves", "SPECIES", 401, 407], ["BRD", "SPECIES", 265, 268], ["respiratory disease", "PROBLEM", 30, 49], ["an RS", "TEST", 60, 65], ["a rectal temperature", "TEST", 86, 106], ["this study", "TEST", 131, 141], ["rectal temperature", "TEST", 162, 180], ["BRD", "PROBLEM", 265, 268], ["Blood sampling", "TEST", 269, 283], ["Material and methodsOn d \u2212", "TEST", 316, 342], ["jugular venepuncture", "TEST", 431, 451], ["subsequent haematological analysis", "TEST", 456, 490], ["neutrophil profiles", "TEST", 494, 513], ["calf", "ANATOMY", 2, 6], ["respiratory", "ANATOMY", 30, 41], ["disease", "OBSERVATION", 42, 49], ["rectal", "ANATOMY", 88, 94], ["rectal", "ANATOMY", 162, 168], ["calves", "ANATOMY", 253, 259], ["calves", "ANATOMY", 287, 293], ["calves", "ANATOMY", 401, 407], ["jugular", "ANATOMY", 431, 438], ["neutrophil profiles", "OBSERVATION", 494, 513]]], ["Blood samples were collected in 6 ml K3Ethylenediaminetetraacetic acid (K3EDTA) tubes (Vacuette, Cruinn Diagnostics, Ireland).", [["Blood samples", "ANATOMY", 0, 13], ["K3Ethylenediaminetetraacetic acid", "CHEMICAL", 37, 70], ["K3EDTA", "CHEMICAL", 72, 78], ["K3Ethylenediaminetetraacetic acid", "CHEMICAL", 37, 70], ["K3EDTA", "CHEMICAL", 72, 78], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["K3Ethylenediaminetetraacetic acid", "SIMPLE_CHEMICAL", 37, 70], ["Blood samples", "TEST", 0, 13], ["6 ml K3Ethylenediaminetetraacetic acid (K3EDTA) tubes", "TREATMENT", 32, 85]]], ["Whole K3EDTA blood samples were analysed immediately after collection using an ADVIA 2120 analyser (ADVIA 2120, Bayer Healthcare, Siemens, UK) which contained software necessary for the analysis of bovine blood.", [["K3EDTA blood samples", "ANATOMY", 6, 26], ["blood", "ANATOMY", 205, 210], ["K3EDTA blood samples", "ORGANISM_SUBSTANCE", 6, 26], ["bovine", "ORGANISM", 198, 204], ["blood", "ORGANISM_SUBSTANCE", 205, 210], ["bovine", "SPECIES", 198, 204], ["bovine", "SPECIES", 198, 204], ["Whole K3EDTA blood samples", "TEST", 0, 26], ["an ADVIA", "TEST", 76, 84], ["the analysis", "TEST", 182, 194], ["bovine blood", "PROBLEM", 198, 210]]], ["The normal reference interval for blood neutrophils is between 600 and 4000/\u03bcl of whole blood (Jones and Allison, 2007).", [["blood neutrophils", "ANATOMY", 34, 51], ["whole blood", "ANATOMY", 82, 93], ["blood", "ORGANISM_SUBSTANCE", 34, 39], ["neutrophils", "CELL", 40, 51], ["blood", "ORGANISM_SUBSTANCE", 88, 93], ["blood neutrophils", "CELL_TYPE", 34, 51], ["blood neutrophils", "TEST", 34, 51], ["normal", "OBSERVATION", 4, 10]]], ["A calf with a neutrophil number greater than 5000/\u03bcl was considered to have a heightened inflammatory response.", [["calf", "ANATOMY", 2, 6], ["neutrophil", "ANATOMY", 14, 24], ["calf", "ORGANISM", 2, 6], ["neutrophil", "CELL", 14, 24], ["calf", "SPECIES", 2, 6], ["a neutrophil number", "TEST", 12, 31], ["a heightened inflammatory response", "PROBLEM", 76, 110], ["calf", "ANATOMY", 2, 6], ["heightened", "OBSERVATION_MODIFIER", 78, 88], ["inflammatory", "OBSERVATION", 89, 101]]], ["This measure was used as a second gold standard (GS2) for positive identification of calves with BRD.Removal of calves from the study ::: Material and methodsOne H-F and one J calf died from pneumonia during the pre-weaning period.", [["BRD", "DISEASE", 97, 100], ["pneumonia", "DISEASE", 191, 200], ["calves", "ORGANISM", 85, 91], ["calves", "ORGANISM", 112, 118], ["calf", "ORGANISM", 176, 180], ["calves", "SPECIES", 85, 91], ["calves", "SPECIES", 112, 118], ["calf", "SPECIES", 176, 180], ["BRD", "SPECIES", 97, 100], ["BRD", "PROBLEM", 97, 100], ["Removal of calves", "TREATMENT", 101, 118], ["the study", "TEST", 124, 133], ["pneumonia", "PROBLEM", 191, 200], ["calves", "ANATOMY", 85, 91], ["BRD", "OBSERVATION", 97, 100], ["calves", "OBSERVATION", 112, 118], ["one J", "OBSERVATION_MODIFIER", 170, 175], ["calf", "ANATOMY", 176, 180], ["died", "OBSERVATION", 181, 185], ["pneumonia", "OBSERVATION", 191, 200]]], ["One H-F calf and one J calf were removed from the study after weaning and placed in an isolation pens due to severe pneumonia.Treatment procedure ::: Material and methodsThe calves were treated when they presented with signs of BRD.", [["pneumonia", "DISEASE", 116, 125], ["BRD", "DISEASE", 228, 231], ["H-F calf", "ORGANISM", 4, 12], ["calf", "ORGANISM", 23, 27], ["calves", "ORGANISM", 174, 180], ["calf", "SPECIES", 8, 12], ["calf", "SPECIES", 23, 27], ["calves", "SPECIES", 174, 180], ["one J calf", "TREATMENT", 17, 27], ["the study", "TEST", 46, 55], ["an isolation pens", "TREATMENT", 84, 101], ["severe pneumonia", "PROBLEM", 109, 125], ["BRD", "PROBLEM", 228, 231], ["calf", "ANATOMY", 8, 12], ["one", "ANATOMY_MODIFIER", 17, 20], ["J calf", "ANATOMY", 21, 27], ["removed", "OBSERVATION", 33, 40], ["severe", "OBSERVATION_MODIFIER", 109, 115], ["pneumonia", "OBSERVATION", 116, 125], ["calves", "ANATOMY", 174, 180], ["BRD", "OBSERVATION", 228, 231]]], ["A veterinarian examined all clinically ill calves, reviewed the GS1 indicated by the human observer and made the decision to treat the calves with antibiotics and/or anti-inflammatory drugs based on his/her diagnosis.Data acquisition ::: Material and methodsEach house was equipped with the hardware of the pig cough monitor (SoundTalks, Belgium).", [["calves", "ORGANISM", 43, 49], ["human", "ORGANISM", 85, 90], ["calves", "ORGANISM", 135, 141], ["pig", "ORGANISM", 307, 310], ["calves", "SPECIES", 43, 49], ["human", "SPECIES", 85, 90], ["calves", "SPECIES", 135, 141], ["pig", "SPECIES", 307, 310], ["human", "SPECIES", 85, 90], ["pig", "SPECIES", 307, 310], ["antibiotics", "TREATMENT", 147, 158], ["anti-inflammatory drugs", "TREATMENT", 166, 189], ["the hardware", "TREATMENT", 287, 299], ["the pig cough monitor", "TEST", 303, 324]]], ["It consisted of one microphone (C-4 Small Diaphragm Condenser Mic, Behringer, Germany) and a sound Card (MAYA44, ESI, Germany).", [["Diaphragm", "ANATOMY", 42, 51]]], ["The sound was recorded in wave format with 16 bit precision and a sampling frequency of 22,050 Hz.", [["a sampling frequency", "TEST", 64, 84], ["sound", "OBSERVATION_MODIFIER", 4, 9]]], ["The sound was continuously recorded from the 1st April to the 31st May 2013.", [["sound", "OBSERVATION_MODIFIER", 4, 9]]], ["In total 4320 h of data were collected.Labelling ::: Material and methodsIn order to develop a classifier to distinguish calf coughs from other sounds, a reference data set was required.", [["coughs", "DISEASE", 126, 132], ["calf", "ORGANISM_SUBDIVISION", 121, 125], ["calf", "SPECIES", 121, 125], ["calf coughs from other sounds", "PROBLEM", 121, 150], ["a reference data set", "TEST", 152, 172], ["calf", "ANATOMY", 121, 125], ["coughs", "OBSERVATION", 126, 132]]], ["From the recorded sound data, the start and end time of each calf cough present in the sound file were identified by a human labeller off-scene using audio-visual scoring of sound on a computer (Aerts et al., 2005, Tullo et al., 2013).", [["cough", "DISEASE", 66, 71], ["calf", "ORGANISM_SUBDIVISION", 61, 65], ["human", "ORGANISM", 119, 124], ["calf", "SPECIES", 61, 65], ["human", "SPECIES", 119, 124], ["human", "SPECIES", 119, 124], ["the recorded sound data", "TEST", 5, 28], ["each calf cough", "PROBLEM", 56, 71], ["calf", "ANATOMY", 61, 65], ["cough", "OBSERVATION", 66, 71]]], ["In total 205 min of the recorded sound data were labelled by a human labeller.", [["human", "ORGANISM", 63, 68], ["human", "SPECIES", 63, 68], ["human", "SPECIES", 63, 68], ["the recorded sound data", "TEST", 20, 43]]], ["This resulted in 385 labelled calf coughs.", [["calf", "ORGANISM_SUBDIVISION", 30, 34], ["calf", "SPECIES", 30, 34], ["labelled calf coughs", "PROBLEM", 21, 41], ["calf", "ANATOMY", 30, 34], ["coughs", "OBSERVATION", 35, 41]]], ["The total number of calf coughs labelled per house is shown in Table 2.", [["calf", "ORGANISM", 20, 24], ["calf", "SPECIES", 20, 24], ["calf coughs", "PROBLEM", 20, 31], ["total", "OBSERVATION_MODIFIER", 4, 9], ["number", "OBSERVATION_MODIFIER", 10, 16], ["calf", "ANATOMY", 20, 24], ["coughs", "OBSERVATION", 25, 31]]], ["The algorithm was later validated using the remaining labelled sound data recorded in houses 1, 2 and 3.", [["the remaining labelled sound data", "TEST", 40, 73]]], ["The latter sounded quieter as if the quality was lower.Event detection ::: Calf cough monitor algorithm ::: Material and methodsInitially, all the possible events in the sound data that could contain a cough were detected by the event detection.", [["cough", "DISEASE", 202, 207], ["Calf", "ORGANISM", 75, 79], ["Calf cough", "PROBLEM", 75, 85], ["the sound data", "TEST", 166, 180], ["a cough", "PROBLEM", 200, 207], ["cough", "OBSERVATION", 80, 85], ["cough", "OBSERVATION", 202, 207]]], ["The sound event detection was based on a method for detecting sound events used for human cough detection (Barry et al., 2006).", [["cough", "DISEASE", 90, 95], ["human", "ORGANISM", 84, 89], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 84, 89], ["a method", "TEST", 39, 47], ["sound events", "PROBLEM", 62, 74], ["human cough detection", "TREATMENT", 84, 105]]], ["The method detected events by searching for sudden differences in the standard deviation of the recorded sound.", [["sudden differences", "PROBLEM", 44, 62]]], ["These sound events could be calf coughs, bird sounds, creaking of the fence, etc. Finally, 5739 events, including the 385 labelled coughs, were found in the labelled sound data.", [["calf", "ORGANISM_SUBDIVISION", 28, 32], ["calf", "SPECIES", 28, 32], ["These sound events", "PROBLEM", 0, 18], ["calf coughs", "PROBLEM", 28, 39], ["bird sounds", "PROBLEM", 41, 52], ["the labelled sound data", "TEST", 153, 176], ["calf", "ANATOMY", 28, 32], ["coughs", "OBSERVATION", 33, 39]]], ["Thus, 385 per 5739 or one per fifteen sound events detected was considered a cough.Feature calculation ::: Calf cough monitor algorithm ::: Material and methodsThe feature calculation divided the sound events into 30 ms hamming windows (Oppenheim and Schafer, 1989) with a 15 ms overlap.", [["cough", "DISEASE", 77, 82], ["Calf", "ORGANISM", 107, 111], ["a cough", "PROBLEM", 75, 82], ["Calf cough", "PROBLEM", 107, 117], ["cough", "OBSERVATION", 77, 82], ["cough", "OBSERVATION", 112, 117], ["sound", "OBSERVATION_MODIFIER", 196, 201]]], ["These numbers were chosen similar to speech analysis in which 20\u201340 ms windows are used (Paliwal et al., 2010).", [["speech analysis", "TEST", 37, 52]]], ["Since background noise was still present in these windows a simple noise reduction method was applied.", [["background noise", "PROBLEM", 6, 22], ["a simple noise reduction method", "TREATMENT", 58, 89], ["simple", "OBSERVATION_MODIFIER", 60, 66], ["noise", "OBSERVATION_MODIFIER", 67, 72], ["reduction", "OBSERVATION_MODIFIER", 73, 82]]], ["In total, one minute of adjacent windows were used for this averaged window.", [["adjacent windows", "TREATMENT", 24, 40], ["this averaged window", "TREATMENT", 55, 75], ["windows", "OBSERVATION", 33, 40]]], ["Finally, the values were transformed in decibel (dB) scale.Feature calculation ::: Calf cough monitor algorithm ::: Material and methodsTo reduce the information contained in these windows and to make a rough spectrogram the frequency values were summed together in twelve linear spaced frequency bands.", [["Calf", "ORGANISM", 83, 87], ["the values", "TEST", 9, 19], ["Calf cough", "PROBLEM", 83, 93], ["a rough spectrogram", "TEST", 201, 220], ["twelve linear spaced frequency bands", "PROBLEM", 266, 302], ["cough", "OBSERVATION", 88, 93]]], ["In Fig. 3, the spectrogram, the spectrogram with the average subtracted and, the rough spectrogram is shown for two coughs.Feature calculation ::: Calf cough monitor algorithm ::: Material and methodsAfter the rough spectrogram was calculated, the algorithm calculated the \u2018duration\u2019 of the cough.", [["cough", "DISEASE", 291, 296], ["Calf", "ORGANISM", 147, 151], ["the spectrogram", "TEST", 11, 26], ["the spectrogram", "TEST", 28, 43], ["the rough spectrogram", "TEST", 77, 98], ["two coughs", "PROBLEM", 112, 122], ["Calf cough", "PROBLEM", 147, 157], ["the rough spectrogram", "TEST", 206, 227], ["the algorithm", "TEST", 244, 257], ["the cough", "PROBLEM", 287, 296], ["cough", "OBSERVATION", 152, 157], ["cough", "OBSERVATION", 291, 296]]], ["As calf coughs have been found to have an average duration of 0.37 s (Ferrari et al., 2010).", [["calf", "ORGANISM", 3, 7], ["calf", "SPECIES", 3, 7], ["calf coughs", "PROBLEM", 3, 14], ["calf", "ANATOMY", 3, 7], ["coughs", "OBSERVATION", 8, 14]]], ["The duration was calculated from the rough spectrogram.", [["the rough spectrogram", "TEST", 33, 54]]], ["The calculation was done in different steps.", [["The calculation", "TEST", 0, 15]]], ["These are displayed as red1 arrows in Fig. 4.", [["Fig", "OBSERVATION_MODIFIER", 38, 41]]], ["The length of each arrow was the duration of that level.", [["length", "OBSERVATION_MODIFIER", 4, 10]]], ["To reduce the information in this feature a straight line was fitted through the durations based on reducing the squared error (Fig. 4).", [["a straight line", "TREATMENT", 42, 57]]], ["First the red arrows were aligned to the left, then the green line was fitted through the right arrows.", [["left", "ANATOMY", 41, 45], ["the red arrows", "PROBLEM", 6, 20], ["the green line", "TREATMENT", 52, 66], ["red arrows", "OBSERVATION", 10, 20], ["left", "ANATOMY_MODIFIER", 41, 45], ["green line", "OBSERVATION", 56, 66], ["right", "ANATOMY_MODIFIER", 90, 95]]], ["The final properties of this straight line, slope and intercept, were called the duration features.Feature calculation ::: Calf cough monitor algorithm ::: Material and methodsAnother feature calculated the number of peaks in the rough spectrogram.", [["Calf", "ORGANISM", 123, 127], ["this straight line", "TREATMENT", 24, 42], ["Calf cough", "PROBLEM", 123, 133], ["straight line", "OBSERVATION", 29, 42], ["cough", "OBSERVATION", 128, 133], ["number", "OBSERVATION_MODIFIER", 207, 213], ["peaks", "OBSERVATION_MODIFIER", 217, 222]]], ["All the frequency values were summed together as in step 1 of the duration calculation.", [["All the frequency values", "TEST", 0, 24], ["the duration calculation", "TEST", 62, 86]]], ["Several sound events had multiple peaks as seen in Fig. 5, while for coughs, multiple peaks were not observed.", [["coughs", "DISEASE", 69, 75], ["Several sound events", "PROBLEM", 0, 20], ["multiple peaks", "PROBLEM", 25, 39], ["coughs", "PROBLEM", 69, 75], ["multiple peaks", "PROBLEM", 77, 91], ["multiple", "OBSERVATION_MODIFIER", 25, 33], ["peaks", "OBSERVATION", 34, 39]]], ["Therefore, this feature expressed whether there were multiple peaks present in the spectrogram.", [["multiple peaks", "PROBLEM", 53, 67], ["the spectrogram", "TEST", 79, 94], ["multiple", "OBSERVATION_MODIFIER", 53, 61], ["peaks", "OBSERVATION", 62, 67]]], ["In Fig. 5, a non-cough sound is shown with the detected peaks.", [["a non-cough sound", "TEST", 11, 28], ["the detected peaks", "PROBLEM", 43, 61]]], ["The peaks are required to be further than 0.1 s from each other before they are detected as two different peaks.Classification ::: Calf cough monitor algorithm ::: Material and methodsEach sound event had to be classified as either a cough or another sound.", [["cough", "DISEASE", 234, 239], ["Calf", "ORGANISM", 131, 135], ["Calf cough", "PROBLEM", 131, 141], ["a cough", "PROBLEM", 232, 239], ["peaks", "OBSERVATION_MODIFIER", 4, 9], ["peaks", "OBSERVATION_MODIFIER", 106, 111], ["cough", "OBSERVATION", 136, 141], ["cough", "OBSERVATION", 234, 239]]], ["The performance of the classification was measured with the sensitivity, specificity and precision.(1)sensitivity=numberoftruepositivesnumberoftruepositives+numberoffalsenegatives(2)specificity=numberoftruenegativesnumberoftruenegatives+numberoffalsepositives(3)precision=numberoftruepositivesnumberoftruepositives+numberoffalsepositives", [["the sensitivity", "TEST", 56, 71], ["sensitivity", "TEST", 102, 113]]]]}